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We are in the position of a little child entering a huge library filled with books in many 
different languages. The child knows someone must have written those books. It does not 
know how. It does not understand the languages in which they are written. The child 
dimly suspects a mysterious order in the arrangement of the books but doesn't know what 
it is. That seems to me, is the attitude of even the most intelligent being toward God. We 
see a universe marvellously arranged and obeying certain laws, but only dimly 
understand those laws. Our limited minds cannot grasp the mysterious force that moves 
the constellations. 
 -Albert Einstein- 
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ABBREVIATIONS 
8-oxoG, 8-oxoguanine 
AD, Alzheimer disease 
ADP, adenosine diphosphate 
ALS, amyotrophic lateral sclerosis 
AML, acute myeloid leukemia 
AP, abasic site 
AP-1, activating protein-1 
APE1, apurinic/apyrimidinic endonuclease-1 
APE1-SCR1, APE1 scramble 
APE1-WT, APE1 wild-type  
APE1-NΔ33, N-terminal APE1 deletion mutant 
BER, base excision repair 
BLM, bleomycin 
CK I and II, casein kinase I and II 
DAPI, 4',6-diamidino-2-phenylindole 
DDR, DNA damage response 
DNA Pol β, DNA polymerase β 
DR, direct repair 
DSB, double-strand breaks 
E3330, 2E-3-[5-(2, 3 dimethoxy-6- methyl-1, 4-benzoquinolyl)]-2-nonyl-2- propenoic 
acid 
Egr-1, early growth response protein-1 
FC, fibrillar center 
FEN1, flap endonuclease 1 
GC, granular component 
GG-NER, global genome NER  
GO, gene ontology 
GSK III, glycogen synthase kinase III 
GzmA and K, granzyme A and K 
HAT, histone acetyltransferase 
HDAC, histone deacetylase 
hnRNP-L, Heterogeneous nuclear ribonucleoprotein L 
hOGG1, human OGG1 
HR, homologous recombination 
IDP, intrinsically disordered regions 
LC-ESI-MS, liquid chromatography-electrospray ionization-mass spectrometry 
LP-BER, long-patch base excision repair 
MDM2, murine double minute 2 
MEF, mouse embryonic fibroblasts 
MMR, mismatch repair 
MMS, Methylmethanesulfonate 
mtBER, mitochondrial BER 
nCaRE, Negative calcium responsive element 
NES, nuclear export signal 
NER, nucleotide-excision repair 
NF-κB, nuclear factor-kappaB 
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NHEJ, non-homologous end joining 
NLS, nuclear localization signal 
NPM1, nucleophosmin 1 
NPM1wt, NPM1 wild-type 
NPM1c+, cytoplasmic nucleophosmin 1 
NO, nitric oxide 
NoLS, nucleolar localization signal 
OGG1, 8-oxoguanine DNA glycosylase 
PARP1, Poly(ADP-ribose) polymerase 1 
PCNA, proliferating cell nuclear antigen 
PD, Parkinson disease 
PKC, protein kinase C 
PTMs, post-translational modifications 
PTH, parathyroid hormone 
Rac1, ras-related C3 botulinum toxin substrate 1 
RF-C, replication factor C 
RNA pol I/II, RNA polymerase I and II 
ROS, reactive oxygen species 
Sir2, silent information regulator 2 
SIRT1, sirtuin 1 
SNPs, single-nucleotide polymorphisms 
SP-BER, short-patch base excision repair 
SSB, single-strand break 
TC-NER, transcription-coupled NER (TC-NER) 
TSH, thyrotropin 
TO-PRO3, Quinolinium, 4-[3-(3-methyl-2(3H)-benzothiazolylidene)-1-propenyl]-1-[3-
(trimethylammonio)propyl], diiodide 
Trx, thioredoxin 
XRCC1, X-ray cross-species complementing 1 
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ABSTRACT 
Apurinic/apyrimidinic endonuclease 1 (APE1) is the main mammalian endonuclease 
involved in the repair of DNA lesions caused predominantly by oxidative and alkylating 
stresses through its participation in base excision repair (BER) pathway. Although APE1 
was discovered for its ability to cleave and remove AP-sites and to enhance the DNA 
binding properties of several cancer-related transcription factors, through redox-
dependent mechanisms (involving its so-called Ref-1 activity), in the latest years 
investigators have described new and broader functions for this DNA repair enzyme. In 
fact, it has been demonstrated a direct role for APE1 in the regulation of gene 
transcription and an unexpected role in the RNA metabolism being able to cleave 
damaged or site-specific RNAs. Despite different works regarding the transcriptional and 
post-translational mechanisms that cells used to control and to redirect APE1 to its 
several functions, it is still a matter of debate the role of the first 33 amino acids, a unique 
evolutionary N-terminus specific for the mammalian protein, that impacts, through 
macromolecules interaction and post-translational modifications, on controlling APE1 
activities. In this work of Thesis, new acetylated lysine residues were identified in vivo 
and the role of acetylation sites at N-terminus (Lys 27-35) in regulating APE1 functions 
and subcellular localization were studied. Moreover, seventeen new interacting partners 
were identified. Among these, the attention was focused on APE1 and Nucleophosmin 1 
(NPM1) interaction within nucleoli and nucleoplasm. NPM1 is a nucleolar protein, 
mainly involved in ribosome biogenesis, stress responses and genome maintenance. 
Growing body of evidences emphasizes a role for NPM1 in DNA repair field, but its 
exact role(s) has not been identified yet. Interestedly, patients with acute myeloid 
leukemias (AMLs), characterized by the expression of a mutated form of NPM1 
(NPM1c+), causative for its aberrant cytoplasmic localization, represent better responders 
to chemotherapy and for favorable overall survival. At present, the molecular reasons 
underneath the role for NPM1 in tumorigenesis of solid tumors and in AMLs are still 
lacking. In this framework, a clear contribution of NPM1 in DNA repair control, through 
the functional regulation of the APE1 endonuclease activity in BER pathway, its 
subcellular localization and stability has been demonstrated in vivo. In this light, the 
positive clinical impact of NPM1c+ in chemotherapeutic response might be related to the 
potential interference with the functions of NPM1 interacting partners, once delocalized 
in the cytoplasm. An intriguing mechanism for explaining also the biological effects of 
APE1 genetic variants, considered in this work of Thesis, supported by the observation 
that the majority of the polymorphisms presents an altered complex network of 
interactions, protein stability and stress response, affecting the APE1 functional status. 
Our findings provide a glimpse into the role of the nucleolus and NPM1 in controlling 
APE1 functions, suggesting a critical role for the intricate network of APE1 interacting 
partners, especially NPM1, and post-translational modifications in BER in vivo that might 
be important for explaining the APE1 dysregulation seen in different types of tumors. 
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1. INTRODUCTION 
1.1 THE “WATSON AND CRICK” DOMINO EFFECT 
Sixty years have passed since Watson and Crick unveiled the structure of the DNA 
double helix and tentatively explained some genetical implications deriving from the 
proposed structure1. Since then, several investigators concentrate their attention on 
understanding the properties and rules that govern our genetic material. Indeed, as 
correctly supposed by Watson “Biology has at least 50 more interesting years”. Maybe 
much more. 
Shortly after this breakthrough, it became quite clear that DNA, for its intrinsic nature, is 
susceptible to numerous DNA damages, being exogenous or endogenous, that could 
ultimately lead to alterations of the coding information of the genome, potentially driving 
to mutagenesis phenomena and activation of cell death programs. The next paragraphs 
will be dedicated to a brief overview of the different types of DNA damages and the 
enzymatic processes evolutionary arise for specifically recognizing the DNA alteration, 
ensuring the accuracy of the genetic material. A particular attention will be given to the 
Base Excision Repair (BER) pathway and to the main mammalian endonuclease, APE1.  
1.2 THE MOLECULAR STRUCTURE OF DNA AND ITS 
INTRINSIC VULNERABILITY 
Within the complex machinery of each cells, all biomolecules, inclusive of proteins, 
lipids and nucleic acids, run into an inescapable series of damages caused both by 
spontaneous reactions, such as hydrolysis, and by numerous endogenous and exogenous 
reactive agents. Of note, DNA damage could have more severe consequences than the 
other damaged molecules, due to its intrinsic nature and function. The other 
macromolecules are all renewable and when they lose their function or stability they 
could be easily replaced; this is not true for nuclear DNA, that accounts for all cellular 
RNA and proteins, being irreplaceable. Acquiring mutations in a permanent way might 
lead to irreversible outcomes, as malignancies predisposition, neurological abnormalities 
and ageing2-4.  
For these reasons, to combat threats posed by DNA damage, eukaryotic cells have 
developed and evolutionary acquired a complex range of DNA damage repair systems, 
tolerance pathways and checkpoint steps, collectively named DNA damage response 
(DDR), to detect DNA lesions, signal their presence and promote their repair, restoring 
the DNA integrity and guaranteeing the genome maintenance during lifespan of an 
organism. Although this intricate apparatus, in case of too severe DNA damages, nature 
has also provided cells with effector machineries for triggering senescence or cell death to 
avoid the transmission of altered genomes. In fact, more complicated and larger the 
genome is, more sensitive to several DNA damages it appears. The chemical events that 
lead to DNA damage, besides exogenous sources as UV and ionizing radiation, are 
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usually triggered by endogenous metabolic processes, i.e. exposure to reactive oxygen 
species (ROS), including superoxide anions, hydrogen peroxide and hydroxyl radicals 
and other reactive metabolites5. Generation of ROS originates other subsequent altered 
products: endogenous alkylating agents, spontaneous hydrolysis and deamination 
products. As estimated by Lindahl and colleagues, an impressive number of lesions 
(roughly thousands of single-strand breaks and spontaneous base losses) occur 
spontaneously per mammalian genome every day. Moreover, with the existence of other 
types of spontaneous damages, this significant number may arise to about ten thousands 
per cell per day6.  
The consequences of DNA injury are determined by several factors: 
 The type of DNA damage. Some lesions are mainly mutagenic (i.e. 8-oxo-G, 
induced by oxidative damage), promoting the development of malignancies; 
others are cytotoxic and lead to senescence and ageing. Bulky lesions, such as 
double-strand breaks or inter-strand cross-links, generally provoke cellular 
senescence or cell death; 
 The frequency and the severity of the DNA damage; 
 The location of DNA injuries in the genome; 
 Efficiency and accuracy of the repair systems involved in removing the DNA 
lesions may depend to cell type or cell cycle stage when damage occurs. 
The wide variety of DNA lesions and their effects have given a boost to the development 
of an intricate system of DNA repair pathways, each selective for a specific subset of 
DNA lesions (Figure 1). Often described as a series of distinct pathways, DNA repair is 
more likely to be a complex and integrated network that coordinates the canonical 
pathways described in literature7. While some lesions are easily repair through a direct 
protein-mediated reversal (direct repair, DR), the majority of injuries requires a complex 
sequence of enzymatic steps mediated by multiple proteins, that belong to the same 
pathway8. In base excision repair (BER), a damaged base is recognized by DNA 
glycosylase, that removes it generating an abasic (AP) sites, before endonuclease (APE1), 
polymerase and ligase proteins complete the repair9. In mismatch repair (MMR), 
detection and removing of biosynthetic errors (insertion/deletion) from newly synthesized 
DNA triggers a single-strand incision, followed by the action of nuclease, polymerase and 
ligase enzymes, improving the fidelity of DNA replication10. The nucleotide excision 
repair (NER) system senses helix-distorting base lesions and operates using two different 
sub-pathways that differ in the mechanism of lesion recognition: transcription-coupled 
NER (TC-NER) that copes with replication blocking lesions, and global genome NER 
(GG-NER). Then they converge for the incision/excision steps and subsequent gap filling 
and ligation steps11. Notably, some lesions are not repair but are by-passed during DNA 
replication by error-prone polymerases. For double-strand break (DSB) repair, nature has 
evolved two different mechanisms: non-homologous end joining (NHEJ) and 
homologous recombination (HR)8. In NHEJ, Ku proteins, after recognition of the break, 
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alkylguanine-DNA alkyltransferase; ATM, ataxia telangiectasia mutated; BER, base excision repair; cis-Pt, 
cisplatin; CPD, cyclobutane pyrimidine dimer; DR, direct repair; GG-NER, global genome NER; HR, 
homologous recombination; O6MeG, O6-methylguanine; MMC, mitomycin C; MMR, mismatch repair; 
NER, nucleotide excision repair; NHEJ, non-homologous end joining; TC-NER, transcription-coupled 
NER. (Adapted image from Postel-Vinay S. et al., Nat Rev Clin Oncol, 2012) 
1.3 APURINIC/APYRIMIDINIC ENDONUCLEASE FACTOR 1 
(APE1) 
The major mammalian Apurinic/apyrimidinic Endonuclease 1/Redox effector factor 1 
(APE1/Ref-1, and from here on referred to as APE1), the mammalian ortholog of 
Escherichia coli Xth (Exo III), is a multifunctional  and essential protein protecting cells 
from oxidative and alkylative insults14, maintaining genome stability through its DNA 
repair, redox signalling and gene regulation activities (Figure 2). It is expressed 
ubiquitously and at high levels in human cells (around 104-105 copies/cell15), although its 
intracellular localization pattern may appear heterogeneous among different tissues16. As 
suggested by its acronym, it exerts two main functions, the AP endonuclease activity in 
the BER pathway, that copes with DNA damages induced by oxidative and alkylating 
agents, through its C-terminus17 and the redox-dependent transcriptional regulatory 
activity in modulating the DNA binding activity of different cancer-related transcription 
factors (i.e. AP-1, NF-kB, p53, Egr-1 and Pax family), function related to its N-terminal 
domain16. The protein C-terminus is highly conserved during phylogenesis, while the N-
terminal domain (~ first 40 residues) is not. In contrast with the DNA repair-dedicated 
domain, conservation of APE1 N-terminus, high in mammals, present wider variability in 
other organisms, suggesting a potential recent evolutionary acquisition. In the last years, 
over the past two decades, several efforts were made for understanding the biological 
functions, mechanisms of action and regulation of APE1. Beside its two principal 
functions, recent findings have demonstrated an unexpected and novel role for APE1 in 
the RNA metabolism. With its N-terminal domain, APE1 contacts and interacts with 
different proteins involved in ribosome biogenesis and pre-mRNA maturation/splicing18 
and it acts as endonuclease towards abasic RNA both in vitro19, as described for the 
mRNA of c-Myc20, and in vivo18, thus indicating a possible role in the RNA quality 
control process21. Another poorly characterized APE1 function is the transcriptional 
regulation of genes by binding in their promoter regions particular negative calcium 
responsive elements, called nCaRE sequences, present for example in the PTH and in 
APE1 promoter itself22. Being involved in several cellular processes, not only limited to 
the DNA repair field, a fine tuning of its functions appear necessary. Regardless of 
transcriptional control, modulation of its interactome network under different conditions 
and post-translational modifications on some specific residues may modify the chemical 
characteristic and structural conformation of the protein, redirecting APE1 toward a 
specific function. Lately, the first 35 amino acids acquired more and more value in the 
eyes of investigators; until few years ago this disordered extreme N-terminus was 
considered useful for a proper subcellular localization but dispensable for protein 
functions. Nowadays, instead, it is emerging a key role of this domain in mediating 
12 | P a g e  
 
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
INTRODUCTION 
protein-protein interactions, with the majority of APE1 binding partners18, in controlling 
the catalytic activity on abasic DNA23 and as acceptor of different post-translational 
modifications, such as acetylation23 and ubiquitination24. While the functional role has 
been described for some post-translational modifications, as acetylation at Lys6/725, 
ubiquitination at Lys24/25/2724 and phosphorylation at Thr23226, the APE1 interacting 
partners which could modulate its functions are still under investigations. Notably, 
dysregulation of APE1, consisting in both its subcellular localization and its 
overexpression, has been associated to tumor differentiation and aggressiveness16,27, and 
the onset of radio- and chemo-resistance28,29. Actually, APE1 is considered as a promising 
therapeutic target for both preventative and curative treatment paradigms. Nevertheless, 
since its pleiotropic involvement in several cellular processes, the effects of its 
attenuation by small molecule compounds have to be carefully defined. In this scenario, 
understanding the molecular mechanism underlying APE1 regulation and biological 
functions represents an important step towards enhancing the efficacy of cancer 
treatments. 
Figure 2: Schematic representation of APE1 structure and its main functions. As highlighted within, 
key elements in the human APE1 protein are marked: the nuclease domain of APE1 encompasses DNA 
repair activity while the N-terminus is involved in the transcriptional regulatory functions. The first 33 
amino acids are responsible for the nuclear localization, protein-protein interaction and RNA metabolism. 
APE1 structure (α/β-sandwich) has shown as ribbon representation. The main functions in which APE1 is 
engaged are depicted; from the top, clockwise, (i) endonuclease activity in BER pathway; (ii) RNA quality 
control; (iii-iv) redox-dependent and independent transcriptional regulation of several cancer-related 
factors; and (v) negative transcriptional regulation by binding nCaRE sequences. (Image from Tell G. et al., 
Cell Mol Life Sci, 2010) 
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40x45x40 Å32,34. Each domain is composed by six-stranded β-sheet surrounded by α-
helices, which pack together to form a four layered α/β sandwich (Figure 4)34. 
Figure 4: Human APE1 ribbon structure. The conserved four-layered α/β-sandwich structural core 
consists of two six-stranded β-sheets surrounded by α-helices, packed together. The strand order is β3-β4-
β2-β1-β1-β13 for domain 1 and β5-β6-β7-β8-β12-β9 for domain 2. The α-helices and β-strands are 
numbered sequentially from the N-terminus. (Image from Gorman M. A. et al., EMBO J, 1997) 
Considering the APE1 biological functions, three functionally independent domains could 
be recognized: 
i. The first 35 N-terminal residues, formed by an unstructured sequence, contains
the bipartite nuclear localization signal (NLS) and is required for protein-protein
interactions, for RNA binding activities and for coordinating the protein catalytic
activity of abasic DNA18,23;
ii. The classical N-terminus, evolutionary acquired in mammals, that spans roughly
from residue 35 to residue 127, is dedicated to the redox activity of APE1;
iii. The C-terminal domain (approximately residue 60 to the end of the protein)
encompasses the nuclease activity and is highly conserved from bacteria to
humans.
The C-terminal and the N-terminal domain, although independent, present a partial 
overlapping (residues 61-80 are involved in the DNA repair activity of the protein)35. The 
next paragraphs will be dedicated to the functional division of APE in domains. 
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1.3.2.1 THE FIRST 33 RESIDUES: A NEW UNSTRUCTURED APE1 N-
TERMINAL DOMAIN
Recent evidences pointed to the first 35 amino acids as a new independent APE1 
functional and structural subdomain. Crystallographic structure demonstrated that the first 
42 residues of APE1 consist of a highly disordered domain36. Long disordered segments, 
called intrinsically disordered regions (IDP), have been observed for a large number of 
proteins under physiological conditions. These regions are characterized by structural 
plasticity, feature as multitasking devices, domains whose functions has to be fluid, 
dynamic and diverse, as common interface for protein binding and acceptor sites for 
covalent modifications, providing an opportunity for alternative splicing. These 
peculiarity may provide important functional advantages. Notably, the nonconserved 
disordered terminal peptide in mammals result essential for several biological functions 
including damage sensing, repair regulation through post-translational modifications, 
macromolecule associations and intracellular localization (bipartite NLS)37. Their 
flexibility, in fact, allows them to interact simultaneously with numerous different targets 
with high affinity and specificity through small common interface, forming dynamic 
complexes. As shown in literature for several hub proteins as NEIL137, this extreme N-
terminal domain of APE1 is involved in protein-protein interactions18, being implicated as 
a common interaction surface. The positively charged residues located in these N-
terminal disordered tails confer the capability to APE1 and other DNA-binding protein to 
scan the DNA through nonspecific and transient DNA binding, followed by a DNA 
recognition by the active site37. Recently, Yu and colleagues also demonstrated that 
concomitant with the DNA binding and catalysis, the APE1 structure may encounter local 
conformational changes of the nucleoprotein complexes, suggesting for the first time that 
this domain acts as a switch to govern redox and nuclease activity on AP-DNA38. 
1.3.2.2 THE CLASSICAL N-TERMINAL DOMAIN 
As discussed in the previous paragraph, the N-terminal domain can be subdivided in two 
subdomains, the first 35 amino acids, formed by a disordered region and residues 
comprised between 43 and 65, required for the APE1 redox transcriptional co-activation 
function, respectively. This section will be dedicated to the latter.  
The usage of reduction-oxidation (redox) mechanism to control the DNA binding 
capability of transcription factors was first suggested for the avian homolog of Jun, a 
mutant in a conserved cysteine, with acquired oncogenic potential, that demonstrated an 
increased DNA binding and resistance to oxidizing agents32. It is known that the 
oxidation of the cysteine residue abolishes DNA binding, whereas reduction to a 
sulphydryl state promotes it. Interestingly, in 1992, Xanthoudakis and Curran identified 
APE1 as a crucial activator of the DNA binding of transcription factors Fos and Jun, 
subunits of activator protein 1 (AP-1)39. Since this initial identification, APE1 has been 
documented as redox co-activator for several transcription factors, like p5335, c-Jun40, 
HIF-alpha41, NF-κB42, and AP-139, facilitating their DNA binding via the reduction of a 
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critical cysteine residue. This region, that forms an extended loop which lies across the β-
strands β13 and β14, contact the globular core of the molecule via numerous hydrogen 
bond and salt bridge interactions. The crucial residues implicated in the redox activity are 
Cys65, Cys93 and Cys99, as recently confirmed by Georgiadis and colleagues40,43. Cys65 
is located on β1 with the side chain pointing into a hydrophobic pocket. Cristallographic 
analysis and solvent accessibility studies suggested that both the residues are inaccessible 
to solvent and would be unable to contact directly the cysteine residue target34,43,44. 
Georgiadis and colleagues proposed a model that involves the exposure of Cys65 where 
APE1 may undergo to conformational change, ceating in this way a binding site that will 
accommodate the different transcription factors44. Further studies are required to 
understand which factors are capable of stimulating this conformational rearrangement. A 
recent cascade model have been recently proposed for the formation of disulfide bonds43.  
Besides the redox mechanisms, an alternative redox-independent mode has been 
described for APE1 activation of transcription factors such as p5345 and AP-135. 
1.3.2.3 THE C-TERMINAL DOMAIN 
The C-terminal domain is dedicated to the AP-endonuclease activity of the protein. 
Mutagenesis studies aimed at characterizing the contributions of residues in nuclease 
activity and sequence alignment analyses comparing E. coli ExoIII and human APE1 
identified potential conserved residues that could represent the APE1’s active site34,46. 
Later, X-ray crystallography analysis by Tainer and colleagues that solved the co-crystal 
structure of human APE1 protein (a fully active N-terminal truncated protein lacking its 
first 40 N-terminal amino acids) bound to its natural substrate, an abasic DNA (AP-DNA) 
and by Rupp and coworkers, that gained more informations about the coordination of the 
metal ions required and kinetic data, detailed all the residues involved and that contribute 
to the formation of the active site36,47. The active site, located in a pocket at the top of the 
α/β sandwich and surrounded by loop regions, is composed by different residues (His309, 
Glu96; Asp283, Thr265, Tyr171, Asn68, Asp210, Asp70 and Asn212), involved in 
hydrogen bonds. A recent APE1 structure reveals a single Mg2+ ion in the active site 
coordinated by two carboxylate groups (Asp70 and Glu96) and four water molecules, one 
of which binds to the imidazole of His309, typically referred to as the “A site”; however 
Drohat and colleagues didn’t found any evidence for a second Mg2+ ion at the “B site”, 
coordinated through side chains of Asp210, Asn212 and His309, as observed 
previously48. Interestingly, in the enzyme-product (EP) complex, recently determined by 
Tainer and colleagues, the Mg2+ ion is coordinated directly by the carboxylate group of 
Glu96, the 3’-OH (leaving group), a nonbridging O atom of the nascent 5’-phosphate and 
by three water molecules, one of which is bound to Asp7049 (Figure 5). The observations 
derived from the alignment structure of the EP complex and the DNA-free bound APE1 
structure determined by Tainer and coworkers and Drohat and colleagues, respectively, 
suggest that Mg2+ might perform its catalytically essential function(s), including 
positioning of the target phosphate, polarization of the P-O bond and stabilization of the 
negative charge developed at 3’-oxygen in the transition state, close to its location in the 
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approximately of 35°. Across from the flipped-out abasic site with a unique mechanisms 
reflecting specific APE1 functions, Met270 and Arg177 insert through the minor and the 
major groove, respectively, to pack against the orphan base of the abasic site and to 
provide a hydrogen bond to the AP site 3’ phosphate, locking APE1 onto abasic DNA47. 
This model, called “passing the baton”, while supported by biochemical and structural 
data, lacks biological evidence31. In spite of these recent evidences illustrating the APE1 
active site and giving light on the stoichiometry and the role of Mg2+ in APE1-catalyzed 
reactions48,49 and our understanding of how APE1 specifically recognizes AP sites, the 
catalytic mechanism used by APE1 to cleave the phosphodiester backbone remains 
controversial. Further studies are needed to delineate the precise APE1 catalytic process.  
1.3.3 APE1 BIOLOGICAL ACTIVITIES 
As already hinted at first, APE1 exerts a crucial role in maintaining genome stability as 
major apurinic/apyrimidinic endonuclease in mammals. Its functions in redox signaling 
and in regulation of gene transcription make APE1 considered as a multifunctional 
protein with unique properties that are beyond the classical DNA repair enzyme. In the 
next paragraph, the major APE1 canonical (DNA repair and redox chaperone functions) 
and non-canonical activities (RNA cleavage and trans-acting modulation) will be 
concisely described.  
1.3.3.1 DNA REPAIR THROUGH PARTICIPATION IN BER PATHWAY 
A common type of DNA lesion is arranged by abasic sites, that threaten cellular viability 
and genomic integrity, blocking DNA replication and being cytotoxic and mutagenic32. 
They arise as a consequence of spontaneous hydrolysis of the N-glycosylic bond 
connecting the deoxyribose sugar moiety and the DNA base, as result from the activity of 
DNA glycosylases and they are generated by exogenous or/and endogenous DNA 
damaging agents. Therefore cells have evolved an intricate mechanism to preserve the 
fidelity of the genetic material and remove baseless lesions. The base excision repair 
(BER) pathway is committed to the removal of small, non-helix distorting base lesion, 
restoring the chemical DNA integrity. Different base lesions are sensed by BER, that 
converts them into a common intermediate, the AP sites, which then are recognized and 
processed by APE1. Subsequent steps follow either of two distinct BER subpathways, the 
short (SP-BER) or long patch repair (LP-BER), that replaces one or 2-13 nucleotides, 
respectively53,54. 
The BER pathway can be described as a process of five sequential steps (Figure 6): 
i. recognition and excision of the inappropriate base moiety (e.g. 8-oxo-dG),
ii. incision of the DNA backbone adjacent to the resulting abasic site,
iii. clean-up of the DNA termini to generate a 3′-hydroxyl group (3′-OH) and a 5′-
phosphate moiety (5′-P),
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iv. repair synthesis to replace the missing nucleotide(s), and
v. DNA ligation to seal the remaining nick.
As just mentioned, the initial step of BER involves the catalytic activity of DNA 
glycosylases, which hydrolyze the N-glycosylic bond connecting the targeted base with 
the deoxyribose sugar moiety. The product of this reaction is an abasic site. Currently, 
there are two major classes of glycosylases; the monofunctional ones excise the damaged 
base, exhibiting only the glycosylase activity, whereas the bifunctionals, which are 
glycosylases/β-lyases, cleave via β- or βδ-elimination the damaged base from the 
deoxyribose moiety and nick the phosphodiester backbone, leaving a 3′-phospho-α,β-
unsaturated aldehyde (3′-PUA) or a 3’-phosphate (3’-P), respectively55,56. Afterwards, in 
mammalian cells, APE1 recognizes the AP sites and nicks, via a Mg2+-dependent 
mechanism, the phosphodiester backbone 5’ to the AP sites, leaving a 3’-hydroxyl group 
(3’-OH) and a 5’-deoxyribose phosphate (dRP) termini flanking the nucleotide gap. 
Before the repair synthesis step, the elimination of the obstructive 3’- and 5’-termini to 
generate the 3’-OH and 5’-P termini, which are the normal substrate for DNA 
polymerases, is required. These termini, in fact, prevent primer extension by DNA 
polymerases and nick ligation by DNA ligases31. APE1 is responsible for removing the 
3’-phospho-α,β-unsaturated aldehyde by β-elimination via its 3’-phosphodiesterase 
activity, while DNA polymerase β (DNA Pol β) removes the 5’-dRP moiety through its 
5’-dRP lyase activity. Since the 3’-phosphate is a poor substrate for APE1, these blocking 
groups are processed in vivo by the phosphatase activity of PNKP56.  
At this point, repair can proceed along with one of the two BER subpathways (SP- or LP-
BER), which rely on a different set of repair proteins and depend on the AP state. Normal 
AP sites are repaired via SP-BER whereas several sites or modified ones are corrected by 
LP-BER32. In the SP-BER, DNA Pol β excises the 5’-dRP moiety and inserts a single 
nucleotide. Then, the complex formed by DNA ligase III and XRCC1 completes the 
repair by sealing the resulting nick. The LP-BER, instead, covers the strand displacement 
of two or more nucleotides surrounding the AP sites. In this case, the repair synthesis 
might be accomplished by polymerase β, δ or ε in a process that requires additional 
factors, sometimes not even acting directly on DNA, such as proliferating cell nuclear 
antigen (PCNA), replication factor C (RF-C) and Poly(ADP-ribose) polymerase 
(PARP1), able to bind immediately to an incised AP sites for recruiting other BER 
factors57,58. Following the replacement of the missing nucleotides, flap endonuclease 1 
(FEN1) removes the 5’-dRP terminus containing displaced strand. The repair is complete 
only when DNA ligase I restores the phosphodiester backbone32. 
Although BER is composed by five distinct steps, in which the DNA molecule is passed 
from one enzyme to the next one in a “passing the baton” scheme, model corroborated by 
macromolecule associations, that avoids the exposure of the DNA to the cellular 
environment, recent evidences of a “irrational” binding priority irrespective of the 
“passing the baton” model propose the existence of a multi-protein repair complexes, that 
require a tight coordination59. Even if how these steps are orchestrated is still under 
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investigation, a clear APE1 function in coordinating BER pathway, interacting directly or 
not with other BER factors, such as glycosylases, DNA Pol β and XRCC1, has 
emerged60-63. The molecular basis of the specificity, the exact role and the biological 
significance of these interactions remains to be determined. 
Figure 6: Base excision repair pathway. Base excision repair (BER) is initiated by removal of the 
modified base by either a monofunctional or bifunctional DNA glycosylase to leave an abasic site (AP). 
Excision by either one of the monofunctional DNA glycosylases (UDG or MPG) is followed by incision of 
the DNA backbone 5′ to the AP site by APE1. Excision by one of the bifunctional DNA glycosylases 
NTH1, OGG1, NEIL1 or NEIL2 is followed by incision 3′ to the AP site via β- or βδ-elimination facilitated 
by the intrinsic 3′ AP lyase activity of these enzymes. The resulting single-strand break will contain either a 
3′ or 5′ obstructive termini. End processing is then performed by Pol β, APE1 or PNKP depending on the 
specific nature of the terminus. PARP1 recognizes single strand breaks and the end processing may utilize 
the additional factors tyrosyl phosphodiesterase 1(TDP1) and aprataxin (APTX). When end processing has 
produced the necessary 3′-OH and 5′-P termini the following BER and single-strand break repair (SSBR) 
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steps diverge into two subpathways, short-patch and long-patch. In short-patch BER/SSBR repair synthesis 
of the single nucleotide gap is by Pol β aided by the XRCC1 scaffold, and subsequent ligation by LIG3α 
finishes the repair. In long-patch BER/SSBR repair synthesis of the 2–13 nucleotide gap is by Pol β, and/or 
Pol δ/ε aided by PCNA and RFC. A resulting 5′ flap is removed by FEN1 and the the final ligation step is 
by LIG1. (Image from Jeppesen D. K. et al., Prog Neurobiol, 2011) 
1.3.3.2 REDOX REGULATION 
Oxidative stress threatens all living aerobic organisms, resulting in macromolecular 
damage to lipids, carbohydrates, proteins and nucleic acids with deleterious consequences 
(i.e. loss of function or DNA mutation)64 and is associated with different diseases such as 
cancer, neurodegeneration and aging65. It refers to the imbalance due to excess of reactive 
oxygen species (ROS) over the capability of the cell through enzymatic and non-
enzymatic systems to sense the oxidants and to mount an effective antioxidant response66. 
Reactive oxygen species are generated mainly during mitochondrial oxidative 
metabolism; any enzyme able to process oxygen may give arise to ROS. Paradoxically, 
beside the toxic effects, ROS play a critical role as signaling molecules, altering the 
cellular and extracellular redox state, in a broad variety of cellular processes as cellular 
proliferation and survival, DNA damage response and gene regulation. A large body of 
research demonstrates a general effect of oxidative stress on gene expression via direct 
modulation of transcription factors activity, regulation mediated by the redox state of 
thiol groups exposed by critic cysteine residues, located within the DNA binding domain 
of the transcription factors. At first, independent studies have identified APE1 as factor 
able to stimulate the binding activity of several transcription factors through a redox-
dependent mechanism39. Since this first report, several transcription factors, both 
ubiquitous (e.g. NF-κB, Egr-1, p53, CREB, HIF-1α) and tissue-specific (e.g. TTF-1 and 
Pax proteins), with opposite effects on cell fate, have been reported to be modulate by 
APE167. Interestingly, it is likely that APE1 could select, in response to specific stimuli, 
which transcription factors regulate, binding them with different efficiencies. It has been 
proposed that APE1 might regulate the binding activity of transcription factors via 
regulation of the cysteine state, located in the DNA binding domain or domains critical 
for their activity, maintaining them in a reduced state by direct interaction (Figure 
7)63,68,69. Three possible mechanisms, not mutually esclusive, may explain the APE1 
redox chaperone activity. In the so called recruitment model, APE1 may facilitate the 
reduction of the transcription factors by bridging them to the reducing molecule (GSH or 
Trx). Second, in the conformational change model, APE1 may induce a conformational 
change in the target factor, rendering accessible the cysteine residues otherwise buried in 
the structure. Third, in the oxidation barrier model, APE1 may stabilize the reduced state, 
preventing the oxidation, via formation of hydrogen bond with thiol groups69. The 
detailed molecular steps for the activation of the transcription factors by APE1 remain to 
be largely investigated. Up to now, however, none of APE1 cysteine has been found in a 
C-X-X-C motif, common to most redox regulatory factors, such as thioredoxin (Trx), 
which is implicated in the redox APE1 cascade restoring APE1 in a reduced form31,70. 
Several evidences propose Cys65 as the redox-active site for APE140,44; however, 3-
dimensional structure demonstrates that none of the APE1 cysteine residues are located in 
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a right position and distance for forming a disulfide bond with Cys65, a prerequisite for 
resolving activity of redox factors. Moreover, both Cys65 and Cys93, residues identified 
as responsible the redox regulation, are buried within the APE1 structure, being surface 
inaccesible, whose activities may be influenced by partial APE1 unfolding43. Recently, 
Georgiadis and coworkers have proposed a new model based on current knowledge, 
suggesting that APE1 is a unique redox factor with properties distinct from those of other 
redox factors. In this model, (i) Cys65 acts as nucleophile for the reduction of the 
disulfide bond in the target factor, (ii) Cys93 operates as resolving residue and (iii) APE1 
undergoes a significant partial unfolding to expose a third cysteine residue, probably 
Cys99, to facilitate the redox reaction43. Further works are needed to delineate the precise 
molecular mechanism of the reaction. 
Figure 7: APE1 redox chaperone activity. Schematic representation of APE1 redox chaperone activity. 
Cysteine residues, located within the DNA binding domain or regulatory domain of transcription factors, 
are maintained in a reduced state by APE1, involved in a redox cycle with reducing molecules as Trx. The 
detailed mechanism by which APE1 control via redox the activity of the transcription factors needs further 
experiments. (Image from Tell G. et al., Cell Mol Life Sci, 2010) 
1.3.3.3 RNA CLEAVAGE 
As its bacterial counterpart, human APE1 possesses, even if at a lesser extent (~400 fold 
lower activity), RNase H activity71. Although Hickson and colleagues showed any 
general nuclease activity towards single- or double-stranded RNA, they found that with 
low affinity APE1 could bind, through Asp219, to intact single- and double-stranded 
nuclei acid substrates and that the presence of an abasic site did not modify the strength of 
these interactions71. Although RNA is oxidized to a greater extent than cellular DNA due 
to its intrinsic nature and to its relatively higher amount72, up to now how cells cope with 
damaged RNA is still uncertain. What is clear is that such damaged RNA can impair 
protein synthesis, affecting cell function and viability. The existence of surveillance 
mechanism for RNA has been put forward from the identification of the biochemical 
activities of the mammalian homolog of AlkB (hABH3) against alkylated RNA72, but a 
possible mechanism for oxidized RNA has not been found yet. The recent and 
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independent findings of Vascotto et al., Barnes et al. and Berquist et al. have indicated a 
direct role for APE1 in RNA metabolic pathways18-20. Recent work has found that APE1 
can cleave abasic single-stranded RNA molecules, depending on their molecule 
conformation, possibly participating in a RNA quality control mechanism18,19. Notably, 
beside the direct binding between APE1 and RNA molecules, a growing body of 
evidences demonstrates that APE1 is able to interact with a variety of protein involved in 
RNA metabolism, as YB173 and hnRNP-L74, suggesting a role for APE1 in RNA 
metabolism. The ability to cleave AP site-containing RNA indicates that APE1 could 
remove damaged RNA from the endogenous pool, being a perfect candidate for a novel 
RNA cleansing mechanism19. Notably, APE1 knock-down leads to an impaired 8-
hydroxyguanine containing rRNA removal, affecting cell growth and gene expression by 
directly acting on RNA quality control mechanisms18. Another way by which APE1 
affects gene expression has been recently described by Lee and colleagues; they identified 
APE1 as endonuclease involved in the cleavage of the coding region determinant (CRD) 
of the c-myc mRNA, resulting in a impaired transcript turnover through mRNA decay20. 
Further analysis based on structure-function comparison reveals that APE1 reuses most of 
the active sites residues (i.e. Glu96 and His309), excluding Asp283, used for its AP-DNA 
cleavage to promote RNA incision, requiring a 2’-hydroxyl group on sugar moiety for the 
catalysis and generating a 3’-phosphate terminus75.  
Altogether, all these data support a direct APE1 involvement, previously unknown, in 
RNA metabolism; additional studies are needed to test the biological role for its RNA 
cleavage function in vivo and to determine its contribute to mRNA turnover, analyzing 
the enzyme specificity for particular mRNA or if its RNA substrates might be other types 
of RNA, affecting a broad variety of cellular functions. 
1.3.3.4 TRANS-ACTING MODULATION 
In addition to its function as redox regulator of several transcription factors, APE1 has 
been identified as a component of a trans-acting complex that bind to negative Ca2+ 
response element (nCaREs, type A and B), modulating gene expression. These elements 
were first identified in the promoter region of the human parathyroid (PTH) gene and 
only later in the APE1 promoter itself22,76. In particular, the mobilization of Ca2+ from the 
storage tissues leads to an increased APE1 protein level with a consequent augmented 
assembly in trans-activating complex to nCaREs of the PTH gene, promoting a gene 
suppression and activating a negative feedback mechanism22. The presence of nCaREs in 
APE1 promoter indicates that APE1 could suppress its own gene transcription in a 
negative feedback loop, representing the first example of such self-regulatory mechanism 
for a DNA repair enzyme74. Evidences that APE1 is not able to directly bind to nCaREs 
suggest the requirement of additional factors for a cooperative binding, later identified in 
the two subunits of the Ku antigen, p70 and p8077, and hnRNP-L protein74. Moreover, the 
complex formation of APE1 with the promoter elements is controlled by the acetylation 
status of two lysine residues (Lys6 and Lys7): an increase of extracellular calcium 
concentration induces p300-dependent APE1 acetylation, resulting in increased APE1 
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binding to nCaREs25. Specific post-translational modifications as acetylation may act as a 
switch to redirect the protein towards a specific function and interaction. Recent 
bioinformatic analyses, looking for other human genes regulated by APE1 through 
nCaREs binding, identified 57 new gene, broadening the spectrum of genes APE1 could 
control. Among these, the sirtuin-1 deacetylase (SIRT1), involved in cell stress responses 
and in the deacetylation of APE1 after genotoxic stress78, has been studied; in particular 
APE1 stably binds through its N-terminus the two nCaREs located within the SIRT1 
promoter in a complex including hOGG1, Ku70 and RNA Polymerase II recruited during 
early oxidative stress response, providing new insights into the role of nCaRE and APE1 
in the transcriptional regulation79. Further work are needed to better determine if APE1 
has a broader role in controlling gene expression via nCaREs or other promoter 
sequences. 
1.3.4 MODULATION OF APE1 SEVERAL FUNCTIONS 
As multifunctional protein, APE1 could play a critical role in determing the cell fate 
participating in several cellular mechanisms. For this reason, a fine-tuning of its functions 
is needed. There are several ways by which cells modulate the activity of a protein, 
redirecting it towards a specific biological function. Generally regulation can be 
accomplished at five possible levels, resulting summarizied in:  
i. Transcriptional regulation of a gene;
ii. Post-transcriptional modulation refers to all the mechanism of maturation,
trafficking and degradation controlling the fate of mRNA. For APE1, no examples
of editing or alternative splicing have been reported;
iii. Post-translational modifications such as phosphorylation, acetylation and
proteolysis, a rapid and reversible covalent chemical modification for regulating
protein functions directly on the final protein product, switching on or off specific
protein’s activities;
iv. Changes in macromolecule associations establishing a different interactome
network may address a protein towards another specific function. These protein
assemblies contain highly coordinated moving parts, and within each protein
assembly, all reactions are carried out one after the other in a very precise and
coordinated way, so that reactions can usually proceed only in one direction80;
v. Intra cellular trafficking in compartments other than the nucleus (i.e. cytoplasm
and mitochondria), enhancing or reducing some protein activity, masking its
natural substrate due to compartimental sequestration.
In the next paragraphs, the main APE1 regulatory mechanisms will be briefly described. 
1.3.4.1 TRANSCRIPTIONAL REGULATION OF APE1 GENE 
As already mentioned in “APE1 gene” paragraph, several potential recognition sites for 
different factors (Sp-1, USF, CREB, ATF and AP-1) have been revealed by in silico 
analyses16, even if two independent works demonstrate any effect for AP-1 binding site 
25 | P a g e
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
INTRODUCTION 
on gene transcription81,82. Later on, Demple and colleagues demonstrated a strong 
correlation between APE1 transcription and cell cycle progression; in particular, the 
APE1 mRNA levels rise after the G1-S transition with a pick (~ 4 fold) in early to mid-S 
phase due to Sp1-2 dependent transcriptional activation in response to cell growth and not 
increased mRNA stability83. Afterwards, although no putative p53 binding sites have 
been retrivied by in silico analyses, a p53 binding element has been located upstream the 
transcription start site, close to the CCAAT box, since a p53-dependent downregulation 
of APE1 mRNA level has been suggested by Bhakat and coworkers84. The authors 
hypothesized that p53 might be indirectly recruited to APE1 promoter through a physical 
interaction with Sp1 bound to Sp1-1 element, inhibiting the basal APE1 gene 
transcription84. These data suggest a stimulating hypothesis about an inversal relationship 
between nuclear p53, as pro-apoptotic factor, and APE1 level, as pro-survival protein. 
Notably, in tumors p53 downregulation, due to gene mutations, corresponds to augmented 
APE1 expression, mechanism that could be at the basis of tumor chemotherapy 
resistence84. 
Besides the regulation of APE1 gene transcription under basal conditions, several reports 
are available in literature concerning mechanisms of inducible activation of APE1 gene, 
such as following stimulation with hormones (i.e. TSH)85 and subtoxic doses of ROS86-88. 
Although the molecular mechanisms of ROS-induced transcriptional activation are not 
still detailed, some authors successfully associate CREB89 and Egr-190 factors, already 
implicated in activation of ROS-responsive genes, in APE1 activation, with a recognition 
site for both the factors upstream the APE1 transcription start site. Future studies will 
better determine the range of this type of regulation.  
Finally, APE1 gene contains also negative regulatory sequence upstream the transcription 
start site, the nCaREs sequences, one of type A and two of type B. As already hinted at 
first, deletion of nCaRE-A sequence does not suppress the expression of a reporter gene, 
suggesting that this element appears dispensable for APE1 regulation. Conversely, the 
deletion of nCaRE-B2 sequence strongly influnces the negative regulation of a reporter 
gene76. Moreover, APE1 stably binds nCaRE-B2 sequences forming complexes. Overall, 
these data indicate the existence of a possible negative loop by which APE1, bound to this 
element, could inhibit its own expression.  
1.3.4.2 POST-TRANSCRIPTIONAL MODIFICATIONS 
Post-translational modifications are covalent chemical modifications occurring on 
proteins and represent a rapid and reversible mechanism to modulate their activities 
within the cellular environment. Regarding APE1, the knowledge of post-translational 
modifications affecting and coordinating its functions has exponentially grown in the last 
years. Up to now, six different types of post-translational modifications (acetylation, 
phosphorylation, ubiquitination, S-nitrosation, proteolysis and redox regulation) occurring 
in vivo have been described and might explain the mechanisms and the stimuli involved 
in switching on and off specific activities of the protein. 
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In Figure 8, several of the post-translational modifications occurring on APE1 in vivo are 
depicted. Major details for APE1 PTMs will be discussed throughout. 
Figure 8: APE1 post-translational modifications. Schematic linear representation of the key post-
translational modification acceptor sites on human APE1. The sites of acetylation, S-nitrosylation, 
phosphorylation, ubiquitination and proteolysis have been precisely mapped on APE1 sequence. The 
nuclease domain spans roughly from residues 64 to 318, with some over-lap with the N-terminus, dedicated 
to the redox regulatory function. Key active site residues for the nuclease activities of APE1 (Glu96, 
Asp210 and His309) are highlighted. NLS, nuclear localization signal; NES, nuclear export signal; MTS, 
mitochondrial targeting sequence. (Adapted image from Li M. and Wilson, D. M. 3rd, Antioxid Redox 
Signal, 2013) 
1.3.4.2.1 ACETYLATION 
To date, APE1 acetylation is the most studied post-translational modification for this 
multifunctional protein. Despite the elevated number of lysine residues, twenty-nine 
along all its sequence, only lysines 6 and 7 have been identified as target of acetylation by 
the histone acetyl transferase p300 both in vitro and in vivo25. The authors demonstrate 
that acetylation at these residues enhance binding of APE1-histone deacetylases (HDAC) 
complex to the nCaRE sequences within the parathyroid hormone (PTH) promoter, 
suggesting an important role for APE1 transcriptional regulatory function25. Recent data 
from our group and from Irani and colleagues show that other stimuli, as oxidative or 
genotoxic stresses, different from extracellular calcium level that was demonstrated to 
stimulate p30025, are capable to induce APE1 acetylation at early times78,91. Notably, few 
years later, Tell and coworkers demonstrate that four lysine residues (Lys27, 31, 32 and 
35), located within the N-terminus of the protein, crucial for APE1 interaction with rRNA 
and NPM1 and for controlling its catalytic activity on abasic DNA, are acetylated in 
vivo23. Moreover, as discussed in the Results paragraph of this work of Thesis, we show 
that APE1 acetylation at Lys27-35 is induced by genotoxic stress and influences the 
APE1 subnuclear distribution92. 
In spite of the identification of p300 as the main histone acetyl transferase responsible for 
APE1 acetylation in vivo, scanty information regarding the deacetylation process are 
available. In the paper of Mitra and coworkers, the authors suggest the involvement of a 
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class I HDAC enzyme25. More recently, Irani et al. show that Sirtuin 1 (SIRT1), the 
closest mammalian ortholog of yeast Silent Information Regulator 2 (Sir2) and 
component of a class III HDAC, may deacetylate APE1 at Lys6 and 7 both in vitro and in 
vivo, shutting down, in a feedback mechanism, the cellular response mediated by APE1 
acetylation78. In fact, in concomitance with APE1 acetylation at Lys6 and 7 induced by 
genotoxic stress, SIRT1 expression level increases. Activation of SIRT1 promotes an 
augmented APE1-XRCC1 complex formation suggesting that SIRT1 plays an important 
role in maintaining genome stability78. Taken together, different groups raise the 
hypothesis that after genotoxic stress, p300 activity prevails over SIRT1, leading to 
increased APE1 acetylation. Later, probably when the lesions are completely removed, 
SIRT1 activity, prevailing over p300 one, restore the basal APE1 acetylation levels. 
Intriguingly, SIRT1 promoter contains two nCaRE sequences, stably bound by APE1 
through its N-terminus. APE1 forms a complex with the glycosylase OGG1, Ku70 and 
RNA polymerase II is recruited on SIRT1 promoter for promoting gene transcription 
under genotoxic stresses, suggesting for the first time a positive role for APE1 
transcriptional regulatory activity79. However further evidences are required to confirm 
this feedback loop mechanism; moreover, the identification of the acetyl transferase 
involved in APE1 acetylation at Lys27-35 has still to be addressed.  
1.3.4.2.2 NITROSYLATION 
Nitric oxide (NO) is a highly reactive free radical, that plays a crucial role in different 
signaling pathways, both cGMP-dependent and independent, the latter involving S-
nitrosation93,94. S-nitrosation is a ubiquitous redox-related modification of cysteine thiols 
by nitric oxide and has been implicated in multiple cellular activities as regulation of gene 
transcription95, protein nuclear translocation96 and enzyme activity97. APE1 contains three 
redox-sensitive cysteine residues; two of these sites (Cys93 and Cys310) may undergo S-
nitrosation after nitric oxide stimulus and are responsible for APE1 reversible shuttling 
from nucleus to cytoplasm in a non canonical CRM1-independent manner98. In addition, 
the authors show that under nitric oxide condition, importin-mediated nuclear import 
systems were repressed, mechanism which may prevent cytosolic APE1 from re-entering 
into the nucleus98. The effect of APE1 nuclear export may negatively reflect on its 
endonuclease and redox regulatory activities, connecting APE1 to nitric oxide 
physiological and pathological processes, as recently demonstrated for non-small cell 
lung cancer (NSCLC)99,100. It remains to elucidate which stimuli and signaling pathways 
could be associated with nitric oxide production within cells and APE1 cytoplasmic 
relocalization. 
1.3.4.2.3 PHOSPHORYLATION 
Several putative phosphorylation sites, located in both the nuclease and the redox 
regulatory APE1 domains, have been identified in vitro for a broad range of kinases, as 
Casein Kinase 1 and 2 (CK-I and CK-II), Glycogen Synthase Kinase 3 (GSK-III) and 
Protein Kinase C (PKC). Phosphorylation may occur on serine/threonine residues86 and 
28 | P a g e
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
INTRODUCTION 
might be responsible in controlling macromolecule (protein-protein and protein-DNA) 
associations involved in redox regulation and in DNA repair101. Early works demonstrate 
that although in vitro phosphorylation by CK-I and PKC has no effect on APE1 
endonuclease activity, CK-II dependent phosphorylation at residues Thr19, Ser123, or 
Thr233 strongly abolished the DNA repair activity102. An in vivo phosphorylation CK-II 
mediated has been also suggested even if never experimentally demonstrated103. In 
addition, the usage of specific CK-II inhibitors in vivo did not confirm in vitro results. 
Despite its ineffectiveness on nuclease activity, PKC-dependent phosphorylation might be 
involved in an augmented APE1 redox activity, hypothesis supported by in vitro and in 
vivo studies, since it has been found to increase in vitro binding of c-Fos and c-Jun to AP-
1 binding elements. Moreover, according with these data, following oxidative stress, a 
stimulus known to induce PKC, in vivo studies have shown that APE1 phosphorylation 
level increased, stimulating its redox activity, though the phosphorylation target site has 
not been identified yet101. Up to date, the biological relevance of these findings has not 
been established.  
More recently, in agreement with a previous study102, Park and colleagues found that 
APE1 was phosphorylated at Thr233 in vivo by threonine kinase CDK5, a paralog of 
CDK2/4, resulting in reduced endonuclease capability. CDK5 is expressed in neurons and 
is speculated to be involved in cell death triggered by uncontrolled DNA damage 
replication. High levels of APE1 phosphorylated at Thr233 was observed in post-mortem 
brain samples from Alzheimer’s and Parkinson’s patients. The APE1 inactivation due to 
CDK5 mediated phosphorylation and consequent accumulation of DNA damage 
contributes to neuronal death, profoundly affecting the severity of the diseases104. Up to 
now, it is not clear if the phenotype observed might be associated with the solely 
endonuclease activity or if other functions might be responsible for it. Further works are 
needed to understand the molecular mechanism of APE1 funtions in neuronal death and 
its role in neurodegenerative diseases. 
1.3.4.2.4 UBIQUITINATION 
The conjugation of ubiquitin, an evolutionary conserved small protein of seventy-six 
residues, to other cellular proteins regulates a broad range of eukaryotic cell functions. An 
E3 enzyme catalyzes the formation of an isopeptide bond between the substrate (or 
ubiquitin) and ubiquitin, tagging and targeting it to the proteasome when poly-
ubiquitinated105. The destruction of proteins is as important as their synthesis for cellular 
homeostasis. Other functions, not involving the proteasomal system, have been 
discovered. Mono-ubiquitination, in fact, could act at different level altering protein 
function or localization106. For the first time in 2009, Izumi and colleagues show that both 
in vitro and in vivo the E3 ligase MDM2 (murine double minute 2), a negative regulator 
of p53, ubiquitinate APE1 at one of these Lys residues (24, 25 or 27)24. Moreover, 
oxidative conditions can induce MDM2-mediated ubiquitination of APE1. For the 
authors, the mono-ubiquitination of APE1 may induce a cytoplasmic translocation24, data 
in contrast with several papers in literacture affirming a role for oxidative stress to induce 
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a net APE1 movement toward the nuclear compartment. Two years later, the same group 
gave further insights in the APE1 ubiquitination process, reporting an interesting cross-
talk between ubiquitination and phosphorylation of APE1 at Thr23326. In particular, 
phosphorylation of APE1 may induce MDM2 activity, leading to augmented 
ubiquitination of APE1. The mono-ubiquitinated form, in contrast with the previous 
work, localized in the nucleus26. Moreover, a recent paper of Dianov’s group identified, 
through in vitro ubiquitination studies, UBR3 as the main enzyme that poly-ubiquitinated 
APE1 at multiple targets within the N-terminal domain, proposing an important role for 
UBR3 in the control of the steady state levels of APE1107. Up to now, no information are 
available about the kinetic of APE1 ubiquitination upon oxidative stress; further work has 
to be done to better clarify the occurrence of ubiquitination in vivo. 
1.3.4.2.5 PROTEOLYTIC CLEAVAGE 
A truncated form of APE1 lacking its first N-terminal 33 or 35 amino acids, lately named 
APE1 N∆33, was first identified by Pommier et al., who isolated a 34 kDa, Mg2+-
dependent endonuclease from apoptotic human promyelocytic leukemia HL-60 cell line, 
characterized for its ability to incise DNA generating single strand breaks108. Only few 
years later, the same authors demonstrated that this enzyme was a truncated form of 
APE1, resulting from a cleavage at its N-terminus by an unidentified trypsin-like enzyme, 
activated during caspase-3 apoptotic process109. An independent study conducted by 
Lieberman’s group involved APE1 in granzyme-induced caspase-independent cell death, 
characterizing APE1 as a component of the SET complex, an endoplasmic reticulum 
(ER)-associated DNA repair complex recruited to the nucleus in response to oxidative 
stress. Within the SET complex, APE1 is targeted by a highly homologous serine 
protease, contained in cytotoxic granules of innate and adaptive immune killer cells110, 
the granzyme A (GzmA). GzmA cleaves APE1 at Lys31 during cell-mediated death and 
this cleavage blocks APE1 binding to DNA and suppresses APE1 redox regulatory and its 
AP endonuclease activities111. Cells overexpressing a noncleavable form of APE1 result 
more resistant to GzmA-mediated cell death, supporting their hypothesis. The authors 
conjectured that cleaving the N-terminus of APE1, GzmA may block cellular repair, 
favouring the apoptotic process111. Few years later, another component of the granzyme 
family, granzyme K (GzmK), has been associated as responsible for APE1 cleavage at the 
N-terminus. GzmK is able to induce the formation of reactive oxygen species, 
accumulation that triggers a cell death program. In this light, since APE1 can antagonize 
reactive oxygen species, suppressing the cell death, APE1 cleavage by GzmK facilitates 
intracellular reactive oxygen species accumulation, enhancing the GzmK-induced cell 
death112. Notably, all the groups identified a role for the APE1 truncated form (APE1 
N∆33) in two different cell death pathways (caspase-dependent and GzmA/K-induced) as 
factor responsable for accumulation of single strand breaks on nuclear DNA. 
Nevertheless, previous evidences on APE1 deletion mutants show that the APE1 N∆33 
maintains both the AP endonuclease and redox functions and did not display any 
additional nuclease activity40. To date, further studies are needed to elucidated the 
mechanisms responsible for the APE1 N∆33 nuclear translocation, since the truncation 
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leads to the loss of the nuclear localization signal. Recently, APE1 N∆33 has been proved 
to localize in the cytoplasm of some cell types, within the mitochondria, where it may act 
as a specific AP endonuclease involved in mitochondrial BER pathway113. A 
mitochondrial targeting sequence has been recently discovered at the C-terminus of APE1 
(residues 289-318), which is normally masked by the intact N-terminal structure114. 
Although interesting, more recent observations contested the accumulation of the 
truncated form within mitochondria, showing that the prevalent form within mitochondria 
is the full length and suggesting a central role of Cys65 in redox-assisted folding of APE1 
and internalization in vivo115. 
In conclusion, the truncation of the N-terminal of APE1 has been associated with 
different cell death programs, being extremely interesting. This irreversible post-
translational modification may represent a regulatory switch for controlling APE1 
functions. Up to now, many unresolved question remain to be answered, regarding the 
identification of the proteases, the stimuli responsible for the generation of the truncated 
form and the effects of such modification on APE1 cellular translocation. 
1.3.4.3 APE1 INTERACTOME NETWORK 
Biological processes encompass a concerted action of multi-protein molecular 
machineries rather then subsequent isolated enzymatic steps. Understanding the network 
in which a protein operates may better elucidate its role and the process involved. 
However, so far information about interactome of APE1 was very limited, especially 
because sensitivity of available techniques was still quite poor. Our group, by using a 
inducible cell model based on HeLa cells, in which endogenous APE1 is replaced by an 
ectopic FLAG-tagged form, has recently identify the APE1 interactome network under 
basal condition and characterized the role of the first 33 N-terminal residues in 
stabilization of this interacting network18. Unexpectedly, most of the new APE1 
interacting partners are involved in ribosome biogenesis and RNA processing as NPM1, 
PRP19 and YB1. During this analysis, what emerged was that the APE1 33 N-terminus is 
required for a stable interaction with the majority of APE1 binding partners, including 
NPM1 and RNA. NPM1 stimulates APE1 endonuclease activity on abasic double-
stranded DNA, decreasing its activity on abasic single-stranded RNA by masking the N-
terminus, required for a stable association with the nucleic acid. Moreover, APE1 
silencing does not alter pre-rRNA synthesis and rRNA processing, but affects the total 
capability of the cell to deal with RNA oxidation; thus suggesting that genotoxic stress 
may reduce NPM1 affinity for APE1, allowing it to act as a cleansing factor on abasic 
RNA. In Table 1 all the APE1 interacting partners retrived in literature are listed. It is 
possible clusterized APE1 binding partners in different groups concerning their main 
fuction or pathway in which they are involved. 
 Group 1. Enzymes involved in DNA repair pathways, in particular base excision
repair (e.g. XRCC1, PCNA, FEN1 and Polβ) and double-strand break repair
(Ku70 and PRP19) pathways;
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 Group 2. Proteins responsible for recognizing damaged nucleic acids (both DNA
and RNA molecules), such as OGG1, hS3 and YB1;
 Group 3. Proteins involved in redox or redox-chaperone activities of APE1 (i.e.
Trx, PRDX6);
 Group 4. Proteins target of APE1-mediated redox regulation, comprising several
transcription factors that physically bind APE1 as p53 and ERα;
 Group 5. Enzymes that account for APE1 post-translational modifications like
MDM2, CDK5, SIRT1 and p300;
 Group 6. Proteins involved in RNA metabolism as YB1 and hS3, that are included
also in other groups. Within the same group we could find factors involved in
rRNA metabolism or in ribosome biogenesis (NPM1 and RLA0), in pre-mRNA
maturation or splicing (hnRNP-L and PRP19) and enzymes operating in general
ribonucleotides metabolism and synthesis pathways (PRPS1 and PRPS2);
 Group 7. Proteins involved in signal transduction and cytoskeleton remodeling,
like K2C8, TWF2 and CAPSN1;
 Group 8. Proteins responsible for cell cycle progression and control as TCEB1,
POLR3D and TERF1/2.
All these interacting networks that encompass diversified cellular pathways, among 
which the newly discovered RNA metabolism, suggest an important role for APE1 as 
central hub within cells.  
Table 1: APE1 binding partners 
Protein Function References 
Ku Antigen (p70 and p80) Double-strand breaks repair of DNA [77] 
Pol β Polymerase in base excision repair of DNA [62] 
p53 
Tumor suppressor protein that  responds to diverse 
cellular stresses to regulate expression of target 
genes, inducing cell cycle arrest, apoptosis, 
senescence, DNA repair, or changes in metabolism 
[116] 
Thioredoxin (Trx) 
Cytoplasmic redox-sensitive signaling factor, that 
facilitates protein–nucleic acid 
interactions 
[117] 
FEN1 Base excision repair of DNA [118] 
PCNA Base excision repair of DNA [118] 
hMYH Glycosylase in base excision repair of DNA [119] 
XRCC1 Base excision repair of DNA [61] 
hnRNP-L 
pre-mRNA splicing, involved in regulating 
chromatin modification 
[74] 
HDACs 
Histone deacetylases, involved in transcriptional 
gene repression 
[25] 
SET 
Associated with the endoplasmic reticulum (ER), 
involved in the nuclear single-stranded DNA 
nicking in GzmA induced apoptosis 
[111] 
MDM2 E3 ubiquitin ligase for p53 [24] 
GzmA 
Released by T- and NK- cells; induces a caspase-
independent cell death pathway with 
[111] 
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Protein Function References 
morphological features of apoptosis 
HMG2 
Involved in facilitating cooperative interactions 
between cis-acting proteins by promoting DNA 
flexibility and in DNA end-joining processes of 
DNA double-strand breaks repair and V(D)J 
recombination 
[111] 
NM23-H1 
Involved in cell proliferation, differentiation and 
development, signal transduction, G protein-coupled 
receptor endocytosis, and gene expression 
[111] 
GzmK 
Protects the host by lysing cells bearing on their 
surface 'nonself' antigens, usually peptides or 
proteins resulting from infection by intracellular 
pathogens 
[112] 
MPG 
Methylpurine glycosylase, involved in base 
excision DNA repair 
[120] 
hS3 Binds to 8-oxoG residues on DNA [121] 
OGG1 
DNA glycosylase involved in base excision DNA 
repair 
[60] 
Rad9/Rad1/Hus1 
DNA damage sensing and signaling pathways; 
the complex plays also a direct role in various 
DNA repair processes 
[122] 
YB1 
It may bind Y-box elements on DNA; it is involved 
in DNA repair pathways; it may bind ssDNA, and 
RNA molecules as well; it protects mRNA against 
degradation; it binds to 8-oxo-G containing RNAs 
[73] 
SIRT1 
Class III histone deacetylase; it is a stress response 
and chromatin-silencing factor, involved in various 
nuclear events such as transcription, DNA 
replication, and DNA repair 
[78] 
ERα 
Transcription factor; hormonal ligand, 17β-estradiol 
facilitates the interaction of the receptor with 
estrogen-response elements (EREs) on DNA 
[123,124] 
NPM1 
Hub protein within nucleolus: it may organize and 
interact with many other nucleolar proteins; 
involved in ribosomal protein assembly and 
transport; involved in control of centrosome 
duplication, and in the 
regulation of the tumor suppressor ARF 
[18] 
TCP1-alpha 
Molecular chaperone that is a member of the 
chaperonin containing TCP1 complex (CCT) 
[18] 
KRT8 Keratin, type II; part of the cytoskeleton [18] 
PRP19 
DNA double-strand break (DSB) repair and 
premRNA 
splicing 
[18] 
RSSA Belongs to the ribosomal protein S2P family [18] 
MEP50 
Component of the 20S PRMT5-containing 
methyltransferase complex, which modifies specific 
arginines to dimethylarginines in several 
spliceosomal Sm proteins 
[18] 
RLA0 
Acidic ribosomal protein, rich in hydrophobic 
amino acid residues 
[18] 
PRPS1 and PRPS2 Phosphoribosylpyrophosphate synthetase 1 and 2 [18] 
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PRDX6 
Redox regulation of several biological processes 
and in protection under oxidative injuries 
[18] 
TDG 
Thymine-DNA glycosylase in base excision DNA 
repair 
[125] 
DNA Lig I 
Function in DNA replication, recombination, and 
the base excision repair process 
[126] 
TCEB1 
Activates elongation by RNA polymerase II by 
suppressing transient pausing of the polymerase at 
many sites within transcription units 
[127] 
TXNRD1 
Reduces thioredoxins and plays a role in selenium 
metabolism and protection against oxidative stress. 
[127] 
TWF2 
Actin-binding protein involved in motile and 
morphological processes 
[127] 
AID 
The ability of activation-induced cytidine deaminase 
(AID) to efficiently mediate class-switch 
recombination (CSR) 
[128] 
ANP32A and ANP32C 
Tumor suppressor pp32 that can inhibit several 
types of cancers 
[111] 
RNF4 
Inhibit the activity of TRPS1, a transcription 
suppressor of GATA-mediated transcription 
[129] 
TRAF2 
Required for TNF-alpha-mediated activation of 
MAPK8/JNK and NF-kappaB and functions as a 
mediator of the anti-apoptotic signals 
[130] 
STAT3 
Mediates the expression of a variety of genes in 
response to cell stimuli, and plays a key role in 
many cellular processes such as cell growth and 
apoptosis. The small GTPase Rac1 has been shown 
to bind and regulate the activity of this protein 
[131] 
p300 
Histone acetyltransferase that regulates transcription 
via chromatin remodeling 
[25,132] 
ARIH2 
E3 ubiquitin-protein ligase mediating 'Lys-48'-and 
'Lys-63'-linked polyubiquitination and subsequent 
proteasomal degradation of modified proteins 
[127] 
CCDC124 
Required for proper progression of late cytokinetic 
stages 
[127] 
hnRNP-K 
Associated with pre-mRNAs in the nucleus and 
appear to influence pre-mRNA processing and other 
aspects of mRNA metabolism and transport. It binds 
tenaciously to poly(C). This protein is also thought 
to have a role during cell cycle progession 
[127] 
PABP1 
Binds to the 3' poly(A) tail of eukaryotic messenger 
RNAs via RNA-recognition motifs, promoting 
ribosome recruitment and translation initiation; it is 
also required for poly(A) shortening which is the 
first step in mRNA decay 
[127] 
GAL1 
Beta-galactoside-binding proteins implicated in 
modulating cell-cell and cell-matrix interactions 
[127] 
CAPNS1 
Calcium-dependent, cysteine proteases. It has been 
implicated in neurodegenerative processes, as their 
activation can be triggered by calcium influx and 
oxidative stress 
[127] 
NAE1 Binds to the beta-amyloid precursor protein and [127] 
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Protein Function References 
plays a role in the pathogenesis of Alzheimer's 
disease. In addition, it can activate NEDD8, a 
ubiquitin-like protein. This protein is required for 
cell cycle progression through the S/M checkpoint 
RIC8A 
Involved in regulation of microtubule pulling forces 
during mitotic movement of chromosomes 
[127] 
hnRNP-UL1 
Binds specifically to adenovirus E1B-55kDa 
oncoprotein. It may play an important role in 
nucleocytoplasmic RNA transport 
[127] 
SK2 
Bifunctional enzyme with both ATP sulfurylase and 
APS kinase activity, which mediates two steps in the 
sulfate activation pathway 
[127] 
PSMG1 
Chaperone protein which promotes assembly of the 
20S proteasome as part of a heterodimer with 
PSMG2 
[127] 
XPOT 
Mediates export of tRNA from the nucleus to the 
cytoplasm 
[127] 
Cdk5 
Proline-directed serine/threonine-protein kinase 
essential for neuronal cell cycle arrest and 
differentiation 
[104] 
SUMO1 and SUMO2 
Binds to target proteins as a post-translational 
modification system and is involved in a variety of 
cellular processes, such as nuclear transport, 
transcriptional regulation, apoptosis, and protein 
stability 
[133,134] 
Ubiquitin C 
It has been associated with protein degradation, 
DNA repair, cell cycle regulation, kinase 
modification, endocytosis, and regulation of other 
cell signaling pathways 
[135] 
HIF-1 alpha 
Master regulator of cellular and systemic 
homeostatic response to hypoxia by activating 
transcription of many genes 
[136] 
NUDT3 
Nudix proteins act as homeostatic checkpoints at 
important stages in nucleoside phosphate metabolic 
pathways, guarding against elevated levels of 
potentially dangerous intermediates, like 8-oxo-
dGTP, which promotes AT-to-CG transversions 
[137] 
Ubc9 
Ubiquitin-conjugating enzyme; involved in 
the protein degradation of Ref-1 [138] 
APP 
Bind to the acetyltransferase complex 
APBB1/TIP60 to promote transcriptional activation 
[139] 
ASCL2 
Member of the basic helix-loop-helix (BHLH) 
family of transcription factors. It activates 
transcription by binding to the E box. Involved in 
the determination of the neuronal precursors in the 
peripheral nervous system and the central nervous 
system 
[132] 
HOX3 
Important role in morphogenesis in all multicellular 
organism 
[140] 
POLR3D 
It leads to a block in progression through the G1 
phase of the cell cycle at nonpermissive 
temperatures 
[140] 
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TCF21 
Transcription factor of the basic helix-loop-helix 
family. The TCF21 product is mesoderm specific 
[140] 
TRF1 and TRF2 
Function as inhibitors of telomerase, acting in cis to 
limit the elongation of individual chromosome ends 
[141] 
TERF21P Complex involved in telomere length regulation [141] 
SMD1 
Act as a charged protein scaffold to promote 
SNRNP 
[142] 
SFPQ 
DNA- and RNA binding protein, involved in several 
nuclear processes and in regulation of signal-
induced alternative splicing 
[142] 
Rev Involved in the late phase of virus replication [143] 
AP-4 
Activates both viral and cellular genes by binding to 
the symmetrical DNA sequence CAGCTG 
[144] 
HHV8GK18_gp81 Maintenance of episomal genome [145] 
CKII 
Casein kinase II is a serine/threonine protein kinase 
that phosphorylates acidic proteins 
[103] 
p21 
Regulator of cell cycle progression at G1; regulatory 
role in S phase DNA replication and DNA damage 
repair 
[146] 
Hsp70-1 
Stabilizes existing proteins against aggregation and 
mediates the folding of newly translated proteins in 
the cytosol and in organelles. It is also involved in 
the ubiquitin-proteasome pathway 
[147,148] 
HMGA-1 
Non-histone protein involved in many cellular 
processes, including regulation of inducible gene 
transcription 
[149] 
HMGA-2 
Architectural factors and essential component of the 
enhancesome. It may act as a transcriptional 
regulating factor. 
[149] 
SRPK1 and SRPK2 
Protein kinase that plays a role in regulation of both 
constitutive and alternative splicing by regulating 
intracellular localization of splicing factors 
[150] 
1.3.4.4 INTRA-CELLULAR TRAFFICKING AND SUBCELLULAR
LOCALIZATION
Alteration of subcellular localization of a protein may represent an important way to 
control its functions. For a multifunctional protein that exerts both nuclear and 
extranuclear function, it could be important to elucidate the molecular mechanisms 
involved in APE1 translocation within the different cellular districts. As main AP 
endonuclease enzyme and regulatory protein acting on several cancer-related 
transcription factors, APE1 has long been recognized as nuclear protein. In the 2005, 
Izumi and colleagues identified the nuclear localization signal harbored within the APE1 
N-terminus: it consists in a bipartite signal within the first twenty amino acids (residues 2-
7, with a classic NLS, and residues 8-13, where two critical acidic amino acids, Glu12 
and Asp13, fall)151. Despite the nuclear targeting sequence, a large number of studies 
indicated that in some cell types, with elevated metabolic and proliferative rates, APE1 
may localized within mitochondria and endoplasmic reticulum16,152. Except for the 
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mitochondrial APE1, which biological significance is emerging, the role of the protein in 
the other districts and its clinical significance are not fully understood yet.  
Stimuli as oxidative stress and other signaling molecules such as TSH or calcium have 
been shown to trigger APE1 nuclear translocation86,87. Moreover, as already mentioned in 
the previous paragragh, APE1 is targeted by different proteases forming a truncated form, 
named APE1 N∆33, that lacks both NLS sequences. Despite the deletion of the NLS 
sequences, APE1 N∆33 results not completely excluded from nuclei18, suggesting that 
additional mechanisms, not yet fully elucidated, may compensate for the absence of a 
classic NLS and regulate the subcellular distribution of APE1. Recently, beside the 
nuclear localization, Tell and coworkers show a strong nucleolar pattern for APE1, maybe 
through protein-protein and protein-nucleic acids interaction18. Intriguingly, other BER 
enzymes such as XRCC1 and FLAP1 endonuclease have been found to accumulate in this 
subnuclear district153, raising the question whether nucleolus acts as a storage site for 
DNA repair proteins or whether they carry out an active repair function within nucleoli, 
maintaining a proper ribosome biogenesis (Poletto et al., submitted to MBoC). 
APE1 cytoplasmic distribution has been demonstrated, raising the hypothesis that in some 
circumstances APE1 need to be sequestered from nuclei; but, the exact mechanism 
responsable for redirecting APE1 in this subcellular compartment remains to be clearly 
elucidated. Up to now, a classic nuclear export sequence (NES) has not been found yet. 
However, two recent papers identify a possible mechanisms for explaining the 
cytoplasmic translocation. Firstly, S-nitrosation at Cys93 and Cys310 has been 
demonstrated to redirect APE1 in the cytoplasm in a CRM1-dependent manner98; 
secondly, a mitochondrial targeting sequence has been retrived in the APE1 C-terminal 
domain (residues 289-318)114. Besides its extranulear role in controlling intracellular ROS 
production through modulation of Rac1-regulated NADPH oxidase154, APE1 localizes 
within mitochondria. Mitochondria are the main cellular source of ROS, resulting from 
the mitochondrial respiratory chain and oxidative phosphorylation. Given its proximity to 
the respiratory chain and its vulnerable status, contrarily from the nuclear genome, 
mitochondrial DNA (mtDNA) is continuously exposed to high levels of ROS. Thus, it has 
not been surprising the observation of different groups regarding the existence of a DNA 
base excision repair (mtBER) within mitochondria155-157. Along with the mtBER 
apparatus, also APE1 has been found in mitochondria. Although a first study 
hypothesized that the truncation of the N-terminal domain of the protein allows the 
protein to be imported in mitochondria113, a more recent paper shows that in different cell 
types APE1 full length is imported within mitochondria, possibly through a mechanism 
that involved a distinct machinery composed by Mia40 and Erv1 via an oxidation-driven 
process115,158. 
All togheter these data suggest that the subcellular APE1 distribution is very dynamic 
(Figure 9). However further studies are needed to elucidate the molecular mechanisms 
responsible for APE1 intracellular trafficking. 
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Figure 9: APE1 intracellular trafficking. APE1 subcellular distribution appears very dynamic. The main 
subcellular compartments where APE1 have been identified and its influence on cell physiology are 
highlighted. (Image from Scott T. L. et al., Antioxid Redox Signal, 2013) 
1.3.5 APE1 IN DISEASE 
As already mentioned, APE1 is a fundamental protein: deletion of both the alleles of 
Apex1, similarly to that of other core enzymes in BER pathway, leads to embryonic 
lethality in mice159 and triggers apoptosis in differentiated cells160, thus suggesting its 
biological and clinical relevance in normal and tumoral cells. Defects in its activities, 
although the exact contribution of each function to the deficiencies observed has not been 
discerned yet, has been linked to human pathologies, ranging from cancer to 
neurodegenerative diseases. Accumulation of oxidative stress and inefficient base 
excision DNA repair have been described as clinical feature of several degenerative 
disorders, including neurophatologies as Alzheimer disease (AD), Parkinson disease (PD) 
or amyotrophic lateral sclerosis (ALS)161,162. Several observations suggest a relationship 
between APE1 and cancer etiology. APE1 deficiences leads to augmented mutagenesis 
and carcinogen susceptibility; moreover, overexpression or dysregulation in terms of 
atypical subcellular localization, usually within cytoplasm, have been found in many 
cancers types, including prostate, pancreatic, ovarian, cervical and colon type31,163. What 
are the causes of the increased APE1 levels or of the subcellular distribution pattern 
observed in several cancer types are largely unknown; what is becoming clear and clearer 
are the consequences. In these tumors, an elevated nuclear level of APE1 correlates with 
aggressive proliferation, reduced sensitivity to chemotherapeutic agents and poor 
prognosis28. Additionally, in some tumors, APE1 is predominantly cytoplasmic. Since 
cancer cells present an high metabolic rate, producing elevated amounts of reactive 
oxygen species as result of the mitochondrial oxidative phosphorylation, an intriguing 
hypothesis concerning a possible role for APE1 in response to ROS for maintaining the 
mtDNA integrity has been put forward154. Elucidating the molecular mechanisms of an 
altered APE1 expression signifies a crucial step for a better treatment for specific cancer 
types. Nowadays, APE1 represents a predictive marker for sensitivity of the tumor toward 
radio- or chemotherapy and a promising target for pharmacological treatment. Even 
though efforts to determine the effects of inhibiting either the DNA repair or redox 
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regulatory functions are still ongoing and the extra-nuclear activities are not fully 
elucidated, several studies suggest that a consequence of the increase AP activity 
accompanying tumorigenesis might account for therapy resistance. Besides the genetic 
variants that have been correlated with repair capacity (see “Genetic variants” section), 
thus, APE1 inhibitors could be used alone or in combination with other chemotherapeutic 
agent such as bleomycin, temozolomide or gemcitabine to enhance the cytotoxic 
effects164. Few compounds were already reported as APE1 redox (soy isoflavones, 
resveratrol and E3330) and DNA repair (CRT0044876, lucanthone, methoxyamine, 
compound 3 and 52) inhibitors (for an exhaustive review of APE1 inhibitors, the reader is 
redirect to Abbotts R. and Madhusudan S., Cancer Treat Rev, 2010)163,165. Though for 
some of these, in particular for methoxyamine, an indirect APE1 inhibitor, the preclinical 
and clinical evidence is promising, for Abbotts and Madhusudan a direct targeting of 
APE1 may represent a better strategy163. Further studies are needed to identified new 
potent APE1 small molecule inhibitors, specific for one function of the protein, and to 
evaluate the side effects of combination therapies with APE1 inhibitors. In conclusion, 
APE1 biological relevance is reflected by its involvement in human pathologies and 
therapeutic approaches aimed to block a specific APE1 activity are very promising.  
1.3.5.1 GENETIC VARIANTS 
DNA repair capability differs among individuals. Estimates suggest that between 10-30% 
of the normal population may be “sensitive” to DNA injuries. This is a fact. But, which is 
the cause of this disparity? The answer to this question is still a matter of debate. Case-
control studies have drawn attention to the correlation between the risks of bladder, 
kidney, esophageal and lung cancer, and who exhibit higher levels of oxidative DNA 
damage166. For sure, with the improvement of sequencing techniques, investigators went 
one step further in the understanding the phenotypes observed within the population. The 
presence of single-nucleotide polymorphisms (SNPs) in regulatory regions of DNA repair 
genes might be responsible for impacting on phenotype, usually resulting in reduced 
DNA repair capacity167. In humans, defects in BER have been linked to cancer risk, 
immunological dysfunction and neurodegenerative disease166,168. Nonetheless, APE1 
deficiencies have not been clearly associated to disease initiation and progression31. Lack 
of core BER components as APE1, Polβ and XRCC1 leads to embryonic or post-natal 
lethality in mice169, probably correlated with elevated DNA damage accumulation 
resulting in aborted development170. Therefore, since complete homozygous knock-out of 
BER enzymes is incompatible with life, mild reduction in BER capability might be 
associated with disease risk and susceptibility. In the latest year, thanks to many re-
sequencing efforts, several genetic variants of APE1 (Figure 10) and other DNA repair 
genes, that potentially represent reduced-function alleles, have been identified within the 
normal and disease population31,166,167. Analysis of the current sequence associated with 
computational studies evidences that (i) rare mutations, with a frequency lower than 3%, 
account for more than 75% of the total and (ii) about one third of the genetic variants 
identified are predicted to be adversely impacting on structure and function166. In some 
instances, the SNP or the mutation identified alters coding sequence of the gene, resulting 
39 | P a g e
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
?????????????
??? ?? ????????????? ??? ??? ?????? ?????? ???? ??????????? ??????????? ???? ???? ???????????
??????????????????????????????????????????????????????????????????????????????????????????
????? ??????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????
?????????? ??? ?????? ???????? ???? ??????? ??? ???? ????????? ?????????? ??? ????????????????????
????????? ???? ???? ???? ??????? ???????????? ????????? ??? ???? ????? ????????????? ????? ??????
????????????????? ???????????????????????? ?????????????????????????????????????????????????
???????????????????? ??????????? ?? ????? ??????????????????????? ??? ???????? ???????????? ???
??????????????????????????????????????????????????????????????????????????????????????????????
???? ?????? ????? ??? ????????????? ????? ???????? ?????????? ????? ????????? ????? ???????????
????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????
?????? ?????????????? ??? ?????? ??? ????????? ???????????? ???????? ?????????? ??????? ???? ???
????????????????????????????????????????????????????????????????????????????????????????????
???????? ????? ?????????????? ???? ??????? ???????? ???? ???? ????? ?????? ????? ?????? ??
?????????????????????????????????????????????????????????????????????????????????????
?????????????? ????????????????????????????????????????????????????????????????
????? ????????
?????????? ?????????? ?????????????????????? ???????????
?????? ??????????????
??????????????????????????????
??????????????????? ???
?????????????????????
????????????????
????????????????????????
??????????????????????????
??????????
??????????????
?????????????????
??????
????????????????????
????????????????
???????????????????????
??????????????? ????????????
???????????????????????????
????????????????????
??????
40 | P a g e
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
INTRODUCTION 
APE1 missense 
variation 
Pathology Association/Frequency References 
D148E 
Amyotrophic lateral 
sclerosis (ALS) 
D148E may contribute to ALS 
etiology 
[178] 
D148E 
Amyotrophic lateral 
sclerosis (ALS) 
No association observed [179] 
D148E 
Parkinson’s disease 
(PD) 
Positive correlation with PD risk [180] 
D148E 
Alzheimer's disease 
(AD) 
No association with AD [181] 
P112L and R237C Endometrial tumor 
3/20 patients exhibit APE1 
polymorphisms. Role for these 
mutation for cancer 
developmental 
[182] 
Q51H and D148E 
Ovarian and 
endometrial cancer 
Authors found a frequency of 
4.8% for Q51H and of 56.2% 
for D148E 
[182] 
Q51H and D148E Prostate cancer 
In association with XRCC1 
variant, increased cancer risk in 
white men population. No 
association for black men 
[183] 
D148E Lung cancer 
Synergistic effect with tobacco 
carcinogen-induced lung cancer 
risk (gene-environment 
interaction) 
[184] 
D148E 
Cutaneous melanoma 
(CM) 
No association. significantly 
Observed a decreased risk of 
CM in D148E samples 
[185] 
D148E 
Squamous cell 
carcinoma of the head 
and neck (SCCHN) 
No altered risk for D148E 
patients 
[186] 
D148E 
Spina bifida and oral 
clefts 
Decreased risk for spina bifida; 
no association for oral clefts 
[187] 
I64V and D148E 
Non-small cell lung 
cancer (NSCLC) 
The variant I64V has a 
protective effect towards 
NSCLC; no association for 
D148E 
[188] 
D148E Bladder cancer 
No overall association. In 
stratified analyses a positive 
association with risk was 
observed with an increasing 
number of D148E alleles among 
never smokers, but not among 
smokers. 
[189] 
D148E Vitiligo 
Increased risk with D148E in 
Chinese population 
[190] 
D148E 
Lung cancer and lung 
adenocarcinoma 
Increased lung cancer risk in 
Asians and smokers; association 
with decreased lung 
adenocarcinoma risk 
[191] 
D148E Cancer No evident association [192] 
D148E Lung cancer 
Significant association 
observed; increased risk of lung 
[193] 
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APE1 missense 
variation 
Pathology Association/Frequency References 
cancer in Caucasians 
D148E Colorectal cancer 
Significant association 
observed; increased risk of 
colorectal cancer in Turkish 
population 
[194] 
D148E Colorectal cancer 
D148E is associated with the 
susceptibility, but not with the 
prognosis in Chinese population 
[195] 
D148E Bladder cancer 
Not associated with bladder 
cancer risk among Asians nor 
non-Asians. 
[196] 
D148E 
Non-small cell lung 
cancer 
D148E displayed a decreased 
risk of p53 mutation in non-
small cell lung cancer. 
[197] 
D148E Lung cancer 
Not associated with lung cancer 
risk among Asians or 
Caucasians. D148E shows an 
increased risk factor for 
developing lung cancer among 
smokers 
[198] 
D148E Gastric cancer 
Marker for the development of 
gastric cancer in Chinese 
population 
[199] 
D148E Cancer 
D148E polymorphism does not 
contribute to the development of 
cancer. 
[200] 
D148E Lung cancer 
D148E may not be directly 
associated with lung cancer risk, 
nor enhance the effects of 
smoking habit on lung cancer 
development in Taiwan 
population 
[201] 
D148E 
Nasopharyngeal 
carcinoma (NPC) 
The combined effects of 
polymorphisms within BER 
genes of XRCC1 and APE1 may 
contribute to a high risk of NPC 
[202] 
D148E Breast cancer 
 Associated with an increased 
risk of breast cancer. Combined 
effect of different SNPs within 
BER genes may be useful in 
predicting breast cancer risk in 
Korean population 
[203] 
D148E Breast cancer 
Two-way SNP-SNP interactions 
(APE1 D148E and RPAP1-
rs2297381) conferred elevated 
risks for breast cancer 
[204] 
D148E 
Coronary artery 
disease (CAD) 
No association for D148E as 
risk factor 
[205] 
D148E 
Endometrial 
carcinoma 
D148E may be associated with 
endometrial carcinoma in 
Turkish population 
[206] 
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APE1 missense 
variation 
Pathology Association/Frequency References 
D148E Cutaneous melanoma 
Not associated with cutaneous 
melanoma risk 
[207] 
D148E 
Acute myeloid 
leukemia (AML) 
No association with AML risk [208] 
D148E 
Non-small cell lung 
cancer 
An association with treatment 
response was suggested for 
D148E 
[209] 
D148E 
Childhood acute 
lymphoblastic 
leukemia 
No significant association 
observed 
[210] 
D148E 
Chronic atrophic 
gastritis 
No significant association 
observed 
[211] 
D148E Lung cancer 
Small but non significant 
increased risk of lung cancer in 
Chinese population 
[212] 
D148E Malignant melanoma 
No significant association 
observed 
[213] 
D148E Prostate cancer 
Any association was found. 
D148E may be indicated as a 
potential marker for prostate 
cancer risk. 
[214] 
D148E Gastric cancer 
Increased association for gastric 
cancer 
[215] 
D148E Bladder cancer 
Increased risk. D148E may 
contribute to susceptibility 
[216] 
D148E Pre-eclampsia Any significant association [217] 
D148E Bladder cancer Any significant association [218] 
D148E Glioblastoma Any significant association [219] 
D148E Breast cancer 
D148E was identified as risk 
factor for breast cancer 
susceptibility in Asian 
population 
[220] 
D148E 
Primary open angle 
glaucoma (POAG) 
D148E may decrease the risk of 
POAG progression in Polish 
population 
[221] 
D148E 
Biliary tract cancer 
and biliary stones 
D148E may alter susceptibility 
to biliary tract cancer and stone. 
Further studies required to 
confirm the data 
[222] 
D148E Lung cancer 
D148E was significantly 
associated with a poorer overall 
survival 
[223] 
D148E 
Pancreatic ductal 
adenocarcinoma 
Significant increase risk for 
carriers of D148E in Caucasians 
[224] 
D148E 
Differentiated thyroid 
carcinoma 
Any significant association [225] 
D148E Breast cancer 
D148E might be involved in 
contributing towards breast 
cancer susceptibility in North 
Indian women 
[226] 
Q51H Colorectal adenoma  Identified a borderline [227] 
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APE1 missense 
variation 
Pathology Association/Frequency References 
significant decreased risk of 
colorectal adenoma 
D148E Pancreatic cancer 
 Observed a weak but significant 
effect on overall survival 
[228] 
D148E Bladder cancer 
D148E showed an ability to 
predict bladder cancer risk 
[229] 
Q51H 
Upper aerodigestive 
tract carcinoma 
(UADT) 
Protective effect for UADT [230] 
D148E 
Non-Hodgkin 
lymphoma (NHL) 
Any significant association with 
NHL 
[231] 
D148E Pancreatic cancer 
XRCC1 R194W polymorphism 
had a significant interaction 
with the APE1 D148E in 
modifying the risk of pancreatic 
cancer 
[232] 
D148E Breast cancer 
D148E allele may be protective 
against the development of 
acute side effects after 
radiotherapy in patients with 
normal weight 
[233] 
D148E 
Esophageal Squamous 
Cell Carcinoma 
(ESCC) 
Any significant association was 
found 
[234] 
D148E Lung cancer 
D148E may alter the risk of 
lung cancer in a special 
population in China 
[235] 
D148E 
Ionizing radiation (IR) 
sensitivity 
D148E may contribute to IR 
hypersensitivity 
[236] 
In spite of several attempts to identify a potential correlation of APE1 genetic variants 
and cancer risk or neuropathology diseases, a restrict number of studies concerns the 
biochemical characterization of a subgroup of APE1 polymorphisms170,237. In these 
papers, the authors demonstrated that D148E, G241R, P112L and G306A variations did 
not alter the AP site incision activity in vitro, whereas L104R, E126D, R237A/C and 
D283G polymorphisms exhibited strong reduction (40-90%) in their endonuclease 
capabilities.  
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1.4 THE NUCLEOLUS: STRUCTURE AND CLASSICAL 
FUNCTION OF THE RIBOSOME FACTORY 
The nucleolus is considered as a ribosome factory of the cells238,239, in which processes of 
synthesis, maturation and processing of ribosomal RNA and assembly with ribosomal 
proteins take place238. It is considered as a dynamic structure240,241, where protein 
complexes are in continuously exchange with the nucleoplasm242. Its classical tripartite 
organization could be distinguished by their morphology using electron microscopy and 
results from the ribosomal activity242, reflecting the different steps of ribosomal 
biogenesis: fibrillar center, where the Polymerase I transcription starts (or in the boundary 
between FC and DFC), dense fibrillar component where the initial stages of processing 
pre-rRNA occurs and granular component (GC) for the late processing238 (Figure 11). 
Transcription of rDNA repeats generates 47S pre-rRNAs that are cleaved and processed 
into 28S, 18S, and 5.8S rRNAs, concomitantly assembled into large and small ribosomal 
subunits together with the 5S rRNA239,243. These complex series of events is controlled, in 
yeast, by 150 small nucleolar RNAs (snoRNAs) and two large RNP complexes, named 
small subunit (SSU) processome for the 40S ribosomal subunit and the large subunit 
(LSU) processome for the 60S ribosomal subunit242. Two types of modified nucleotides 
(2’-O-methylation and pseudouridylation) are added during the maturation steps from 
snoRNAs, belonging to the box C/D snoRNAs or the box H/ACA snoRNAs families, and 
mediate endonucleolytic cleavages of pre-RNAs242,243. Moreover, ribosomal gene 
transcription is regulated by modulation of the transcriptional apparatus and by epigenetic 
silencing244. Mature ribosome particles (large and small) are independently exported in 
the cytoplasm through a CRM1 and Ran-GTP-dependent mechanism: export of 60S 
subunit requires the exchange of complexes Noc1-Noc2 by Noc3-Noc2245 and the 
association with the adaptor shuttling protein NDM3246, whereas the 40S needs the 
heterodimer Noc4p/Nop14p247. Few years later, Hinsby and collegues applied a machine 
learning-based predictor of NES to analyze the late stage pre-40S complex suggesting a 
role also for the human homolog of yeast DIM2p in targeting and translocation of late 
40S in the cytoplasm248.  
The organization, the number and the size of these nuclear sub-structures is directly 
dependent of the nucleolar activity (RNA Pol I transcription), which in turn depends on 
cell growth and metabolism249: generally in highly proliferating cells, these present many 
small nucleoli238,242. Ribosomal biosynthesis is a high cellular energy and resources 
consuming process250, tightly regulated by changes in cell proliferation, growth rates and 
metabolic activities. Nucleoli constantly receive and respond to different signaling events, 
maintaining the ribosomal subunit pool necessary to support protein synthesis during cell 
growth and division239.  
Biosynthesis of ribosomes is very efficient process, since could be estimated that 14,000 
new ribosomal subunits can be synthesized every minute in an exponentially growing 
cell251. The process has to be fine-tuned and several evidences indicate that ubiquitin and 
UBL-based regulatory circuits control different stages of ribosome formation252. Lam and 
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collegues253 demonstrated that the levels of unassembled ribosomal protein within the 
nucleoli exceeds the required RP:rRNA ratio and identified an ubiquitin-mediated 
proteasome mechanism on the ribosome biosynthesis pathway to monitor and degrade 
this exceed254. Ribosomal structural protein are imported from the cytoplasm in supra 
stoichiometric levels and exported in the form of assembled ribosomal subunits: the 
excess of protein not required for the process undergoes ubiquitinylation and degradation 
in the nucleoplasm by the proteasome system252,255, indicating that mammalian cells 
produce large amount of these protein and degrade those that are not assembled with 
rRNA.  
Figure 11: Visualization, organization of the nucleolus and the ribosome biogenesis model. HeLa cells 
were subjected to different imaging techniques, used to identify distinct aspects of nucleolar morphology 
and composition (left panel). a | Hela cell with prominent nucleoli (indicated by white arrows) visualized as 
differential interference contrast (DIC). b | Nucleolar subcompartments identified with the marker proteins 
enriched for each compartment NPM1 (GC – shown in green), fibrillarin (DFC – shown in red) and RNA 
polymerase I subunit RPA39 (FC – shown in blue) by immunofluorescence labelling. c | Nucleus with 
nucleolus (Nu) imaged by transmission EM following uranyl-acetate-staining. d | Nuclear region analyzed 
by electron spectroscopic imaging for the nucleic acids containing. Right panel. Representation of the 
different steps of the ribosome biogenesis within the three nucleolar subregions. (Adapted image from 
Boisvert F. M. et al., Nat Rev Mol Cell Biol, 2007). 
1.4.1 DYNAMIC TRAFFICKING, KEYWORDS FOR NUCLEOLAR 
PHYSIOLOGY
Nucleolus appears as a very dynamic organelle and different types of movement could be 
ascribed to this complex: first, the ribosome assembly is a vectorial process, where the 
ribosomal particles move away from their biogenesis sites; second kind of motion, the 
constant flux of proteins from nucleoli to the nucleoplasm; and third, nucleolar 
components present scheduled movements every cell cycle during steps of 
assembling/disassembling for the redistribution on nucleolar components between the two 
daughter cells256. Infact, nucleoli are subjected to cyclic assembling/disassembling 
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processes during the cell cycle: they assemble at the end of the mitosis and until the start 
of the next mitosis they are functionally active238,240. The nucleolar disassembling during 
mitosis could be linked to rDNA repression caused by CDK1-cyclin B-directed 
phosphorylation of components of the rDNA transcription machinery242. Conversely, the 
formation of functional nucleoli at the exit from mitosis, instead, is not governed solely 
by the resumption of rDNA transcription but by a two-steps process regulated by CDK(s) 
that connect the resumption of rDNA transcription and restoration of rRNA 
processing242.During late telophase, nucleoli form around the nucleolar organization 
regions (NORs), chromosomal region where rDNA, formed by a transcribed sequence 
and an external non-transcribed spacer242 and clustered in head-to-tail arrays238,241. This 
sub-compartment allows the cells to locally concentrate all the factors required for the 
ribosomal biogenesis239,249. In human mitotic cells, rDNA clusters are localized on the 
short arm of the five pairs of chromosomes 13, 14, 15, 21 and 22242. 
1.4.1.1 THE WAY TO MOVE: VISITORS VS RESIDENTS NUCLEOLAR
PROTEINS
Different from NLS, nucleolar targeting sequences (NoLSs) are not well characterized 
and any consensus sequence has been described242,254. At the moment all the NoLSs 
described presents richness in basic residues as Arg and Lys257, but also Trp residues 
were described as functional for the nucleolar localization of NPM1 (B23)258. The 
capability of different proteins to localize in the nucleolus has been correlated with 
interaction with already anchored resident protein as NPM1, acting as a transporter into 
the nucleolar compartment or as retention block in the nucleoli, supporting the idea that 
the residence time of nucleolar proteins is strongly related to their specific 
interactions242,254,257. In theory, all the molecules resident in the nucleoplasm could entry 
in the nucleoli, but only those with an affinity for nucleolar resident proteins would be 
retained for longer times256. Some authors, in fact, suggest the term “retention signal” 
instead of targeting signal for the nucleoli259. Since the residence time is very brief and 
most of the nucleolar protein shuttles from nucleoli to nucleoplasm and vice versa, these 
nucleolar proteins-anchored proteins interactions appear reversible254,256. Current models 
show that proteins and RNAs are continually in a state of flux and freely diffuse through 
the nuclear space244: the mean residence time of most nucleolar proteins in nucleoli can 
be calculated to be only a few tens of seconds. The nucleolus appears as a steady state 
structure with its component in dynamic equilibrium with the surrounding 
nucleoplasm259. Since the mass per unit volume of nucleoli is only twice higher than that 
of nucleoplasm, all diffusing macromolecules could enter in nucleoli: for this reason the 
residence time of nucleolar proteins depends from their relative affinities for the pre-
anchored complexes present within the nucleolus254,255. However, in spite of this 
continual exchange of molecules between these two compartments (nucleolus and 
nucleoplasm), nucleolar domains are maintained because the number of proteins within a 
domain is higher to the number of proteins that are released from the same domain243. 
These proteins, able to connect and bind multiple protein partners, are considered as hub 
proteins and might be responsible for the nucleolar localization of the majority of visitor 
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protein in absence of RNA-protein binding. Each hub protein may have different 
recognition requirements, fact that may explain the occurrence of several NoLSs. Two 
great examples of hub proteins are considered Nucleolin and NPM1, which contain 
disordered regions, involved in nucleolar protein-RNA interactions257. 
Recently, a protein retention method based on GTP-driven cycle has been identified for 
Nucleostemin259, but the exchange of GTP-GDP is not the only characterized intracellular 
signal able to move nucleolar proteins: stimulus as hydrogen ion was described by 
Mekhail et al.260, that demonstrated how the nucleolar sequestration of von Hippel-
Lindau (VHL) protein after an increase of pH promotes the stabilization of hypoxia-
inducible factor (HIF), giving arise to a general cell response to hypoxic conditions254.  
1.4.1.2 NEW CONCEPTS FOR THE NUCLEOLUS: BEYOND THE
RIBOSOME FACTORY
In the 1960s, through the identification and localization of ribosomal genes (rDNAs)242, 
the main function of the nucleolus had been already described from several groups and it 
was nicely summarized in “an organelle formed by the act of building a ribosome’’248. In 
the last decades, thanks to the evolution of techniques as isolation of large amount of 
nucleoli and the improvement of high-throughput mass-spectometry-based proteomic 
approaches, several proteomic analysis were undertaken partially unveiling the 
nucleolome239,240,243,251,261. Over 4500 proteins were described to localize in the nucleoli 
and bibliographic and bioinformatic analyses allowed the classification into 9 major 
functional groups (ribosomal proteins, ribosome biogenesis, chromatin structure, mRNA 
metabolism, translation, chaperones, fibrous proteins, others, and unpredictable 
function)239,243,249,262,263. A further idea of complexity has been added to the 
characterization of nucleolar proteome under different stress conditions (e.g. Actinomycin 
D), suggesting how dynamic the nucleolome could be261. 
The protein composition includes protein related to cell cycle regulation, DNA damage 
and pre-mRNA processing241, suggesting that this organelle acts as a multifunctional 
domain and it is more than a “simple” ribosome factory, highlighting its 
plurifunctionality238,239,241,248,251. This variety could possibly be related to the different 
nucleolar proteins that act as multifunctional proteins, i.e. Nucleolin and Nopp140264. 
Nucleoli carry out many non-ribosomal activities238 such as cell cycle and cell 
proliferation control sequestrating key factors normally active in the 
nucleoplasm238,242,248, stress sensing239,262,265-269 and tumor surveillance pathways, DNA 
damage repair239,241,270, regulation of protein stability and apoptosis, telomere 
metabolism239, maturation of small RNAs, including tRNA and snRNA of the 
spliceosome and the signal recognition particle (SRP), a complex of an RNA with several 
proteins that targets translation of certain protein in the endoplasmic reticulum248,254,259, 
viral life-cycle238,271, acting in several ways as a sequestration core facility248,257,267 
(Figure 12). The nucleolar proteins unrelated to ribosome assembly mostly contain an 
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RNA-binding motif or have a chaperone function and shuttle between the nucleolus and 
the nucleoplasm264.  
Seven most abundant motifs found in nucleolar proteins include RNA recognition motif, 
DEAD/DEAH box helicase, helicase conserved C-terminal domain, WD domain, 
intermediate filaments proteins, myosin tail and elongation factor Tu GTP-binding 
domain264. 
The assumption that a protein acts and executes its functions where it is more abundant 
does not work for some nucleolar component: a quantitative signal might not correspond 
to a protein’s concentration in a cellular compartment255. A great example is represented 
by the many DNA repair proteins that resides in the nucleoli (see more in “The nucleolus 
as stress responsive organelle” paragraph), where nucleoli act as a storage site. Following 
nucleolar stress or DNA damage, these proteins can freely re-localize in the nucleoplasm. 
The nucleolar stress might carry out a physiological aim and could be considered as a 
control surveillance mechanism that monitors the synthesis and the correct assembly of 
ribosomal units: it may halt the cell cycle progression until enough functional ribosomes 
are built or it may induce p53-mediated apoptosis or senescence250.  
Figure 12: The nucleolus, a multifunctional domain. Unveiling of the “nucleolome” allows the 
understanding of the complexity of the nucleolus, first described only as a ribosome factory. The 
multifunctionality of the nucleolus includes different noncanonical functions as the control of cell 
proliferation and cell growth, regulation of protein stability, stress and DNA damage response, telomere 
metabolism, maturation of small RNAs and control of viral life-cycle. An illustrative mechanism for each 
function is summarized. CRM1, Exportin 1; snoRNA, small nucleolar RNA; NPM1, Nucleophosmin 1; 
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NCL, Nucleolin; MDM2, Mouse double minute 2 homolog; ARF, p14 alternative reading frame; p53, 
tumor protein p53; ADAR2, Double-stranded RNA-specific adenosine deaminase 2; NS, Nucleostemin; 
VHL, von Hippel-Lindau; HIF, hypoxia-inducible factor; Ing1, inhibitor of growth family, member 1; 
Ki67, antigen KI-67; Cdc28, cyclin-dependent kinase 28; Cdc14, Tyrosine-protein phosphatase; Clb2, 
G2/mitotic-specific cyclin; Net1, nucleolar protein; PML, promyelocytic leukemia protein; DNA Topo I, 
DNA Topoisomerase I; Ku70, ATP-dependent DNA helicase 2 subunit KU70; TERC, telomerase RNA 
component; TERT, telomerase reverse transcriptase; GNL3L, guanine nucleotide binding protein-like 3 
(nucleolar)-like; TRF1, telomeric repeat-binding factor 1; TRF2, telomeric repeat-binding factor 2; REV, 
Regulator of Expression of Virion Protein; Tat, Trans-Activator of Transcription; Nup98, nucleoporin 
98kDa; Nup214, nucleoporin 214kDa; Ub, ubiquitin. (Image from Antoniali G. et al., Antiox Redox Signal, 
2013) 
1.4.1.3 THE NUCLEOLUS AS A STRESS RESPONSE ORGANELLE 
The main function of the nucleolus is a rapid and efficient production of ribosomes, 
process strictly regulated for a correct cell proliferation and growth249. Under stress, cells, 
in an attempt to compensate and to maintain cellular energy homeostasis272, halt and 
inhibit several cellular processes as replication, transcription and ribosome biogenesis, a 
highly energy-consuming process, altering their metabolism to allow a quick cell 
response through the activation of specific stress response pathways (e.g. DNA repair). 
The response of the stress could lead to different cellular results ranging from cell-cycle 
arrest to apoptosis, depending on the severity of the insult and to the capability of the cell 
to recover from the damage72,249. In this scenario, the nucleolus reacts to several form of 
cellular stress (e.g. DNA damage, cytotoxic drugs and agents that inhibits transcription by 
RNA polymerase I-complex) which disturb the normal nucleolar functions and appears a 
central hub in stress response, where tumor suppressor p53 and its negative regulator 
MDM2 represent the key players of the nucleolar stress response72,249,266,267,273. 
Commonly, the perturbation of nucleolar activity is accompanied by dramatic changes in 
its architectural organization and composition261,274-276, in well-described phenomenon 
called nucleolar segregation, caused by DNA damage (UV irradiation, etoposide) and /or 
RNA Pol I inhibition (Actinomycin D) and characterized by the condensation of FC and 
GC with the concomitant formation on “nucleolar caps”249. Nucleolar stress signaling 
pathways rely on translocation from nucleoli to the nucleoplasm or targeting to the 
nucleoli in a dynamic way proteins involved in stress response249. Several players of this 
nucleolar sensing have been described, such the Cdc14B-Cdh1-Plk1 axis in yeast, with 
the translocation of cdc14B upon DNA damage to the nucleoplasm activating the G2 
checkpoint277, the opposite axis RelA-COMMD1, that leads to apoptosis following the 
nucleolar stress-dependent targeting of RelA278 and the well-described NPM1-p14ARF-
p53 pathway266. This pathway leads to the stabilization and activation of p53 via 
interaction of p14ARF with MDM2, a negative controller of p53254,266. In the 
nucleoplasm, p53 up regulates the transcription of RNA Polymerase II-transcribed genes 
and inhibits RNA Pol I transcription, whereas in the cytoplasm it triggers apoptosis via 
mitochondria279. Under physiological conditions, p53 levels are kept low through its 
interactions with MDM2 (called Hdm2 in human), an E3 ubiquitin ligase, that targets p53 
to the proteasomal degradation. To keep the cellular homeostasis, p14ARF, a negative 
regulator of MDM2, is kept within nucleoli by the interaction with NPM1. Upon stress, 
the p53 stability is increased via protein-protein interaction involving the up regulation of 
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p14ARF. This up regulation prevents the proliferation of cells with damaged DNA 
preventing the duplication of injured cells: p14ARF binds MDM2, blocking its interaction 
with p53 and in turn leading to the stabilization of it. NPM1 itself and other ribosomal 
proteins, as L5, L11, L23 and S7, translocate from the nucleoli to the nucleoplasm 
following stress, binding directly MDM2 and preventing the degradation of p53249. 
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1.5 NUCLEOPHOSMIN 1 (NPM1) 
Nucleophosmin 1, also known as B23, NO38 and numatrin280 and hereafter indicated with 
the acronym NPM1, was first identified as a nucleolar phosphoprotein281, ubiquitously 
expressed in the granular region of the nucleolus282, belonging to the nuclear 
Nucleoplasmin/Nucleophosmin chaperone family283. NPM presents a high degree of 
homology within the vertebrates and is widely distributed among different species; 
alternative splicing events generated three protein isoforms (NPM1, NPM2 and 
NPM3)280.  
To date, several distinct cellular functions for NPM1, related to both proliferative and 
growth suppressive roles, have been described280,281. Even though it resides 
predominantly within nucleoli, carrying out important nucleolar activities, as factor in 
ribosome biogenesis, transporting pre-ribosomal particles284 and as retention block for 
non-resident nucleolar protein257, by shuttling between cellular compartments, from 
nucleoli to the cytoplasm, NPM1 could take part in various cellular processes. They 
include the nucleolar stress response and the control of stability of p53 and p14ARF (see 
“The nucleolus as stress response organelle” paragraph), the maintenance of genome 
stability, controlling the ploidy of cells during centrosome duplication280, the regulation 
of the chromatin condensation status and the involvement in different DNA repair 
pathways281. The acquisition of a deeper comprehension of the intricate network of all the 
biological roles played by NPM1 contributes to the emerging of a more complex scenario 
that had been expected. Much of the interest for this multifunction protein has been 
sustained by its implications in human tumorigenesis. It is frequently overexpressed in 
solid tumors of different histological origin (gastric, colon, prostate and ovarian 
carcinomas)285 and the NPM1 locus is involved in chromosomal 
translocations/mutations/deletions in several haematological malignancies, as acute 
myeloid leukemia (AML), where in high percent of cases (35%), NPM1 has been found 
to be mutated and to be aberrantly localized in the cytoplasm of blasts286, and solid 
tumours281. 
1.5.1 STRUCTURE OF THE GENE AND THE PROTEIN ENCODED 
The NPM1 gene maps to the chromosome 5q35 in humans and contains 12 exons. NPM1 
is translated from exons 1 to 9 and 11 to 12287. It encodes for 3 alternatively spliced 
isoforms, but NPM1 is the prevalent one.  
NPM1 is a 294 amino acids protein of about 37kDa and presents functional modular 
organization in mainly independent, but slightly overlapping, domains (Figure 13).  
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The N-terminus region, that contains a hydrophobic portion, controls the oligomerization 
status of the protein: in resting and proliferative cells, in fact, more than 95% of cellular 
content of NPM1 consists of pentamers, in which five wedge-shaped monomers are 
linked by apolar interactions287,288. The oligomerization by apolar contacts confers higher 
thermostable properties to NPM1, critical for its molecular chaperone activity avoiding 
protein aggregation at high temperatures288. This domain is also responsable for the 
chaperone activity of NPM1 towards protein, nucleic acids and histones281,287,288 and for 
the regulation of acetylation-dependent transcription289. The central portion, responsible 
for the histone binding and nucleosome assembly, presents two acidic stretches whereas 
the fragment in between and part of the C-terminus domain are devoted to ribonuclease 
activity. The C-terminus region, characterized by basic regions for the nucleic acid 
binding, presents the nucleolar localization signal (NoLS), an aromatic section composed 
by tryptophan 288 and 290, required for its binding to nucleoli and responsible for its 
prevailing cellular localization281,290. The C-terminal domain is composed by three right-
handed helix bundle that confers to the domain a well-defined tertiary structure290. The 
three helices are interconnected with each other and the overall structure is stabilized by a 
hydrophobic core, formed by aromatic residues (Phe268, Phe276, Trp288 and Trp290)291. 
Sequence alignments indicate that the folding of this domain and the aromatic core is 
strictly conserved along the evolutionary tree, with any insertions and/or deletion to 
perturb the helix bundle (Figure 14)290,291.  
Figure 13: Structural organization of NPM1 gene and modular structure of the encoded protein. The 
NPM1 gene contains 12 exons. Three different regions could be defined within the protein structure: the N-
terminus, a nonpolar domain required for oligomerization and heterodimerization, with a functional nuclear 
export signal (NES) and a metal-binding (MB) domain; a central portion characterized by two acidic 
stretches (Ac), responsable for histone binding, and a bipartite nuclear localization signal (NLS). This 
region confers ribonuclease activity. The C-terminus presents ribonuclease activity and basic regions 
involved in nucleic-acid binding. Two tryptophan residues (Trp288 and 290) form an aromatic region, 
constituting the nucleolar localization signal of the protein (NoLS). (Image from Falini B. et al., Blood, 
2006)
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Figure 14: Schematic representation of the C-terminus region of NPM1 and sequence alignment of 
structurally and functionally important aromatic residues conserved within species. A | Lowest energy 
structure representation of the NPM1 C-terminus as prepared by PyMOL. The NPM1 C-terminal domain is 
formed by three right-handed helices. Helices H1 and H3 are coaxial but divergent, whereas the connecting 
helix H2 is tilted by 45° with respect the other two. B-D | C-terminal domain of NPM1 with functionally 
important residues that formed the hydrophobic core (B and C) and conserved lysines (D) represented as 
sticks. The two tryptophan residues represents a unique NoLS for NPM1. E | Sequence alignments, using 
ClustalW and Jalview programs, of NPM1 C-terminus and related proteins. In shades of blue are marked 
the conserved amino acids throughout the evolutionary tree. The helices are colored blue to red from the N- 
to the C-terminus domain. (Adapted image from Grummit C.G. et al., J Biol Chem, 2008) 
Within this domain, several lysine and arginine residues are found distributed throughout 
all the C-terminus length291; in particular three lysine residues (Lys248, 263 and 267) 
appear highly conserved and surface-exposed, indicating a hypothetical functional role 
for these residues290. Lys-to-Ala mutations demonstrated an important structural role for 
Lys248 in maintenance of the tertiary structure, since it forms a salt bridge with Asp286, 
whereas Lys263 and Lys267, freely orientate on the surface, with Cys275, play a role in 
the nucleolar localization of NPM1, probably through the binding with protein or nucleic 
acids abundant in the nucleoli, although they are not critical to the structural integrity of 
this domain (Figure 15)290. 
54 | P a g e
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
?????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????
????????????? ??????????????? ??? ????????????????? ???? ????????? ??? ????????????? ?????????? ????????????????
?????????????? ?????????????? ???????????????????????????????????? ?????????????????? ?????????????? ?? ?????
????? ???? ??????? ???????????? ??? ????? ??????? ??????????????? ?? ??????????? ???????? ????????????? ???? ????? ????
???????????????????????????????????????????????????????????????????????????????????????????????????????
??????? ??? ???? ??????? ???? ????? ??????? ???? ?????????? ??????????? ???? ????????????? ?????? ???????? ?????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????? ????????? ??? ????????????????????????????????????? ????????? ???????????????????
?????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????
???? ?????????? ???? ????? ??????? ????? ??? ????????? ????? ?? ?????????? ???????? ?????????????
??????? ?????? ??? ???? ??????????????????????????? ???????????????????????????? ??????? ??????
??????? ??? ?????????????????????? ???????????????????????????????????? ???????????????
???? ??? ?????????? ??? ???? ???????????? ????? ??????????? ???????? ????????? ??????? ?????
?????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????
???????????????? ?????????????? ???????????????
????????????????????????????????????????????????????????????????????????????????????????????
?????????? ??? ?????????? ??????????? ??????????? ???????????? ???? ?????????????? ???????????
????????? ?? ???????? ??????????? ?????? ???? ????????????? ???? ???? ????????? ???? ???????????
?????????????????????????????????????????????????????????
55 | P a g e
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
?????????????
? ????? ?????????? ??? ?? ???????? ??? ?????????????????? ?????????????? ????? ??
???????????????????????? ???????????????????? ???????????????????? ??????????
????????????????? ???? ?????????????????????? ????? ????????? ???? ????? ???????????
?????????????????????????????????????????????????????
? ??? ?????????? ??????? ???? ?????????? ?????????????? ????? ??????? ???? ??????????
???????????????????????????????????????????????????? ??????????
? ????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????
???? ????????? ??????? ??? ???? ???????? ???????????? ????????????? ???????? ???? ??????????
???????????????
? ????? ??????? ???? ???????????? ??????? ???????????? ???? ???? ????????????????? ????? ???
?????? ???? ??????????? ??? ???? ???????????????????????? ??????????? ??? ?????? ?????? ??
?????????????????????????????????? ??????????? ????????? ??????????????? ??????????? ??
????????????????????????????????????????????????????????????????????????????????????
?????????????????
?? ??????????????????? ???? ??? ??? ????? ???? ???? ????????? ?????????????????????????????????
?????????? ??? ?????? ?????? ?????????? ?? ???? ?????????? ???????????? ???? ???? ???????????
?????????????
??????????????????????????????????????? ???????????????????????????????????????????? ?????? ??????????
????? ??? ????????????????????????????????????????????????????????????????????????? ???????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????
?????? ???? ???????? ?????????????????? ???????????? ???? ???????????? ????? ????? ????????????????? ????????
?????????????????????????????????????????????????
????????? ?????? ??????????? ??? ????? ??? ??????????????? ???? ???????? ????????? ????? ?????
??????????? ??? ???? ??? ???????????????? ?????? ??? ?????? ???????? ???????? ????? ????? ????????????
??????????????????????????????????????????????????????????????????????????????????????
????????????? ??? ????????? ??? ???? ???????????????????????????????????????????? ????? ????
??????????? ???? ????????? ??? ??????? ??????? ??? ????? ????????? ??? ??????????? ????? ??
??????????????????????? ????????? ???????????????? ???????????? ???? ????? ??? ??????????????
56 | P a g e
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
INTRODUCTION 
nucleoli by disrupting RNA-protein binding interaction of NPM1303,304 and inhibits the 
GCN5-mediated histone acetylation305. During mitosis, NPM1 has been also found 
phosphorylated by Plk1 which might have a critical role in mediating mitosis306. De-
phosphorylation events take place on three threonine residues (Thr199, 234 and 237) by 
the serine/threonine phosphatase called PP1β in response to DNA damage (UV 
irradiation), facilitating the DNA repair process307,308. Interestingly, a role for Nek2A has 
been recently demonstrated for the phosphorylation of NPM1 at Ser70 and Ser88: such 
modification, antagonized by PP1β when it is activated by ATM, seems to be 
fundamental in controlling the ARF stability in an ATM-dependent pathway, elucidating 
the role of the ATM-ARF-NPM1 axis in the DNA damage response308.  Acetylation 
p300-mediated, described especially at the C-terminus domain of NPM1, increases its 
binding affinity to histones289,294. Association of factors involved in poly-(ADP-
rybosil)ation such as PARP-1 and PARP-2 has been documented for NPM1, event which 
might correlate with the functional transcription within nucleoli309. Two different 
ubiquitination processes (BRCA1-BARD1299- and p14ARF284-mediated) have been 
recognized for NPM1, although only the p14ARF one redirects the protein to the 
proteasome-dependent protein degradation. Last, SUMOylation is another mechanism by 
which cells control NPM1 functions. NPM1 has been described to be SUMOylated by 
p14ARF, modulating its stability and leading to a re-localization of 
NPM1295,297.However, the complete profile of post-translational modifications remains to 
be fully elucidated. 
1.5.3 NPM1 AS A MULTIFUNCTION PROTEIN 
Elucidating the various physiological functions of NPM1 has become a new research 
issue, especially for cancer research. NPM1 has been described as a critical protein 
involved in a wide range of biological processes. It has been associated with different 
human pathologies (the reader is redirected to the paragraph “Alteration of NPM1 in 
human cancers” for more details), so a deep comprehension of the complicate network of 
molecular mechanisms controlling NPM1 and of the scenarios in which it operates might 
improve the therapeutic approaches. In Table 3, all the physiological functions are listed; 
each of those will be briefly introduced to the reader in the following paragraphs. 
Table 3: List of all the known NPM1 physiological functions. 
NPM1: summary of physiological functions and posttranslational 
modifications involved in its regulation   
 Molecular chaperone (304,310-318) 
 Involvement in ribosome biogenesis (284,313,319-322)
 Regulation of transcription (289,294,304,305,323-334) 
 Inhibition of apoptosis (293,335-341) 
 Modulation of tumour suppressors (281,284,326,329,341-350)
 Maintenance of genomic stability (337,342) 
 Regulation of cell cycle (239,281,314) 
 DNA repair (18,280,281,285,322,337,342,351,352) 
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1.5.3.1 NPM1 AS A MOLECULAR CHAPERONE 
The ability of NPM1, through its N-terminal domain, to bind denatured proteins, 
preventing their aggregation, misfolding and denaturation, and nucleic acids, controlling 
chromatin assembly and disassembly, define NPM1 as molecular chaperone311,312,353. 
Initially, NPM1 was described as ribosome chaperone or assembly factor, since it 
associates with pre-ribosomal particles and exerts different activities on rRNA transcripts 
and ribosome biogenesis313,314. Recent works, on the contrary, ignited particular interest 
in the function of NPM1 as histone chaperone304,315-317 suggesting a dual role for NPM1 
as nucleolar histone and ribosome chaperone and reinforcing the multi-functionality of 
this protein. 
1.5.3.2 A ROLE FOR NPM1 IN THE RIBOSOME BIOGENESIS
MACHINERY
NPM1 plays a key role in ribosome synthesis since it presents all the necessary features 
for the processing and assembly of ribosomes, as the abundant nucleolar localization, its 
capability to shuttle between nucleus and cytoplasm and its role as ribosome chaperone in 
transporting ribosomal particles319. NPM1 has been found to have ribonuclease activity 
towards pre-ribosomal RNA, processing the internal transcribed sequence (ITS2)284,320,321, 
activity facilitated by the chaperone ability of NPM1, avoiding nucleolar protein 
aggregates during the ribosome biogenesis. Knocking-down of NPM1 leads to an 
inhibition of the processing of pre-ribosomal RNA and to changes in the ribosomal 
profiles284,322, supporting the significance of NPM1 in this process. Moreover, acting as 
histone chaperone, NPM1 controls the transcription of genes involved in the ribosome 
synthesis, promoting the maintenance of an open chromatin conformation accessible for 
the synthetic machinery of the ribosome. Indirect observations of a close association of 
NPM1 with this machinery have been collected; in fact NPM1 regulates the export and 
transport of numerous ribosomal components such as L5 (rpL5) and its cargo 5S rRNA in 
a CRM-1-dependent mechanism313. Inhibition of NPM1 shuttling or knock-down of the 
protein causes a block of rpL5 export and leads to cell-cycle arrest313, providing new 
evidences for the important role of NPM1 as ribosome chaperone. 
1.5.3.3 REGULATION OF GENE TRANSCRIPTION BY NPM1 
NPM1 contributes to the regulation of gene transcription and ultimately to the cell growth 
control; its correlation with gene transcription has been related to several mechanisms. Of 
particular interest, several lines of evidences point toward an important role for NPM1 in 
both RNA Pol I and Pol II transcription. First, NPM1 interacts with different transcription 
factors, including p53323, NF-κB324, YY1325, ARF326, ATF5327 and IRF1328, controlling 
their stability and activity and acts as co-repressor or co-activator. Second, through the 
direct binding to c-Myc, NPM1 facilitates the RNA Pol II recruitment at the promoter of 
the c-Myc target genes330 and controls its subcellular localization331. NPM1, regulating 
the c-Myc turnover through the control of Fbw7γ329, may have an important role on cell 
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growth and tumor development. Third, recently has been demonstrated an association in 
vitro and in vivo of NPM1 with HEXIM1, an inhibitor of positive transcription elongation 
factor b (P-TEFb), a key regulator of RNA Pol II machinery332. The binding of NPM1 
with HEXIM1 leads to a negative regulation for the inhibitor, enhancing the P-TEFb-
driven transcription. Fourth, a key role for acetylation has been found for NPM1 
transcriptional activity. Swaminathan et al. demonstrated that NPM1 could enhance 
transcription in an acetylation-dependent manner and may have an impact on chromatin 
remodelling: the combination of acetylation of the core histones, which NPM1 interacts 
with (H3, H2B and H4), and NPM1 itself generates an open chromatin conformation by 
disrupting the nucleosomal structure, resulting in the transcriptional activation289. 
Moreover, the p300-acetylated form of NPM1 interacts in the nucleoplasm with the 
transcriptionally active RNA Pol II: either inhibition of p300 or mutation of acetylatable 
lysine residues of NPM1 results in a reduced occupancy of NPM1 on target gene 
promoters294. On the other hand, during mitosis NPM1 negatively regulates the 
acetyltransferase GCN5, inhibiting its activity towards both free and mononucleosomal 
histones305. Fifth, NPM1 is also involved in the regulation of RNA Pol I transcription 
within the nucleolus: as a nucleolar histone chaperone, NPM1 associates with rRNA gene 
chromatin, facilitating its transcription and the cell growth rate318, and induces, during 
G2/M, the rDNA transcription factor TAF(I)48
333, required for the recruitment of the 
Upstream Binding Factor (UBF) to rDNA. All these factors are responsible for initiating 
the transcription of ribosomal RNA by RNA Pol I in the nucleolus. Interestingly, the 
RNA binding activity of NPM1, inhibited during mitosis by Cdc2 kinase-mediated 
phosphorylation, and the recruitment of UBF are essential features for NPM1 binding to 
the chromatin304. Furthermore, NPM1 controls the subnuclear localization of TTF-1, the 
RNA Pol I transcription terminator factor, and might promote its nucleolar import, in 
contrast to the action of ARF, facilitating its role in rRNA synthesis334. 
1.5.3.4 INHIBITION OF APOPTOSIS 
Accumulating evidences support the concept that an overexpression on NPM1, as found 
in actively proliferating and cancer cells, could promote cell survival by inhibition of 
cellular apoptosis elicited by various stimuli336. On the contrary, loss of NPM1 induces 
cell death. Different studies aimed to deciphering the anti-apoptotic function of NPM1 
have been conducted. First evidences demonstrated a nuclear association between NPM1 
and the phosphatidylinositol 3,4,5-triphosphate [PI(3,4,5)P3], interaction that mediates 
the anti-apoptotic effect of nerve growth factor (NGF) by inhibiting DNA fragmentation 
activity of caspase-activated DNase (CAD) in PC12 cells335. Frequently, the anti-
apoptotic effect of NPM1 hinges on its prompt up-regulation following different stimuli, 
such as UV irradiation337, hypoxia338, ionizing radiation (IR)339 and extra- and intra-
cellular cues that activates the interferon-inducible, double-stranded RNA-dependent 
protein kinase (PKR)340, resulting in an increased resistance to apoptosis and enhanced 
protein synthesis. Additionally, the cellular protection from apoptosis exerted by NPM1 
has been related to a mechanism involving p53293,338,339. NPM1 might inhibit the 
activating phosphorylation of p53 (Ser15), suppressing in this way the p21-driven 
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response. Lastly, NPM1 interacts with the pro-apoptotic factor GADD45α, an important 
player in cell cycle arrest during G2/M in response to genotoxic stress that lacks a 
functional NLS and for this reason it needs the aid of a nuclear chaperone. Gao et al. 
identified NPM1 as chaperone involved in controlling GADD45α; it mediates the nuclear 
import of GADD45α, localization required to induce the cell cycle arrest341. 
1.5.3.5 MODULATION OF TUMOUR SUPPRESSORS 
NPM1 is engaged in the regulation of activity and stability of some key tumor 
suppressors as Miz1347, Fbwγ, required for c-Myc degradation329, p53 and ARF281. The 
association between NPM1 and ARF influences the stability of the latter: NPM1 retards 
the turnover of ARF296,348, resulting in a maintenance of its biological function within 
cells. Inhibition of the proteasome, in cell expressing ARF mutants unable to interact with 
NPM1, only partially restores the stability of ARF proteins, indicating that the protective 
role exerted by NPM1 on ARF turnover involves both proteasome-dependent and –
independent degradation348. ARF prevents cell proliferation through p53-dependent and –
independent mechanisms284,349: it blocks the cell cycle progression via MDM2-p53 axis326 
and concomitantly inhibits the ribosomal biogenesis through the retardation of rRNA 
production involving a p53-independent pathway343,350. On the contrary, deficiencies in 
NPM1 expression/functions are correlated with accelerated transformation, probably 
attributed to ARF destabilization344 and mislocalization342. To sum up, NPM1 has a key 
role in the cellular response to oncogenic stimulus, modulating ARF functions. Cells 
lacking NPM1 gene shows decreased stability of ARF protein and susceptibility to 
tumorigenesis, supporting the concept of NPM1 as tumor suppressor, in which expression 
level and localization are features of major interest.  
The tumor suppressor p53 protein, crucial for preventing proliferation or survival of cells 
with irreparable damage and genomic instability345, has been found to be another tumor 
suppressor gene regulated by NPM1. Tumor protein p53 expression levels are controlled 
by MDM2, a p53-specific ubiquitin ligase that constantly mediates its degradation, but is 
inhibited during cellular stresses. The nucleolar integrity plays has an important role in 
p53 stability in proliferating cells266. During stresses able to disrupt nucleoli, NPM1 
redistributes in the nucleoplasm269; such redistribution might lead to a stabilization of p53 
through the inhibition of MDM2 activity346. The cross-talk NPM1-p53 also involves 
proteins downstream of p53, as GADD45α341 (for more details, the reader is redirected to 
the previous paragraph). In conclusion, NPM1 might facilitate DNA repair followed 
oncogenic and genotoxic stresses, reinforcing the p53 pathways, acting again as a tumor 
suppressor molecule. 
1.5.3.6 THE MAINTENANCE OF GENOMIC STABILITY 
NPM1 has been implicated in the maintenance of genomic stability through the control of 
chromosomal ploidy and DNA repair. Interestingly, UV-irradiation leads to a rapidly up-
regulation of NPM1; elevated NPM1 expression levels have been associated with 
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improved DNA repair processes337 and, on the contrary, loss of NPM1 causes 
accumulation of γ-H2Ax, a downstream target of the DNA repair kinases ataxia 
telangiectasia mutated (ATM) and ataxia telangiectasia and RAD3-related (ATR), with 
increased number of ATM positive foci342. NPM1’s role in maintenance of genomic 
stability has been associated with its studied and physiological function in cell cycle 
regulation. 
1.5.3.7 REGULATION OF CELL CYCLE BY NPM1 
During mitosis, within eukaryotic cells profound changes in their structure and 
architecture take place. Nucleoli, as dynamic structure, undergo reversible disassembling 
when cells enter in the mitosis and transcription shut down239. Many nucleolar proteins, 
including NPM1, re-localize in the cytoplasm where NPM1, from the chromosome 
periphery, migrates at the poles of the mitotic spindles together with NUMA, a nuclear 
mitotic apparatus protein associated with the mitotic spindle. The presence of NPM1 at 
the mitotic spindle seems to protect cell to centrosome hyper-amplification, allowing the 
cells to proceed in the G2/M phase. It has been demonstrated that NPM1 associates with 
the unduplicated centrosome and following a CDK2-cyclin E-dependent phosphorylation 
at Thr199 it dissociates from the centrosome, enabling the initiation of duplication281. 
Npm1-/- cells show increased genomic instability with consequent augmented oncogenic 
transformation281. Moreover, NPM1 also associates with a centromere protein A 
(CENPA), complex necessary for a correct segregation during mitosis, suggesting a novel 
role for NPM1 in centromere control, possibly mediated by its histone chaperone 
function314. In summary, NPM1 plays a key role in maintenance of genomic stability 
through a proper regulation of centrosome duplication and its loss causes aneuploidy and 
the activation of proliferation checkpoints during the cell cycle. 
1.5.3.8 PARTICIPATION OF NPM1 IN DNA REPAIR 
DNA strand breaks, resulting in global and local chromatin structural modifications, 
trigger activation of cellular pathways resulting in DNA damage response and DNA 
repair with the recruitment of several repair proteins and signaling factors at the damage 
sites. Growing body of evidences emphasize a role for NPM1 in the so called DNA 
damage response (DDR), response that encompasses DNA repair mechanisms, cell cycle 
control pathways, replication bypass mechanisms and, when damage is excessive, cell 
death pathways280,285,342. Several groups have demonstrated that NPM1 knock-out leads to 
embryonic lethality, highlighting the essentiality of the protein for the development; loss 
of a functional allele of NPM1 gene and the formation of oncogenic fusion proteins or 
mutated ones contribute to the onset on genomic instability and to uncontrolled cell 
proliferation, facilitating the process of tumorigenesis281,285,322. Interestingly, NPM1 has 
been implicated in DNA repair, although its exact role(s) has not been identified yet. An 
early response to damage involves a rapid transcriptional up-regulation of NPM1 and its 
augmented expression has been linked to an improve DNA repair process337 whereas the 
absence has been correlated with downstream target of ATM/ATR kinases (γH2Ax foci). 
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Upon sensing DNA damage, NPM1 translocates from the nucleolus to the nucleoplasm in 
IR-induced DNA damage foci351 and acts as chromatin-binding factor after DNA double–
strand breaks281,342,352. Our group recently has demonstrated a physical association 
between APE1 and NPM1 within nucleoli and in nucleoplasm of tumor cells18. It is 
reasonable that NPM1 may act as a histone chaperone under or following DNA repair. 
1.5.4 ALTERATION OF NPM1 IN HUMAN CANCERS 
NPM1 has been widely implicated in cancer pathogenesis for both its growth promoting 
and tumor suppressive functions. In general, overexpression of NPM1 enhances cell 
growth and cell proliferation, probably through promoting ribosome biogenesis, 
stimulating rDNA transcription and ribosome export, DNA replication during S-phase 
and inhibiting cellular apoptosis281. It has been suggested a proto-oncogenic activity for 
NPM1: as Ras, it was found that its overexpression leads to cellular senescence in human 
fibroblasts323. The level of NPM1 is generally more elevated in tumor cells compared to 
normal cells and it is overexpressed in many solid tumors of different origins, but not 
limited to, including tumors of the gastric, colon, liver, breast, ovarian, prostate, bladder, 
thyroid, brain and multiple myeloma281,314. The ability of NPM1 to inhibit apoptosis and 
to promote and stimulate the DNA repair might be a significant aspect for its pro-survival 
role during tumor development. In addition to its overexpression, genetic alteration of 
NPM1 were found in common solid cancer, as lung and hepatocellular carcinoma, but 
particularly in human hematopoietic malignancies (leukemias and lymphomas)314,354. 
Disruption of the NPM1 gene by frame-shift mutations, translocations and deletions has 
been found in acute promyelocytic leukemia (APL), anaplastic large cell lymphoma 
(ALCL) and in premalignant myelodysplastic syndromes (MDS)314,354. Translocations 
occur usually at the N-terminal domain of NPM1 that fuses with the C-terminus of the 
other gene involved in the translocation. The results usually produce an oncogenic fusion 
protein; the remaining functional allele encodes a reduced amount of NPM1 wild-type 
protein. The major genes involved in this fusion are anaplastic lymphoma kinase (ALK), 
retinoic receptor α (RARα) or myeloid leukemia factor 1 (MLF1) in ALCL, APL and 
MDS, respectively354. In all these cases, NPM1 activates the oncogenic potential of the 
fused genes, contributing to cancer development. The fused protein localized in the 
cytoplasm but was unexpectedly found also in the nucleoplasm, since it keeps its ability 
to oligomerize with the wild-type form, protein that retains the nuclear localization 
signal354. A breakthrough in this field was the finding that one-third of adult acute 
myeloid leukemia (AML) cases display aberrant cytoplasmic localization of NPM1, due 
to a frame-shift mutation in exon 12 in patients with AML carrying a normal karyotype, 
implying for the first time a direct involvement of NPM1 as cancer gene286. In the next 
section, a dedicate review of AML with abnormal cytoplasmic NPM1 (NPM1c+) will be 
covered. 
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1.5.4.1 ACUTE MYELOID LEUKEMIA CARRYING CYTOPLASMIC
NPM1 (NPM1C+ AML) 
NPMc+ AML accounts for one-third of all cases of adult AML, up to two-third of 
patients with normal karyotype but presents a less frequency in children (~7%)282,286. A 
recent report documents 55 somatic NPM1 mutations, including insertions, insertions and 
deletions, base substitutions in exon 12 that result in similar alterations at the C-terminus 
of the protein (a complete destabilization of the domain without any regular tertiary 
structure290), producing NPM1c+282. All these mutations generate a shift in the reading 
frame of the transcripts from the point of insertion/deletion. Even though the 
numerousness of the found alterations, the most common mutation, accounting for 70-
80% of adult NPM1c+ AML, is a duplication of a 4-base sequence (TCTG) at position 
956-959 of the sequence286. This duplication leads to two crucial events at the C-terminus 
of the protein for the aberrant cytoplasmic localization292. First, this insertion leads to the 
loss of both Trp288 and Trp290 or just Trp290, residues that constitute the nucleolar 
localization signal for NPM1258, disrupting the C-terminus and reducing NPM1 nucleolar 
storage290. Second, the duplication produces a new leucine-rich NES motif in the C-
terminus, in addition to the NES signals already present in the NPM1 sequence (Figure 
17)292. Interestingly, the C-domain as a whole plays a role in regulating the NPM1 
localization: AML-independent mutations (F268A and F276A) within the C-terminus 
predicted to disrupt the tertiary structure of the domain while retaining the two 
tryptophans lead to a nucleoplasmic localization of NPM1 without any strong 
accumulation in the nucleoli, demonstrating the importance on this domain290. Moreover, 
depending of the exact position of the insertion, leading to the loss of both tryptophans or 
not, the new NES motif presents different efficiency in delocalize NPM1 in the 
cytoplasm: the balancing between the NES and tryptophans’forces determines the 
subcellular localization of NPM1355. Usually Trp288-remaining mutants are always 
associated with a strong new NES motif; a weak NES sequence together with the 
retention of Trp288 has never been detected in AML, suggesting a selective pressure 
towards the nuclear export of NPM1 in favor of a cytoplasmic localization and pointing 
out to this re-localization as a crucial event in leukomogenesis355.  
63 | P a g e
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
INTRODUCTION 
Figure 17: NPM1c+ loses its nucleolar localization signal and acquire a new NES motif.  Schematic 
view of all the signals that govern NPM1 trafficking within cells. The mutated form of protein, found in 
AML, differs from the wild-type form for the insertion at the C-terminus that disrupts the reading frame of 
the transcript. The mutation leads to the loss of the two tryptophan residues, or just tryptophan 290, and to 
the formation, in concomitance, of a new NES motif, bound by Crm1. On the top, the 3-helix structure of 
the C-terminus with the two tryptophans highlighted by arrows within the hydrophobic core (Image from 
Falini B. et al., Leukemia, 2009) 
Recently, another additional mechanism to explain the aberrant cytoplasmic localization 
of NPM1c+ has been demonstrated. The existence of a direct correlation between NPM1 
C-terminal folding, G-quadruplex binding and proper nucleolar localization has been 
shown291,356: through the C-terminus NPM1 binds G-quadruplex structures found in 
ribosomal DNA both in vivo and in vitro357, whereas the leukemic variant completely 
loses this capability due to a G-quadruplex binding domain destabilization356. The 
disruption of the binding of G-quadruplex in rDNA and NPM1 wild-type using a specific 
ligand for the G-quadruplex leads to a loss in nucleolar NPM1 accumulation, suggesting a 
novel role for these structure in assuring the proper localization for NPM1356. In NPM1c+ 
AML, since the leukemic blast is heterozygous retaining one wild-type allele354, a 
nucleolar/nucleoplasmic localization could be found for the wild-type protein while the 
mutated form is limited to the cytoplasm292,358. However, the mutated form acts as a 
negative dominant, due to the fact that it maintains the ability to form oligomers: hence, 
NPM1c+ could generate a heterodimer with the wild-type protein, delocalizing the latter 
in the cytoplasm (Figure 18).  
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Figure 18: Mechanism of the NPM1 shuttling from the nucleoli to the cytoplasm in normal cells (top, 
left) and in NPM1c+ AML cells (top, right). In normal cells, NPM1 wild-type localizes mainly in the 
nucleoli, since the nuclear import prevails over the Crm1-mediated export. On the contrary, in AML cells, 
both of the coexisting NPM1 forms (wild-type and mutated) delocalizes in the cytoplasm due to the 
prevalence of the export to the nuclear import. Purple squares indicate tryptophans 288 and 290; black 
squares the mutated tryptophans; light blue rectangle indicates the NLS sequence and the red circles 
indicate the NES motifs. To notice that NPM1c+ presents three NES motifs while the wild-type counterpart 
two sugnals. (Bottom panel) Confocal 3D-reconstruction of NIH-3T3 cells expressing NPM1 wild-type 
GFP tagged protein (a); NPM1c+ GFP tagged mutant (b) and NPM1c+ GFP tagged mutant after incubation 
with the Crm1 inhibitor Leptomycin B (LMB) (c). The nucleus is counterstained in red with the propidium 
iodide. In contrast to the wild-type protein that localizes mainly in the nucleoli, the NPM1c+ mutant shows 
a prevalent localization in the cytoplasm. The treatment with LMB blocks the NPM1c+ export and the 
mutant present a strong accumulation within nucleoli. The nucleus was cut electronically to analyse the 
localization of NPM1 within the subcellular compartment (Image from Falini B. et al., Leukemia, 2009)
This aberrant cytoplasmic localization of NPM1c+ may play a crucial role in 
leukemogenesis, and besides the founder genetic lesion, secondary cooperating mutations 
participate in the process; however, the causative link between this gene mutation and the 
occurrence of NPM1c+ AML remains elusive. Two main aspects should be pointed out: 
the remaining NPM1 wild-type allele produces a reduced amount of wild-type protein in 
comparison to a condition of homozygosis, and often the protein results dislocated in the 
nucleoplasm and in the cytoplasm due to the formation of heterodimers with NPM1c+. In 
addition, the mutated allele produces NPM1c+ protein, localized in the cytoplasm: this 
mutated form may recruit and bind several natural NPM1 partners, dislocating them from 
the normal subcellular compartment and abrogating their physiological function, as 
already demonstrated for ARF358-360, HEXIM1332, Fbw7γ329 and Miz1347, and may also 
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interact with new different protein partners in the cytoplasm, where it acquires new 
functions (i.e. inhibition of apoptosis through the binding to the cleaved forms of Caspase 
6 and 8)361. The attenuation of the physiological functions of these protein partners may 
lead in some cases, such as for Fbw7γ and Miz1, to the stabilization of c-Myc and to the 
deactivation of cell barriers (ARF358-360 and Miz1-controlled cell cycle inhibitors as p21, 
p15Ink4b347), conditions that could affect the oncogenic potential of NPM1c+, 
contributing to the transformation and to uncontrolled cell proliferation329,347. All these 
phenomena perturb ultimately multiple cellular pathways in which the protein takes part, 
establishing a condition of “loss of function”, as result of the NPM1 partners 
delocalization in the cytoplasm, and/or “gain of function”, as a consequence of the 
increased nuclear export of NPM1362. Mutant mice with only one functional NPM1 allele 
leads to genomic instability, promoting cancer susceptibility both in vivo and in vitro and 
developing of hematological malignancies362. Interestingly, the NPM1c+ AML defines a 
subgroup of AML with distinctive features such as a determined gene expression profile, 
including up-regulation of HOX genes and other genes involved in the stem cell 
maintenance and down-regulation of CD-34, and a specific microRNA signature, with the 
up-regulation of miR-10a and miR-10b362. Patients with NPM1c+ AML demonstrate a 
good-response to therapy and the prognosis is positive in absence of FTL3-ITD 
mutations362. 
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2. AIMS OF THE PROJECT
As discussed previously, APE1 is an essential gene and exerts a key role in the 
maintenance of genome stability and redox signaling through its two main functions, the 
DNA repair and the redox regulation of different cancer-related transcription factors. 
These two functions are exerted by two independent domains. Through its C-terminus 
(residues 61-318), it acts as an essential endonuclease in the base excision repair (BER) 
pathway of DNA damages caused by endogenous and exogenous oxidative and alkylating 
agents. On the other hand, its N-terminal domain (residues 1-127) is devoted to redox 
regulation of different transcription factors, maintaining them in an active reduced state. 
Even if these two activities are quite well characterized and studied, the mechanisms that 
regulate cellular APE1 functions are still poorly understood. Intriguingly, in the latest 
years, a novel role for the first 35 amino acids of the protein has been revealed, although 
until few years ago, this extreme disordered N-terminal domain was considered 
dispensable for protein functions. This unique functional feature endowed by disorder 
within the first 35 amino acids contributes to and influences the mechanisms of action of 
APE1. It has been described that this lack of an ordered structure leads to several benefits, 
as an increased ability to bind to several proteins, allowing an extremely important 
plasticity in cellular response through a process of adaptation in recognizing the different 
partners, both proteins and nucleic acids18,61,363,364, a controlled catalytic activity on abasic 
DNA through the regulation of product binding, as recently demonstrated by our group23 
and an effective regulation by degradation after a proteolytic event111,112. Moreover, as a 
multifunction protein, after gene transcription APE1, and its N-terminus, can be edited by 
different post-translational modifications in vivo, as reported previously for acetylation at 
Lys residues 6 and 725 and for ubiquitylation at Lys24, 25 and 2724, acting as a novel and 
rapid mechanism for APE1 to modulate its different protein functions and dynamically 
coordinate its signaling networks. In addition, the complex protein networks in which 
APE1 takes place is a further mechanism able to redirect APE1 toward a specific 
function, by controlling its trafficking within the cells and its expression.  However, a 
clear picture of the multiple ways by which cells regulates APE1 is still missing; for these 
reasons my PhD project aimed to fill this gap. In particular, I focus on the role of 
acetylation at APE1 N-terminus (Lys27, 31, 32 and 35) in controlling APE1/NPM1 
interaction, its activity and its trafficking; interestingly, NPM1 itself, a new APE1 
interacting partner, controls APE1 expression and AP endonuclease activity within cells. 
Finally, the effect of APE1 genetic variants in a cellular context was studied, with 
particular attention to the APE1 interaction with its binding partners. Accumulating 
evidences, in fact, indicate a firm linkage between the APE1 genetic variants and cancer 
etiology, but the molecular basis is still unknown. Elucidating the mechanisms and the 
consequences of an altered APE1/NPM1 interaction, possibly associated to the different 
APE1 polymorphic variants, and their role in tumorigenesis represent a critical step 
towards better patient treatments or therapeutic strategies for specific cancer types.  
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3.1.2 CHARACTERIZATION OF APE1 INTERACTOME MAP AND 
THE ROLE OF APE1 ACETYLATION IN CONTROLLING APE1 
COMPLEX WITH ITS PROTEIN PARTNERS
Our group previously characterized the APE1 interacting partners under basal conditions 
through a functional proteomic approach based on 2-DE resolution of APE1 
immunopurified complexes from HeLa cells18. This approach has the limitation of a poor 
efficiency for the analysis of proteins having a high molecular mass, a poor solubility and 
a basic pI value. Since post-translational modifications, including acetylation, can affect 
APE1 interaction with its associated proteins, we decided to extend APE1 interactome 
analysis, in order to evaluate the role of acetylation and of its N-terminus in controlling 
APE1 equilibrium with its partners. Therefore, to prevent any methodological bias, we 
now separated immunopurified complexes through SDS-PAGE and applied nLC-ESI-IT-
MS/MS analysis directly to gel slice digests from protein having an apparent mass of 50-
300 kDa (Figure 20). To evaluate the effect of the loss of the APE1 N-terminal domain on 
protein interactome, we first compared immunopurified APE1 complexes obtained from 
HeLa cell lines stably expressing a FLAG-tagged APE1-WT with that of the APE1-N∆33
deletion mutant (Figure 20, left); experiments were performed under basal conditions as 
previously described18. Then, we analyzed the impact of HDACs-inhibitor trichostatin A 
(TSA), which is known to induce APE1 hyperacetylation on lysine residues 6 and 725,91, 
by comparatively evaluating the APE1 interactome under basal conditions and after 
treatment of cells with TSA (Figure 20, right). As a control, we used immunoprecipitated 
material from HeLa cells stably transfected with the empty vector and expressing a 
scrambled siRNA sequence (APE1-SCR-1). In both comparative interactome analyses, 
identified components were subtracted from protein entries occurring in gel portions 
associated with control (APE-SCR1).  
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Besides confirming a number of APE1 interacting partners18, highlighted in italics in 
Table 4, 17 novel protein species were identified. Again, the majority of these proteins 
classified within RNA metabolism (RL14, RL3, RL4, hnRNP-H, hnRNP-U, NCL, 
PABP1 and YB1), cytoskeleton dynamics (ACTN-1, KIF11, MOES, MYH9, MYO1C), 
secretion (SPTB2), transcriptional regulatory processes (BASP1 and THRAP3) and RNA 
metabolism, transcriptional activation and non-homologous end joining repair of DNA 
double strand breaks (SFPQ).  
Taken together with results obtained in our previous work18, a list of 26 specific APE1 
interacting partners was obtained (Table 4). Interestingly, most of them required the 
APE1 N-terminal domain for stable interaction and were modulated by acetylation. 
Notably, our approach did not identified known DNA-repair enzymes involved in BER, 
such as Polβ or XRCC1, which are already known binding to APE1 and that were found 
by subsequent Western blot analyses in this work of Thesis61. This may be essentially due 
to the low sensitivity of the method we used, able to efficiently recognize only highly 
abundant proteins, and to the low representation of DNA repair enzymes in mammalian 
cells365.  
As confirmatory data, validation experiments with some of the identified protein species 
(Figure 20 and Table 4) and evaluation of the effect of the N-terminus truncation and 
acetylation after TSA treatment on the other interacting partners identified were 
performed by Western blot analysis on an independent set of immunoprecipitated 
material (Figure 22). 
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Table 4: List of APE1 interacting partners as revealed by combined SDS-PAGE/nLC-ESI-IT-MS/MS analysis and previous combined 2-DE/MALDI-TOF peptide 
mass fingerprint analysis. Protein name, accession number (SwissProt entry), molecular mass (kDa), sequence coverage, number of identified peptides and known protein 
functions are listed. Interacting protein ability to bind APE1-N∆33 and modulation of protein interacting partners after TSA treatment are also indicated. Down-arrows 
indicate a decrease interaction with respect to APE1-WT. 
Protein identity Swiss Prot entry 
Mr 
(kDa) 
Sequence
coverage 
% 
Peptide 
number Function 
Interaction with 
APE1-N∆33 
TSA 
treatment Slice nr 
40S ribosomal protein SA (RSSA) P08865 33 4,41 2 
Required for the assembly and/or stability of the 
40S ribosomal subunit. Processes the 20S 
rRNA-precursor to mature 18S rRNA 
↓ 
60S acidic ribosomal protein P0 
(RLA0) P05388 34 13 7 Functional equivalent of E.coli protein L10 No 
60S ribosomal protein L14 (RL14) P50914 23 9,39 3 Component of the large subunit of cytoplasmic ribosomes + T1 
60S ribosomal protein L3 (RL3) P39023 46 5,21 3 Component of the large subunit of cytoplasmic ribosomes - A6 
60S ribosomal protein L4 (RL4) P36578 48 2,58 4 Component of the large subunit of cytoplasmic ribosomes No 
A3, A4, A5, 
T5, T6 
Alpha-actinin-1 (ACTN1) P12814 103 2,47 4 F-actin cross-linking protein - A3 
Aminopeptidase N (hAPN) P15144 109 3,41; 1,45 11, 4 
Broad specificity aminopeptidase. Used as a 
marker for acute myeloid leukemia and played a 
role in tumor invasion 
A2, T2 
Brain acid soluble protein 1 (BASP1) P80723 23 48,46 20 Trascriptional corepressor and promoter binding protein Yes 
A3, A4, A5, 
N4, N5 
Heterogeneous nuclear 
ribonucleoprotein F (hnRNP-F) P52597 46 8,21 4 
Component of the heterogeneous nuclear 
ribonucleoprotein (hnRNP) complexes A6, T6 
Heterogeneous nuclear 
ribonucleoprotein H (hnRNP-H) P31943 49 7,57 4 
Component of the heterogeneous nuclear 
ribonucleoprotein (hnRNP) complexes + T5 
Heterogeneous nuclear 
ribonucleoprotein U (hnRNP-U) Q00839 90 5,22 2 
Binds to pre-mRNA and to to double- and single-
stranded DNA and RNA + T2 
Keratin, type II cytoskeletal 8 (K2C8) P05787 50 12 9 
Helps to link contractile apparatus to dystrophin 
at costameres of striated muscle. Belongs to 
ribosomal protein S2P family 
No 
Kinesin-like protein (KIF11) P52732 119 3,6 10 Motor protein No A1, A2, T1, T2 
Moesin (MOES) P26038 68 1,73 2 Connects  major cytoskeletal structures to the plasma membrane No A4 
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Myosin-9 (MYH9) P35579 227 2,14 6 Role in cytokinesis, cell shape, and specialized functions + T1 
Myosin-Ic (Myosin I beta) (MYO1C) O00159 118 2,82 3 
Unconventional myosins involved in intracellular 
movements ans Involved in glucose transporter 
recycling in response to insulin 
+ T2 
Nucleolin (Protein C23) (NCL) P19338 77 2,97 6 
Role in pre-rRNA transcription and ribosome 
assembly. Chromatin decondensation inducing 
protein 
No A2, A3, A4, A5, T2, T3 
Nucleophosmin (NPM1) P06748 35 19 9 
Associated with nucleolar ribonucleoprotein 
structures and binding to single-stranded nucleic 
acids; assembly and transport of ribosome 
No 
Peroxiredoxin 6 (PRDX6) P30041 25 37 7 
Involved in redox regulation of cell and 
protection against oxidative injury (lipid 
peroxidation) 
↓ 
Polyadenylate-binding protein 1-A 
(PABP 1) P11940 71 7,9 4 Binds the poly(A) tail of mRNA - A4 
Pre-mRNA-processing factor (PRP19) Q9UMS4 53 22 6 DNA double strand break repair and pre-mRNA splicing reaction No 
Ribose-phosphate 
pyrophosphokinase 1 (PRPS1) P60891 31 29 8 Ribose metabolism Yes 
Ribose-phosphate 
pyrophosphokinase 2 (PRPS2) P11908 31 19 6 Ribose metabolism Yes 
Spectrin beta chain, brain 1 (SPTB2) Q01082 275 0,89 3 Involved in secretion, interacts with calmodulin in a calcium-dependent manner + T1 
Splicing factor, proline- and 
glutamine-rich (SFPQ) P23246 76 2,15 4 
DNA and RNA binding protein; pre-mRNA 
splicing factor. Involved in NHEJ and required for 
double strand break. Trascriptional regulator 
No A3 
T-complex protein 1 subunit alpha 
(TCPA) P17987 57 20 10 Molecular chaperone No 
Thyroid hormone receptor-associated 
protein 3 (THRAP3) Q9Y2W1 109 0,95 4 Role in transcriptional coactivation No A2 
Y-box-binding protein (YB1) P67809 36 20,19 8 
Mediates pre-mRNA alternative splicing 
regulation. Binds and stabilizes cytoplasmic 
mRNA 
No A6, T6 
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Genotoxic treatment therefore may switch APE1 interactome network from binding to 
protein partners involved in RNA metabolism to those involved in DNA repair and 
directly to DNA as a substrate.  
Since genotoxic damage, such as MMS, is able to induce APE1 acetylation at Lys27-3592 
and modulates its interacting network, switching APE1 binding towards DNA repair 
partners, we decided to better characterize the functional role of acetylation at Lys27-35 
during genotoxic damage and its relevance in vivo92. In our recent paper, we 
demonstrated that in cells expressing a specific K-to-A mutant (APE1-K4pleA), 
mimicking a constitutive acetylated form of the protein, APE1 presents a nuclear 
localization, showing nucleolar deficiency, and an increased AP activity. Cells expressing 
this mutant are more resistant to genotoxic treatment than those expressing the wild-type, 
although its nucleolar absence negatively influences the cellular proliferation. Notably, 
the acetylation status of Lys27-35 is strongly connected with that observed at Lys6/Lys7, 
involved in the coordination of BER activity, through a mechanism regulated by sirtuin 1 
deacetylase (SIRT1)78. Of interest, structural studies show that acetylation at Lys27-K35 
may account for local conformational changes on APE1 protein structure. All these 
results highlight the emerging role of acetylation of critical Lys residues in regulating 
APE1 functions. They also suggest the existence of cross-talk between different Lys 
residues of APE1 occurring upon genotoxic damage, which may modulate APE1 
subnuclear distribution and enzymatic activity in vivo92. 
These evidences allowed to draw a model (Figure 27) that describes how, during DNA 
damage stress response, acetylated APE1 dissociates from NPM1 within nucleoli and 
accumulates into the nucleoplasm, where it can exert its endonuclease activity on 
damaged DNA. Notably, genotoxic treatment significantly alters the APE1 interactome 
network redirecting the enzyme from protein complexes associated with RNA 
metabolism toward those involved in DNA repair.  
Through multiple interactions with various protein partners and coordinated occurrence of 
different post-transcriptional modifications, such as acetylation and ubiquitylation24, 
subcellular distribution of APE1 and its enzymatic activity seem to be finely tuned, on 
demand, in a time-dependent manner. Nucleolar role of APE1 storage and regulation may 
have profound biological consequences during cell response to stressor signals, also in 
light of recent evidences pointing to nucleolus as a central hub in DNA damage.  
As importantly, data obtained in this work show that nucleoli may not only act as a 
storage site for securing a proper amount of APE1 readily available for maintenance of 
genome stability, but also emphasize that nucleolar APE1 may control cell proliferation, 
possibly through its rRNA cleansing function or through an hypothetical role on 
ribogenesis. Accordingly, APE1-K4pleA expressing cells, under basal conditions, showed 
impairment in proliferation rate with respect to APE-WT expressing ones. Therefore, it 
may be speculated that nucleolar APE1 is responsible for functional activity of the 
nucleolus in ribosome biogenesis. APE1 release from nucleoli upon genotoxic treatment 
may constitute a signal for blocking active protein synthesis and allowing activation of 
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RESULTS 
Figure 30: NPM1-/- MEFs displays increased sensitivity to a wide range of DNA damaging agents. A | 
MTS assay was used to evaluate cell viability of MEF cells after treatment with increasing amounts of 
MMS for 8 hr. B | Cell viability were tested using MTS assay on MEFs. After 24 hr-pretreatment with MX, 
cells were incubated with increasing doses of H2O2 for 1 hr. C | Evaluation of cell survival of MEFs after 
KBrO3 treatment (40 mM for 30 min) using MTS assay. After removing the compound, cells were allowed 
to recover for the indicated periods of time. D | Trypan blue cell counting was used to measure cytotoxicity 
of BLM in MEF cells. Mean±SD values are the result of three independent experiments. 
Remarkably, DNA lesions induced by PJ34, a PARP-inhibitor374, and UVC, that require a 
NER participation for recovery, did not lead to any significant differential sensitivity 
between the two cell lines, supporting a specific impairment of BER pathway, involving 
APE1, in NPM1-/- cells (Figure 31). 
Figure 31: NPM1-/- MEFs did not display any differential sensitivity to DNA lesions repaired by NER. 
A |PARP inhibitor PJ34 was used as damaging agents that elicit a NER response to evaluate the cell 
viability by using WST-1 cell proliferation assay. Cells were incubated with increasing amounts of PJ34 for 
48 hr. B | Cell survival was evaluated after UVC light on MEFs cells by cell counting. Cells were exposed 
to the indicated amounts of UVC light followed by a recover of 48 hr. 
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To assess whether the effect presented so far were directly linked to NPM1 loss and not to 
some other unspecific effect due to the knock-down of the gene, NPM1-/- MEFs were 
transfected with a vector encoding for NPM1, restoring NPM1 expression in this cell line. 
Figure 33: Absence of NPM1 impaired the APE1 AP-incision activity. A | Endonuclease assay 
comparing equal amounts of nuclear cell extracts (600ng) from NPM1+/+ and NPM1-/- MEFs. A 
representative image shows the conversion of the substrate (S) in the product (P) operated by APE1 at the 
indicated periods of time. In the diagram on the right, the densitometric quantification of the product 
formation of three independent experiments is shown. Western blotting indicating the amount of cell extract 
used during the analysis is reported. LSD1 is used as nuclear marker. B | In vitro endonuclease assay 
performed using comparable amount of nuclear APE1, as shown by Western blotting analysis after 
normalization of the two nuclear cell extracts. A representative image shows the conversion of the substrate 
(S) in the product (P) during time, as indicated. The diagram on the right displays the product formation as 
obtained by densitometric quantification of three independent experiments.
On this background, the APE1 AP-incision activity was re-tested by endonuclease assay 
using nuclear cell extracts (Figure 34) 
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3.3  FUNCTIONAL REGULATION OF TUMOUR ASSOCIATED-
APE1 GENETIC VARIANTS 
Although abnormal APE1 expression and localization patterns have been demonstrated 
for different types of solid and liquid tumours63 and have been associated with several 
tumorigenic processes16, the investigators have never looked into the molecular 
mechanisms that drive the overexpression and/or a cytoplasmic accumulation of APE1 
seen in pathology. As proposed in this work of Thesis, a molecular explanation involving 
a critical role of its complicated network of interacting partners in regulating APE1 
functions has been provided, with particular attention to NPM1. Altered levels of its 
partners or abnormal expression of them in nucleus/cytoplasm, as for example NPM1c+, 
may impact on APE1 subcellular distribution rather than a mutation in APE1 itself. 
Interestingly, in the latest years few APE1 amino acids genetic polymorphic variants have 
been identified throughout normal and disease population166, but none of these occurs on 
residues responsible for neither the DNA repair activity, nor the redox functions of the 
protein and is possibly explained by the strong selective pressure on these vital functions 
of the protein. However, in most cases, it is still unclear the possible effect of the 
sequence variation on the AP-endonuclease activity and the DNA repair capability in 
vivo; notably, it has been hypothesized that these genetic variants might lead to changes 
in mRNA stability, translation efficiency or protein structure/function, rather than causing 
a severe effect on its AP-endonuclease activity. These observations suggest a role for 
APE1 polymorphisms in disease progression or initiation, which may lead to increased 
disease susceptibility within the population. Some of these polymorphisms occur at the 
N-terminal domain of the protein, suggesting that they might influence APE1 
macromolecule associations, since the N-terminus has been described as fundamental for 
establishing protein-protein interactions18. At present, little information is available 
regarding the biological roles of these variants in vivo. The last part of this work of 
Thesis, which is still in progress, is aimed to fill in this gap. 
3.3.1 COMPUTATIONAL EVALUATION OF APE1 VARIANT 
STRUCTURE AND FUNCTION
As initial analysis, four different computational on-line approaches were used to evaluate 
the possible impact of the tumour associated-polymorphisms studied in this work of 
Thesis (Figure 45) on APE1 structure/functions, as recently did by Illuzzi and co-workers 
for others APE1 variants170. 
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Table 5: APE1 genetic variants considered and impact of amino acids substitution on APE function/structure as predicted by four online modeling methods. For the 
PROVEAN software (http://provean.jcvi.org/index.php), a cut-off of -2.5 was used. Scores ≤-2.5 are considered as deleterious, while values greater than the cut-off are 
predicted as neutral. The SIFT modeling (http://sift.jcvi.org/) considered scores ≤0.05 as deleterious whereas >0.05 as tolerated. As template, the APE1 sequence 
(NP_001632.2) was used. For the PolyPhen-2 tool (http://genetics.bwh.harvard.edu/pph2/) and PROVEAN model, APE1 UniProtKB sequence (P27695) was used as query. 
CUPSAT predictions (http://cupsat.tu-bs.de/) were obtained using a thermal experimental method and the PDB APE1 protein structure (1DE8) was employed. N/A = not 
available. Once = observed a single time. 
APE1 
genetic 
variants 
Source 
Percentage 
of 
frequency 
Functional 
consequences 
PROVEAN SIFT CUPSAT PolyPhen-2 
Score Prediction Score Prediction 
Overall 
stability 
Torsion Score Prediction 
L104R ALS once 
Reduced AP 
endonuclease 
activity (~40%)237 
-4.925 Deleterious 0.00 
Affected 
protein 
function 
Stabilizing Unfavorable 0.987 
Probably 
damaging 
P112L Tumor once 
Normal 3’ to 
5’ exonuclease 
and 3’-damage 
excision activities 
and AP-DNA 
complex 
stability170 
-5.106 Deleterious 0.05 
Affected 
protein 
function 
Destabilizing Favorable 0.632 
Possibly 
damaging 
E126D ALS once 
Reduced AP 
endonuclease 
activity (~40%)237 
-1.000 Neutral 0.44 Tolerated Destabilizing Unfavorable 0.004 Benign 
D148E 
NCBI 
rs113040
8 
48.5 
Normal AP 
endonuclease 
activity170,237 
-0.204 Neutral 1.00 Tolerated Destabilizing Favorable 0.000 Benign 
R237A NCBI N/A 
Reduced AP 
endonuclease 
activity (~65%)237 
-5.907 Deleterious 0.00 
Affected 
protein 
function 
Stabilizing Favorable 1.000 
Probably 
damaging 
R237C 
Tumor 
(NCBI 
once 
Reduced 3’ to 
5’ exonuclease 
-7.884 Deleterious 0.00 
Affected 
protein 
Stabilizing Unfavorable 1.000 
Probably 
damaging 
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rs375526
265) 
and 3’-damage 
excision 
activities; slightly 
reduced AP-DNA 
complex 
stability170 
function 
D283G ALS once 
Reduced AP 
endonuclease 
activity (~90%)237 
-6.910 Deleterious 0.00 
Affected 
protein 
function 
Destabilizing Unfavorable 1.000 
Probably 
damaging 
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subcellular localization of the different APE1 genetic variants. Ectopic APE1 staining (α-FLAG, green) 
was used to localize HeLa cells positively transfected with the FLAG-tagged APE1 genetic variants 
constructs. TO-PRO3 counter-staining was used to mark nuclei; bars correspond to 15.85 µM. 
In conclusion, APE1 genetic variants displayed a similar distribution pattern to the wild-
type protein, as already suggested by Illuzzi and coworkers170 for the other APE1 
polymorphisms examined (Q51H, I64V, G241R, P311S, A317V). 
3.3.3 APE1 POLYMORPHISMS AFFECT THE COMPLEX NETWORK 
OF MACROMOLECULE ASSOCIATIONS
We decided to focus our attention on three polymorphisms (L104R, D148E and R237C) 
whereof two of them (L104R and R237C) were predicted to impact on APE1 functions, 
being probably damaging, whereas the D148E was calculated not to influence APE1 
activities and appears benign by our computational analyses (Table 5). 
To assess the possible effect of this subgroup of APE1 variants (L104R, R237C and 
D148E) in establishing protein-protein interactions, co-immunoprecipitation analyses 
were carried out on HeLa cells after transient transfection with FLAG-tagged APE1 
plasmid constructs. The binding with six known APE1 interacting partners were tested 
(Figure 48): four are involved in RNA metabolism functions, as NPM1, PRP-19, PABP-1 
and YB-1, while the other two (XRCC1 and DNA Polβ) participate with APE1 in DNA 
repair through BER pathway. In general, APE1 D148E, predicted as tolerated with all the 
four analyses tools used, presents an association pattern with both RNA metabolism and 
DNA repair proteins comparable with the wild-type protein. Only a slight decrease was 
detected for the interaction with YB-1 protein, reduction that was analogous to that 
observed for the other APE1 genetic variants. On the contrary, a completely different 
scenario appeared for L104R and R237C variants. Notably, the expression of the two 
impacting polymorphisms (L104R and R237C) leads to an overall diminished association 
with all the interacting partners analysed; this strong effect was observed and was similar 
for all the proteins except for NPM1. Interestingly, for NPM1 the behaviour of the two 
forms completely differs, showing an opposite effect: the L104R presents an increased 
association with NPM1 (~ 2 fold) while the R237C halves its interaction in comparison to 
the wild-type one. The same results were also obtained for the D283G change, even if the 
NPM1 reduction observed was less pronounced than the R237C one (data not shown). 
In conclusion, all these data demonstrate that although the overall intracellular 
localization for the entire APE1 genetic variants array was similar to that of the APE1wt 
with a nuclear and nucleolar distribution, the amino acid substitutions considered (L104R, 
R237C and D283G), all predicted to affect the protein structure/function lead to a marked 
reduction in its interacting network. This suggest a possible explanation about one of the 
mechanisms through which APE1 polymorphisms, though not directly affecting neither 
the DNA repair nor the redox functions, can ultimately affect DNA repair or 
transcriptional regulation, thus leading to disease susceptibility. Further studies are 
underway for better characterizing the effects of APE1 polymorphisms on its 
endonuclease and transcriptional activities in vivo.  
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Figure 52: APE1 genetic variants exhibit a protective role towards genotoxic damage. A | MTS assay 
was used to evaluate cell viability of APE1 genetic variant clones after treatment with increasing amounts 
of MMS for 8hr. B | Cell viability were tested using MTS assay on APE1 polymorphisms clones. Cells 
were incubated for 24hr with increasing doses of cisplatin, as indicated. Mean±SD values are the result of 
three independent experiments. 
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4 DISCUSSION 
Abasic sites are a common form of DNA damage, generating by spontaneous reactions or 
damage-induced hydrolysis. APE1 possesses a stong AP endonuclease activity, acting as 
the main mammalian endonuclease in base excision repair (BER) pathway. In addition to 
its role in DNA repair, several biochemical and cell-based observations support the 
relevance of its redox regulatory function and gene regulation in modulating different 
cellular contexts, including proliferation and growth, apoptosis, stress responses and 
metabolism, to name a few, supporting the notion of a multifunctional protein, with 
features that go beyond the classical DNA repair enzyme activities. How these various 
functions of APE1 are regulated is still poorly understood; however, in the latest years, a 
novel role for the first 35 amino acids of the protein has been revealed. Several evidences 
suggest a possible role of protein-protein interactions and post-translational modifications 
in controlling the different APE1 cellular activities. Though considered for many years 
dispensable for APE1 activities, the APE1 N-terminus could be targeted by numerous 
post-translational modifications, such as phosphorylation, ubiquitination, proteolysis and 
acetylation. Moreover, this disordered domain seems to account for protein-protein 
interactions with APE1 binding partners. Nowadays, although several studies show that 
APE1 deficit strongly impairs cell survival and sensitivity to DNA-damaging agents with 
a consequent enhanced risk of disease development, a firm linkage between an APE1 
defect and human disease has not been established yet, probably due to the fact that a 
severe APE1 deficiency would be incompatible with life. APE1 appears as a promising 
candidate for therapeutic approaches and few compunds, that inhibit the DNA repair or 
the redox activities, have been used alone or in combination therapy with the classic 
chemotherapeutic agents for specific cancer types in pre-clinical and clinical studies. 
Thus, understanding the molecular mechanisms involved in modulating APE1 functions 
may be helpful for designing better therapeutic treatment to enhance cytotoxicity only in 
tumoral cells. Although this increasing interest in post-translational control of APE1, a 
clear picture of the multiple ways by which APE1 different functions are regulated is still 
missing. For these reasons, during my PhD I focused my attention on the biological roles 
and relevance of the post-translational modifications occurring on a specific portion of 
APE1 N-terminus, the first 35 amino acids, with particular attention to the role of APE1 
acetylation occurring at lysine residues 27-35 in controlling APE1/NPM1 interaction, its 
activity and its trafficking. Here, prompted by previous work of our lab indicating that 
acetylation occurring at N-terminal domain of APE1 may modulate its association with 
rRNA and NPM118,23, through a systematic analysis I identified fourteen lysine residues 
acetylated in vivo, including twelve novel sites (Lys27, 31, 32, 35, 125, 141, 194, 197, 
203, 224, 227, 228) in addition to the two previously described (Lys6 and 7)25. 
Interestingly, the majority of the acetylated sites found, fell within the N-terminus and 
localized close to the identified proteolytic site (Lys31 and 32), indicating a possible role 
in regulating the protein cleavage. Then, in order to evaluate the role of acetylation and of 
its N-terminus in controlling APE1 equilibrium with its protein partners, by using an 
unbiased approach, I extended the APE1 interacting map, identifying new nineteen 
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interacting proteins, involved in RNA metabolism, cytoskeleton dynamics, secretion and 
transcriptional regulatory processes. Most of them required the APE1 N-terminal domain 
for a stable interaction and were modulated by acetylation. These data reinforced the idea 
of APE1 as multifunctional protein, further highlighting the new role of APE1 in the 
RNA metabolism. Intriguingly, genotoxic stresses may switch APE1 interactome network 
from binding to protein partners involved in RNA metabolism to those involved in DNA 
repair and directly to DNA as a substrate. In addition, increased acetylation at Lys27-35 
was observed during cell response to genotoxic damage92. We hypothesized that under 
physiological conditions, non acetylated APE1 may be stored in the nucleoli through its 
binding to NPM1 and rRNA (Figure 27). In our recent paper, we investigated the role of 
acetylation at Lys27-35 in vivo in controlling APE1 subcellular distribution and DNA 
damage response92. A K-to-A mutation at residues Lys27-35, mimicking a constitutive 
acetylated APE1 form, poorly binds NPM1 and rRNA in vivo, with a consequent inability 
to accumulate within nucleolar structures. Genotoxic damage experiments, performed on 
reconstituted HeLa cells with this mutant upon treatment with alkylating agents (MMS) 
show a protective phenotype through increased DNA-repair activity, although its 
nucleolar absence negatively influences the cellular proliferation, probably through its 
RNA cleansing activity. Furthermore, we demonstrated a cross-talk between acetylation 
occurring at Lys6 and 7 with Lys27-35 residues, involving the deacetyl-transferase 
SIRT1. All these observations, prompted us to draw a model (Figure 27), in which, under 
physiological conditions APE1 mainly localized in the nucleoli, where it is required for 
the maintenance of a proper ribosome biogenesis (Poletto et al., submitted to MBoC), 
acting as a putative storage site and central hub in DNA damage262. Following genotoxic 
stress, a still unknown acetyltransferase, present within nucleoli, may acetylate APE1 at 
the N-terminus, shifting the equilibrium from the nonacetylated toward the acetylated 
APE1 form and favouring the release of the interaction from NPM1 and rRNA for a 
proper activation of DNA-repair mechanisms. The acetylated form accumulates in the 
nucleoplasm where it could act on abasic DNA as AP endonuclease in BER pathway. 
When the DNA damage is repaired, SIRT1 deacetylates APE1 in the nucleoplasm, 
redirecting APE1 within the nucleoli and restoring a pre-damaged condition. From this 
model, what emerged is the relevance of the unstructured N-terminal domain of APE1 
with its post-traslational modifications (i.e. acetylation) for association with both proteins 
and nucleic acids, supporting an evolutionary “gain-of-function” hypothesis, but also a 
crucial role for NPM1 in controlling APE1 subcellular redistribution upon stress 
conditions. Therefore, subcellular distribution of APE1 and its enzymatic activity may be 
finely tuned through macromolecular associations and coordinated occurrence of different 
post-translational modifications. Prompted by these observations, I focused my attention 
to NPM1 and its possible role as APE1 regulator. Here, for the first time, I demonstrated 
that NPM1 plays an indirect but significant role in base excision repair through a 
functional regulation of APE1 andonuclease activity, thus indicating a novel role for 
NPM1 in DNA repair. NPM1 knock-down cell showed a differential sensitivity to 
different genotoxicants, as alkylating agents, oxidative stressors and chemotherapeutic 
agents, thus implying an impaired ability of these cells to repair DNA-strand breaks. 
Nevertheless, treatment with PARP1 inhibitor (PJ-34) or UV-treatment excluded a 
107 | P a g e
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
DISCUSSION 
possible involvement of dysregulated strand-break repair systems, within the two isogenic 
cell lines, supporting a BER impairment as the main process affected by the loss of 
NPM1 expression. Notably, the effect of NPM1c+, a NPM1 mutation found in one third 
of acute myeloid leukemia (AML), on APE1 subcellular distribution and APE1/NPM1 
interaction may explain the response to chemotherapy observed for patients with AML 
expressing NPM1c+ mutation. As already described for other NPM1 interacting partners, 
some biological effect observed in AML with NPM1c+ may be caused by impaired 
function of NPM1 binding proteins, due to an abnormal cytoplasmic dislocation285,359. In 
cells expressing NPM1 c+ (ectopically as in transient transfected HeLa cells or 
constitutively as in OCI/AML3 cells and blasts from AML patients), APE1 showed an 
increased cytoplasmic localization, associated with an impaired DNA repair activity and a 
general higher sensitivity to DNA-damaging agents. In many types of cancers, APE1 
presents a different localization pattern, being cytoplasmic or nuclear/cytoplasmic and its 
increased expression is associated with higher tumor aggressiveness and 
chemoresistance16,63. Beside its nuclear activities, extranuclear APE1 functions within 
mitochondria were demonstrated to play a role in repairing mitochondrial DNA damages 
and in controlling the intracellular reactive oxygen species production through inhibition 
of Rac1 have been described154. However, the molecular mechanisms that drive the APE1 
cytoplasmic translocation and its association with tumors are not fully characterized. The 
data presented in this work of Thesis may explain at least one mechanism for APE1 
delocalization in the cytoplasm of AML cells with NPM1c+. Moreover, in OCI/AML3 
cells, as well in AML blasts with NPM1c+, APE1 is destabilized in a granzyme A-
indpendent manner. It can be inferred that, in accordance to the case of p19Arf, NPM1 
may act as a chaperone for APE1, ensuring a proper subcellular localization and 
protecting it from degradation. All these data are in accordance with the model shown in 
Figure 53, that extends a previous one285 and  explains the relative contribution (both 
direct and indirect) of NPM1 expression to cellular transformation. This model takes into 
account the evidence that hematopoietic malignancies, as AML, are associated with 
NPM1 wild-type deficit (panel A) whereas solid tumors show increased expression of 
NPM1 wild-type protein (panel B). In the first case (panel A), the NPM1 mutation is 
causally linked to the transformation process. Reduced nuclear NPM1 levels may lead to 
genomic instability due to BER impairment, with a consequent accumulation of DNA 
damage. Thus, the impaired DNA-damage response may inefficiently block cell 
proliferation: as a consequence some cells would escape DNA damage checkpoints, 
establishing an immortalized clone prone to further oncogenic transformation. In case of 
solid tumors (panel B), elevated NPM1 wt expression levels would contribute to the 
generation of a permissive status for oncogenic transformation. High levels of NPM1 wt 
may limit DNA damage, promoting DNA-damage response, due to an increased BER 
activity, and therefore it may support cell survival and eventually transformation. Our 
evidences suggest that interfering with the APE1/NPM1 interaction, that could be 
associated with the genomic instability, may sensitize tumor cells to chemotherapy and 
radiotherapy.  
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Figure 53: APE/NPM1 role in cellular transformation. A | Reduced nuclear NPM1 levels, caused by the 
loss of one wt allele, lead to genomic instability thorugh BER impairment and accumulation of DNA 
damage. As a result, DNA damage response may block cell proliferation, but few cells may escape and an 
immortalized clone could be transformed by oncogene activation. B | In solid tumors, with elevated NPM1 
expression levels, DNA damage response may be limited by augmented BER, supporting cell survival and 
transformation. This model also includes APE1 protein in both the cases; in the first APE1 may have a 
causative role in transformation whereas in the latter its increased expression level may generate a 
permissive condition for transformation. 
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Notably, up to now, deleterious mutations in the core BER components, as APE1, Polβ 
and XRCC1, have not been clearly associated with human pathologies, even if an 
increasing number of evidences indicated a possible linkage between APE1 and cancer 
etiology. The absence of “disease alleles”, due to the vital role of APE1 within cells, has 
prompted different scientist to pursue the hypothesis of “susceptibility alleles”. Mild 
reduction in BER capacity might be associated with enhanced disease risk. As the 
majority of the polymorphisms involve residues not apparently responsible for neither the 
AP endonuclease activity nor the redox regulatory function, other mechanisms may 
account for the possible role of APE1 genetic variants in tumors. A reasonable 
explanation for the APE1 variants effect observed in tumors may be ascribed to 
alterations of a complex network of interactions affecting the APE1 functional status. 
Nowadays, the molecular basis is still unknown. Through the work conducted herein, I 
explored the functional consequences of a subgroup of APE1 genetic variants for APE1 
subcellular localization and in terms of macromolecular associations. Different 
computational methods used for predicting the genetic variants impact on protein 
structure/ function provided a negative outcome for most of the mutations, excluding 
D148E and E126D. Despite the result of the computational approach, none of the 
previous studies show a parallel significant biochemical or structural defects for most of 
them. To gain further insights in APE1 polymorphisms effects, the subcellular 
localization of APE1 genetic variants was analyzed, showing any significant difference 
with the wild-type protein. Then, the macromolecular associations for three variants 
(L104R, R237C and D148E) with partners involved both in RNA metabolism and DNA 
repair were studied. Interestingly, our evidences indicated that the APE1 single point 
mutations (L104R and R237C) negatively affect APE1 protein-protein interactions. 
Notably, the endometrial cancer-related R237C variant has recently been shown to have 
reduced functions. Although the precise mechanism for the impaired function is still 
unknown, the authors implied a probable disturbance of the local structural integrity, with 
a consequent reduced overall complex stability with nucleic acids170. The data presented 
here are in accordance with a reduced stability of macromolecule associations for this 
variant. To check the cellular response to DNA damages elicited by BER and to test the 
biological impact of these variants in a cellular context, I generated reconstituted cell 
lines expressing each of the polymorphic variants in place of the endogenous APE1 
which was knocked down through RNAi technology. Unexpectledy, all the 
polymorphisms tested, with some different magnitude, showed an increased resistance to 
genotoxic damage, somehow in contrast with the previous in vitro studies indicating a 
reduced BER activity for D283G and R237C170,237. This behavior might be explained 
through the different macromolecule network, highlighted for these APE1 genetic 
variants, as already observed for the K-to-A APE1 mutant, that loses NPM1 interaction92. 
Notably, the mutant shows a higher resistance to genotoxic damages, including MMS and 
cisplatin (Poletto et al., submitted to MBoC)92, supporting recent unpublished data from 
our group regarding an active role for APE1 and, possibly, other BER enzymes, in 
regulation of ribosome biogenesis. Nowadays, an impact for these polymorphisms on 
APE1 ribosomal function(s) could not be excluded, yet. Experiments are now ongoing to 
explore these hypotheses. Further studies for a better comprehension of the molecular 
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mechanisms and the impact of these genetic variants are needed. Whether the APE1 
single point mutations are causative to disease etiology are still matter of debate and it 
will be absorbed a lot of future energies of the scientists to clarify it. 
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5 MATERIALS AND METHODS 
5.1 CELL LINES CULTURE AND REAGENTS 
HeLa, MEF p53-/- NPM1+/+ (NPM1+/+)342 and MEF p53-/- NPM1-/- (NPM1-/-)342 cell lines 
were grown in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (Euroclone, Milan, Italy), 100 U/ml penicillin 
and 10 μg/ml streptomycin sulfate (Euroclone). OCI/AML2 and 3 cells were grown in 
alpha-MEM (Euroclone) supplemented with 20% fetal bovine serum (Euroclone), 100 
U/ml penicillin and 10 μg/ml streptomycin sulfate (Euroclone). Leukemic cells were 
obtained from the bone marrow of patients with acute leukemia during diagnostic 
procedures. Mononuclear cells were separated on a Ficoll–Hystopaque 1077 (Sigma-
Aldrich, Milan, Italy) density gradient, then were washed twice in phosphate-buffered 
saline, checked for viability by using the trypan blue exclusion test and suspended in 
phosphate-buffered saline. Presence of mutations in the NPM1 gene was detected as 
previously described385. Blasts from patients were grown in RPMI (Invitrogen, Monza, 
Italy) supplemented with 20% fetal bovine serum (Euroclone). All chemical reagents 
were supplied from Sigma-Aldrich (Sigma-Aldrich) unless otherwise specified. Cisplatin 
was freshly resuspended in dimethylformamide before each use. Bleomycin Sulfate was 
purchased from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
5.2 APE1 AND NPM1 PLASMID CONSTRUCTS 
Human APE1 variant expression constructs (L104R, P112L, E126D, D148E, R237A, 
R237C and D283G) were created using the QuikChange II Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA, USA). Forward and reverse primers containing the relevant 
nucleotide change (Table 6) were generated following the mutagenic primer design 
guidelines of the manufacturer. To obtain duplex DNAs that harbor the specified 
nucleotide/amino acid change, the appropriate primer pair (125 ng of each 
oligonucleotide) was mixed with 20 ng of wild-type pCMV5.1-FLAG- or p3X-FLAG-
CMV-APE1 plasmids, dNTPs and Pfu-Ultra HF DNA polymerase, and subjected to the 
basic thermal cycling protocol outlined by the manufacturer. After digestion with Dpn1, 
the DNA mix was transformed into XL1-blue Competent cells (Stratagene), and selected 
clones were sequence confirmed by sequencing (Eurofins MWG Operon, Ebersberg, 
Germany). To avoid nonspecific mutagenesis, the APE1 variants cDNA were digested 
with EcoRI and BamHI (Thermo Fisher Scientific, Waltham, MA, USA) and subcloned 
into the same empty vector of origin (Sigma-Aldrich). Recombinant plasmid sequences 
were confirmed by endonuclease restriction analysis. 
The construct pcDNA3-HA-NPM1c+ was generated by using the Quickchange II XL 
Mutagenesis kit (Stratagene) and the pcDNA3-HA-NPM1-WT as template following the 
manufacturer’s instructions. Direct sequencing was performed in order to verify the 
sequence accuracy (Eurofins MWG Operon). NPM1wt and NPM1c+ cDNA were also 
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subcloned in pCMV5.1-FLAG and p3X-FLAG-CMV vectors for reconstitution 
experiments on MEF-NPM1-/- cells. 
Table 6: List of oligonucleotides used for mutageneis. The mutated bases are underlined.  
Primer 
name 
Sequence (5’to 3’) 
L104R 
For - AAATGTTCAGAGAACAAACGACCAGCTGAACTTCAGGAG 
Rev - CTCCTGAAGTTCAGCTGGTCGTTTGTTCTCTGAACATTT 
P112L 
For - TGAACTTCAGGAGCTGCTTGGACTCTCTCATCAAT 
Rev - ATTGATGAGAGAGTCCAAGCAGCTCCTGAAGTTCA 
E126D 
For - CAGCTCCTTCGGACAAGGACGGGTACAGTG 
Rev - CACTGTACCCGTCCTTGTCCGAAGGAGCTG 
D148E 
For - CTTACGGCATAGGCGAAGAGGAGCATGATCAGG 
Rev - CCTGATCATGCTCCTCTTCGCCTATGCCGTAAG 
R237A 
For - CACGCCACAAGAGGCCCAAGGCTTCGGG 
Rev - CCCGAAGCCTTGGGCCTCTTGTGGCGTG 
R237C 
For - CACGCCACAAGAGTGCCAAGGCTTCGG 
Rev - CCGAAGCCTTGGCACTCTTGTGGCGTG 
D283G 
For - TGTTGGTTGGCGCCTTGGTTACTTTTTGTTGTCCC 
Rev - GGGACAACAAAAAGTAACCAAGGCGCCAACCAACA 
5.3 GENERATION OF STABLE CELL LINES RE-EXPRESSING 
NPM1WT IN NPM1-/- BACKGROUND 
Stable cell lines re-expressing NPM1wt in the MEF NPM1-/- background were obtained 
as previously described18. Briefly, for generation of the reconstituted MEF NPM1-/- cell 
line, NPM1-/- cells were transfected with the p3X-FLAG-CMV/NPM1wt vector, 
previously linearized with ScaI (Thermo Fisher Scientific). Positive transfectants 
underwent selection with Geneticin (Invitrogen) for 14 days and individual clones were 
isolated by using cell cloning cylinders (Sigma-Aldrich). As control, a mock-reconstituted 
NPM1-/- cell line was generated by transfection with the p3X-FLAG-CMV-14 empty 
vector. Stable cell clone were grown in Dulbecco's modified Eagle's medium (Invitrogen) 
in presence of Geneticin (700µg/ml). 
5.4 INDUCIBLE APE1 KNOCK-DOWN AND GENERATION OF 
APE1 KNOCK-IN CELL LINES 
The procedure for the generation of the inducible APE1 knock-down clone has been 
previously described18,92. For generation of APE1 genetic variants knock-in cell lines, the 
APE1 siRNA clone was transfected with p3X-FLAG-CMV/APE1 genetic variants 
constructs (L104R, R237C and D283G), previously digested with ScaI (Thermo Fisher 
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Scientific); 48 hr after transfection, the cells were subjected to selection with Geneticin 
(Invitrogen) for 14 days and selected for the acquired resistance. Thirty individual clones 
for each polymorphism were isolated by using cell cloning cylinders (Sigma-Aldrich), 
transferred, and grown stepwise into 48-well, 24-well, 12-well, and 6-well plates for 
expansion to 107 cells in the presence of selective antibiotics. After 8 days of doxycycline 
treatment at the final concentration of 1 µg/ml, total cellular extracts were analyzed for 
APE1 expression by immunoblotting, thus revealing the silencing of the endogenus APE1 
and the expression of the ectopic flagged-mutant forms of the protein.  The HeLa control 
cell clone was identified as SCR-1, while the APE1-knocked-down cell clone was 
identified as CL.3. All biologic data were reproduced in at least two different cell clones 
for each model. 
5.5 TRANSIENT TRANSFECTION EXPERIMENTS 
One day before transfection, cells were seeded in 10 cm plates at a density of 3×106 
cells/plate. Cells were then transiently transfected with plasmids of interest by using 
Lipofectamine 2000 reagent (Invitrogen), according to the manufacturer's instructions. 
Cells were harvested 48 hr after transfection. 
5.6 PREPARATION OF TOTAL, CYTOPLASMIC AND 
NUCLEAR CELL EXTRACTS 
For preparation of total cell lysates and co-immunoprecipitation, cells were harvested by 
trypsinization and centrifuged at 250 x g for 5 min at 4°C. Supernatant was removed, and 
the pellet was washed once with ice-cold phosphate-buffered saline (PBS) and then 
centrifuged again as described before. Cell pellet was resuspended in Lysis buffer 
containing 50 mM Tris HCl (pH 7.4), 150 mM NaCl, 1mM EDTA, and 1% [wt/vol] 
Triton X-100 supplemented with 1x protease inhibitor cocktail (Sigma-Aldrich), 0.5 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 mM NaF, and 1mM Na3VO4, at a cell density 
of 107 cells/ml and rotated for 30 min at 4°C. After centrifugation at 12,000 x g for 10 
min at 4°C, the supernatant was collected as total cell lysate.  
Cytoplasmic and nuclear cell extracts were prepared as follows. Cells were washed and 
scraped into cold PBS and then centrifuged at 2,000 x g for 10 min at 4°C. Supernatant 
was removed, and the pellet was resuspended in buffer A (10 mM Tris-HCl [pH 7.5], 1.5 
mM MgCl2, and 10 mM KCl supplemented with 1x protease inhibitor cocktail, 0.5 mM 
PMSF, 1 mM NaF and 1 mM Na3VO4) at a cell density of 3 x 10
7 cells/ml and incubated 
on ice for 10 min. The nuclei were collected by centrifugation at 2,000 x g for 10 min at 
4°C. The resulting supernatant was considered as cytoplasmic fraction. Then, nuclear 
pellet were resuspended in buffer B (20 mM Tris-HCl [pH 7.5], 0.42 M KCl, 1.5 mM 
MgCl2, 20% [vol/vol] glycerol supplemented with 1x protease inhibitor cocktail, 0.5 mM 
PMSF, 1 mM NaF, and 1 mM Na3VO4) and rotated for 30 min at 4°C. The suspension 
was centrifuged at 15,000 x g for 30 min at 4°C. The supernatant was collected as nuclear 
114 | P a g e  
 
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
MATERIALS AND METHODS 
 
protein extract. The protein concentration was determined using Bio-Rad protein assay 
reagent (Bio-Rad, Hercules, CA, USA). 
5.7 CO-IMMUNOPRECIPITATION 
Cells transfected with FLAG-tagged APE1wt and genetic variants were lysed in 50 mM 
Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 supplemented with 1x 
protease inhibitor cocktail, 0.5 mM PMSF, 1 mM NaF, 1 mM Na3VO4 under gentle 
rocking for 20 minutes at 4°C. The cell extract was clarified by centrifugation and co-
immunoprecipitation was carried out for 3 hours using the anti-FLAG M2 affinity gel 
(Sigma-Aldrich) as per manufacturer’s indications. Co-immunoprecipitated material was 
eventually eluted by incubation with 0.15 mg/ml 1x FLAG peptide in Tris-buffered saline 
(TBS) and analyzed as indicated. 
5.8 ANTIBODIES AND WESTERN BLOTTING ANALYSIS 
For Western blotting analyses, the indicated amounts of cell extracts were resolved in 
12% SDS-PAGE and transferred to nitrocellulose membranes (Schleicher & Schuell, 
BioScience, Dassel, Germany). Membranes were blocked with 5% w/v non-fat dry milk 
in PBS containing 0.1% (vol/vol) Tween-20 and probed with the indicated antibodies; 
blots were developed by using the ECL enhanced chemiluminescence procedure (GE 
Healthcare, Piscataway, NJ, USA) or Western Lightning Ultra (Perkin Elmer, Waltham, 
MA, USA). Polyclonal  and monoclonal anti-APE1 were from Novus (NB 100-101 and 
NB 100-116, respectively) (Novus Biologicals, Littleton, CO, USA), monoclonal or 
polyclonal anti-NPM1 were from Invitrogen (32-5200) and Abcam (ab15440) (Abcam, 
Cambridge, England), respectively, monoclonal anti-XRCC1 was from Thermo Fisher 
Scientific (MS-434-P0), polyclonal anti-Polβ was from Abcam (ab26343), a monoclonal 
anti-Nucleolin was from Invitrogen (39-6400), polyclonal anti-YB-1 was from Abcam 
(ab12148), monoclonal anti-PABP-1 was from Abcam (ab6125), polyclonal anti-SFPQ 
was from Abcam (ab38148), monoclonal anti-PRDX-6 was from Abcam (ab16947), 
polyclonal anti-PRP-19 was from Abcam (ab27692), monoclonal anti-hnRNP-U was 
from Abcam (ab89413), polyclonal anti-APE1 acetyl K6K7 and monoclonal anti-
NPM1c+ were a kind gift from Dr. Kishor K. Bhakat (University of Nebraska Medical 
Center) and from Dr. Emanuela Colombo (European Institute of Oncology), respectively. 
Normalization was performed by using a monoclonal anti-Tubulin antibody (Sigma-
Aldrich, T0198), a polyclonal anti-Actin (Sigma-Aldrich, A2066), a polyclonal anti-
LSD1 (Abcam, ab129195) or a monoclonal anti-FLAG (Sigma-Aldrich, A8592). Blots 
were quantified by using a Chemidoc XRS video densitometer (Bio-Rad). 
5.9 DETERMINATION OF AP ENDONUCLEASE ACTIVITY 
AND ABASIC SITE ASSAY 
The determination of AP endonuclease activity was performed using an oligonucleotide 
cleavage assay as described previously92. Nuclear cell extracts were incubated with a 5’-
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32P-end-labeled 26-mer oligonucleotide containing a single tetrahydrofuranyl (here called 
dsFDNA) artificial AP site at position 14, which is cleaved to a 14-mer in the presence of 
AP endonuclease activity. Reactions from reaction mixtures (10 µl) containing the 
proteins of interest, 2.5 pmol of the 5’-32P end-labeled oligonucleotide dsFDNA, 50 mM 
HEPES, 50 mM KCl, 10 mM MgCl2,1 µg/µl bovine serum albumin, and 0.05% (wt/vol) 
Triton X-100 (pH 7.5) were allowed to proceed for the indicated time points in a 37°C 
water bath. Reactions were halted by adding 10 µl of 96% (vol/vol) formamide and 10 
mM EDTA, with xylene cyanol and bromophenol blue as dyes. AP assay products (5 µl) 
were separated on a 20% polyacrylamide gel containing 7 M urea. Gels were wrapped in 
Saran wrap and exposed to film for autoradiography. The amount of 14-mer to 26-mer 
was determined by scanning the exposed film by a Gel Doc scanner (Bio-Rad).  
Total abasic damage in chromosomal DNA was measured with an aldehyde-reactive 
probe as previously described92. Genomic DNA was isolated from 2 x 106  cells by using 
DNAzol® Reagent (Invitrogen) and then concentration and purity were determined using 
a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific). Samples of 0.1 mg/ml of 
genomic DNA were analysed by using the DNA Damage Quantification Kit (Dojndo, 
Gaithersburg, MD, USA), according to the manufacturer’s instructions. 
5.10 RECOMBINANT APE1 PROTEINS PURIFICATION 
pTAC-MAT expression plasmids (Sigma-Aldrich) containing either wild-type APE1 or 
APE1 R237C variant or pGEX-4T expression vectors (Sigma-Aldrich) containing either 
wild-type NPM1 or the empty vector were transformed into E. coli BL21 (DE3) bacterial 
cells (Stratagene). Bacterial cells were grown at 37°C to an absorbance of 0.8 at OD600. 
Isopropyl-b-D-thiogalactopyranoside (IPTG) was then added to a final concentration of 1 
mM, and cells were grown for 4 hr for NPM1 and GST and for 5 hr for APE1 proteins at 
37°C. Bacteria were harvested and lysed by sonication, and the recombinant proteins 
were purified from the clarified extracts on an AKTA Prime FPLC system (GE 
Healthcare) using GSTrap HP and HisTrap HP columns (GE Healthcare) for GST-tagged 
and MAT-tagged proteins, respectively. The quality of purification was checked by 
Coomassie-stained SDS–PAGE analysis. Extensive dialysis against PBS was performed 
to remove any trace of imidazole from the HisTrap-purified proteins. Accurate 
quantification of all recombinant proteins was performed by colorimetric Bradford assays 
(Bio-Rad) and confirmed by SDS–PAGE and western blotting analysis using anti-GST 
peroxidase-conjugated antibody (Sigma-Aldrich, A7340) and anti-MAT tag antibody 
(Sigma-Aldrich, M6693). 
5.11 GST PULL-DOWN ASSAY 
For the GST pull-down experiments, 0.15 nmol of either GST or full-length GST-NPM1 
protein was incubated, together with 0.45 nmol of either APE1wt-MAT tag or APE1 
R237C-MAT tag, in cold PBS supplemented with 1 mM DTT and 0.5 mM PMSF for 2 hr 
under rotation at 4°C. Then 15µl of glutathione-Sepharose 4B beads (GE Healthcare) 
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were added to the mixture. Binding with the beads was performed in cold PBS 
supplemented with 1 mM DTT and 0.5 mM PMSF for 2 hr under rotation at 4°C. The 
beads were washed five times with washing buffer (PBS supplemented with 0.1% 
(vol/vol) Igepal CA-630 (Sigma-Aldrich), 1 mM DTT, and 0.5 mM PMSF). Beads were 
boiled in 1x Laemmli sample buffer containing 100 mM DTT for 5 min, and the 
supernatant was loaded onto 12% (wt/vol) SDS-PAGE gels followed by Western blotting. 
The presence of APE1 protein was detected using anti-APE1 monoclonal antibody, while 
the presence of NPM1 protein was revealed using anti-GST peroxidase-conjugated 
antibody. 
5.12 CELL VIABILITY ASSAYS 
Cell viability was measured by using the MTS assay (Celltiter 96 Aqueous One solution 
cell proliferation assay; Promega, Madison, WI) on HeLa and MEF cells grown in 96-
well plates. Briefly, 5 x 103 cells were plated and after MMS, KBrO3 or acute H2O2 
treatment, 20 µl of the MTS solution was added to each well and the plates were 
incubated for 2 hr at 37°C. Absorbance was measured at 490 nm by using a EnSpire 
multimode plate reader (Perkin Elmer). The values were standardized to wells containing 
media alone. Cytotoxicity induced by BLM was evaluated using a trypan blue exclusion 
assay. A total of 4 x 104 cells per well were plated in six-well plates, treated for 60 min 
with reported amounts of BLM and then grown for 2 additional days in fresh media. Cell 
viability for OCI/AML cell lines (2.5 x 104 cells) was measured by CellTiter-Glo 
Luminescent Cell Viability Assay (Promega) according to the manufacturer’s protocol. 
Cells were incubated with the indicated doses of MMS for 8 hr at 37°C in agitation. 
Luminescent signals were measured using the Turner BioSystems Luminometer 
(Promega). Cell survival upon inhibition of APE1 AP endonuclease activity was 
measured with the Cell Counting Kit-8 assay (Dojindo). MEF cells were seeded onto 96-
well plates (6x103 cells) and allowed to adhere for 24 hr. MEFs were then incubated with 
the indicated amounts of compound 3 (N-(3-(benzo[d]thiazol-2-yl)-6-isopropyl-4,5,6,7-
tetrahydrothieno[2,3-c]pyridin-2-yl)acetamide)165, and viability was measured 24 hr later 
as per the manufacturer’s instructions. 
5.13 RNA ISOLATION, REVERSE TRANSCRIPTION AND 
QPCR 
Total RNA from MEF cells were extracted with the SV Total RNA isolation 
System kit (Promega). One microgram of total RNA was reverse transcribed using the 
iScript cDNA synthesis kit (Bio-Rad), according to the manufacturer’s instructions. qRT-
PCR was performed with a CFX96 Real-Time System (Bio-Rad. The following primers 
for mouse APE1 were used: APE1_for: 5’-CGTCACAGCGATGCCAAAGC-3’ and 
APE1_rev: 5’-ATCTGGAGGGTCCTCGTACAGG-3’. DNA was amplified in 96-well 
plates using primers for APE1_for and APE1_rev using the 2x iQ™ SYBR® Green 
Supermix (Bio-Rad) (100 mM KCl, 40 mM Tris-HCl [pH 8.4], 0.4 mM of each 
deoxynucleoside triphosphate [dNTP], 50U/ml iTaq DNA polymerase, 6 mM MgCl2, 
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SYBR green I, 20 nM fluorescein, and stabilizers) and 10 μM of the specific sense and 
antisense primers, in a final volume of 15 μl for each well. Each analysis was performed 
in triplicate. As negative control, a sample without template was used. The cycling 
parameters were: i) denaturation at 95°C, for 10 s; ii) annealing/extension at 60°C, for 30 
s (repeated 40 times). In order to verify the specificity of the amplification, a melting-
curve analysis was performed, immediately after the amplification protocol. Gene 
expression analysis was carried out using the CFX ManagerTM Software (Bio-Rad) and 
ACTB as reference gene. The results of the qRT-PCR assay for each sample were 
reported as fold of activation respect to the APE1 mRNA in MEF NPM1+/+. 
5.14 IMMUNOFLUORESCENCE AND PLA 
For immunofluorescence analysis on HeLa and MEFs, cells were grown on glass 
coverslips, whereas blasts and OCI/AML2 and 3 cells were centrifuged onto glass slides 
using a cytospin. Then, cells were fixed with 4% (wt/vol) paraformaldehyde for 20 min at 
room temperature and permeabilized for 5 min with phosphate-buffered saline-0.25% 
(vol/vol) Triton X-100. Cells were incubated for 30 min with 10% fetal bovine serum in 
TBS–0.1% (vol/vol) Tween-20 (blocking solution) to block unspecific binding of the 
antibodies. Cells were then incubated with primary antibodies diluted in blocking 
solutions: monoclonal anti-APE1 (diluted 1:50, 3hr, 37°C), polyclonal or monoclonal 
anti-NPM1 (diluted 1:200, overnight, 4°C), monoclonal a-FLAG-FITC conjugated 
(diluted 1:100, 3 hr, 37°C) and polyclonal anti-HA (diluted 1:500, overnight, 4°C). Then 
cells were washed three times for 5 min each with TBS-0.1% (vol/vol) Tween-20 
(Washing Solution) and incubated with secondary antibody: anti-mouse or anti-rabbit 
Rhodamine Red-conjugated or Alexa Fluor 488-conjugated (diluted 1:200, 2 hr, 25°C) 
(Jackson Immuno, West Grove, PA). After washing three times, coverslips were mounted 
on microscope slides with a mounting media containing TO-PRO®-3 Iodide (Invitrogen) 
or 4’, 6-diamidino-2-phenylindole (DAPI) as nuclear counterstains and an anti-fade 
reagent. For PLA analysis on HeLa cells transiently transfected with construct encoding 
for NPM1c+ or blasts from patient’s, primary antibody anti-APE1 was previously labeled 
with the Zenon anti-Mouse IgG Labeling Kit (Invitrogen) using the Alexa Fluor 488 
according to the manufacturer’s instructions. To study the interaction of APE1 with 
NPM1 in vivo, we used the in situ PLA technology (Olink Bioscience, Uppsala, Sweden). 
After incubation with monoclonal anti-APE1 (1:50) or anti-FLAG antibody (1:100) for 
3hr at 37°C, cells were incubated with polyclonal anti-NPM1 (1:200) or polyclonal anti-
HA antibody (Sigma-Aldrich, H9658) (1:500) overnight at 4°C. PLA was performed 
following the manufacturer’s instructions and as previously reported92. Technical 
controls, represented by the omission of anti-NPM1/anti-HA primary antibody, resulted 
in the complete loss of PLA signal. Images were captured through a confocal microscope, 
and quantification of PLA signal was performed using the Blob Finder software (Center 
for Image Analysis, Uppsala University).  
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5.15 CONFOCAL LASER SCANNING MICROSCOPY 
All images were collected using a confocal laser scanning microscopy LEICA TCS SP 
(Leica Microsystems, Milan, Italy) supplemented with an Argon laser, a Helium/Neon 
laser and equipped with 63x oil immersion lenses or a DMB6000B inverted microscope 
equipped with a DFC300FX digital camera (Leica Microsystems). In double and triple 
staining, confocal sections of fluorescent signals were taken using the sequential mode 
(between lines) and merged images of the two signals were obtained using confocal 
microscope software (Leica Microsystems). 
5.16 IDENTIFICATION OF APE1 PROTEIN BINDING 
PARTNERS 
Identification of differential protein interacting partners of APE1-SCR-1, APE1wt 
and APE1-N∆33 was performed as already described18,380. Protein samples were added 
with sample buffer containing DTT, boiled and separated by SDS-PAGE. Gel lanes were 
cut into 6 identical portions in the region 40-350kDa, which were minced and washed 
with water. Proteins were in-gel alkylated and digested with trypsin, as previously 
reported386. Protein digests were analyzed by nanoLC-ESI-LIT-MS/MS using a LTQ XL 
mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) equipped with a 
Proxeon nanospray source connected to an Easy-nanoLC (Proxeon, Odense, 
Denmark)386,387. Peptide mixtures were separated on an Easy C18 column (10 × 0.075 
mm, 3 mm) (Proxeon A/S, Odens C, Denmark) using a gradient of acetonitrile containing 
0.1% formic acid in aqueous 0.1% formic acid; acetonitrile ramped from 5% to 40% over 
40 min, from 40% to 80% over 10 min, and from 80% to 80% over 5 min, at a flow rate 
of 300 nL/min. Spectra were acquired in the range m/z 400-2000. Acquisition was 
controlled by a data-dependent product ion scanning procedure over the three most 
abundant ions, enabling dynamic exclusion (repeat count 1 and exclusion duration 1 min). 
The mass isolation window and collision energy in CID experiments were set to m/z 3 
and 35%, respectively. Each analysis was performed in duplicate. SEQUEST (Thermo 
Fisher Scientific) and MASCOT (Matrix Science, UK) within the Proteome Discoverer 
software package version 1.0 SP1 (Thermo Fisher Scientific) were used to identify 
proteins present within each gel portion unambiguously from an updated human non-
redundant sequence database (UniProtKB). Thus, nanoLC-ESI-LIT-MS/MS data were 
searched by using a mass tolerance value of 2 Da for precursor ion and 0.8 Da for MS/MS 
fragments, trypsin as proteolytic enzyme, a missed cleavages maximum value of 2 and 
Cys carbamidomethylation and Met oxidation as fixed and variable modification, 
respectively. Candidates with more than 2 assigned tryptic peptides with an individual 
SEQUEST score versus charge state > 1.5 for charged state (CS) 1, >2.0 for CS 2, >2.5 
for CS 3, > 3.0 for CS 4, > 3.2 for CS 5, and/or a MASCOT score >20 (corresponding to 
p<0.01 for a significant identification) were considered confidently identified. They were 
further evaluated by the comparison with their calculated mass values, using the 
experimental values obtained from SDS-PAGE. To identify real APE1 binding partners, 
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protein identification lists from APE1wt, APE1-N∆33 and APE1-TSA-treated samples 
were subtracted with data from corresponding control (APE1-SCR-1).  
5.17 GENE ANNOTATIONS CO-OCCURRENCE ANALYSIS 
Gene IDs corresponding to the list of APE1 interacting proteins identified by mass 
spectrometry analysis and the list of all the APE1 interacting partners were submitted to 
GeneCodis (http://genecodis.cnb.csic.es/), a web-based tool for the ontological analysis, 
selecting Homo sapiens as the source for the annotations and Gene Ontology categories to 
perform the gene annotation co-occurrence analysis. 
5.18 STATISTICAL ANALYSES 
Statistical analyses were performed by using the Excel (Microsoft, Redmond, WA, USA) 
data analysis program for Student’s t test analysis. P < 0.05 was considered as statistically 
significant. 
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7 APPENDIX 
Supplementary Table 1: Complete data reporting all the significant functional enrichments obtained performing GeneCodis analysis for the APE1 interactors 
identified in this work of Thesis. ‘GO term ID’ and ‘Annotations’ columns represent the Gene Ontology codes of annotations and the textual description of annotations, 
respectively. MF and BP refer to ‘molecular function’ and ‘biological process’ category of Gene Ontology annotation, respectively. Third and fourth columns represent the 
number of genes in the input list and the reference list for a given annotation, respectively. P-values calculated using hypergeometric distribution and its correction using the 
stimulation-based approach are reported. The ‘Genes’ column identifies the set of genes in the input list showing a given annotation. 
GO term ID Annotations 
# of 
annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list) 
# of annotated 
genes in the 
reference list 
(Total # of 
genes in the 
reference list) 
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0006281 
protein binding (MF), DNA repair 
(BP) 
3 (26) 195 (34208) 0.000430529 0.000463647 NPM1,PRPF19,SFPQ 
GO:0005515,GO:0044419 
protein binding (MF), interspecies 
interaction between organisms (BP) 
3 (26) 232 (34208) 0.000713427 0.000730828 NPM1,KRT8,RPLP0 
GO:0019901 protein kinase binding (MF) 3 (26) 237 (34208) 0.000758852 0.000758852 NPM1,MSN,KIF11 
GO:0005524,GO:0000166,
GO:0042803 
ATP binding (MF), nucleotide 
binding (MF), protein 
homodimerization activity (MF) 
3 (26) 76 (34208) 2.64088e-05 2.99775e-05 PRPS1,MYH9,PRPS2 
GO:0003677,GO:0005515,
GO:0008380,GO:0003723 
DNA binding (MF), protein binding 
(MF), RNA splicing (BP), RNA 
binding (MF) 
3 (26) 16 (34208) 2.1683e-07 3.79453e-07 HNRNPU,YBX1,SFPQ 
GO:0003677,GO:0005515,
GO:0000398,GO:0008380 
DNA binding (MF), protein binding 
(MF), nuclear mRNA splicing, via 
spliceosome (BP), RNA splicing 
3 (26) 17 (34208) 2.63161e-07 4.42111e-07 HNRNPU,PRPF19,YBX1 
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GO term ID Annotations 
# of 
annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list) 
# of annotated 
genes in the 
reference list 
(Total # of 
genes in the 
reference list) 
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
(BP) 
GO:0005515,GO:0003723,
GO:0010467,GO:0044267,
GO:0006412,GO:0016070,
GO:0016071 
protein binding (MF), RNA binding 
(MF), gene expression (BP), 
cellular protein metabolic process 
(BP), translation (BP), RNA 
metabolic process (BP), mRNA 
metabolic process (BP) 
3 (26) 19 (34208) 3.74626e-07 5.82752e-07 RPL14,PABPC1,RPLP0 
GO:0003779,GO:0005516 
actin binding (MF), calmodulin 
binding (MF) 
3 (26) 44 (34208) 5.05613e-06 6.43508e-06 MYO1C,MYH9,SPTBN1 
GO:0000166,GO:0008022 
nucleotide binding (MF), protein C-
terminus binding (MF) 
3 (26) 45 (34208) 5.41456e-06 6.49747e-06 PABPC1,MYO1C,NCL 
GO:0003677,GO:0005515,
GO:0000166,GO:0003723 
DNA binding (MF), protein binding 
(MF), nucleotide binding (MF), 
RNA binding (MF) 
3 (26) 22 (34208) 5.94481e-07 8.91722e-07 HNRNPU,NCL,SFPQ 
GO:0005515,GO:0000166,
GO:0000398,GO:0008380,
GO:0003723,GO:0010467,
GO:0003676 
protein binding (MF), nucleotide 
binding (MF), nuclear mRNA 
splicing, via spliceosome (BP), 
RNA splicing (BP), RNA binding 
(MF), gene expression (BP), 
nucleic acid binding (MF) 
3 (26) 23 (34208) 6.83309e-07 9.56633e-07 PABPC1,HNRNPU,HNRNPH1 
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GO term ID Annotations 
# of 
annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list) 
# of annotated 
genes in the 
reference list 
(Total # of 
genes in the 
reference list) 
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0010467,
GO:0006414,GO:0031018,
GO:0044267,GO:0006412,
GO:0016070,GO:0016032,
GO:0016071,GO:0006415,
GO:0019058,GO:0019083,
GO:0003735 
protein binding (MF), gene 
expression (BP), translational 
elongation (BP), endocrine 
pancreas development (BP), cellular 
protein metabolic process (BP), 
translation (BP), RNA metabolic 
process (BP), viral reproduction 
(BP), mRNA metabolic process 
(BP), translational termination 
(BP), viral infectious cycle (BP), 
viral transcription (BP), structural 
constituent of ribosome (MF) 
3 (26) 23 (34208) 6.83309e-07 9.56633e-07 RPL14,RPSA,RPLP0 
GO:0042803 
protein homodimerization activity 
(MF) 
4 (26) 514 (34208) 0.000579314 0.000608279 PRPS1,NPM1,MYH9,PRPS2 
GO:0003677,GO:0005515,
GO:0003723 
DNA binding (MF), protein binding 
(MF), RNA binding (MF) 
4 (26) 50 (34208) 5.89425e-08 1.23779e-07 HNRNPU,NCL,YBX1,SFPQ 
GO:0005515,GO:0000166,
GO:0008380,GO:0003723 
protein binding (MF), nucleotide 
binding (MF), RNA splicing (BP), 
RNA binding (MF) 
4 (26) 53 (34208) 7.48294e-08 1.36645e-07 
PABPC1,HNRNPU,SFPQ,HNRN
PH1 
GO:0005515,GO:0000398,
GO:0008380,GO:0003723,
GO:0010467 
protein binding (MF), nuclear 
mRNA splicing, via spliceosome 
(BP), RNA splicing (BP), RNA 
binding (MF), gene expression (BP) 
4 (26) 53 (34208) 7.48294e-08 1.36645e-07 
PABPC1,HNRNPU,YBX1,HNR
NPH1 
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GO term ID Annotations 
# of 
annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list) 
# of annotated 
genes in the 
reference list 
(Total # of 
genes in the 
reference list) 
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0003723,GO:0010467,
GO:0006414,GO:0031018,
GO:0044267,GO:0006412,
GO:0016070,GO:0016032,
GO:0016071,GO:0006415,
GO:0019058,GO:0019083,
GO:0003735 
RNA binding (MF), gene 
expression (BP), translational 
elongation (BP), endocrine 
pancreas development (BP), cellular 
protein metabolic process (BP), 
translation (BP), RNA metabolic 
process (BP), viral reproduction 
(BP), mRNA metabolic process 
(BP), translational termination 
(BP), viral infectious cycle (BP), 
viral transcription (BP), structural 
constituent of ribosome (MF) 
4 (26) 53 (34208) 7.48294e-08 1.36645e-07 RPL3,RPL14,RPLP0,RPL4 
GO:0003677,GO:0005515,
GO:0008380 
DNA binding (MF), protein binding 
(MF), RNA splicing (BP) 
4 (26) 27 (34208) 4.54521e-09 1.46845e-08 HNRNPU,PRPF19,YBX1,SFPQ 
GO:0005515,GO:0003779 
protein binding (MF), actin binding 
(MF) 
4 (26) 106 (34208) 1.23529e-06 1.67362e-06 MSN,MYH9,SPTBN1,ACTN1 
GO:0005515,GO:0010467,
GO:0044267,GO:0006412,
GO:0016070,GO:0016071 
protein binding (MF), gene 
expression (BP), cellular protein 
metabolic process (BP), translation 
(BP), RNA metabolic process (BP), 
mRNA metabolic process (BP) 
4 (26) 31 (34208) 8.13224e-09 2.27703e-08 RPL14,PABPC1,RPSA,RPLP0 
GO:0005515,GO:0000166,
GO:0003723,GO:0003676 
protein binding (MF), nucleotide 
binding (MF), RNA binding (MF), 
nucleic acid binding (MF) 
4 (26) 74 (34208) 2.90873e-07 4.69872e-07 
PABPC1,HNRNPU,NCL,HNRNP
H1 
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GO term ID Annotations 
# of 
annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list) 
# of annotated 
genes in the 
reference list 
(Total # of 
genes in the 
reference list) 
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0010467,GO:0006414,
GO:0031018,GO:0044267,
GO:0006412,GO:0016070,
GO:0016032,GO:0016071,
GO:0006415,GO:0019058,
GO:0019083,GO:0003735 
gene expression (BP), translational 
elongation (BP), endocrine 
pancreas development (BP), cellular 
protein metabolic process (BP), 
translation (BP), RNA metabolic 
process (BP), viral reproduction 
(BP), mRNA metabolic process 
(BP), translational termination 
(BP), viral infectious cycle (BP), 
viral transcription (BP), structural 
constituent of ribosome (MF) 
5 (26) 81 (34208) 4.15404e-09 1.45392e-08 RPL3,RPL14,RPSA,RPLP0,RPL4 
GO:0005515,GO:0003723,
GO:0003676 
protein binding (MF), RNA binding 
(MF), nucleic acid binding (MF) 
5 (26) 85 (34208) 5.30725e-09 1.59217e-08 
NPM1,PABPC1,HNRNPU,NCL,
HNRNPH1 
GO:0005515,GO:0008380,
GO:0003723 
protein binding (MF), RNA splicing 
(BP), RNA binding (MF) 
5 (26) 96 (34208) 9.83423e-09 2.58149e-08 
PABPC1,HNRNPU,YBX1,SFPQ,
HNRNPH1 
GO:0005515,GO:0000398,
GO:0008380 
protein binding (MF), nuclear 
mRNA splicing, via spliceosome 
(BP), RNA splicing (BP) 
5 (26) 100 (34208) 1.20882e-08 2.98649e-08 
PABPC1,HNRNPU,PRPF19,YB
X1,HNRNPH1 
GO:0003779 actin binding (MF) 5 (26) 289 (34208) 2.36456e-06 3.10349e-06 
MSN,MYO1C,MYH9,SPTBN1,A
CTN1 
GO:0003723,GO:0010467,
GO:0044267,GO:0006412,
GO:0016070,GO:0016071 
RNA binding (MF), gene 
expression (BP), cellular protein 
metabolic process (BP), translation 
(BP),RNA metabolic process (BP), 
5 (26) 58 (34208) 7.51703e-10 3.50795e-09 
RPL3,RPL14,PABPC1,RPLP0,R
PL4 
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GO term ID Annotations 
# of 
annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list) 
# of annotated 
genes in the 
reference list 
(Total # of 
genes in the 
reference list) 
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
mRNA metabolic process (BP) 
GO:0005515,GO:0000166,
GO:0003723 
protein binding (MF), nucleotide 
binding (MF), RNA binding (MF) 
5 (26) 119 (34208) 2.90402e-08 6.41942e-08 
PABPC1,HNRNPU,NCL,SFPQ,H
NRNPH1 
GO:0003677,GO:0005515 
DNA binding (MF), protein binding 
(MF) 
5 (26) 564 (34208) 5.91104e-05 6.53326e-05 
HNRNPU,PRPF19,NCL,YBX1,S
FPQ 
GO:0005515,GO:0000166 
protein binding (MF), nucleotide 
binding (MF) 
6 (26) 784 (34208) 2.21198e-05 2.58064e-05 
PABPC1,MYH9,HNRNPU,NCL,
SFPQ,HNRNPH1 
GO:0005515,GO:0003723,
GO:0010467 
protein binding (MF), RNA binding 
(MF), gene expression (BP) 
6 (26) 81 (34208) 3.23481e-11 2.71724e-10 
RPL14,PABPC1,HNRNPU,RPLP
0,YBX1,HNRNPH1 
GO:0010467,GO:0044267,
GO:0006412,GO:0016070,
GO:0016071 
gene expression (BP), cellular 
protein metabolic process (BP), 
translation (BP), RNA metabolic 
process (BP), mRNA metabolic 
process (BP) 
6 (26) 90 (34208) 6.17785e-11 4.32449e-10 
RPL3,RPL14,PABPC1,RPSA,RP
LP0,RPL4 
GO:0005515,GO:0008380 
protein binding (MF), RNA splicing 
(BP) 
6 (26) 157 (34208) 1.81169e-09 6.91735e-09 
PABPC1,HNRNPU,PRPF19,YB
X1,SFPQ,HNRNPH1 
GO:0005515,GO:0010467 
protein binding (MF), gene 
expression (BP) 
7 (26) 235 (34208) 3.8862e-10 2.04026e-09 
RPL14,PABPC1,RPSA,HNRNPU
,RPLP0,YBX1,HNRNPH1 
GO:0044267 
cellular protein metabolic process 
7 (26) 284 (34208) 1.45109e-09 6.09459e-09 
RPL3,RPL14,PABPC1,RPSA,TC
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GO term ID Annotations 
# of 
annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list) 
# of annotated 
genes in the 
reference list 
(Total # of 
genes in the 
reference list) 
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
(BP) P1,RPLP0,RPL4 
GO:0003723,GO:0010467 
RNA binding (MF), gene 
expression (BP) 
8 (26) 139 (34208) 8.90125e-14 3.73852e-12 
RPL3,RPL14,PABPC1,HNRNPU
,RPLP0,YBX1,HNRNPH1,RPL4 
GO:0005524,GO:0000166 
ATP binding (MF), nucleotide 
binding (MF) 
8 (26) 1367 (34208) 5.22756e-06 6.45758e-06 
PRPS1,KIF11,MYO1C,MYH9,T
CP1,HNRNPU,PRPS2,THRAP3 
GO:0010467 gene expression (BP) 9 (26) 408 (34208) 1.16833e-11 1.22675e-10 
RPL3,RPL14,PABPC1,RPSA,HN
RNPU,RPLP0,YBX1,HNRNPH1,
RPL4 
GO:0005515,GO:0003723 
protein binding (MF), RNA binding 
(MF) 
9 (26) 268 (34208) 2.70313e-13 5.67657e-12 
NPM1,RPL14,PABPC1,HNRNP
U,RPLP0,NCL,YBX1,SFPQ,HN
RNPH1 
GO:0003723 RNA binding (MF) 11 (26) 623 (34208) 4.04001e-13 5.65601e-12 
RPL3,NPM1,RPL14,PABPC1,H
NRNPU,RPLP0,NCL,YBX1,SFP
Q,HNRNPH1,RPL4 
GO:0000166 nucleotide binding (MF) 12 (26) 2120 (34208) 1.32823e-08 3.09921e-08 
PRPS1,PABPC1,KIF11,MYO1C,
MYH9,TCP1,HNRNPU,PRPS2,N
CL,SFPQ,HNRNPH1,THRAP3 
GO:0005515 protein binding (MF) 18 (26) 4463 (34208) 6.36433e-11 3.8186e-10 
PRDX6,NPM1,MSN,RPL14,PAB
PC1,RPSA,MYH9,KRT8,HNRN
PU,PRPF19,SPTBN1,ACTN1,RP
LP0,BASP1,NCL,YBX1,SFPQ,H
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GO term ID Annotations 
# of 
annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list) 
# of annotated 
genes in the 
reference list 
(Total # of 
genes in the 
reference list) 
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
NRNPH1 
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Supplementary Table 2: Complete data reporting all the significant functional enrichments obtained performing GeneCodis analysis for all the APE1 interactors. 
‘GO term ID’ and ‘Annotations’ columns represent the Gene Ontology codes of annotations and the textual description of annotations, respectively. MF and BP refer to 
‘molecular function’ and ‘biological process’ category of Gene Ontology annotation, respectively. Third and fourth columns represent the number of genes in the input list 
and the reference list for a given annotation, respectively. P-values calculated using hypergeometric distribution and its correction using the stimulation-based approach are 
reported. The ‘Genes’ column identifies the set of genes in the input list showing a given annotation. 
GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515 protein binding (MF) 59 (73) 4463 (34208) 2,58E-39 9,98E-37 
HOXC13,XRCC6,MCC,SIRT1,P
RDX6,GZMA,NPM1,UBE2I,CD
KN1A,TRAF6,MDM2,MSN,RPL
14,MUTYH,PABPC1,HMGB2,O
GG1,SPTA1,TXN,RPSA,HIF1A,S
ET,TP53,CSNK2A1,MYH9,ESR1
,HNRNPL,KRT8,UBC,HDAC1,D
CTN1,XRCC1,Cdk5,PCNA,SUM
O2,SUMO1,MPG,HNRNPU,FEN
1,EIF6,CCNA1,ANP32A,EP300,P
AK2,PRPF19,SPTBN1,ACTN1,R
PLP0,XRCC5,BASP1,NCL,YBX1
,HMGA1,SFPQ,HNRNPH1,NME
1,HSPA1A,ARF6,POLB 
GO:0000166 nucleotide binding (MF) 23 (73) 2120 (34208) 4,11E-11 6,90E-10 
PRPS1,XRCC6,UBE2I,PABPC1,
NXF2,KIF11,MYO1C,CSNK2A1,
MYH9,HNRNPL,TCP1,Cdk5,HN
RNPU,PAK2,PRPS2,XRCC5,NC
L,SFPQ,HNRNPH1,NME1,HSPA
1A,THRAP3,ARF6 
GO:0003677 DNA binding (MF) 19 (73) 1785 (34208) 4,16E-09 3,08E-08 
XRCC6,HMGB2,HIF1A,TP53,TC
F21,ESR1,PCNA,MPG,HNRNPU,
FEN1,POLR3D,EP300,PRPF19,X
RCC5,NCL,YBX1,HMGA1,SFPQ
,POLB 
GO:0003677,GO:0005515 
DNA binding (MF), protein binding 
(MF) 
17 (73) 564 (34208) 2,92E-15 1,61E-13 
XRCC6,HMGB2,HIF1A,TP53,ES
R1,PCNA,MPG,HNRNPU,FEN1,
EP300,PRPF19,XRCC5,NCL,YB
X1,HMGA1,SFPQ,POLB 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005524 ATP binding (MF) 17 (73) 1489 (34208) 1,15E-08 5,43E-08 
PRPS1,XRCC6,UBE2I,KIF11,TP
53,MYO1C,CSNK2A1,MYH9,TC
P1,Cdk5,HNRNPU,PAK2,PRPS2,
XRCC5,NME1,HSPA1A,THRAP
3 
GO:0005515,GO:0000166 
protein binding (MF), nucleotide 
binding (MF) 
16 (73 784 (34208) 7,79E-12 1,88E-10 
XRCC6,UBE2I,PABPC1,CSNK2
A1,MYH9,HNRNPL,Cdk5,HNRN
PU,PAK2,XRCC5,NCL,SFPQ,HN
RNPH1,NME1,HSPA1A,ARF6 
GO:0005524,GO:0000166 
ATP binding (MF), nucleotide 
binding (MF) 
16 (73) 1367 (34208) 2,38E-08 1,01E-07 
PRPS1,XRCC6,UBE2I,KIF11,MY
O1C,CSNK2A1,MYH9,TCP1,Cdk
5,HNRNPU,PAK2,PRPS2,XRCC
5,NME1,HSPA1A,THRAP3 
GO:0005515,GO:0006281 
protein binding (MF), DNA repair 
(BP) 
15 (73) 195 (34208) 1,37E-19 2,65E-17 
XRCC6,SIRT1,NPM1,MUTYH,O
GG1,UBC,XRCC1,PCNA,SUMO
1,MPG,FEN1,PRPF19,XRCC5,SF
PQ,POLB 
GO:0005515,GO:0045892 
protein binding (MF), negative 
regulation of transcription, DNA-
dependent (BP) 
15 (73) 283 (34208) 3,79E-17 3,66E-15 
XRCC6,SIRT1,UBE2I,TRAF6,M
DM2,HMGB2,SET,TP53,HDAC1,
Cdk5,SUMO1,XRCC5,BASP1,Y
BX1,HMGA1 
GO:0006355 
regulation of transcription, DNA-
dependent (BP) 
14 (73) 1609 (34208) 6,68E-06 1,02E-05 
HOXC13,OGG1,TXN,HIF1A,TP5
3,CSNK2A1,TCF21,ESR1,HDAC
1,ANP32A,EP300,YBX1,HMGA1
,SFPQ 
GO:0006355,GO:0005515 
regulation of transcription, DNA-
dependent (BP), protein binding 
(MF) 
13 (73) 518 (34208) 7,15E-11 1,15E-09 
HOXC13,OGG1,TXN,HIF1A,TP5
3,CSNK2A1,ESR1,HDAC1,ANP3
2A,EP300,YBX1,HMGA1,SFPQ 
GO:0003723 RNA binding (MF) 13 (73) 623 (34208) 6,80E-10 6,56E-09 
RPL3,NPM1,RPL14,PABPC1,NX
F2,HNRNPL,HNRNPU,RPLP0,N
CL,YBX1,SFPQ,HNRNPH1,RPL
4 
GO:0044419 
interspecies interaction between 
organisms (BP) 
12 (73) 328 (34208) 5,38E-12 1,48E-10 
SIRT1,NPM1,UBE2I,MDM2,TP5
3,KRT8,HDAC1,EP300,PAK2,HL
A-B,RPLP0,HMGA1 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0044419 
protein binding (MF), interspecies 
interaction between organisms (BP) 
11 (73) 232 (34208) 2,71E-12 8,04E-11 
SIRT1,NPM1,UBE2I,MDM2,TP5
3,KRT8,HDAC1,EP300,PAK2,RP
LP0,HMGA1 
GO:0010467 gene expression (BP) 11 (73) 408 (34208) 1,11E-09 1,05E-08 
RPL3,RPL14,PABPC1,RPSA,ES
R1,HNRNPL,HNRNPU,RPLP0,Y
BX1,HNRNPH1,RPL4 
GO:0000122 
negative regulation of transcription 
from RNA polymerase II promoter 
(BP) 
11 (73) 416 (34208) 1,37E-09 1,25E-08 
SIRT1,UBE2I,TRAF6,MDM2,TX
N,TP53,TCF21,HDAC1,PCNA,EP
300,YBX1 
GO:0005524,GO:0005515 
ATP binding (MF), protein binding 
(MF) 
11 (73) 578 (34208) 4,03E-08 1,44E-07 
XRCC6,UBE2I,TP53,CSNK2A1,
MYH9,Cdk5,HNRNPU,PAK2,XR
CC5,NME1,HSPA1A 
GO:0045944 
positive regulation of transcription 
from RNA polymerase II promoter 
(BP) 
11 (73) 578 (34208) 4,03E-08 1,44E-07 
XRCC6,SIRT1,TRAF6,HMGB2,
HIF1A,TP53,TCF21,ESR1,HDAC
1,EP300,THRAP3 
GO:0016070,GO:0016071 
RNA metabolic process (BP), 
mRNA metabolic process (BP) 
10 (73) 218 (34208) 3,93E-11 6,90E-10 
RPL3,RPL14,PABPC1,RPSA,SET
,UBC,ANP32A,RPLP0,HSPA1A,
RPL4 
GO:0005515,GO:0000122 
protein binding (MF), negative 
regulation of transcription from 
RNA polymerase II promoter (BP) 
10 (73) 255 (34208) 1,83E-10 2,35E-09 
SIRT1,UBE2I,TRAF6,MDM2,TX
N,TP53,HDAC1,PCNA,EP300,Y
BX1 
GO:0005515,GO:0003723 
protein binding (MF), RNA binding 
(MF) 
10 (73) 268 (34208) 2,97E-10 3,18E-09 
NPM1,RPL14,PABPC1,HNRNPL
,HNRNPU,RPLP0,NCL,YBX1,SF
PQ,HNRNPH1 
GO:0016032 viral reproduction (BP) 10 (73) 329 (34208) 2,15E-09 1,84E-08 
XRCC6,RPL3,RPL14,RPSA,UBC
,PAK2,RPLP0,XRCC5,HMGA1,R
PL4 
GO:0005524,GO:0005515,G
O:0000166 
ATP binding (MF), protein binding 
(MF), nucleotide binding (MF) 
10 (73) 547 (34208) 2,54E-07 6,12E-07 
XRCC6,UBE2I,CSNK2A1,MYH9
,Cdk5,HNRNPU,PAK2,XRCC5,N
ME1,HSPA1A 
GO:0005515,GO:0006284 
protein binding (MF), base-excision 
repair (BP) 
9 (73) 26 (34208) 1,67E-18 2,15E-16 
MUTYH,OGG1,TP53,XRCC1,PC
NA,MPG,FEN1,HMGA1,POLB 
GO:0005515,GO:0042981 
protein binding (MF), regulation of 
apoptotic process (BP) 
9 (73) 135 (34208) 1,39E-11 3,15E-10 
SIRT1,TRAF6,TP53,ESR1,UBC,
Cdk5,PAK2,ACTN1,NME1 
GO:0003723,GO:0010467 
RNA binding (MF),gene expression 
(BP) 
9 (73) 139 (34208) 1,81E-11 3,88E-10 
RPL3,RPL14,PABPC1,HNRNPL,
HNRNPU,RPLP0,YBX1,HNRNP
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
H1,RPL4 
GO:0005515,GO:0010467 
protein binding (MF), gene 
expression (BP) 
9 (73) 235 (34208) 1,94E-09 1,70E-08 
RPL14,PABPC1,RPSA,ESR1,HN
RNPL,HNRNPU,RPLP0,YBX1,H
NRNPH1 
GO:0005515,GO:0045944 
protein binding (MF), positive 
regulation of transcription from 
RNA polymerase II promoter (BP) 
9 (73) 330 (34208) 3,66E-08 1,47E-07 
XRCC6,SIRT1,TRAF6,HMGB2,
HIF1A,TP53,ESR1,HDAC1,EP30
0 
GO:0046872,GO:0005515 
metal ion binding (MF), protein 
binding (MF) 
9 (73) 768 (34208) 3,72E-05 4,73E-05 
SIRT1,CDKN1A,TRAF6,MDM2,
MUTYH,TP53,ESR1,EP300,POL
B 
GO:0003677,GO:0005515,G
O:0006281 
DNA binding (MF), protein binding 
(MF), DNA repair (BP) 
8 (73)  80 (34208) 7,42E-12 1,91E-10 
XRCC6,PCNA,MPG,FEN1,PRPF
19,XRCC5,SFPQ,POLB 
GO:0005515,GO:0019899 
protein binding (MF), enzyme 
binding (MF) 
8 (73)  124 (34208) 2,62E-10 3,16E-09 
SIRT1,UBE2I,MDM2,TP53,ESR1
,HDAC1,HMGA1,POLB 
GO:0005515,GO:0016070,G
O:0016071 
protein binding (MF), RNA 
metabolic process (BP), mRNA 
metabolic process (BP) 
8 (73)  125 (34208) 2,79E-10 3,27E-09 
RPL14,PABPC1,RPSA,SET,UBC,
ANP32A,RPLP0,HSPA1A 
GO:0005515,GO:0016032 
protein binding (MF), viral 
reproduction (BP) 
8 (73) 156 (34208) 1,63E-09 1,47E-08 
XRCC6,RPL14,RPSA,UBC,PAK2
,RPLP0,XRCC5,HMGA1 
GO:0005515,GO:0008134 
protein binding (MF), transcription 
factor binding (MF) 
8 (73) 175 (34208) 4,05E-09 3,06E-08 
UBE2I,HIF1A,TP53,ESR1,HDAC
1,PCNA,EP300,HMGA1 
GO:0019901 protein kinase binding (MF) 8 (73) 237 (34208) 4,30E-08 1,50E-07 
NPM1,TRAF6,MSN,HIF1A,KIF1
1,TP53,CCNA1,PAK2 
GO:0003700,GO:0005515 
sequence-specific DNA binding 
transcription factor activity (MF), 
protein binding (MF) 
8 (73) 336 (34208) 6,15E-07 1,30E-06 
HOXC13,HMGB2,HIF1A,TP53,E
SR1,HDAC1,YBX1,HMGA1 
GO:0006915,GO:0005515 
apoptotic process (BP), protein 
binding (MF) 
8 (73) 344 (34208) 7,34E-07 1,54E-06 
GZMA,TRAF6,HMGB2,TP53,UB
C,EP300,PAK2,ARF6 
GO:0007165,GO:0005515 
signal transduction (BP), protein 
binding (MF) 
8 (73) 493 (34208) 1,04E-05 1,52E-05 
MCC,NPM1,TRAF6,TXN,HIF1A,
CSNK2A1,ESR1,PAK2 
GO:0006355,GO:0003677 
regulation of transcription, DNA-
dependent (BP), DNA binding (MF) 
8 (73) 977 (34208) 0,00112218 0,00119 
HIF1A,TP53,TCF21,ESR1,EP300,
YBX1,HMGA1,SFPQ 
GO:0005515,GO:0006281,G
O:0006284 
protein binding (MF), DNA repair 
(BP), base-excision repair (BP) 
7 (73) 19 (34208) 7,40E-15 3,57E-13 
MUTYH,OGG1,XRCC1,PCNA,M
PG,FEN1,POLB 
GO:0005515,GO:0003684 protein binding (MF), damaged 7 (73) 38 (34208) 1,80E-12 5,77E-11 HMGB2,OGG1,TP53,XRCC1,MP
147 | P a g e  
 
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
APPENDIX 
 
GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
DNA binding (MF) G,FEN1,POLB 
GO:0005515,GO:0003723,G
O:0010467 
protein binding (MF), RNA binding 
(MF), gene expression (BP) 
7 (73) 81 (34208) 4,60E-10 4,67E-09 
RPL14,PABPC1,HNRNPL,HNRN
PU,RPLP0,YBX1,HNRNPH1 
GO:0005515,GO:0000122,G
O:0045892 
protein binding (MF), negative 
regulation of transcription from 
RNA polymerase II promoter (BP), 
negative regulation of transcription, 
DNA-dependent (BP) 
7 (73) 102 (34208) 2,36E-09 1,98E-08 
SIRT1,UBE2I,TRAF6,MDM2,TP
53,HDAC1,YBX1 
GO:0005515,GO:0044212 
protein binding (MF), transcription 
regulatory region DNA binding 
(MF) 
7 (73) 124 (34208) 9,26E-09 6,27E-08 
XRCC6,HMGB2,HIF1A,TP53,H
NRNPL,XRCC5,BASP1 
GO:0005515,GO:0008380 
protein binding (MF), RNA splicing 
(BP) 
7 (73) 157 (34208) 4,74E-08 1,59E-07 
PABPC1,HNRNPL,HNRNPU,PR
PF19,YBX1,SFPQ,HNRNPH1 
GO:0008022 protein C-terminus binding (MF) 7 (73) 159 (34208) 5,17E-08 1,71E-07 
XRCC6,SIRT1,UBE2I,PABPC1,
MYO1C,XRCC5,NCL 
GO:0005515,GO:0019901 
protein binding (MF), protein kinase 
binding (MF) 
7 (73) 164 (34208) 6,39E-08 2,04E-07 
NPM1,TRAF6,MSN,HIF1A,TP53,
CCNA1,PAK2 
GO:0006355,GO:0003700,G
O:0005515 
regulation of transcription, DNA-
dependent (BP), sequence-specific 
DNA binding transcription factor 
activity (MF), protein binding (MF) 
7 (73) 177 (34208) 1,08E-07 3,10E-07 
HOXC13,HIF1A,TP53,ESR1,HD
AC1,YBX1,HMGA1 
GO:0003677,GO:0045944 
DNA binding (MF), positive 
regulation of transcription from 
RNA polymerase II promoter (BP) 
7 (73) 242 (34208) 8,90E-07 1,80E-06 
XRCC6,HMGB2,HIF1A,TP53,TC
F21,ESR1,EP300 
GO:0006355,GO:0003677,G
O:0005515 
regulation of transcription, DNA-
dependent (BP), DNA binding (MF), 
protein binding (MF) 
7 (73) 247 (34208) 1,02E-06 2,01E-06 
HIF1A,TP53,ESR1,EP300,YBX1,
HMGA1,SFPQ 
GO:0000166,GO:0003723 
nucleotide binding (MF), RNA 
binding (MF) 
7 (73) 282 (34208) 2,46E-06 4,31E-06 
PABPC1,NXF2,HNRNPL,HNRN
PU,NCL,SFPQ,HNRNPH1 
GO:0044267 
cellular protein metabolic process 
(BP) 
7 (73) 284 (34208) 2,58E-06 4,48E-06 
RPL3,RPL14,PABPC1,RPSA,TC
P1,RPLP0,RPL4 
GO:0007049 cell cycle (BP) 7 (73) 435 (34208) 4,05E-05 5,08E-05 
UBE2I,CDKN1A,KIF11,TP53,CS
NK2A1,Cdk5,EP300 
GO:0045893 
positive regulation of transcription, 
DNA-dependent (BP) 
7 (73) 468 (34208) 6,42E-05 7,65E-05 
XRCC6,HMGB2,HIF1A,TP53,H
DAC1,HMGA1,THRAP3 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0044419,G
O:0045892,GO:0019899 
protein binding (MF), interspecies 
interaction between organisms (BP), 
negative regulation of transcription, 
DNA-dependent (BP), enzyme 
binding (MF) 
6 (73) 8 (34208) 2,14E-15 1,37E-13 
SIRT1,UBE2I,MDM2,TP53,HDA
C1,HMGA1 
GO:0005515,GO:0003684,G
O:0006284 
protein binding (MF), damaged 
DNA binding (MF), base-excision 
repair (BP) 
6 (73) 8 (34208) 2,14E-15 1,37E-13 
OGG1,TP53,XRCC1,MPG,FEN1,
POLB 
GO:0003677,GO:0005515,G
O:0006284 
DNA binding (MF), protein binding 
(MF), base-excision repair (BP) 
6 (73) 18 (34208) 1,39E-12 4,89E-11 
TP53,PCNA,MPG,FEN1,HMGA1
,POLB 
GO:0005515,GO:0044419,G
O:0000122 
protein binding (MF), interspecies 
interaction between organisms (BP), 
negative regulation of transcription 
from RNA polymerase II promoter 
(BP) 
6 (73) 27 (34208) 2,19E-11 4,02E-10 
SIRT1,UBE2I,MDM2,TP53,HDA
C1,EP300 
GO:0000166,GO:0008022 
nucleotide binding (MF), protein C-
terminus binding (MF) 
6 (73) 45 (34208) 5,84E-10 5,78E-09 
XRCC6,UBE2I,PABPC1,MYO1C
,XRCC5,NCL 
GO:0006355,GO:0005515,G
O:0008134 
regulation of transcription, DNA-
dependent (BP), protein binding 
(MF), transcription factor binding 
(MF) 
6 (73) 67 (34208) 6,89E-09 4,93E-08 
HIF1A,TP53,ESR1,HDAC1,EP30
0,HMGA1 
GO:0005515,GO:0045944,G
O:0045892 
protein binding (MF), positive 
regulation of transcription from 
RNA polymerase II promoter (BP), 
negative regulation of transcription, 
DNA-dependent (BP) 
6 (73) 82 (34208) 2,36E-08 1,01E-07 
XRCC6,SIRT1,TRAF6,HMGB2,T
P53,HDAC1 
GO:0005515,GO:0003723,G
O:0003676 
protein binding (MF), RNA binding 
(MF), nucleic acid binding (MF) 
6 (73) 85 (34208) 2,93E-08 1,20E-07 
NPM1,PABPC1,HNRNPL,HNRN
PU,NCL,HNRNPH1 
GO:0003677,GO:0005515,G
O:0008134 
DNA binding (MF), protein binding 
(MF), transcription factor binding 
(MF) 
6 (73) 90 (34208) 4,14E-08 1,45E-07 
HIF1A,TP53,ESR1,PCNA,EP300,
HMGA1 
GO:0010467,GO:0044267,G
O:0006412,GO:0016070,GO
:0016071 
gene expression (BP), cellular 
protein metabolic process (BP), 
translation (BP), RNA metabolic 
process (BP), mRNA metabolic 
process (BP) 
6 (73) 90 (34208) 4,14E-08 1,45E-07 
RPL3,RPL14,PABPC1,RPSA,RP
LP0,RPL4 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0008380,G
O:0003723 
protein binding (MF), RNA splicing 
(BP), RNA binding (MF) 
6 (73) 96 (34208) 6,10E-08 1,98E-07 
PABPC1,HNRNPL,HNRNPU,YB
X1,SFPQ,HNRNPH1 
GO:0005515,GO:0000398,G
O:0008380 
protein binding (MF), nuclear 
mRNA splicing, via spliceosome 
(BP), RNA splicing (BP) 
6 (73) 100 (34208) 7,79E-08 2,46E-07 
PABPC1,HNRNPL,HNRNPU,PR
PF19,YBX1,HNRNPH1 
GO:0003677,GO:0005515,G
O:0045892 
DNA binding (MF), protein binding 
(MF), negative regulation of 
transcription, DNA-dependent (BP) 
6 (73) 114 (34208) 1,70E-07 4,66E-07 
XRCC6,HMGB2,TP53,XRCC5,Y
BX1,HMGA1 
GO:0005515,GO:0008022 
protein binding (MF), protein C-
terminus binding (MF) 
6 (73) 116 (34208) 1,89E-07 4,79E-07 
XRCC6,SIRT1,UBE2I,PABPC1,X
RCC5,NCL 
GO:0005515,GO:0000166,G
O:0003723 
protein binding (MF), nucleotide 
binding (MF), RNA binding (MF) 
6 (73) 119 (34208) 2,20E-07 5,47E-07 
PABPC1,HNRNPL,HNRNPU,NC
L,SFPQ,HNRNPH1 
GO:0005515,GO:0006916 
protein binding (MF), anti-apoptosis 
(BP) 
6 (73) 124 (34208) 2,80E-07 6,68E-07 
NPM1,TRAF6,UBC,HDAC1,HSP
A1A,POLB 
GO:0016070,GO:0016032,G
O:0016071 
RNA metabolic process (BP), viral 
reproduction (BP), mRNA metabolic 
process (BP) 
6 (73) 132 (34208) 4,05E-07 9,21E-07 
RPL3,RPL14,RPSA,UBC,RPLP0,
RPL4 
GO:0003677,GO:0005515,G
O:0045944 
DNA binding (MF), protein binding 
(MF), positive regulation of 
transcription from RNA polymerase 
II promoter (BP) 
6 (73) 151 (34208) 8,93E-07 1,79E-06 
XRCC6,HMGB2,HIF1A,TP53,ES
R1,EP300 
GO:0005515,GO:0007411 
protein binding (MF), axon guidance 
(BP) 
6 (73) 151 (34208) 8,93E-07 1,79E-06 
SPTA1,CSNK2A1,MYH9,Cdk5,P
AK2,SPTBN1 
GO:0045944,GO:0000122 
positive regulation of transcription 
from RNA polymerase II promoter 
(BP), negative regulation of 
transcription from RNA polymerase 
II promoter (BP) 
6 (73) 154 (34208) 1,00E-06 1,98E-06 
SIRT1,TRAF6,TP53,TCF21,HDA
C1,EP300 
GO:0006355,GO:0000122 
regulation of transcription, DNA-
dependent (BP), negative regulation 
of transcription from RNA 
polymerase II promoter (BP) 
6 (73) 155 (34208) 1,04E-06 2,04E-06 
TXN,TP53,TCF21,HDAC1,EP300
,YBX1 
GO:0005515,GO:0043066 
protein binding (MF), negative 
regulation of apoptotic process (BP) 
6 (73) 179 (34208) 2,40E-06 4,23E-06 
SIRT1,CDKN1A,MDM2,TP53,H
DAC1,XRCC5 
GO:0045944,GO:0045893 
positive regulation of transcription 
from RNA polymerase II promoter 
6 (73) 180 (34208) 2,48E-06 4,33E-06 
XRCC6,HMGB2,HIF1A,TP53,H
DAC1,THRAP3 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
(BP), positive regulation of 
transcription, DNA-dependent (BP) 
GO:0005515,GO:0008285 
protein binding (MF), negative 
regulation of cell proliferation (BP) 
6 (73) 189 (34208) 3,29E-06 5,57E-06 
NPM1,CDKN1A,TP53,HMGA1,
NME1,HSPA1A 
GO:0005515,GO:0042802 
protein binding (MF), identical 
protein binding (MF) 
6 (73) 190 (34208) 3,39E-06 5,71E-06 
SIRT1,TP53,PCNA,PAK2,PRPF1
9,NME1 
GO:0006355,GO:0045944 
regulation of transcription, DNA-
dependent (BP), positive regulation 
of transcription from RNA 
polymerase II promoter (BP) 
6 (73) 201 (34208) 4,69E-06 7,63E-06 
HIF1A,TP53,TCF21,ESR1,HDAC
1,EP300 
GO:0003677,GO:0003700,G
O:0005515 
DNA binding (MF), sequence-
specific DNA binding transcription 
factor activity (MF), protein binding 
(MF) 
6 (73) 203 (34208) 4,96E-06 7,98E-06 
HMGB2,HIF1A,TP53,ESR1,YBX
1,HMGA1 
GO:0005515,GO:0000278 
protein binding (MF), mitotic cell 
cycle (BP)  
6 (73) 203 (34208) 4,96E-06 7,98E-06 
CDKN1A,UBC,DCTN1,PCNA,F
EN1,CCNA1 
GO:0005515,GO:0007049 protein binding (MF), cell cycle (BP) 6 (73) 259 (34208) 1,98E-05 2,68E-05 
UBE2I,CDKN1A,TP53,CSNK2A
1,Cdk5,EP300 
GO:0005515,GO:0045893 
protein binding (MF), positive 
regulation of transcription, DNA-
dependent (BP) 
6 (73) 306 (34208) 5,02E-05 6,15E-05 
XRCC6,HMGB2,HIF1A,TP53,H
DAC1,HMGA1 
GO:0046872,GO:0008270,G
O:0005515 
metal ion binding (MF), zinc ion 
binding (MF), protein binding (MF) 
6 (73) 468 (34208) 0,000498533 0,000540545 
SIRT1,TRAF6,MDM2,TP53,ESR
1,EP300 
GO:0016787 hydrolase activity (MF) 6 (73) 971 (34208) 0,0175277 0,0177577 
XRCC6,PRDX6,MUTYH,NUDT3
,HDAC1,MPG 
GO:0005515,GO:0044419,G
O:0000122,GO:0045892,GO
:0019899 
protein binding (MF), interspecies 
interaction between organisms (BP), 
negative regulation of transcription 
from RNA polymerase II promoter 
(BP), negative regulation of 
transcription, DNA-dependent (BP), 
enzyme binding (MF) 
5 (73) 5 3,85E-14 1,65E-12 
SIRT1,UBE2I,MDM2,TP53,HDA
C1 
GO:0005515,GO:0003684,G
O:0006281,GO:0006284 
protein binding (MF), damaged 
DNA binding (MF), DNA repair 
(BP), base-excision repair (BP) 
5 (73) 7 8,06E-13 3,11E-11 OGG1,XRCC1,MPG,FEN1,POLB 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0008134,G
O:0019899 
protein binding (MF), transcription 
factor binding (MF), enzyme binding 
(MF) 
5 (73) 16 1,65E-10 2,20E-09 
UBE2I,TP53,ESR1,HDAC1,HMG
A1 
GO:0005524,GO:0005515,G
O:0045892 
ATP binding (MF), protein binding 
(MF), negative regulation of 
transcription, DNA-dependent (BP) 
5 (73) 17 2,33E-10 2,91E-09 
XRCC6,UBE2I,TP53,Cdk5,XRCC
5 
GO:0003677,GO:0005515,G
O:0003684 
DNA binding (MF), protein binding 
(MF), damaged DNA binding (MF) 
5 (73) 18 3,23E-10 3,37E-09 HMGB2,TP53,MPG,FEN1,POLB 
GO:0005515,GO:0044419,G
O:0008134 
protein binding (MF), interspecies 
interaction between organisms (BP), 
transcription factor binding (MF) 
5 (73) 28 3,64E-09 2,87E-08 
UBE2I,TP53,HDAC1,EP300,HM
GA1 
GO:0046872,GO:0005515,G
O:0019899 
metal ion binding (MF), protein 
binding (MF), enzyme binding (MF) 
5 (73) 33 8,72E-09 6,01E-08 SIRT1,MDM2,TP53,ESR1,POLB 
GO:0005515,GO:0045892,G
O:0043066 
protein binding (MF), negative 
regulation of transcription, DNA-
dependent (BP), negative regulation 
of apoptotic process (BP) 
5 (73) 33 8,72E-09 6,01E-08 
SIRT1,MDM2,TP53,HDAC1,XR
CC5 
GO:0006355,GO:0003700,G
O:0005515,GO:0008134 
regulation of transcription, DNA-
dependent (BP), sequence-specific 
DNA binding transcription factor 
activity (MF), protein binding (MF), 
transcription factor binding (MF) 
5 (73) 35 1,19E-08 5,53E-08 
HIF1A,TP53,ESR1,HDAC1,HMG
A1 
GO:0006355,GO:0005515,G
O:0045944,GO:0008134 
regulation of transcription, DNA-
dependent (BP), protein binding 
(MF), positive regulation of 
transcription from RNA polymerase 
II promoter (BP), transcription factor 
binding (MF) 
5 (73) 37 1,59E-08 7,06E-08 
HIF1A,TP53,ESR1,HDAC1,EP30
0 
GO:0005515,GO:0000166,G
O:0008022 
protein binding (MF), nucleotide 
binding (MF), protein C-terminus 
binding (MF) 
5 (73) 37 1,59E-08 7,06E-08 
XRCC6,UBE2I,PABPC1,XRCC5,
NCL 
GO:0006355,GO:0003677,G
O:0005515,GO:0008134 
regulation of transcription, DNA-
dependent (BP), DNA binding (MF), 
protein binding (MF), transcription 
factor binding (MF) 
5 (73) 46 4,93E-08 1,64E-07 
HIF1A,TP53,ESR1,EP300,HMGA
1 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0003677,GO:0005515,G
O:0003690 
DNA binding (MF), protein binding 
(MF), double-stranded DNA binding 
(MF) 
5 (73) 48 6,14E-08 1,97E-07 
XRCC6,HMGB2,FEN1,XRCC5,Y
BX1 
GO:0005515,GO:0000166,G
O:0008380,GO:0003723 
protein binding (MF), nucleotide 
binding (MF), RNA splicing (BP), 
RNA binding (MF) 
5 (73) 53 1,02E-07 2,96E-07 
PABPC1,HNRNPL,HNRNPU,SF
PQ,HNRNPH1 
GO:0005515,GO:0000398,G
O:0008380,GO:0003723,GO
:0010467 
protein binding (MF), nuclear 
mRNA splicing, via spliceosome 
(BP), RNA splicing (BP), RNA 
binding (MF), gene expression (BP) 
5 (73) 53 1,02E-07 2,96E-07 
PABPC1,HNRNPL,HNRNPU,YB
X1,HNRNPH1 
GO:0005515,GO:0045892,G
O:0044212 
protein binding (MF), negative 
regulation of transcription, DNA-
dependent (BP), transcription 
regulatory region DNA binding 
(MF) 
5 (73) 55 1,23E-07 3,50E-07 
XRCC6,HMGB2,TP53,XRCC5,B
ASP1 
GO:0003723,GO:0010467,G
O:0044267,GO:0006412,GO
:0016070,GO:0016071 
RNA binding (MF), gene expression 
(BP), cellular protein metabolic 
process (BP), translation (BP), RNA 
metabolic process (BP), mRNA 
metabolic process (BP) 
5 (73) 58 1,62E-07 4,52E-07 
RPL3,RPL14,PABPC1,RPLP0,RP
L4 
GO:0005515,GO:0008134,G
O:0000122 
protein binding (MF), transcription 
factor binding (MF), negative 
regulation of transcription from 
RNA polymerase II promoter (BP) 
5 (73) 67 3,35E-07 7,80E-07 
UBE2I,TP53,HDAC1,PCNA,EP3
00 
GO:0046872,GO:0008270,G
O:0005515,GO:0045944 
metal ion binding (MF), zinc ion 
binding (MF), protein binding (MF), 
positive regulation of transcription 
from RNA polymerase II promoter 
(BP) 
5 (73) 68 3,61E-07 8,35E-07 SIRT1,TRAF6,TP53,ESR1,EP300 
GO:0005515,GO:0000166,G
O:0003723,GO:0003676 
protein binding (MF), nucleotide 
binding (MF), RNA binding (MF), 
nucleic acid binding (MF) 
5 (73) 74 5,53E-07 1,19E-06 
PABPC1,HNRNPL,HNRNPU,NC
L,HNRNPH1 
GO:0046872,GO:0008270,G
O:0005515,GO:0000122 
metal ion binding (MF), zinc ion 
binding (MF), protein binding (MF), 
negative regulation of transcription 
from RNA polymerase II promoter 
5 (73) 75 5,92E-07 1,26E-06 
SIRT1,TRAF6,MDM2,TP53,EP30
0 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
(BP) 
GO:0010467,GO:0006414,G
O:0031018,GO:0044267,GO
:0006412,GO:0016070,GO:0
016032,GO:0016071,GO:00
06415,GO:0019058,GO:001
9083,GO:0003735 
gene expression (BP), translational 
elongation (BP), endocrine pancreas 
development (BP), cellular protein 
metabolic process (BP), translation 
(BP), RNA metabolic process (BP), 
viral reproduction (BP), mRNA 
metabolic process (BP), translational 
termination (BP), viral infectious 
cycle (BP), viral transcription (BP), 
structural constituent of ribosome 
(MF) 
5 (73) 81 8,70E-07 1,77E-06 RPL3,RPL14,RPSA,RPLP0,RPL4 
GO:0003677,GO:0005515,G
O:0044212 
DNA binding (MF), protein binding 
(MF), transcription regulatory region 
DNA binding (MF) 
5 (73) 85 1,11E-06 2,13E-06 
XRCC6,HMGB2,HIF1A,TP53,XR
CC5 
GO:0003677,GO:0005515,G
O:0000166 
DNA binding (MF), protein binding 
(MF), nucleotide binding (MF) 
5 (73) 92 1,64E-06 3,00E-06 
XRCC6,HNRNPU,XRCC5,NCL,S
FPQ 
GO:0005515,GO:0006974 
protein binding (MF), response to 
DNA damage stimulus (BP) 
5 (73) 92 1,64E-06 3,00E-06 
XRCC6,SIRT1,CDKN1A,TP53,P
OLB 
GO:0005524,GO:0007049 ATP binding (MF), cell cycle (BP) 5 (73) 94 1,82E-06 3,32E-06 
UBE2I,KIF11,TP53,CSNK2A1,C
dk5 
GO:0006355,GO:0005515,G
O:0000122 
regulation of transcription, DNA-
dependent (BP),  protein binding 
(MF),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP) 
5 (73) 97 2,13E-06 3,79E-06 TXN,TP53,HDAC1,EP300,YBX1 
GO:0003700,GO:0005515,G
O:0045892 
sequence-specific DNA binding 
transcription factor activity 
(MF),  protein binding 
(MF),  negative regulation of 
transcription, DNA-dependent (BP) 
5 (73) 99 2,36E-06 4,17E-06 
HMGB2,TP53,HDAC1,YBX1,H
MGA1 
GO:0005515,GO:0045892,G
O:0045893 
protein binding (MF),  negative 
regulation of transcription, DNA-
dependent (BP),  positive regulation 
5 (73) 101 2,60E-06 4,50E-06 
XRCC6,HMGB2,TP53,HDAC1,H
MGA1 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
of transcription, DNA-dependent 
(BP) 
GO:0005515,GO:0045944,G
O:0000122 
protein binding (MF),  positive 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP) 
5 (73) 104 3,00E-06 5,13E-06 
SIRT1,TRAF6,TP53,HDAC1,EP3
00 
GO:0006355,GO:0003677,G
O:0045944 
regulation of transcription, DNA-
dependent (BP),  DNA binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP) 
5 (73) 118 5,59E-06 8,69E-06 HIF1A,TP53,TCF21,ESR1,EP300 
GO:0003700,GO:0005515,G
O:0045893 
sequence-specific DNA binding 
transcription factor activity 
(MF),  protein binding 
(MF),  positive regulation of 
transcription, DNA-dependent (BP) 
5 (73) 120 6,06E-06 9,40E-06 
HMGB2,HIF1A,TP53,HDAC1,H
MGA1 
GO:0006355,GO:0003677,G
O:0003700,GO:0005515 
regulation of transcription, DNA-
dependent (BP),  DNA binding 
(MF),  sequence-specific DNA 
binding transcription factor activity 
(MF),  protein binding (MF) 
5 (73) 121 6,31E-06 9,71E-06 
HIF1A,TP53,ESR1,YBX1,HMGA
1 
GO:0005515,GO:0004842 
protein binding (MF),  ubiquitin-
protein ligase activity (MF) 
5 (73) 134 1,04E-05 1,52E-05 
UBE2I,TRAF6,MDM2,UBC,PRP
F19 
GO:0005515,GO:0042493 
protein binding (MF),  response to 
drug (BP) 
5 (73) 135 1,08E-05 1,57E-05 
CDKN1A,TP53,XRCC1,EP300,N
ME1 
GO:0005515,GO:0045944,G
O:0045893 
protein binding (MF),  positive 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  positive regulation of 
transcription, DNA-dependent (BP) 
5 (73) 138 1,20E-05 1,72E-05 
XRCC6,HMGB2,HIF1A,TP53,H
DAC1 
GO:0003677,GO:0005515,G
O:0045893 
DNA binding (MF),  protein binding 
(MF),  positive regulation of 
transcription, DNA-dependent (BP) 
5 (73) 140 1,28E-05 1,81E-05 
XRCC6,HMGB2,HIF1A,TP53,H
MGA1 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0003700,GO:0005515,G
O:0045944 
sequence-specific DNA binding 
transcription factor activity 
(MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP) 
5 (73) 156 2,16E-05 2,90E-05 
HMGB2,HIF1A,TP53,ESR1,HDA
C1 
GO:0008283,GO:0005515 
cell proliferation (BP),  protein 
binding (MF) 
5 (73) 157 2,23E-05 2,98E-05 TXN,TP53,Cdk5,PCNA,XRCC5 
GO:0005515,GO:0030154 
protein binding (MF),  cell 
differentiation (BP) 
5 (73) 173 3,55E-05 4,57E-05 SIRT1,HIF1A,TP53,NME1,ARF6 
GO:0000287 magnesium ion binding (MF) 5 (73) 178 4,07E-05 5,06E-05 
PRPS1,NUDT3,FEN1,PRPS2,NM
E1 
GO:0003677,GO:0000122 
DNA binding (MF),  negative 
regulation of transcription from 
RNA polymerase II promoter (BP) 
5 (73) 193 5,97E-05 7,16E-05 TP53,TCF21,PCNA,EP300,YBX1 
GO:0016301 kinase activity (MF) 5 (73) 227 0,000128113 0,000146306 
PRPS1,CDKN1A,Cdk5,PRPS2,N
ME1 
GO:0005515,GO:0016787 
protein binding (MF),  hydrolase 
activity (MF) 
5 (73) 259 0,000236292 0,000264373 
XRCC6,PRDX6,MUTYH,HDAC1
,MPG 
GO:0003779 actin binding (MF) 5 (73) 289 0,000390608 0,000425918 
MSN,MYO1C,MYH9,SPTBN1,A
CTN1 
GO:0007399 nervous system development (BP) 5 (73) 410 0,00185907 0,00193946 
PRPS1,DCTN1,EP300,NME1,AR
F6 
GO:0007596 blood coagulation (BP) 5 (73) 457 0,00296893 0,00306419 
KIF11,TP53,HDAC1,Cdk5,ACTN
1 
GO:0042803 
protein homodimerization activity 
(MF) 
5 (73) 514 0,0048797 0,00499619 
PRPS1,GZMA,NPM1,MYH9,PRP
S2 
GO:0005515,GO:0044419,G
O:0000122,GO:0045892,GO
:0019899,GO:0043066 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription, DNA-
dependent (BP),  enzyme binding 
(MF),  negative regulation of 
apoptotic process (BP) 
4 (73) 4 (34208) 1,91E-11 3,68E-10 SIRT1,MDM2,TP53,HDAC1 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0033158 
protein binding (MF),  regulation of 
protein import into nucleus, 
translocation (BP) 
4 (73) 4 (34208) 1,91E-11 3,68E-10 SIRT1,CDKN1A,OGG1,TXN 
GO:0046872,GO:0008270,G
O:0005515,GO:0045944,GO
:0042981 
metal ion binding (MF),  zinc ion 
binding (MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  regulation of 
apoptotic process (BP) 
4 (73) 5 (34208) 9,52E-11 1,31E-09 SIRT1,TRAF6,TP53,ESR1 
GO:0003677,GO:0005515,G
O:0003684,GO:0006284 
DNA binding (MF),  protein binding 
(MF),  damaged DNA binding 
(MF),  base-excision repair (BP) 
4 (73) 5 (34208) 9,52E-11 1,31E-09 TP53,MPG,FEN1,POLB 
GO:0005515,GO:0044419,G
O:0008134,GO:0045892,GO
:0019899 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  transcription factor binding 
(MF),  negative regulation of 
transcription, DNA-dependent 
(BP),  enzyme binding (MF) 
4 (73) 5 (34208) 9,52E-11 1,31E-09 UBE2I,TP53,HDAC1,HMGA1 
GO:0005515,GO:0003824,G
O:0006281,GO:0006284 
protein binding (MF),  catalytic 
activity (MF),  DNA repair 
(BP),  base-excision repair (BP) 
4 (73) 5 (34208) 9,52E-11 1,31E-09 MUTYH,OGG1,MPG,POLB 
GO:0006355,GO:0003700,G
O:0005515,GO:0008134,GO
:0019899 
regulation of transcription, DNA-
dependent (BP),  sequence-specific 
DNA binding transcription factor 
activity (MF),  protein binding 
(MF),  transcription factor binding 
(MF),  enzyme binding (MF) 
4 (73) 6 (34208) 2,85E-10 3,15E-09 TP53,ESR1,HDAC1,HMGA1 
GO:0005515,GO:0000122,G
O:0045892,GO:0016567 
protein binding (MF),  negative 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  negative regulation of 
transcription, DNA-dependent 
(BP),  protein ubiquitination (BP) 
4 (73) 6 (34208) 2,85E-10 3,15E-09 SIRT1,UBE2I,TRAF6,MDM2 
GO:0046872,GO:0008270,G
O:0005515,GO:0044419,GO
:0000122 
metal ion binding (MF),  zinc ion 
binding (MF),  protein binding 
(MF),  interspecies interaction 
4 (73) 9 (34208) 2,38E-09 1,92E-08 SIRT1,MDM2,TP53,EP300 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
between organisms (BP),  negative 
regulation of transcription from 
RNA polymerase II promoter (BP) 
GO:0005515,GO:0045892,G
O:0006281 
protein binding (MF),  negative 
regulation of transcription, DNA-
dependent (BP),  DNA repair (BP) 
4 (73) 9 (34208) 2,38E-09 1,92E-08 XRCC6,SIRT1,SUMO1,XRCC5 
GO:0005515,GO:0044419,G
O:0045944,GO:0000122 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription from 
RNA polymerase II promoter (BP) 
4 (73) 10 (34208) 3,97E-09 3,06E-08 SIRT1,TP53,HDAC1,EP300 
GO:0005515,GO:0044419,G
O:0008134,GO:0000122 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  transcription factor binding 
(MF),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP) 
4 (73) 11 (34208) 6,23E-09 4,53E-08 UBE2I,TP53,HDAC1,EP300 
GO:0003677,GO:0005515,G
O:0006281,GO:0006284 
DNA binding (MF),  protein binding 
(MF),  DNA repair (BP),  base-
excision repair (BP) 
4 (73) 13 (34208) 1,34E-08 6,11E-08 PCNA,MPG,FEN1,POLB 
GO:0005515,GO:0045892,G
O:0042981 
protein binding (MF),  negative 
regulation of transcription, DNA-
dependent (BP),  regulation of 
apoptotic process (BP) 
4 (73) 13 (34208) 1,34E-08 6,11E-08 SIRT1,TRAF6,TP53,Cdk5 
GO:0005524,GO:0005515,G
O:0000166,GO:0045892 
ATP binding (MF),  protein binding 
(MF),  nucleotide binding 
(MF),  negative regulation of 
transcription, DNA-dependent (BP) 
4 (73) 14 (34208) 1,88E-08 8,15E-08 XRCC6,UBE2I,Cdk5,XRCC5 
GO:0005515,GO:0045892,G
O:0002039 
protein binding (MF),  negative 
regulation of transcription, DNA-
dependent (BP),  p53 binding (MF) 
4 (73) 14 (34208) 1,88E-08 8,15E-08 SIRT1,MDM2,TP53,Cdk5 
GO:0003677,GO:0005515,G
O:0006281,GO:0000723 
DNA binding (MF),  protein binding 
(MF),  DNA repair (BP),  telomere 
maintenance (BP) 
4 (73) 15 (34208) 2,56E-08 1,06E-07 XRCC6,PCNA,FEN1,XRCC5 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0045892,G
O:0008022 
protein binding (MF),  negative 
regulation of transcription, DNA-
dependent (BP),  protein C-terminus 
binding (MF) 
4 (73) 15 (34208) 2,56E-08 1,06E-07 XRCC6,SIRT1,UBE2I,XRCC5 
GO:0006355,GO:0005515,G
O:0044419,GO:0008134 
regulation of transcription, DNA-
dependent (BP),  protein binding 
(MF),  interspecies interaction 
between organisms 
(BP),  transcription factor binding 
(MF) 
4 (73) 16 (34208) 3,41E-08 1,38E-07 TP53,HDAC1,EP300,HMGA1 
GO:0005515,GO:0043388 
protein binding (MF),  positive 
regulation of DNA binding (BP) 
4 (73) 17 (34208) 4,45E-08 1,51E-07 HMGB2,TXN,EP300,NME1 
GO:0005515,GO:0042802,G
O:0042981 
protein binding (MF),  identical 
protein binding (MF),  regulation of 
apoptotic process (BP) 
4 (73) 17 (34208) 4,45E-08 1,51E-07 SIRT1,TP53,PAK2,NME1 
GO:0005515,GO:0006913 
protein binding 
(MF),  nucleocytoplasmic transport 
(BP) 
4 (73) 17 (34208) 4,45E-08 1,51E-07 NPM1,SET,Cdk5,ANP32A 
GO:0003677,GO:0005515,G
O:0003690,GO:0045892 
DNA binding (MF),  protein binding 
(MF),  double-stranded DNA 
binding (MF),  negative regulation of 
transcription, DNA-dependent (BP) 
4 (73) 18 (34208) 5,71E-08 1,87E-07 XRCC6,HMGB2,XRCC5,YBX1 
GO:0045944,GO:0042826 
positive regulation of transcription 
from RNA polymerase II promoter 
(BP),  histone deacetylase binding 
(MF) 
4 (73) 21 (34208) 1,11E-07 3,18E-07 TRAF6,HIF1A,TCF21,HDAC1 
GO:0003677,GO:0005515,G
O:0006302 
DNA binding (MF),  protein binding 
(MF),  double-strand break repair 
(BP) 
4 (73) 22 (34208) 1,36E-07 3,82E-07 XRCC6,TP53,FEN1,XRCC5 
GO:0006355,GO:0003700,G
O:0005515,GO:0008134,GO
:0045893 
regulation of transcription, DNA-
dependent (BP),  sequence-specific 
DNA binding transcription factor 
activity (MF),  protein binding 
(MF),  transcription factor binding 
(MF),  positive regulation of 
transcription, DNA-dependent (BP) 
4 (73) 23 (34208) 1,64E-07 4,52E-07 HIF1A,TP53,HDAC1,HMGA1 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0000166,G
O:0000398,GO:0008380,GO
:0003723,GO:0010467,GO:0
003676 
protein binding (MF),  nucleotide 
binding (MF),  nuclear mRNA 
splicing, via spliceosome 
(BP),  RNA splicing (BP),  RNA 
binding (MF),  gene expression 
(BP),  nucleic acid binding (MF) 
4 (73) 23 (34208) 1,64E-07 4,52E-07 
PABPC1,HNRNPL,HNRNPU,HN
RNPH1 
GO:0003677,GO:0005515,G
O:0019899 
DNA binding (MF),  protein binding 
(MF),  enzyme binding (MF) 
4 (73) 24 (34208) 1,96E-07 4,92E-07 TP53,ESR1,HMGA1,POLB 
GO:0005515,GO:0071456 
protein binding (MF),  cellular 
response to hypoxia (BP) 
4 (73) 24 (34208) 1,96E-07 4,92E-07 SIRT1,MDM2,HIF1A,TP53 
GO:0006355,GO:0003700,G
O:0005515,GO:0045944,GO
:0008134 
regulation of transcription, DNA-
dependent (BP),  sequence-specific 
DNA binding transcription factor 
activity (MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  transcription 
factor binding (MF) 
4 (73) 25 (34208) 2,33E-07 5,66E-07 HIF1A,TP53,ESR1,HDAC1 
GO:0046872,GO:0005515,G
O:0006974 
metal ion binding (MF),  protein 
binding (MF),  response to DNA 
damage stimulus (BP) 
4 (73) 25 (34208) 2,33E-07 5,66E-07 SIRT1,CDKN1A,TP53,POLB 
GO:0005524,GO:0005515,G
O:0042981 
ATP binding (MF),  protein binding 
(MF),  regulation of apoptotic 
process (BP) 
4 (73) 25 (34208) 2,33E-07 5,66E-07 TP53,Cdk5,PAK2,NME1 
GO:0005515,GO:0045944,G
O:0019899 
protein binding (MF),  positive 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  enzyme binding (MF) 
4 (73) 25 (34208) 2,33E-07 5,66E-07 SIRT1,TP53,ESR1,HDAC1 
GO:0046872,GO:0008270,G
O:0005515,GO:0019899 
metal ion binding (MF),  zinc ion 
binding (MF),  protein binding 
(MF),  enzyme binding (MF) 
4 (73) 26 (34208) 2,75E-07 6,60E-07 SIRT1,MDM2,TP53,ESR1 
GO:0003677,GO:0005515,G
O:0008380 
DNA binding (MF),  protein binding 
(MF),  RNA splicing (BP) 
4 (73) 27 (34208) 3,23E-07 7,64E-07 HNRNPU,PRPF19,YBX1,SFPQ 
GO:0006355,GO:0003677,G
O:0005515,GO:0045944,GO
:0008134 
regulation of transcription, DNA-
dependent (BP),  DNA binding 
(MF),  protein binding 
4 (73) 28 (34208) 3,76E-07 8,58E-07 HIF1A,TP53,ESR1,EP300 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  transcription 
factor binding (MF) 
GO:0046872,GO:0008270,G
O:0005515,GO:0000122,GO
:0045892 
metal ion binding (MF),  zinc ion 
binding (MF),  protein binding 
(MF),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription, DNA-
dependent (BP) 
4 (73) 28 (34208) 3,76E-07 8,58E-07 SIRT1,TRAF6,MDM2,TP53 
GO:0046872,GO:0008270,G
O:0005515,GO:0045944,GO
:0000122 
metal ion binding (MF),  zinc ion 
binding (MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription from 
RNA polymerase II promoter (BP) 
4 (73) 29 (34208) 4,35E-07 9,82E-07 SIRT1,TRAF6,TP53,EP300 
GO:0005515,GO:0010467,G
O:0044267,GO:0006412,GO
:0016070,GO:0016071 
protein binding (MF),  gene 
expression (BP),  cellular protein 
metabolic process (BP),  translation 
(BP),  RNA metabolic process 
(BP),  mRNA metabolic process 
(BP) 
4 (73) 31 (34208) 5,75E-07 1,23E-06 RPL14,PABPC1,RPSA,RPLP0 
GO:0006355,GO:0003677,G
O:0003700,GO:0005515,GO
:0008134 
regulation of transcription, DNA-
dependent (BP),  DNA binding 
(MF),  sequence-specific DNA 
binding transcription factor activity 
(MF),  protein binding 
(MF),  transcription factor binding 
(MF) 
4 (73) 32 (34208) 6,56E-07 1,38E-06 HIF1A,TP53,ESR1,HMGA1 
GO:0003677,GO:0005515,G
O:0045892,GO:0044212 
DNA binding (MF),  protein binding 
(MF),  negative regulation of 
transcription, DNA-dependent 
(BP),  transcription regulatory region 
DNA binding (MF) 
4 (73) 34 (34208) 8,43E-07 1,72E-06 XRCC6,HMGB2,TP53,XRCC5 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0006977,G
O:0000075 
protein binding (MF),  DNA damage 
response, signal transduction by p53 
class mediator resulting in cell cycle 
arrest (BP),  cell cycle checkpoint 
(BP) 
4 (73) 34 (34208) 8,43E-07 1,72E-06 CDKN1A,MDM2,TP53,UBC 
GO:0007165,GO:0005515,G
O:0019901 
signal transduction (BP),  protein 
binding (MF),  protein kinase 
binding (MF) 
4 (73) 35 (34208) 9,50E-07 1,89E-06 NPM1,TRAF6,HIF1A,PAK2 
GO:0005524,GO:0005515,G
O:0000166,GO:0007411 
ATP binding (MF),  protein binding 
(MF),  nucleotide binding 
(MF),  axon guidance (BP) 
4 (73) 36 (34208) 1,07E-06 2,07E-06 CSNK2A1,MYH9,Cdk5,PAK2 
GO:0005524,GO:0000166,G
O:0008022 
ATP binding (MF),  nucleotide 
binding (MF),  protein C-terminus 
binding (MF) 
4 (73) 36 (34208) 1,07E-06 2,07E-06 XRCC6,UBE2I,MYO1C,XRCC5 
GO:0006915,GO:0005515,G
O:0045944 
apoptotic process (BP),  protein 
binding (MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP) 
4 (73) 37 (34208) 1,19E-06 2,28E-06 TRAF6,HMGB2,TP53,EP300 
GO:0006355,GO:0003700,G
O:0005515,GO:0045892 
regulation of transcription, DNA-
dependent (BP),  sequence-specific 
DNA binding transcription factor 
activity (MF),  protein binding 
(MF),  negative regulation of 
transcription, DNA-dependent (BP) 
4 (73) 39 (34208) 1,48E-06 2,82E-06 TP53,HDAC1,YBX1,HMGA1 
GO:0046872,GO:0005515,G
O:0043066 
metal ion binding (MF),  protein 
binding (MF),  negative regulation of 
apoptotic process (BP) 
4 (73) 45 (34208) 2,66E-06 4,59E-06 SIRT1,CDKN1A,MDM2,TP53 
GO:0005515,GO:0006928 
protein binding (MF),  cellular 
component movement (BP) 
4 (73) 46 (34208) 2,91E-06 4,99E-06 MSN,TXN,MYH9,ARF6 
GO:0003700,GO:0005515,G
O:0045892,GO:0045893 
sequence-specific DNA binding 
transcription factor activity 
(MF),  protein binding 
(MF),  negative regulation of 
transcription, DNA-dependent 
(BP),  positive regulation of 
transcription, DNA-dependent (BP) 
4 (73) 47 (34208) 3,18E-06 5,40E-06 HMGB2,TP53,HDAC1,HMGA1 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0006355,GO:0007165,G
O:0005515 
regulation of transcription, DNA-
dependent (BP),  signal transduction 
(BP),  protein binding (MF) 
4 (73) 48 (34208) 3,46E-06 5,80E-06 TXN,HIF1A,CSNK2A1,ESR1 
GO:0003677,GO:0005515,G
O:0045944,GO:0045893,GO
:0044212 
DNA binding (MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  positive regulation 
of transcription, DNA-dependent 
(BP),  transcription regulatory region 
DNA binding (MF) 
4 (73) 49 (34208) 3,76E-06 6,28E-06 XRCC6,HMGB2,HIF1A,TP53 
GO:0003677,GO:0005515,G
O:0003723 
DNA binding (MF),  protein binding 
(MF),  RNA binding (MF) 
4 (73) 50 (34208) 4,08E-06 6,79E-06 HNRNPU,NCL,YBX1,SFPQ 
GO:0005515,GO:0045944,G
O:0000122,GO:0045892 
protein binding (MF),  positive 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription, DNA-
dependent (BP) 
4 (73) 51 (34208) 4,42E-06 7,23E-06 SIRT1,TRAF6,TP53,HDAC1 
GO:0003677,GO:0005515,G
O:0045892,GO:0045893 
DNA binding (MF),  protein binding 
(MF),  negative regulation of 
transcription, DNA-dependent 
(BP),  positive regulation of 
transcription, DNA-dependent (BP) 
4 (73) 52 (34208) 4,78E-06 7,75E-06 XRCC6,HMGB2,TP53,HMGA1 
GO:0006355,GO:0045944,G
O:0000122 
regulation of transcription, DNA-
dependent (BP),  positive regulation 
of transcription from RNA 
polymerase II promoter 
(BP),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP) 
4 (73) 53 (34208) 5,16E-06 8,13E-06 TP53,TCF21,HDAC1,EP300 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0003723,GO:0010467,G
O:0006414,GO:0031018,GO
:0044267,GO:0006412,GO:0
016070,GO:0016032,GO:00
16071,GO:0006415,GO:001
9058,GO:0019083,GO:0003
735 
RNA binding (MF),  gene expression 
(BP),  translational elongation 
(BP),  endocrine pancreas 
development (BP),  cellular protein 
metabolic process (BP),  translation 
(BP),  RNA metabolic process 
(BP),  viral reproduction 
(BP),  mRNA metabolic process 
(BP),  translational termination 
(BP),  viral infectious cycle 
(BP),  viral transcription 
(BP),  structural constituent of 
ribosome (MF) 
4 (73) 53 (34208) 5,16E-06 8,13E-06 RPL3,RPL14,RPLP0,RPL4 
GO:0005515,GO:0048015 
protein binding 
(MF),  phosphatidylinositol-
mediated signaling (BP) 
4 (73) 54 (34208) 5,57E-06 8,70E-06 MDM2,HMGB2,PCNA,FEN1 
GO:0005515,GO:0016070,G
O:0016032,GO:0016071 
protein binding (MF),  RNA 
metabolic process (BP),  viral 
reproduction (BP),  mRNA 
metabolic process (BP) 
4 (73) 54 (34208) 5,57E-06 8,70E-06 RPL14,RPSA,UBC,RPLP0 
GO:0005515,GO:0045944,G
O:0045892,GO:0045893 
protein binding (MF),  positive 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  negative regulation of 
transcription, DNA-dependent 
(BP),  positive regulation of 
transcription, DNA-dependent (BP) 
4 (73) 56 (34208) 6,44E-06 9,87E-06 XRCC6,HMGB2,TP53,HDAC1 
GO:0003677,GO:0003700,G
O:0005515,GO:0045892 
DNA binding (MF),  sequence-
specific DNA binding transcription 
factor activity (MF),  protein binding 
(MF),  negative regulation of 
transcription, DNA-dependent (BP) 
4 (73) 58 (34208) 7,42E-06 1,13E-05 HMGB2,TP53,YBX1,HMGA1 
GO:0005515,GO:0047485 
protein binding (MF),  protein N-
terminus binding (MF) 
4 (73) 60 (34208) 8,50E-06 1,27E-05 TRAF6,TP53,CSNK2A1,HSPA1A 
GO:0006915,GO:0005515,G
O:0042981 
apoptotic process (BP),  protein 
binding (MF),  regulation of 
4 (73) 65 (34208) 1,17E-05 1,69E-05 TRAF6,TP53,UBC,PAK2 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
apoptotic process (BP) 
GO:0005515,GO:0030308 
protein binding (MF),  negative 
regulation of cell growth (BP) 
4 (73) 65 (34208) 1,17E-05 1,69E-05 SIRT1,CDKN1A,TP53,HSPA1A 
GO:0005524,GO:0005515,G
O:0007049 
ATP binding (MF),  protein binding 
(MF),  cell cycle (BP) 
4 (73) 66 (34208) 1,24E-05 1,77E-05 UBE2I,TP53,CSNK2A1,Cdk5 
GO:0005515,GO:0000278,G
O:0000082 
protein binding (MF),  mitotic cell 
cycle (BP),  G1/S transition of 
mitotic cell cycle (BP) 
4 (73) 68 (34208) 1,40E-05 1,95E-05 CDKN1A,UBC,PCNA,CCNA1 
GO:0005515,GO:0000278,G
O:0000084 
protein binding (MF),  mitotic cell 
cycle (BP),  S phase of mitotic cell 
cycle (BP) 
4 (73) 69 (34208) 1,49E-05 2,06E-05 CDKN1A,UBC,PCNA,FEN1 
GO:0003677,GO:0005524,G
O:0005515 
DNA binding (MF),  ATP binding 
(MF),  protein binding (MF) 
4 (73) 79 (34208) 2,54E-05 3,36E-05 XRCC6,TP53,HNRNPU,XRCC5 
GO:0005515,GO:0001525 
protein binding (MF),  angiogenesis 
(BP) 
4 (73) 80 (34208) 2,67E-05 3,50E-05 SIRT1,HIF1A,MYH9,NCL 
GO:0003700,GO:0005515,G
O:0045944,GO:0045893 
sequence-specific DNA binding 
transcription factor activity 
(MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  positive regulation 
of transcription, DNA-dependent 
(BP) 
4 (73) 85 (34208) 3,39E-05 4,39E-05 HMGB2,HIF1A,TP53,HDAC1 
GO:0005515,GO:0031625 
protein binding (MF),  ubiquitin 
protein ligase binding (MF) 
4 (73) 86 (34208) 3,55E-05 4,58E-05 TP53,SUMO2,SUMO1,HSPA1A 
GO:0003677,GO:0003700,G
O:0005515,GO:0045893 
DNA binding (MF),  sequence-
specific DNA binding transcription 
factor activity (MF),  protein binding 
(MF),  positive regulation of 
transcription, DNA-dependent (BP) 
4 (73) 87 (34208) 3,72E-05 4,73E-05 HMGB2,HIF1A,TP53,HMGA1 
GO:0006355,GO:0003677,G
O:0000122 
regulation of transcription, DNA-
dependent (BP),  DNA binding 
(MF),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP) 
4 (73) 88 (34208) 3,89E-05 4,92E-05 TP53,TCF21,EP300,YBX1 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005524,GO:0000166,G
O:0007049 
ATP binding (MF),  nucleotide 
binding (MF),  cell cycle (BP) 
4 (73) 89 (34208) 4,06E-05 5,07E-05 UBE2I,KIF11,CSNK2A1,Cdk5 
GO:0005515,GO:0006260 
protein binding (MF),  DNA 
replication (BP) 
4 (73) 91 (34208) 4,43E-05 5,45E-05 SIRT1,SET,PCNA,FEN1 
GO:0003677,GO:0003700,G
O:0005515,GO:0045944 
DNA binding (MF),  sequence-
specific DNA binding transcription 
factor activity (MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP) 
4 (73) 103 (34208) 7,19E-05 8,52E-05 HMGB2,HIF1A,TP53,ESR1 
GO:0005515,GO:0003779 
protein binding (MF),  actin binding 
(MF) 
4 (73) 106 (34208) 8,04E-05 9,49E-05 MSN,MYH9,SPTBN1,ACTN1 
GO:0005515,GO:0019904 
protein binding (MF),  protein 
domain specific binding (MF) 
4 (73) 111 (34208) 9,62E-05 0,000111815 SIRT1,HMGB2,ACTN1,BASP1 
GO:0003677,GO:0005515,G
O:0000122 
DNA binding (MF),  protein binding 
(MF),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP) 
4 (73) 118 (34208) 0,00012185 0,0001404 TP53,PCNA,EP300,YBX1 
GO:0007399,GO:0005515 
nervous system development 
(BP),  protein binding (MF) 
4 (73) 134 (34208) 0,000198719 0,000224285 DCTN1,EP300,NME1,ARF6 
GO:0005515,GO:0048011 
protein binding (MF),  nerve growth 
factor receptor signaling pathway 
(BP) 
4 (73) 137 (34208) 0,000216294 0,000242702 TRAF6,MDM2,UBC,HDAC1 
GO:0005515,GO:0045087 
protein binding (MF),  innate 
immune response (BP) 
4 (73) 151 (34208) 0,000313404 0,000345639 TRAF6,TXN,UBC,EP300 
GO:0005524,GO:0000166,G
O:0016301 
ATP binding (MF),  nucleotide 
binding (MF),  kinase activity (MF) 
4 (73) 155 (34208) 0,000346089 0,000378443 PRPS1,Cdk5,PRPS2,NME1 
GO:0007067 mitosis (BP) 4 (73) 187 (34208) 0,000701244 0,00075609 UBE2I,KIF11,DCTN1,CCNA1 
GO:0046872,GO:0003677,G
O:0005515 
metal ion binding (MF),  DNA 
binding (MF),  protein binding (MF) 
4 (73) 193 (34208) 0,000788856 0,000843486 TP53,ESR1,EP300,POLB 
GO:0005515,GO:0007596 
protein binding (MF),  blood 
coagulation (BP) 
4 (73) 251 (34208) 0,00207178 0,00214975 TP53,HDAC1,Cdk5,ACTN1 
GO:0051301 cell division (BP) 4 (73) 286 (34208) 0,00331245 0,00340962 UBE2I,KIF11,Cdk5,CCNA1 
GO:0005515,GO:0004872 
protein binding (MF),  receptor 
activity (MF) 
4 (73) 362 (34208) 0,00756756 0,00770733 MCC,RPSA,ESR1,HSPA1A 
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# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0016740 transferase activity (MF) 4 (73) 616 (34208) 0,0428217 0,0430447 PRPS1,PRPS2,NME1,POLB 
GO:0006355,GO:0003700,G
O:0005515,GO:0044419,GO
:0008134,GO:0045892,GO:0
045893,GO:0019899 
regulation of transcription, DNA-
dependent (BP),  sequence-specific 
DNA binding transcription factor 
activity (MF),  protein binding 
(MF),  interspecies interaction 
between organisms 
(BP),  transcription factor binding 
(MF),  negative regulation of 
transcription, DNA-dependent 
(BP),  positive regulation of 
transcription, DNA-dependent 
(BP),  enzyme binding (MF) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 TP53,HDAC1,HMGA1 
GO:0046872,GO:0008270,G
O:0005515,GO:0044419,GO
:0045944,GO:0000122,GO:0
042771 
metal ion binding (MF),  zinc ion 
binding (MF),  protein binding 
(MF),  interspecies interaction 
between organisms (BP),  positive 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP),  DNA damage 
response, signal transduction by p53 
class mediator resulting in induction 
of apoptosis (BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 SIRT1,TP53,EP300 
GO:0046872,GO:0008270,G
O:0005515,GO:0044419,GO
:0000122,GO:0045892,GO:0
019899,GO:0043066,GO:00
02039,GO:0071456 
metal ion binding (MF),  zinc ion 
binding (MF),  protein binding 
(MF),  interspecies interaction 
between organisms (BP),  negative 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  negative regulation of 
transcription, DNA-dependent 
(BP),  enzyme binding 
(MF),  negative regulation of 
apoptotic process (BP),  p53 binding 
3 (73) 3 (34208) 9,32E-09 4,44E-08 SIRT1,MDM2,TP53 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
(MF),  cellular response to hypoxia 
(BP) 
GO:0046872,GO:0008270,G
O:0005515,GO:0045944,GO
:0000122,GO:0045892,GO:0
042981 
metal ion binding (MF),  zinc ion 
binding (MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  negative regulation of 
transcription, DNA-dependent 
(BP),  regulation of apoptotic 
process (BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 SIRT1,TRAF6,TP53 
GO:0046872,GO:0005515,G
O:0042493,GO:0007049 
metal ion binding (MF),  protein 
binding (MF),  response to drug 
(BP),  cell cycle (BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 CDKN1A,TP53,EP300 
GO:0046872,GO:0005515,G
O:0030308,GO:0071479,GO
:0043066,GO:0006974 
metal ion binding (MF),  protein 
binding (MF),  negative regulation of 
cell growth (BP),  cellular response 
to ionizing radiation (BP),  negative 
regulation of apoptotic process 
(BP),  response to DNA damage 
stimulus (BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 SIRT1,CDKN1A,TP53 
GO:0046872,GO:0005515,G
O:0043066,GO:0006977,GO
:0000075 
metal ion binding (MF),  protein 
binding (MF),  negative regulation of 
apoptotic process (BP),  DNA 
damage response, signal transduction 
by p53 class mediator resulting in 
cell cycle arrest (BP),  cell cycle 
checkpoint (BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 CDKN1A,MDM2,TP53 
GO:0003677,GO:0005524,G
O:0005515,GO:0045892,GO
:0044212,GO:0006302 
DNA binding (MF),  ATP binding 
(MF),  protein binding 
(MF),  negative regulation of 
transcription, DNA-dependent 
3 (73) 3 (34208) 9,32E-09 4,44E-08 XRCC6,TP53,XRCC5 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
(BP),  transcription regulatory region 
DNA binding (MF),  double-strand 
break repair (BP) 
GO:0003677,GO:0005515,G
O:0003690,GO:0006281,GO
:0006302,GO:0000723 
DNA binding (MF),  protein binding 
(MF),  double-stranded DNA 
binding (MF),  DNA repair 
(BP),  double-strand break repair 
(BP),  telomere maintenance (BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 XRCC6,FEN1,XRCC5 
GO:0003677,GO:0005515,G
O:0045892,GO:0016032,GO
:0019047,GO:0019059,GO:0
051575 
DNA binding (MF),  protein binding 
(MF),  negative regulation of 
transcription, DNA-dependent 
(BP),  viral reproduction 
(BP),  provirus integration 
(BP),  initiation of viral infection 
(BP),  5'-deoxyribose-5-phosphate 
lyase activity (MF) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 XRCC6,XRCC5,HMGA1 
GO:0003677,GO:0005515,G
O:0019899,GO:0006284 
DNA binding (MF),  protein binding 
(MF),  enzyme binding (MF),  base-
excision repair (BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 TP53,HMGA1,POLB 
GO:0008283,GO:0005524,G
O:0005515,GO:0045892 
cell proliferation (BP),  ATP binding 
(MF),  protein binding 
(MF),  negative regulation of 
transcription, DNA-dependent (BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 TP53,Cdk5,XRCC5 
GO:0005524,GO:0005515,G
O:0045892,GO:0007049 
ATP binding (MF),  protein binding 
(MF),  negative regulation of 
transcription, DNA-dependent 
(BP),  cell cycle (BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 UBE2I,TP53,Cdk5 
GO:0005515,GO:0044419,G
O:0045944,GO:0000122,GO
:0045892,GO:0019899,GO:0
043066 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  negative regulation of 
transcription, DNA-dependent 
3 (73) 3 (34208) 9,32E-09 4,44E-08 SIRT1,TP53,HDAC1 
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# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
(BP),  enzyme binding 
(MF),  negative regulation of 
apoptotic process (BP) 
GO:0005515,GO:0044419,G
O:0008134,GO:0000122,GO
:0045892,GO:0019899 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  transcription factor binding 
(MF),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription, DNA-
dependent (BP),  enzyme binding 
(MF) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 UBE2I,TP53,HDAC1 
GO:0005515,GO:0044419,G
O:0008134,GO:0000122,GO
:0007049 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  transcription factor binding 
(MF),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP),  cell cycle (BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 UBE2I,TP53,EP300 
GO:0005515,GO:0044419,G
O:0000122,GO:0008284,GO
:0045892,GO:0019899,GO:0
043066 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP),  positive regulation 
of cell proliferation (BP),  negative 
regulation of transcription, DNA-
dependent (BP),  enzyme binding 
(MF),  negative regulation of 
apoptotic process (BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 SIRT1,MDM2,HDAC1 
GO:0005515,GO:0044419,G
O:0000122,GO:0045892,GO
:0016567,GO:0019899 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription, DNA-
dependent (BP),  protein 
ubiquitination (BP),  enzyme binding 
3 (73) 3 (34208) 9,32E-09 4,44E-08 SIRT1,UBE2I,MDM2 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
(MF) 
GO:0005515,GO:0044419,G
O:0045892,GO:0019899,GO
:0006461 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  negative regulation of 
transcription, DNA-dependent 
(BP),  enzyme binding 
(MF),  protein complex assembly 
(BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 MDM2,TP53,HMGA1 
GO:0005515,GO:0045944,G
O:0030154,GO:0071456 
protein binding (MF),  positive 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  cell differentiation 
(BP),  cellular response to hypoxia 
(BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 SIRT1,HIF1A,TP53 
GO:0005515,GO:0003684,G
O:0003824,GO:0006281,GO
:0006284 
protein binding (MF),  damaged 
DNA binding (MF),  catalytic 
activity (MF),  DNA repair 
(BP),  base-excision repair (BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 OGG1,MPG,POLB 
GO:0005515,GO:0045892,G
O:0006281,GO:0008022 
protein binding (MF),  negative 
regulation of transcription, DNA-
dependent (BP),  DNA repair 
(BP),  protein C-terminus binding 
(MF) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 XRCC6,SIRT1,XRCC5 
GO:0005515,GO:0003824,G
O:0006281,GO:0006284,GO
:0006285,GO:0045007 
protein binding (MF),  catalytic 
activity (MF),  DNA repair 
(BP),  base-excision repair 
(BP),  base-excision repair, AP site 
formation (BP),  depurination (BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 MUTYH,OGG1,MPG 
GO:0005515,GO:0030154,G
O:0042802,GO:0042981 
protein binding (MF),  cell 
differentiation (BP),  identical 
protein binding (MF),  regulation of 
apoptotic process (BP) 
3 (73) 3 (34208) 9,32E-09 4,44E-08 SIRT1,TP53,NME1 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0046872,GO:0008270,G
O:0006915,GO:0005515,GO
:0045944,GO:0000122 
metal ion binding (MF),  zinc ion 
binding (MF),  apoptotic process 
(BP),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription from 
RNA polymerase II promoter (BP) 
3 (73) 4 (34208) 3,72E-08 1,36E-07 TRAF6,TP53,EP300 
GO:0046872,GO:0008270,G
O:0005515,GO:0045944,GO
:0019899,GO:0042981 
metal ion binding (MF),  zinc ion 
binding (MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  enzyme binding 
(MF),  regulation of apoptotic 
process (BP) 
3 (73) 4 (34208) 3,72E-08 1,36E-07 SIRT1,TP53,ESR1 
GO:0046872,GO:0008270,G
O:0005515,GO:0000122,GO
:0045892,GO:0016567 
metal ion binding (MF),  zinc ion 
binding (MF),  protein binding 
(MF),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription, DNA-
dependent (BP),  protein 
ubiquitination (BP) 
3 (73) 4 (34208) 3,72E-08 1,36E-07 SIRT1,TRAF6,MDM2 
GO:0046872,GO:0005515,G
O:0019899,GO:0006974 
metal ion binding (MF),  protein 
binding (MF),  enzyme binding 
(MF),  response to DNA damage 
stimulus (BP) 
3 (73) 4 (34208) 3,72E-08 1,36E-07 SIRT1,TP53,POLB 
GO:0003677,GO:0005515,G
O:0003684,GO:0006281,GO
:0006284 
DNA binding (MF),  protein binding 
(MF),  damaged DNA binding 
(MF),  DNA repair (BP),  base-
excision repair (BP) 
3 (73) 4 (34208) 3,72E-08 1,36E-07 MPG,FEN1,POLB 
GO:0006468,GO:0005524,G
O:0005515,GO:0000166,GO
:0046777,GO:0004674,GO:0
007411 
protein phosphorylation (BP),  ATP 
binding (MF),  protein binding 
(MF),  nucleotide binding 
(MF),  protein autophosphorylation 
(BP),  protein serine/threonine kinase 
3 (73) 4 (34208) 3,72E-08 1,36E-07 CSNK2A1,Cdk5,PAK2 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
activity (MF),  axon guidance (BP) 
GO:0005524,GO:0005515,G
O:0000166,GO:0045892,GO
:0008022 
ATP binding (MF),  protein binding 
(MF),  nucleotide binding 
(MF),  negative regulation of 
transcription, DNA-dependent 
(BP),  protein C-terminus binding 
(MF) 
3 (73) 4 (34208) 3,72E-08 1,36E-07 XRCC6,UBE2I,XRCC5 
GO:0005515,GO:0044419,G
O:0042802,GO:0042981 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  identical protein binding 
(MF),  regulation of apoptotic 
process (BP) 
3 (73) 4 (34208) 3,72E-08 1,36E-07 SIRT1,TP53,PAK2 
GO:0005515,GO:0045892,G
O:0042981,GO:0002039 
protein binding (MF),  negative 
regulation of transcription, DNA-
dependent (BP),  regulation of 
apoptotic process (BP),  p53 binding 
(MF) 
3 (73) 4 (34208) 3,72E-08 1,36E-07 SIRT1,TP53,Cdk5 
GO:0045944,GO:0000122,G
O:0060766 
positive regulation of transcription 
from RNA polymerase II promoter 
(BP),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of androgen receptor 
signaling pathway (BP) 
3 (73) 4 (34208) 3,72E-08 1,36E-07 SIRT1,TCF21,HDAC1 
GO:0006355,GO:0046872,G
O:0003677,GO:0008270,GO
:0005515,GO:0045944,GO:0
008134,GO:0003682 
regulation of transcription, DNA-
dependent (BP),  metal ion binding 
(MF),  DNA binding (MF),  zinc ion 
binding (MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  transcription 
factor binding (MF),  chromatin 
binding (MF) 
3 (73) 5 (34208) 9,29E-08 2,74E-07 TP53,ESR1,EP300 
173 | P a g e
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
APPENDIX 
 
GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0006355,GO:0003677,G
O:0003700,GO:0005515,GO
:0008134,GO:0019899 
regulation of transcription, DNA-
dependent (BP),  DNA binding 
(MF),  sequence-specific DNA 
binding transcription factor activity 
(MF),  protein binding 
(MF),  transcription factor binding 
(MF),  enzyme binding (MF) 
3 (73) 5 (34208) 9,29E-08 2,74E-07 TP53,ESR1,HMGA1 
GO:0006355,GO:0003700,G
O:0005515,GO:0045944,GO
:0008134,GO:0019899 
regulation of transcription, DNA-
dependent (BP),  sequence-specific 
DNA binding transcription factor 
activity (MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  transcription 
factor binding (MF),  enzyme 
binding (MF) 
3 (73) 5 (34208) 9,29E-08 2,74E-07 TP53,ESR1,HDAC1 
GO:0003677,GO:0005515,G
O:0008134,GO:0006284 
DNA binding (MF),  protein binding 
(MF),  transcription factor binding 
(MF),  base-excision repair (BP) 
3 (73) 5 (34208) 9,29E-08 2,74E-07 TP53,PCNA,HMGA1 
GO:0006915,GO:0005515,G
O:0019901,GO:0042981 
apoptotic process (BP),  protein 
binding (MF),  protein kinase 
binding (MF),  regulation of 
apoptotic process (BP) 
3 (73) 5 (34208) 9,29E-08 2,74E-07 TRAF6,TP53,PAK2 
GO:0005515,GO:0044419,G
O:0007569 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  cell aging (BP) 
3 (73) 5 (34208) 9,29E-08 2,74E-07 SIRT1,NPM1,TP53 
GO:0005515,GO:0000122,G
O:0045892,GO:0016874,GO
:0004842,GO:0016567 
protein binding (MF),  negative 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  negative regulation of 
transcription, DNA-dependent 
(BP),  ligase activity 
(MF),  ubiquitin-protein ligase 
activity (MF),  protein ubiquitination 
(BP) 
3 (73) 5 (34208) 9,29E-08 2,74E-07 UBE2I,TRAF6,MDM2 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0006281,G
O:0004519,GO:0006284 
protein binding (MF),  DNA repair 
(BP),  endonuclease activity 
(MF),  base-excision repair (BP) 
3 (73) 5 (34208) 9,29E-08 2,74E-07 MUTYH,OGG1,FEN1 
GO:0005515,GO:0006281,G
O:0016829 
protein binding (MF),  DNA repair 
(BP),  lyase activity (MF) 
3 (73) 5 (34208) 9,29E-08 2,74E-07 XRCC6,OGG1,POLB 
GO:0006355,GO:0005515,G
O:0044419,GO:0045944,GO
:0008134,GO:0000122 
regulation of transcription, DNA-
dependent (BP),  protein binding 
(MF),  interspecies interaction 
between organisms (BP),  positive 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  transcription factor binding 
(MF),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP) 
3 (73) 6 (34208) 1,86E-07 4,74E-07 TP53,HDAC1,EP300 
GO:0006355,GO:0005515,G
O:0006284 
regulation of transcription, DNA-
dependent (BP),  protein binding 
(MF),  base-excision repair (BP) 
3 (73) 6 (34208) 1,86E-07 4,74E-07 OGG1,TP53,HMGA1 
GO:0006355,GO:0005515,G
O:0050790 
regulation of transcription, DNA-
dependent (BP),  protein binding 
(MF),  regulation of catalytic activity 
(BP) 
3 (73) 6 (34208) 1,86E-07 4,74E-07 HIF1A,TP53,CSNK2A1 
GO:0006915,GO:0005515,G
O:0050852,GO:0042981 
apoptotic process (BP),  protein 
binding (MF),  T cell receptor 
signaling pathway (BP),  regulation 
of apoptotic process (BP) 
3 (73) 6 (34208) 1,86E-07 4,74E-07 TRAF6,UBC,PAK2 
GO:0005524,GO:0005515,G
O:0042802,GO:0042981 
ATP binding (MF),  protein binding 
(MF),  identical protein binding 
(MF),  regulation of apoptotic 
process (BP) 
3 (73) 6 (34208) 1,86E-07 4,74E-07 TP53,PAK2,NME1 
GO:0005515,GO:0000166,G
O:0000398,GO:0008380,GO
:0003723,GO:0010467,GO:0
003676,GO:0006396 
protein binding (MF),  nucleotide 
binding (MF),  nuclear mRNA 
splicing, via spliceosome 
(BP),  RNA splicing (BP),  RNA 
binding (MF),  gene expression 
(BP),  nucleic acid binding 
3 (73) 6 (34208) 1,86E-07 4,74E-07 HNRNPL,HNRNPU,HNRNPH1 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
(MF),  RNA processing (BP) 
GO:0005515,GO:0045944,G
O:0045892,GO:0006974 
protein binding (MF),  positive 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  negative regulation of 
transcription, DNA-dependent 
(BP),  response to DNA damage 
stimulus (BP) 
3 (73) 6 (34208) 1,86E-07 4,74E-07 XRCC6,SIRT1,TP53 
GO:0005515,GO:0000122,G
O:0045892,GO:0048011 
protein binding (MF),  negative 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  negative regulation of 
transcription, DNA-dependent 
(BP),  nerve growth factor receptor 
signaling pathway (BP) 
3 (73) 6 (34208) 1,86E-07 4,74E-07 TRAF6,MDM2,HDAC1 
GO:0005515,GO:0006281,G
O:0006916 
protein binding (MF),  DNA repair 
(BP),  anti-apoptosis (BP) 
3 (73) 6 (34208) 1,86E-07 4,74E-07 NPM1,UBC,POLB 
GO:0005515,GO:0004842,G
O:0048011 
protein binding (MF),  ubiquitin-
protein ligase activity (MF),  nerve 
growth factor receptor signaling 
pathway (BP) 
3 (73) 6 (34208) 1,86E-07 4,74E-07 TRAF6,MDM2,UBC 
GO:0006355,GO:0005515,G
O:0008013 
regulation of transcription, DNA-
dependent (BP),  protein binding 
(MF),  beta-catenin binding (MF) 
3 (73) 7 (34208) 3,24E-07 7,59E-07 CSNK2A1,ESR1,EP300 
GO:0016740,GO:0005524,G
O:0000166,GO:0016301,GO
:0000287 
transferase activity (MF),  ATP 
binding (MF),  nucleotide binding 
(MF),  kinase activity 
(MF),  magnesium ion binding (MF) 
3 (73) 7 (34208) 3,24E-07 7,59E-07 PRPS1,PRPS2,NME1 
GO:0046872,GO:0005515,G
O:0006284 
metal ion binding (MF),  protein 
binding (MF),  base-excision repair 
(BP) 
3 (73) 8 (34208) 5,18E-07 1,12E-06 MUTYH,TP53,POLB 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0003677,GO:0005515,G
O:0003690,GO:0045892,GO
:0044212 
DNA binding (MF),  protein binding 
(MF),  double-stranded DNA 
binding (MF),  negative regulation of 
transcription, DNA-dependent 
(BP),  transcription regulatory region 
DNA binding (MF) 
3 (73) 8 (34208) 5,18E-07 1,12E-06 XRCC6,HMGB2,XRCC5 
GO:0003677,GO:0005515,G
O:0048015 
DNA binding (MF),  protein binding 
(MF),  phosphatidylinositol-
mediated signaling (BP) 
3 (73) 8 (34208) 5,18E-07 1,12E-06 HMGB2,PCNA,FEN1 
GO:0005524,GO:0007596,G
O:0007049 
ATP binding (MF),  blood 
coagulation (BP),  cell cycle (BP) 
3 (73) 8 (34208) 5,18E-07 1,12E-06 KIF11,TP53,Cdk5 
GO:0005515,GO:0006281,G
O:0042802 
protein binding (MF),  DNA repair 
(BP),  identical protein binding (MF) 
3 (73) 8 (34208) 5,18E-07 1,12E-06 SIRT1,PCNA,PRPF19 
GO:0005515,GO:0006289,G
O:0006284 
protein binding (MF),  nucleotide-
excision repair (BP),  base-excision 
repair (BP) 
3 (73) 8 (34208) 5,18E-07 1,12E-06 OGG1,TP53,PCNA 
GO:0000122,GO:0043425 
negative regulation of transcription 
from RNA polymerase II promoter 
(BP),  bHLH transcription factor 
binding (MF) 
3 (73) 8 (34208) 5,18E-07 1,12E-06 SIRT1,UBE2I,TCF21 
GO:0005524,GO:0005515,G
O:0047485 
ATP binding (MF),  protein binding 
(MF),  protein N-terminus binding 
(MF) 
3 (73) 9 (34208) 7,76E-07 1,60E-06 TP53,CSNK2A1,HSPA1A 
GO:0005515,GO:0000166,G
O:0044212 
protein binding (MF),  nucleotide 
binding (MF),  transcription 
regulatory region DNA binding 
(MF) 
3 (73) 9 (34208) 7,76E-07 1,60E-06 XRCC6,HNRNPL,XRCC5 
GO:0005515,GO:0007596,G
O:0042981 
protein binding (MF),  blood 
coagulation (BP),  regulation of 
apoptotic process (BP) 
3 (73) 9 (34208) 7,76E-07 1,60E-06 TP53,Cdk5,ACTN1 
GO:0005515,GO:0046982,G
O:0019901 
protein binding (MF),  protein 
heterodimerization activity 
(MF),  protein kinase binding (MF) 
3 (73) 10 (34208) 1,11E-06 2,13E-06 NPM1,HIF1A,TP53 
GO:0006355,GO:0003677,G
O:0005515,GO:0044419,GO
:0008134 
regulation of transcription, DNA-
dependent (BP),  DNA binding 
(MF),  protein binding 
3 (73) 11 (34208) 1,52E-06 2,81E-06 TP53,EP300,HMGA1 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
(MF),  interspecies interaction 
between organisms 
(BP),  transcription factor binding 
(MF) 
GO:0006355,GO:0045944,G
O:0042826 
regulation of transcription, DNA-
dependent (BP),  positive regulation 
of transcription from RNA 
polymerase II promoter 
(BP),  histone deacetylase binding 
(MF) 
3 (73) 11 (34208) 1,52E-06 2,81E-06 HIF1A,TCF21,HDAC1 
GO:0003677,GO:0005515,G
O:0000166,GO:0008022 
DNA binding (MF),  protein binding 
(MF),  nucleotide binding 
(MF),  protein C-terminus binding 
(MF) 
3 (73) 11 (34208) 1,52E-06 2,81E-06 XRCC6,XRCC5,NCL 
GO:0006915,GO:0005515,G
O:0045944,GO:0045892 
apoptotic process (BP),  protein 
binding (MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription, DNA-
dependent (BP) 
3 (73) 11 (34208) 1,52E-06 2,81E-06 TRAF6,HMGB2,TP53 
GO:0005515,GO:0016925 
protein binding (MF),  protein 
sumoylation (BP) 
3 (73) 11 (34208) 1,52E-06 2,81E-06 UBE2I,SUMO2,SUMO1 
GO:0045944,GO:0000122,G
O:0042826 
positive regulation of transcription 
from RNA polymerase II promoter 
(BP),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP),  histone 
deacetylase binding (MF) 
3 (73) 11 (34208) 1,52E-06 2,81E-06 TRAF6,TCF21,HDAC1 
GO:0005524,GO:0045944,G
O:0045893 
ATP binding (MF),  positive 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  positive regulation of 
transcription, DNA-dependent (BP) 
3 (73) 12 (34208) 2,02E-06 3,62E-06 XRCC6,TP53,THRAP3 
GO:0005515,GO:0045087,G
O:0000122 
protein binding (MF),  innate 
immune response (BP),  negative 
regulation of transcription from 
3 (73) 12 (34208) 2,02E-06 3,62E-06 TRAF6,TXN,EP300 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
RNA polymerase II promoter (BP) 
GO:0005515,GO:0000122,G
O:0042802 
protein binding (MF),  negative 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  identical protein binding (MF) 
3 (73) 12 (34208) 2,02E-06 3,62E-06 SIRT1,TP53,PCNA 
GO:0005515,GO:0000122,G
O:0051091 
protein binding (MF),  negative 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  positive regulation of 
sequence-specific DNA binding 
transcription factor activity (BP) 
3 (73) 12 (34208) 2,02E-06 3,62E-06 UBE2I,TRAF6,EP300 
GO:0046872,GO:0003677,G
O:0005515,GO:0019899 
metal ion binding (MF),  DNA 
binding (MF),  protein binding 
(MF),  enzyme binding (MF) 
3 (73) 15 (34208) 4,16E-06 6,84E-06 TP53,ESR1,POLB 
GO:0003677,GO:0006915,G
O:0005515,GO:0045944 
DNA binding (MF),  apoptotic 
process (BP),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP) 
3 (73) 15 (34208) 4,16E-06 6,84E-06 HMGB2,TP53,EP300 
GO:0005515,GO:0045892,G
O:0007596 
protein binding (MF),  negative 
regulation of transcription, DNA-
dependent (BP),  blood coagulation 
(BP) 
3 (73) 15 (34208) 4,16E-06 6,84E-06 TP53,HDAC1,Cdk5 
GO:0006355,GO:0003700,G
O:0005515,GO:0000122,GO
:0045892 
regulation of transcription, DNA-
dependent (BP),  sequence-specific 
DNA binding transcription factor 
activity (MF),  protein binding 
(MF),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription, DNA-
dependent (BP) 
3 (73) 16 (34208) 5,12E-06 8,13E-06 TP53,HDAC1,YBX1 
GO:0003677,GO:0005515,G
O:0008380,GO:0003723 
DNA binding (MF),  protein binding 
(MF),  RNA splicing (BP),  RNA 
binding (MF) 
3 (73) 16 (34208) 5,12E-06 8,13E-06 HNRNPU,YBX1,SFPQ 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0044419,G
O:0019901 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  protein kinase binding (MF) 
3 (73) 16 (34208) 5,12E-06 8,13E-06 NPM1,TP53,PAK2 
GO:0003677,GO:0005515,G
O:0000398,GO:0008380 
DNA binding (MF),  protein binding 
(MF),  nuclear mRNA splicing, via 
spliceosome (BP),  RNA splicing 
(BP) 
3 (73) 17 (34208) 6,21E-06 9,58E-06 HNRNPU,PRPF19,YBX1 
GO:0005515,GO:0044419,G
O:0008285 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  negative regulation of cell 
proliferation (BP) 
3 (73) 18 (34208) 7,43E-06 1,12E-05 NPM1,TP53,HMGA1 
GO:0005515,GO:0045892,G
O:0019904 
protein binding (MF),  negative 
regulation of transcription, DNA-
dependent (BP),  protein domain 
specific binding (MF) 
3 (73) 18 (34208) 7,43E-06 1,12E-05 SIRT1,HMGB2,BASP1 
GO:0005515,GO:0051092,G
O:0006916 
protein binding (MF),  positive 
regulation of NF-kappaB 
transcription factor activity 
(BP),  anti-apoptosis (BP) 
3 (73) 18 (34208) 7,43E-06 1,12E-05 NPM1,TRAF6,UBC 
GO:0006355,GO:0003700,G
O:0005515,GO:0045944,GO
:0008134,GO:0045893 
regulation of transcription, DNA-
dependent (BP),  sequence-specific 
DNA binding transcription factor 
activity (MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  transcription 
factor binding (MF),  positive 
regulation of transcription, DNA-
dependent (BP) 
3 (73) 19 (34208) 8,82E-06 1,30E-05 HIF1A,TP53,HDAC1 
GO:0005515,GO:0045944,G
O:0042826 
protein binding (MF),  positive 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  histone deacetylase binding 
(MF) 
3 (73) 19 (34208) 8,82E-06 1,30E-05 TRAF6,HIF1A,HDAC1 
180 | P a g e  
 
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
APPENDIX 
 
GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0003723,G
O:0010467,GO:0044267,GO
:0006412,GO:0016070,GO:0
016071 
protein binding (MF),  RNA binding 
(MF),  gene expression 
(BP),  cellular protein metabolic 
process (BP),  translation 
(BP),  RNA metabolic process 
(BP),  mRNA metabolic process 
(BP) 
3 (73) 19 (34208) 8,82E-06 1,30E-05 RPL14,PABPC1,RPLP0 
GO:0005524,GO:0005515,G
O:0000166,GO:0016032 
ATP binding (MF),  protein binding 
(MF),  nucleotide binding 
(MF),  viral reproduction (BP) 
3 (73) 20 (34208) 1,04E-05 1,53E-05 XRCC6,PAK2,XRCC5 
GO:0006355,GO:0003677,G
O:0003700,GO:0005515,GO
:0008134,GO:0045893 
regulation of transcription, DNA-
dependent (BP),  DNA binding 
(MF),  sequence-specific DNA 
binding transcription factor activity 
(MF),  protein binding 
(MF),  transcription factor binding 
(MF),  positive regulation of 
transcription, DNA-dependent (BP) 
3 (73) 21 (34208) 1,21E-05 1,72E-05 HIF1A,TP53,HMGA1 
GO:0003677,GO:0005515,G
O:0045944,GO:0045892,GO
:0045893,GO:0044212 
DNA binding (MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription, DNA-
dependent (BP),  positive regulation 
of transcription, DNA-dependent 
(BP),  transcription regulatory region 
DNA binding (MF) 
3 (73) 21 (34208) 1,21E-05 1,72E-05 XRCC6,HMGB2,TP53 
GO:0005515,GO:0006281,G
O:0016032 
protein binding (MF),  DNA repair 
(BP),  viral reproduction (BP) 
3 (73) 21 (34208) 1,21E-05 1,72E-05 XRCC6,UBC,XRCC5 
GO:0003677,GO:0005515,G
O:0000166,GO:0003723 
DNA binding (MF),  protein binding 
(MF),  nucleotide binding 
(MF),  RNA binding (MF) 
3 (73) 22 (34208) 1,39E-05 1,95E-05 HNRNPU,NCL,SFPQ 
GO:0008283,GO:0005515,G
O:0000122 
cell proliferation (BP),  protein 
binding (MF),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP) 
3 (73) 22 (34208) 1,39E-05 1,95E-05 TXN,TP53,PCNA 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0042493,G
O:0008285 
protein binding (MF),  response to 
drug (BP),  negative regulation of 
cell proliferation (BP) 
3 (73) 22 (34208) 1,39E-05 1,95E-05 CDKN1A,TP53,NME1 
GO:0006355,GO:0003677,G
O:0003700,GO:0005515,GO
:0045944,GO:0008134 
regulation of transcription, DNA-
dependent (BP),  DNA binding 
(MF),  sequence-specific DNA 
binding transcription factor activity 
(MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  transcription 
factor binding (MF) 
3 (73) 23 (34208) 1,60E-05 2,18E-05 HIF1A,TP53,ESR1 
GO:0003677,GO:0005515,G
O:0042802 
DNA binding (MF),  protein binding 
(MF),  identical protein binding 
(MF) 
3 (73) 23 (34208) 1,60E-05 2,18E-05 TP53,PCNA,PRPF19 
GO:0005515,GO:0010467,G
O:0006414,GO:0031018,GO
:0044267,GO:0006412,GO:0
016070,GO:0016032,GO:00
16071,GO:0006415,GO:001
9058,GO:0019083,GO:0003
735 
protein binding (MF),  gene 
expression (BP),  translational 
elongation (BP),  endocrine pancreas 
development (BP),  cellular protein 
metabolic process (BP),  translation 
(BP),  RNA metabolic process 
(BP),  viral reproduction 
(BP),  mRNA metabolic process 
(BP),  translational termination 
(BP),  viral infectious cycle 
(BP),  viral transcription 
(BP),  structural constituent of 
ribosome (MF) 
3 (73) 23 (34208) 1,60E-05 2,18E-05 RPL14,RPSA,RPLP0 
GO:0005515,GO:0008285,G
O:0030308 
protein binding (MF),  negative 
regulation of cell proliferation 
(BP),  negative regulation of cell 
growth (BP) 
3 (73) 23 (34208) 1,60E-05 2,18E-05 CDKN1A,TP53,HSPA1A 
GO:0005515,GO:0006281,G
O:0000278,GO:0000084 
protein binding (MF),  DNA repair 
(BP),  mitotic cell cycle (BP),  S 
phase of mitotic cell cycle (BP) 
3 (73) 23 (34208) 1,60E-05 2,18E-05 UBC,PCNA,FEN1 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005524,GO:0005515,G
O:0000166,GO:0042981 
ATP binding (MF),  protein binding 
(MF),  nucleotide binding 
(MF),  regulation of apoptotic 
process (BP) 
3 (73) 24 (34208) 1,83E-05 2,48E-05 Cdk5,PAK2,NME1 
GO:0006355,GO:0003677,G
O:0003700,GO:0005515,GO
:0045892 
regulation of transcription, DNA-
dependent (BP),  DNA binding 
(MF),  sequence-specific DNA 
binding transcription factor activity 
(MF),  protein binding 
(MF),  negative regulation of 
transcription, DNA-dependent (BP) 
3 (73) 25 (34208) 2,07E-05 2,79E-05 TP53,YBX1,HMGA1 
GO:0005515,GO:0048011,G
O:0006916 
protein binding (MF),  nerve growth 
factor receptor signaling pathway 
(BP),  anti-apoptosis (BP) 
3 (73) 25 (34208) 2,07E-05 2,79E-05 TRAF6,UBC,HDAC1 
GO:0003677,GO:0005515,G
O:0006974 
DNA binding (MF),  protein binding 
(MF),  response to DNA damage 
stimulus (BP) 
3 (73) 26 (34208) 2,34E-05 3,10E-05 XRCC6,TP53,POLB 
GO:0005524,GO:0005515,G
O:0008285 
ATP binding (MF),  protein binding 
(MF),  negative regulation of cell 
proliferation (BP) 
3 (73) 26 (34208) 2,34E-05 3,10E-05 TP53,NME1,HSPA1A 
GO:0005515,GO:0032436 
protein binding (MF),  positive 
regulation of proteasomal ubiquitin-
dependent protein catabolic process 
(BP) 
3 (73) 27 (34208) 2,63E-05 3,46E-05 MDM2,SUMO2,SUMO1 
GO:0005515,GO:0006334 
protein binding (MF),  nucleosome 
assembly (BP) 
3 (73) 28 (34208) 2,94E-05 3,85E-05 NPM1,HMGB2,SET 
GO:0003677,GO:0008283,G
O:0005515 
DNA binding (MF),  cell 
proliferation (BP),  protein binding 
(MF) 
3 (73) 29 (34208) 3,27E-05 4,25E-05 TP53,PCNA,XRCC5 
GO:0007165,GO:0005515,G
O:0042981 
signal transduction (BP),  protein 
binding (MF),  regulation of 
apoptotic process (BP) 
3 (73) 29 (34208) 3,27E-05 4,25E-05 TRAF6,ESR1,PAK2 
GO:0003677,GO:0005515,G
O:0000166,GO:0006281 
DNA binding (MF),  protein binding 
(MF),  nucleotide binding 
(MF),  DNA repair (BP) 
3 (73) 30 (34208) 3,63E-05 4,64E-05 XRCC6,XRCC5,SFPQ 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0051015 
protein binding (MF),  actin filament 
binding (MF) 
3 (73) 30 (34208) 3,63E-05 4,64E-05 SPTA1,MYH9,ACTN1 
GO:0003677,GO:0003700,G
O:0005515,GO:0045892,GO
:0045893 
DNA binding (MF),  sequence-
specific DNA binding transcription 
factor activity (MF),  protein binding 
(MF),  negative regulation of 
transcription, DNA-dependent 
(BP),  positive regulation of 
transcription, DNA-dependent (BP) 
3 (73) 31 (34208) 4,01E-05 5,05E-05 HMGB2,TP53,HMGA1 
GO:0005515,GO:0006281,G
O:0006974 
protein binding (MF),  DNA repair 
(BP),  response to DNA damage 
stimulus (BP) 
3 (73) 31 (34208) 4,01E-05 5,05E-05 XRCC6,SIRT1,POLB 
GO:0006355,GO:0005515,G
O:0007049 
regulation of transcription, DNA-
dependent (BP),  protein binding 
(MF),  cell cycle (BP) 
3 (73) 32 (34208) 4,42E-05 5,45E-05 TP53,CSNK2A1,EP300 
GO:0006915,GO:0005515,G
O:0045087 
apoptotic process (BP),  protein 
binding (MF),  innate immune 
response (BP) 
3 (73) 32 (34208) 4,42E-05 5,45E-05 TRAF6,UBC,EP300 
GO:0005515,GO:0045944,G
O:0019901 
protein binding (MF),  positive 
regulation of transcription from 
RNA polymerase II promoter 
(BP),  protein kinase binding (MF) 
3 (73) 32 (34208) 4,42E-05 5,45E-05 TRAF6,HIF1A,TP53 
GO:0006355,GO:0003677,G
O:0045944,GO:0000122 
regulation of transcription, DNA-
dependent (BP),  DNA binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription from 
RNA polymerase II promoter (BP) 
3 (73) 34 (34208) 5,32E-05 6,48E-05 TP53,TCF21,EP300 
GO:0005515,GO:0006281,G
O:0016787 
protein binding (MF),  DNA repair 
(BP),  hydrolase activity (MF) 
3 (73) 34 (34208) 5,32E-05 6,48E-05 XRCC6,MUTYH,MPG 
GO:0006915,GO:0005515,G
O:0044419 
apoptotic process (BP),  protein 
binding (MF),  interspecies 
interaction between organisms (BP) 
3 (73) 35 (34208) 5,81E-05 6,99E-05 TP53,EP300,PAK2 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0003700,GO:0005515,G
O:0045944,GO:0045892,GO
:0045893 
sequence-specific DNA binding 
transcription factor activity 
(MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  negative 
regulation of transcription, DNA-
dependent (BP),  positive regulation 
of transcription, DNA-dependent 
(BP) 
3 (73) 35 (34208) 5,81E-05 6,99E-05 HMGB2,TP53,HDAC1 
GO:0005524,GO:0005515,G
O:0044419 
ATP binding (MF),  protein binding 
(MF),  interspecies interaction 
between organisms (BP) 
3 (73) 35 (34208) 5,81E-05 6,99E-05 UBE2I,TP53,PAK2 
GO:0005524,GO:0000166,G
O:0007049,GO:0051301 
ATP binding (MF),  nucleotide 
binding (MF),  cell cycle (BP),  cell 
division (BP) 
3 (73) 35 (34208) 5,81E-05 6,99E-05 UBE2I,KIF11,Cdk5 
GO:0005515,GO:0045087,G
O:0002218 
protein binding (MF),  innate 
immune response (BP),  activation of 
innate immune response (BP) 
3 (73) 36 (34208) 6,33E-05 7,56E-05 TRAF6,TXN,UBC 
GO:0003677,GO:0005515,G
O:0008134,GO:0000122 
DNA binding (MF),  protein binding 
(MF),  transcription factor binding 
(MF),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP) 
3 (73) 37 (34208) 6,88E-05 8,17E-05 TP53,PCNA,EP300 
GO:0003677,GO:0003700,G
O:0005515,GO:0045944,GO
:0045893,GO:0044212 
DNA binding (MF),  sequence-
specific DNA binding transcription 
factor activity (MF),  protein binding 
(MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP),  positive regulation 
of transcription, DNA-dependent 
(BP),  transcription regulatory region 
DNA binding (MF) 
3 (73) 39 (34208) 8,06E-05 9,49E-05 HMGB2,HIF1A,TP53 
GO:0005515,GO:0000209,G
O:0004842 
protein binding (MF),  protein 
polyubiquitination (BP),  ubiquitin-
protein ligase activity (MF) 
3 (73) 40 (34208) 8,70E-05 0,000101801 TRAF6,UBC,PRPF19 
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GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
GO:0005515,GO:0006979 
protein binding (MF),  response to 
oxidative stress (BP) 
3 (73) 40 (34208) 8,70E-05 0,000101801 SIRT1,PRDX6,OGG1 
GO:0005515,GO:0042393 
protein binding (MF),  histone 
binding (MF) 
3 (73) 41 (34208) 9,38E-05 0,000109338 SIRT1,NPM1,SET 
GO:0046872,GO:0005515,G
O:0006281 
metal ion binding (MF),  protein 
binding (MF),  DNA repair (BP) 
3 (73) 43 (34208) 0,000108212 0,000125435 SIRT1,MUTYH,POLB 
GO:0003779,GO:0005516 
actin binding (MF),  calmodulin 
binding (MF) 
3 (73) 44 (34208) 0,000115953 0,000134005 MYO1C,MYH9,SPTBN1 
GO:0005515,GO:0006281,G
O:0006260 
protein binding (MF),  DNA repair 
(BP),  DNA replication (BP) 
3 (73) 45 (34208) 0,000124045 0,000142081 SIRT1,PCNA,FEN1 
GO:0005515,GO:0005200 
protein binding (MF),  structural 
constituent of cytoskeleton (MF) 
3 (73) 45 (34208) 0,000124045 0,000142081 MSN,SPTA1,SPTBN1 
GO:0005515,GO:0044419,G
O:0016032 
protein binding (MF),  interspecies 
interaction between organisms 
(BP),  viral reproduction (BP) 
3 (73) 48 (34208) 0,000150504 0,00017137 PAK2,RPLP0,HMGA1 
GO:0007165,GO:0005515,G
O:0045944 
signal transduction (BP),  protein 
binding (MF),  positive regulation of 
transcription from RNA polymerase 
II promoter (BP) 
3 (73) 49 (34208) 0,000160074 0,000181731 TRAF6,HIF1A,ESR1 
GO:0007399,GO:0000166 
nervous system development 
(BP),  nucleotide binding (MF) 
3 (73) 51 (34208) 0,000180382 0,000204186 PRPS1,NME1,ARF6 
GO:0005524,GO:0019901 
ATP binding (MF),  protein kinase 
binding (MF) 
3 (73) 53 (34208) 0,000202291 0,000227652 KIF11,TP53,PAK2 
GO:0006355,GO:0003677,G
O:0005515,GO:0000122 
regulation of transcription, DNA-
dependent (BP),  DNA binding 
(MF),  protein binding 
(MF),  negative regulation of 
transcription from RNA polymerase 
II promoter (BP) 
3 (73) 57 (34208) 0,000251129 0,000279353 TP53,EP300,YBX1 
GO:0005515,GO:0000278,G
O:0000082,GO:0000084 
protein binding (MF),  mitotic cell 
cycle (BP),  G1/S transition of 
mitotic cell cycle (BP),  S phase of 
mitotic cell cycle (BP) 
3 (73) 57 (34208) 0,000251129 0,000279353 CDKN1A,UBC,PCNA 
GO:0003774 motor activity (MF) 3 (73) 60 (34208) 0,000292354 0,000324278 MYO1C,MYH9,DCTN1 
GO:0005515,GO:0000278,G protein binding (MF),  mitotic cell 3 (73) 61 (34208) 0,000307006 0,000339554 CDKN1A,DCTN1,CCNA1 
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# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
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Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
O:0000086 cycle (BP),  G2/M transition of 
mitotic cell cycle (BP) 
GO:0003677,GO:0005515,G
O:0010467 
DNA binding (MF),  protein binding 
(MF),  gene expression (BP) 
3 (73) 62 (34208) 0,000322124 0,000353238 ESR1,HNRNPU,YBX1 
GO:0005524,GO:0005515,G
O:0000166,GO:0007049 
ATP binding (MF),  protein binding 
(MF),  nucleotide binding (MF),  cell 
cycle (BP) 
3 (73) 62 (34208) 0,000322124 0,000353238 UBE2I,CSNK2A1,Cdk5 
GO:0003677,GO:0005524,G
O:0005515,GO:0000166 
DNA binding (MF),  ATP binding 
(MF),  protein binding 
(MF),  nucleotide binding (MF) 
3 (73) 71 (34208) 0,000480156 0,000522085 XRCC6,HNRNPU,XRCC5 
GO:0005524,GO:0000166,G
O:0042803 
ATP binding (MF),  nucleotide 
binding (MF),  protein 
homodimerization activity (MF) 
3 (73) 76 (34208) 0,000586093 0,000633703 PRPS1,MYH9,PRPS2 
GO:0005515,GO:0008219 
protein binding (MF),  cell death 
(BP) 
3 (73) 83 (34208) 0,000757873 0,000814872 DCTN1,Cdk5,POLB 
GO:0006355,GO:0003700,G
O:0005515,GO:0043565 
regulation of transcription, DNA-
dependent (BP),  sequence-specific 
DNA binding transcription factor 
activity (MF),  protein binding 
(MF),  sequence-specific DNA 
binding (MF) 
3 (73) 84 (34208) 0,000784744 0,00084142 HOXC13,HIF1A,ESR1 
GO:0005515,GO:0016301 
protein binding (MF),  kinase 
activity (MF) 
3 (73) 85 (34208) 0,000812213 0,000866062 CDKN1A,Cdk5,NME1 
GO:0000166,GO:0015031 
nucleotide binding (MF),  protein 
transport (BP) 
3 (73) 94 (34208) 0,00108725 0,00115614 MYO1C,MYH9,ARF6 
GO:0005515,GO:0007283 
protein binding 
(MF),  spermatogenesis (BP) 
3 (73) 96 (34208) 0,00115539 0,00122187 SIRT1,HMGB2,CCNA1 
GO:0005515,GO:0007067 protein binding (MF),  mitosis (BP) 3 (73) 100 (34208) 0,00129963 0,00137065 UBE2I,DCTN1,CCNA1 
GO:0005515,GO:0006886 
protein binding (MF),  intracellular 
protein transport (BP) 
3 (73) 102 (34208) 0,00137581 0,00144703 NPM1,Cdk5,PCNA 
GO:0005515,GO:0001701 
protein binding (MF),  in utero 
embryonic development (BP) 
3 (73) 106 (34208) 0,00153645 0,00160723 TP53,MYH9,YBX1 
GO:0005515,GO:0001666 
protein binding (MF),  response to 
hypoxia (BP) 
3 (73) 106 (34208) 0,00153645 0,00160723 HIF1A,XRCC1,EP300 
GO:0005515,GO:0043065 protein binding (MF),  positive 3 (73) 116 (34208) 0,0019881 0,00206848 SIRT1,GZMA,TP53 
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APPENDIX 
GO term ID Annotations 
# of annotated 
genes in the 
input list 
(Total # of 
genes in the 
input list)  
# of annotated 
genes in the 
reference list 
(Total # of genes 
in the reference 
list)  
Hypergeometric 
Distribution 
(Fisher's exact 
test) 
Corrected 
Hypergeometric 
Dist. (Fisher's 
exact test) 
Genes 
regulation of apoptotic process (BP) 
GO:0051082 unfolded protein binding (MF) 3 (73) 120 (34208) 0,0021895 0,0022658 NPM1,TCP1,HSPA1A 
GO:0051301,GO:0007067 cell division (BP),  mitosis (BP) 3 (73) 148 (34208) 0,00395537 0,00406057 UBE2I,KIF11,CCNA1 
GO:0005515,GO:0051301 
protein binding (MF),  cell division 
(BP) 
3 (73) 173 (34208) 0,0061005 0,00622961 UBE2I,Cdk5,CCNA1 
GO:0003713 
transcription coactivator activity 
(MF) 
3 (73) 220 (34208) 0,0117293 0,0119145 NPM1,EP300,THRAP3 
GO:0005515,GO:0042803 
protein binding (MF),  protein 
homodimerization activity (MF) 
3 (73) 259 (34208) 0,0180844 0,0182737 GZMA,NPM1,MYH9 
GO:0005515,GO:0007275 
protein binding (MF),  multicellular 
organismal development (BP) 
3 (73) 263 (34208) 0,0188251 0,0189726 HOXC13,SIRT1,TP53 
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ORIGINAL ARTICLE
Functional regulation of the apurinic/apyrimidinic endonuclease 1
by nucleophosmin: impact on tumor biology
C Vascotto1, L Lirussi1, M Poletto1, M Tiribelli2, D Damiani2, D Fabbro1, G Damante1, B Demple3, E Colombo4 and G Tell1
Nucleophosmin 1 (NPM1) is a nucleolar protein involved in ribosome biogenesis, stress responses and maintaining genome
stability. One-third of acute myeloid leukemias (AMLs) are associated with aberrant localization of NPM1 to the cytoplasm
(NPM1cþ ). This mutation is critical during leukemogenesis and constitutes a good prognostic factor for chemotherapy. At present,
there is no clear molecular basis for the role of NPM1 in DNA repair and the tumorigenic process. We found that the nuclear
apurinic/apyrimidinic endonuclease 1 (APE1), a core enzyme in base excision DNA repair (BER) of DNA lesions, specifically interacts
with NPM1 within nucleoli and the nucleoplasm. Cytoplasmic accumulation of APE1 is associated with cancers including, as we
show, NPM1cþ AML. Here we show that NPM1 stimulates APE1 BER activity in cells. We provide evidence that expression of the
NPM1cþ variant causes cytoplasmic accumulation of APE1 in: (i) a heterologous cell system (HeLa cells); (ii) the myeloid cell line
OCI/AML3 stably expressing NPM1cþ ; and (iii) primary lymphoblasts of NPM1cþ AML patients. Consistent with impaired APE1
localization, OCI/AML3 cells and blasts of AML patients have impaired BER activity. Cytoplasmic APE1 in NPM1cþ myeloid cells is
truncated due to proteolysis. Thus, the good prognostic response of NPM1cþ AML to chemotherapy may result from the
cytoplasmic relocalization of APE1 and the consequent BER deficiency. NPM1 thus has an indirect but significant role in BER in vivo
that may also be important for NPM1cþ tumorigenesis.
Oncogene (2013) 0, 000–000. doi:10.1038/onc.2013.251
Keywords: APE1/Ref-1; NPM1; acute myeloid leukemia; base excision repair
INTRODUCTION
The nucleolar protein nucleophosmin 1 (NPM1) is implicated in a
variety of cellular processes including ribosome biogenesis and
centrosome duplication, and NPM1 is frequently altered in some
cancers.1 NPM1 physically interacts with p53 and is believed
to regulate this tumor-suppressor protein, thus contributing
to maintenance of genome integrity.2,3 However, a direct
involvement of NPM1 in DNA repair has not been demonstrated.
NPM1 mutations are the most frequently known gene altera-
tions in cytogenetically normal acute myeloid leukemia (AML)
patients and are considered as positive prognostic factors.4
The NPM1 mutations identified so far in cytogenetically normal
AML patients generate a new nuclear export signal while also
disrupting the nucleolar localization signal (Supplementary
Figure S1), which relocalizes mutated NPM1 to the cytoplasm
(NPM1cþ ).5,6 A formal in vivo demonstration that mutant
NPM1cþ is endowed with oncogenic potential has been
recently presented.7 A plausible hypothesis is that NPM1cþ
causes abnormal cytoplasmic localization of important NPM1-
interacting proteins that impairs their functions.1,8–15 All NPM1cþ
AMLs are characterized by haploinsufficient expression, with only
one NPM1 allele affected by the mutation. NPM1cþ is dominant
by forming mixed oligomers with wild-type (WT) NPM1 and
moving it to the cytoplasm. The presence of the NPM1cþ
mutation is a favorable marker for relapse-free and overall survival
in AML with a normal karyotype, and for complete remission
after chemotherapy using DNA-damaging compounds (that is,
daunorubicin, cytarabine and so on).
Interestingly, overexpression of WT NPM1 has been
described in a number of solid malignancies such as hepatic,
gastric, ovarian and prostate cancers.1,16 In those cases, it has been
suggested that increased amounts of NPM1 could limit
the DNA-damage response to help effect cellular transfor-
mation. However, molecular support for this hypothesis is
still lacking.
We recently demonstrated that NPM1 physically interacts
with apurinic/apyrimidinic endonuclease 1/redox effector
factor 1 (APE1/Ref-1) within nucleoli and in the nucleoplasm
of tumor cells.17 APE1 has a crucial role in the maintenance of
genome stability, in redox signaling and other processes,18 and it
is a promising target for augmenting chemotherapy.18,19 APE1 is
the main apurinic/apyrimidinic (AP) endonuclease in mammalian
cells and a multifunctional protein. APE1 is an essential enzyme in
the base excision DNA repair (BER) pathway for DNA damage
caused by both endogenous and exogenous oxidizing or
alkylating agents, including chemotherapeutic drugs.20–23 APE1
can also act as a redox-regulatory protein, maintaining cancer-
related transcription factors (Egr-1, NF-kB, p53, HIF-1a, AP-1 and
Pax proteins) in an active reduced state,18,24–28 and it may act as a
transcriptional repressor.29 APE1 binds and cleaves abasic sites
in RNA17,30,31 and can control c-Myc expression by nicking its
mRNA.32 In this context, we have shown that the first 35 amino
acids of APE1 are required for a stable interaction with NPM1 and
other proteins involved in ribosome biogenesis/RNA processing,17
and for APE1 stable binding to RNA.30,33 The direct interaction
with NPM1 stimulates the enzymatic activity of APE1 on abasic
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DNA in vitro,17,30 although the in vivo effects were not known. This
work presented here is aimed at filling this gap.
RESULTS
NPM1 / cells are more sensitive than control cells to DNA
damages repaired through the BER pathway
We earlier demonstrated that NPM1 stimulates the APE1
endonuclease activity in vitro by means of protein–protein
interaction.17,30 Our data clearly showed that, although the Km
of APE1 for the abasic substrate is not significantly affected by
the presence of NPM1, its catalytic activity is increased almost
10-fold in the presence of a two-fold excess of NPM1 recombinant
protein. As product release by APE1 appears to be rate-
limiting,34,35 these observations suggest that interaction
with NPM1 increases the speed of this reaction step. To evaluate
the role of the APE1/NPM1 interaction in vivo, we tested
the effect of NPM1 absence on the BER capacity exploiting a
NPM1 / cell model developed on the p53 / background for
immortalization.36
First, we checked whether NPM1 expression affected the
amount of APE1 protein and its subcellular localization. APE1
and NPM1 protein levels were evaluated by immunoblot analysis
of nuclear and cytoplasmic fractions of p53 / mouse embryonic
fibroblasts (MEFs) with NPM1þ /þ or NPM1 / alleles36 (Figure 1a
left and Supplementary Figure S2). Quantification of the
immunoblots (Figure 1a right and Supplementary Figure S3)
showed that NPM1 / cells had about 40% more nuclear APE1
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than cells expressing WT NPM1 protein. This increased content
was associated with a slightly increased APE1 transcription, as
measured by quantitative PCR analysis (not shown). Immuno-
fluorescence (IF) analysis (Figure 1b) showed that, in NPM1þ /þ
cells, APE1 localization was nuclear with a strong accumulation in
nucleolar structures, as previously shown for some tumor cell
lines.17 In contrast, in NPM1 / cells, APE1 did not accumulate
within nucleoli, although nucleolar structures are still intact
in these cells (data not shown).36 Reexpression of NPM1 in
MEF-NPM1 / cells promoted APE1 nucleolar accumulation
(Figure 1c and Supplementary Figure S4), demonstrating that
interaction with NPM1 is essential for APE1 nucleolar distribution.
Moreover, recent data from our laboratory also showed that
expression of an APE1 mutant not able to interact with NPM1 was
unable to accumulate within nucleoli, demonstrating that a
functional interaction with NPM1 is required for physical
accumulation of APE1 within nucleoli.37
To test the functional relevance of NPM1 in BER, we next
assayed the sensitivity of the NPM1 / cells to different
genotoxic treatments known to cause DNA lesions that are
repaired through the BER pathway.38 First, we used methyl
methanesulfonate (MMS), which is a monofunctional methylating
agent causing lesions repaired predominantly by BER pathway.39
Cell viability experiments showed that NPM1 / cells were
significantly more sensitive than NPM1þ /þ cells to MMS
(Figure 1d). We then evaluated the ability of the MEFs to
efficiently remove AP sites from the DNA of MMS-treated cells.
As shown in Figure 1e, NPM1 / cells retained a significantly
higher level of AP sites following MMS treatment than did
NPM1þ /þ cells. Notably, this difference was also apparent under
basal conditions, further pointing to an impairment in the AP-site
incision step within the BER pathway in NPM1 / cells.
BER removes also damages caused by reactive oxygen species,
such as oxidized bases (for example, 8-oxoG). Thus, we performed
cell viability experiments with acute doses of H2O2 as genotoxic
agent, combined with treatment of the cells with methoxyamine,
an inhibitor of APE1-dependent repair.40 Data reported in
Supplementary Figure S5A clearly showed that NPM1 / cells
were significantly more sensitive to this treatment than NPM1þ /þ
cells. To confirm this result with an alternative oxidizing agent, we
used KBrO3, a carcinogenic agent known to induce predominantly
8-oxoG lesions on DNA after reduction of the bromate by cellular
thiols, such as glutathione, or reduced cysteines.41 As displayed in
Figure 1f, treatment with KBrO3, NPM1
 / cells were significantly
less viable than control cells at all the release time points.
We also determined the sensitivity of NPM1 / cells to the
radiomimetic bleomycin (BLM), as still another DNA-damaging
agent that requires BER intervention.42 BLM, which targets both
single-stranded DNA and double-stranded DNA, as well as
RNA molecules, causes formation of 4-oxidized AP sites or
30-phosphoglycolate products that account for the majority of
the BLM-induced DNA lesions.42,43 Cell viability was measured on
MEFs after a 1-h treatment with increasing doses of BLM, followed
by 48 h of recovery. Data reported in Figure 1g and
Supplementary Figure S5B clearly confirmed the protective
function exerted by NPM1 against BLM treatment. Notably, the
differential sensitivity of the two isogenic cell lines was not
apparent when using the poly (ADP-ribose) polymerase-inhibitor
PJ34 (Supplementary Figure S6A) or upon ultraviolet-C irradiation,
which promotes DNA damages repaired through NER
(Supplementary Figure S6B). Comet assay analysis performed
under basal condition (data not shown) did not reveal any
significant difference between the steady-state level of DNA
damage of the two isogenic cell lines. The latter observations
suggest that, if any, only a marginal involvement of the other
pathways, besides BER, may account for the observed effects on
cell viability exerted by the genotoxicants used in this study,
which, besides AP sites, may cause DNA-strand breaks.
Collectively, these data indicate that NPM1 is essential for cell
protection from different genotoxic treatments that elicit a BER
response.
The lower APE1 BER activity of NPM1 / cells is rescued by NPM1
reconstitution
To define the BER defect accompanying NPM1 deficiency, we
measured the APE1 enzymatic activity in nuclear extracts from the
two MEF cell lines. Endonuclease assays showed that despite the
higher expression levels of APE1 protein in NPM1 / cells, their
AP endonuclease activity did not significantly differ from that of
the control cells (Figure 2a). Treatment of the two cell lines with
two different APE1 inhibitors (that is, methoxyamine39 and
compound 344) alone demonstrated that NPM1 / cells were
significantly more sensitive to AP endonuclease activity inhibition,
confirming the hypothesis that APE1 functional activity, under
genotoxic conditions, strictly depends on NPM1 expression
Figure 1. Absence of NPM1 is associated to a higher sensitivity of cells to genotoxic treatments causing DNA lesions repaired through BER.
(a) Left: representative western blotting analysis of MEF-NPM1þ /þ and NPM1 / nuclear extracts of three independent subfractionation
experiments. Nuclear cell extracts of 5 mg of the two cell lines were analyzed through western blotting for the expression of APE1 and NPM1
content. Lysine demethylase (LSD1) was used as nuclear marker and loading control, whereas tubulin was used to evaluate cytoplasmic
contaminations. Right: relative percentages of chemiluminescence intensity of APE1 signals are reported in the histogram showing a
significant increase of APE1 nuclear expression in NPM1 / clone (40±9%) with respect to NPM1þ /þ cells. Histograms, showing the amount
of APE1 nuclear protein, represent the mean±s.d. values of three independent experiments. (b) APE1 subcellular localization was detected
through confocal analysis on MEF-NPM1þ /þ and NPM1 / cells using a specific monoclonal a-APE1 antibody and a secondary antibody a-
mouse conjugated with Rhodamine-Red. Yellow arrows indicate APE1 accumulation within nucleoli. A diffused nuclear staining without
nucleolar accumulation could be observed in the NPM1 / cells. (c) Confocal analysis of APE1/NPM1 colocalization in MEF-NPM1 / after
reexpression of NPM1. NPM1 / cells transfected with the empty vector (Empty) showed a uniform nuclear staining for APE1 (red). On the
contrary, NPM1 / cells transfected with pCMV5.1 vector expressing NPM1 in fusion with a C-term FLAG (NPM1 rec.) show APE1
accumulation within nucleolar structure and colocalization with NPM1 (yellow arrows). (d) MTS assay was used to evaluate cell viability of
MEF-NPM1þ /þ and NPM1 / cells after treatment with increasing amounts of MMS for 8 h. Absence of NPM1 negatively affects cell viability
making NPM1 / cells more sensitive to genotoxic damages. Mean±s.d. values are the result of three independent experiments. (e) The
amount of abasic (AP) sites was measured in MEF-NPM1þ /þ and NPM1 / cells under basal conditions and after treatment with 0.5mM of
MMS for 4 h. NPM1 / cells display a significantly higher amount of AP sites if compared with NPM1þ /þ cells. Treatment with an alkylating
agent leads to the accumulation of AP sites in NPM1 / cells (5.14±0.25/105 bp) if compared with NPM1þ /þ cells (3.58±0.20/105 bp).
Mean±s.d. values are the result of three independent experiments. (f ) MTS assay was used to evaluate cell viability of MEF-NPM1þ /þ and
NPM1 / cells. After Potassium bromate (40mM for 30min) treatment, cells were allowed to recover for the indicated periods of time.
Absence of NPM1 negatively affects cell viability, making NPM1 / cells more sensitive to genotoxic damages. Mean±s.d. values are the
result of three independent experiments. (g) Trypan blue cell counting was used to measure cytotoxicity of BLM in MEF cells. Mean±s.d.
values are the result of three independent experiments.
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(Figures 2b and c). We circumstantiated these findings by
measuring the endonuclease activity of APE1, using nuclear
extracts of MEF cells after normalization for APE1 content.
Consistent with our previous in vitro findings,17 APE1
endonuclease activity in NPM1 / extracts was significantly
lower than that from NPM1þ /þ cells (Figure 2d). Thus, the
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increased APE1 nuclear content observed in NPM1 / cells could
reflect a compensatory mechanism to maintain overall BER activity
that still remains insufficient to efficiently correct genotoxic damage.
To confirm that the APE1 defect observed in NPM1 / cells
was due to NPM1 loss, rather than some other effect of the
knockout gene, we restored NPM1 in the NPM1 / cell lines by
ectopic expression of the WT protein from a plasmid vector and
measured the AP endonuclease activity in these cells (Figure 2e).
The results showed that NPM1 reexpression in NPM1 / cells
increased their AP endonuclease activity when compared with
control cells transfected with the empty expression vector. We
biologically circumstantiated these biochemical data, by performing
cell viability experiments in stable cell lines reexpressing the WT
NPM1 protein in the NPM1 / background. Data reported in
Figure 2f confirmed the hypothesis made, clearly showing that
reexpression of NPM1 significantly reduced the sensitivity of
NPM1 / cells to genotoxic treatment.
Collectively, our data demonstrate that NPM1 is a novel indirect
effector of BER by regulating APE1 localization and activity in vivo.
Ectopic expression of the NPM1cþ AML protein causes increased
cytoplasmic APE1 localization in HeLa cells
We examined the oncological relevance of our findings by testing
the effect of the NPM1cþ mutation on BER, and by studying the
effect of NPM1cþ on the APE1–NPM1 interaction. To address the
latter, we assessed the extent of APE1–NPM1 interaction using the
proximity ligation assay (PLA).45 HeLa cells expressing the
NPM1cþmutant protein showed relocalization of NPM1 to the
cytoplasmic compartment of the protein. As expected, the control
WT protein presented its typical nucleolar staining (Figure 3a). The
specificity of the PLA analysis was tested by comparing the ability
of NPM1 to interact with APE1WT, or with an APE1ND33-deletion
mutant that has lower affinity for NPM1.17 Specificity was clearly
demonstrated (Supplementary Figure S7 and Supplementary
Movies) by the presence of nuclear and nucleolar PLA spots only
when APE1WT was expressed. When the APE1ND33 protein was
instead expressed, the PLA signals were reduced in number and
relocalized to the cytoplasmic compartment in accordance with
APE1ND33 pancellular localization. We then tested the ability of the
NPM1cþ 46 mutant protein to interact with Flag-tagged APE1
protein. In control cells (NPM1WT), the APE1–NPM1 interaction
occurred primarily in the nucleolar and nucleoplasmic compart-
ments, whereas the interaction with NPM1cþ protein was mostly
apparent in the cytoplasmic compartment (Figure 3b). Quantifica-
tion of these results, through scoring of the PLA signals, showed
that the NPM1cþ mutation significantly reduced the APE1–NPM1
association within the nuclei of transfected cells, leading to a
significant increase of the APE1–NPM1 interaction within the
cytoplasmic compartment. Accordingly, only in the case of cells
expressing the NPM1cþmutant protein, the APE1 staining was
extranuclear, consistent with the PLA signal distribution (Figures
3b and c). These observations indicate the existence of a direct
correlation between expression of the NPM1cþ protein and the
presence of APE1 in the cytoplasm.
NPM1cþ expression is associated with altered APE1 protein
stability in both AML cell lines and blasts from AML patients
We assessed the biochemical relevance of the APE1 cytoplasmic
relocalization due to NPM1cþ expression in the myeloid cell line
OCI/AML3, which stably expresses a NPM1cþmutant protein.47
We analyzed the distribution of APE1 using IF and by
quantification of the nuclear and cytoplasmic levels of APE1 in
subcellular fractions of OCI/AML3 and control OCI/AML2 cell lines
through western blot analysis. The mRNA expression levels of
APE1 were similar between the two cell lines, as demonstrated by
quantitative PCR analyses (data not shown). IF analysis showed
that NPM1cþ expression was associated with APE1 accumulation
in the cytoplasmic compartment of OCI/AML3 cells (Figure 4a).
Immunoblot analysis indicated that a significant amount of
truncated APE1 protein could be detected in the whole and in
the cytoplasmic extracts of OCI/AML3 cell line (Figure 4b).
Strikingly, accumulation of this truncated protein form was also
apparent in blasts from AML patients (Figure 4c), confirming the
biological relevance of this observation. Several groups have
demonstrated that APE1 is targeted by granzymes A and K, to
generate truncation products (APE1ND31-35) that functionally
inactivate APE1 in DNA repair and to take part in apoptosis.48–50
We have also recently shown that expression of non-cleavable
proficient form of APE1 protein protects cells from genotoxic
stresses,51 thus confirming that the N-terminal deletion of the
protein causes its functional impairment in vivo. This truncated
protein corresponded to the APE1ND33 truncation derivative
already described,48–50 but was due to a specific proteolytic
activity, independent of granzyme A protein, which is not
expressed in these cell lines (Lirussi et al., in preparation).
Figure 2. Absence of NPM1 negatively affects APE1 endonuclease activity. (a) The same amount of whole-cell extracts (600 ng) from MEF-
NPM1þ /þ and NPM1 / was used to evaluate APE1’s endonuclease activity in the two cell lines. A representative image shows the
conversion of the substrate (S) to product (P) operated by APE1. In the diagram on the right, the mean±s.d. values of the densitometric
analyses of three independent experiments are reported. (b) MTS assay was used to evaluate cell viability of MEF-NPM1þ /þ and NPM1 /
cells after treatment with increasing amount of methoxyamine (MX) for 24 h. Absence of NPM1 negatively affects cell viability, making
NPM1 / cells more sensitive to the damage. Mean±s.d. values are the result of three independent experiments. (c) WST-8 assay was used to
evaluate the sensitization of MEF-NPM1þ /þ and NPM1 / cells to the inhibition of the APE1 endonuclease activity. Cells were incubated
with the indicated amounts of the APE1-inhibitor compound 3, and viability was measured 24 h later. Mean±s.d. values are the result of three
independent experiments. (d) Left: on the basis of western blotting analysis of MEF-NPM1þ /þ and NPM1 / cells reported in Figure 1a,
normalized amount of nuclear cell extract (NCE) was loaded onto SDS–PAGE to obtain equal amounts of APE1. Immunoblot analysis
confirmed the presence of the same amount of APE1 protein in the nuclear extracts of the two cell lines. LSD1 was used as nuclear marker,
whereas tubulin was used to evaluate cytoplasmic contaminations. Right: normalized amount of NCE from both cell lines was used to evaluate
APE1 endonuclease activity. A representative image shows the conversion of the substrate (S) to product (P) operated by APE1. In the diagram
below are reported the mean±s.d. values of the densitometric analysis of three independent experiments. (e) Left: MEF-NPM1 / cells were
transiently transfected with pCMV5.1 vector expressing NPM1 in fusion with a C-term FLAG (NPM1 rec.) or the empty vector (Empty) as
control. Total cell extracts of 7.5 mg from Empty and NPM1-transfected cells were separated onto SDS–PAGE, and western blotting analysis was
performed using a-NPM1 and a-APE1 antibodies. Right: cell extracts of 50 ng from Empty and NPM1-reconstituted MEF-NPM1 / cells were
used to evaluate APE1 endonuclease activity. The representative image reported shows the conversion of the substrate (S) to product
(P) by the endonuclease activity of APE1. In the diagram below are reported the mean±s.d. values of the densitometric analyses of three
independent experiments. (f ) Left: MEF-NPM1 / cells were stably transfected with p3X-FLAG-CMV vector expressing NPM1 in fusion with a
C-term FLAG (NPM1) or the empty vector (Empty) as control. Total cell extracts of 7.5 mg of each clone were separated onto SDS–PAGE, and
western blotting analysis was performed using a-NPM1 and a-tubulin antibodies. Right: MTS assay was used to evaluate cell viability of MEF-
NPM1 / cells reconstituted with NPM1 after treatment with increasing amounts of MMS for 8 h. Reexpression of NPM1 rescues cell viability,
making NPM1 / reconstituted cells less sensitive to genotoxic damages. Mean±s.d. values are the result of three independent experiments.
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Though total APE1 protein levels were comparable between
OCI/AML3 and OCI/AML2 control cells, NPM1cþ expressing cells,
having almost 50% less WT NPM1 protein, have lower APE1
nuclear content (Figure 4b). AP endonuclease assays performed
with nuclear extracts of the two cell lines confirmed that
OCI/AML3 cells have a significantly reduced APE1 DNA incision
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activity (Figure 4d). We then evaluated the ability of the AML cells
to efficiently remove AP sites from the DNA of MMS-treated cells.
As shown in Figure 4e, OCI/AML3 cells retained a significantly
higher level of AP sites both under basal conditions and following
MMS treatment than did OCI/AML2 cells. Cell-viability experiments
were in agreement with these observations showing that OCI/
AML3 cells were significantly more sensitive to MMS treatment
than OCI/AML2 cells (Figure 4f).
To provide additional mechanistic insights into the role of APE1
delocalization in NPM1cþ cells and to prove which of the APE1
known functions (that is, DNA repair or redox) are affected by
NPM1cþ expression accounting for the higher sensitivity of OCI/
AML3 cells to genotoxicants, we performed sensitization experi-
ments to MMS treatment with specific APE1 inhibitors. Methoxy-
amine, as an APE1 DNA-repair inhibitor, and the well-known E3330
redox inhibitor52 were used for this purpose. Data obtained
(Supplementary Fig S8) show that treatment with the DNA-repair
inhibitor, but not with the E3330 redox inhibitor, sensitizes OCI/
AML2 cells to MMS treatment and phenocopies the response of
the NMP1cþ expressing cells. Moreover, this experiment demon-
strates that the functional impairment of the APE1 DNA repair
in NPM1cþ cells does not further increase the sensitivity of
NPM1cþ cells to genotoxic damage.
Altogether, these data allow to conclude that APE1 functional
suppression by NPM1cþ induced relocalization is important for
regulating cellular sensitivity to DNA damage in NPM1cþ cells.
Blasts from AML patients, expressing the NPM1cþmutant protein,
have increased cytoplasmic APE1–NPM1 interaction and show
impaired BER activity
We tested whether the altered interaction between APE1 and
NPM1cþ observed upon ectopic expression of the mutant
protein in cell lines also occurs in blasts from AML patients
constitutively expressing the NPM1cþ protein. IF and PLA
analyses (Figures 5a and b) clearly showed that the NPM1cþ
mutations leads to a reduction of the APE1/NPM1 interaction in
nuclei, coupled to a strong increase of the APE1/NPM1 association
in the cytoplasms of AML blasts. This phenotype is associated with
the relocalization of APE1 protein to the cytoplasm, as previously
observed in a heterologous cell system (Figure 3b).
To evaluate the physiological relevance of the altered interac-
tion between APE1 and NPM1cþ , we compared the sensitivity of
blasts from AML patients expressing either the WT or the cþ form
of NPM1 with that of healthy donors to DNA-alkylation damage
induced by MMS. Cell-viability experiments demonstrated that
blasts from AML patients expressing the NPM1cþ form were
significantly more sensitive to MMS than healthy control cells and
AML-WT NPM1 blasts (Figure 5c). These data support the
conclusion that alteration of APE1 distribution due to the
NPM1cþ mutation has a significant impact on the BER activity
in vivo and has a functional relevance in AML pathogenesis.
DISCUSSION
Here we demonstrated that NPM1 has an indirect but significant
role in BER through functional regulation of the APE1 endonu-
clease activity. This observation is the first evidence highlighting a
clear function of NPM1 in DNA repair, and these new results
provide a possible alternative explanation for a role of NPM1 in
the maintenance of genomic stability in addition to its known
effect on p53 stability.2,3 It has been recently shown that
homologous recombination-impaired BRCA-deficient cells are
hypersensitive to poly (ADP-ribose) polymerase inhibitors that
block repair of single-strand breaks, a subpathway of BER.
Interestingly, NPM1 functionally interacts with BRCA2 having a
role in centrosome duplication.53 Therefore, it could be speculated
that the differential sensitivity of NPM1 / cells to genotoxicants
used in this study could be ascribed to an impaired ability of these
cells to repair DNA-strand breaks. However, our data showing no
differential sensitivity to poly (ADP-ribose) polymerase inhibitors,
together with a similar efficiency of repair of strand breaks (as
measured through comet assays) by the two isogenic cell lines,
would exclude this hypothesis, leaving BER impairment as the
main process affected by the loss of NPM1 expression. Moreover,
our findings may illuminate the prompt response to
chemotherapy of AML expressing the NPM1cþ mutation. Our
data support the hypothesis that some biological effects of
NPM1cþ may be exerted through impaired functions of
important NPM1-interacting proteins caused by their abnormal
cytoplasmic localization.1,8–13
APE1 subcellular distribution within different cell types is mainly
nuclear and critically controls the cellular proliferation rate,54–56
however, in some tumors APE1 can be cytoplasmic or nuclear/
cytoplasmic.18,28 Increased expression of APE1 is associated with
different tumorigenic processes.28 In particular, a higher
expression of APE1, with consequently increased BER activity,
has been described in several cancer types,28 where it correlates
with a higher tumor aggressiveness and is associated with
chemoresistance.18 Extranuclear APE1 has a role within
mitochondria in repairing mitochondrial DNA damage57–59 and
in controlling the intracellular reactive oxygen species production
through inhibition of Rac1.60,61 However, a possible causal role of
an increased APE1 expression in tumorigenesis, as well as the
mechanisms responsible for the unusual APE1 accumulation in the
cytoplasmic compartment, has never been investigated in detail.
The observations reported herein provide a molecular explana-
tion for the delocalization of APE1 to the cytoplasm observed in
AML tumors associated with NPM1cþ . Because APE1 interacts
with many different partners involved in RNA metabolism,17,31,37
the occurrence of extranuclear APE1 localization may be explained
on the basis of altered expression levels of its protein partners that
may undergo delocalization, as is the case of NPM1cþ itself.
Alternatively, increased expression of APE1 cytoplasmic partners,
rather than mutations occurring in APE1 itself, may directly affect
the distribution of the protein. Notably, no polymorphisms
Figure 3. NPM1 mutation alters APE1 localization in HeLa cells. (a) Representative confocal microscopy images of HeLa cells transiently
transfected with pcDNA-HA vectors expressing WT NPM1 or the NPM1cþ mutant. Twenty-four hours after transfection cells were fixed and
stained with a primary antibody a-HA-Tag and a secondary antibody a-rabbit conjugated with Rhodamine Red. In cells expressing WT NPM1,
the ectopic HA-tagged protein localizes, as expected, only within the granular component of nucleoli. On the contrary, cells expressing
NPM1cþ mutant show also strong cytoplasm positivity. (b) PLA technology was used on HeLa cells to quantify the occurrence of in vivo
interaction between APE1 and NPM1. Cells were transiently transfected with APE1-FLAG and NPM1-HA-WT or the NPM1cþ mutant. Confocal
microscopy analysis highlights the presence of distinct fluorescent red dots (PLA signals), indicating the occurrence of in vivo interaction
between APE1-FLAG and NPM1-HA, whereas green fluorescence shows APE1-FLAG-tagged protein localization. PLA control is represented by
cells incubated only with a-FLAG antibody. In cells transfected with WT NPM1, APE1 accumulates within the nucleus where also PLA signals
are mostly present. In NPM1cþ expressing cells, a diffused cytoplasmic APE1 staining could be observed along with the relocalization of PLA
signal. (c) Blob Finder software was used to quantify the relative distribution of PLA signals between nucleus and cytoplasm of cells transfected
with WT NPM1 or NPM1cþmutant. In NPM1cþ expressing cells, most of the interaction between APE1 and NPM1 occurs within the
cytoplasm (nuclear: 26±7%), whereas in WT NPM1 cells, PLA signal is predominantly nuclear (nuclear: 79±8%). Reported results are the mean
of 30 cells for each condition.
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Figure 4. NPM1cþ mutation alters APE1 subcellular localization and affects its endonuclease activity in OCI/AML3 cell line. (a) Representative
images of fluorescence microscopy analysis of APE1 on OCI/AML2 (WT NPM1) and OCI/AML3 (NPM1cþ ) cell lines. A total of 2 104 cells were
centrifuged onto glass slides using a cytospin, and IF was performed as reported in Materials and Methods section. A secondary a-mouse
Rhodamine Red-conjugated antibody was used to visualize APE1. Nuclei are stained with 4’,6-diamidino-2-phenylindole. A predominant cytoplasmic
positivity of APE1 could be observed in OCI/AML3 cells only, linking NPM1cþ mutation with APE1 cytoplasmic relocalization. (b) In all, 10mg of total
cell extract (WCE), 10mg of cytoplasmic cell extract (CCE) and 5mg of nuclear cell extract (NCE) of OCI/AML2 and 3 were separated onto SDS–PAGE,
immunoblotted and analyzed for their content of APE1 and NPM1 (WT and cþ ). NPM1cþ protein was detected with a specific antibody
recognizing only the NPM1cþmutant form.47 Western blotting analysis showed the presence of truncated APE1 protein (*) only in the whole and
cytoplasmic extracts from OCI/AML3 cell line. Actin was used as loading control, whereas tubulin and LSD1 were used as markers of cytoplasmic and
nuclear fraction enrichment, respectively. (c) Total cell extracts of 10mg from OCI/AML2 and 3 and of blast from AML patients expressing WT NPM
and NPM1cþ mutant were separated onto SDS–PAGE, immunoblotted and analyzed for their APE1 content. The expression of NPM1cþmutant
form is associated with the presence of truncated APE1 protein (*) in extracts from both the OCI/AML3 cell line and blasts from a patient carrying this
mutation. Actin was used as loading control. (d) OCI/AML2 and OCI/AML3 nuclear cell extracts of 50ng were used to evaluate the APE1
endonuclease activity. A representative image shows the conversion of the substrate (S) to product (P) operated by APE1. OCI/AML3 cells show
lower AP-incision activity, in accordance with the decreased nuclear APE1 content. The diagram below reports the mean±s.d. values obtained from
the densitometric analysis of three independent experiments. (e) The amount of abasic (AP) sites was measured in OCI/AML2 and OCI/AML3 cells
under basal conditions and after treatment with 0.5 and 1mM MMS for 4h. OCI/AML3 cells display a significantly higher amount of AP sites if
compared with OCI/AML2 cells. Mean±s.d. values are the result of three independent experiments. (f ) CellTiter-Glo Luminescent Cell Viability assay
was used to evaluate the sensitization of OCI/AML2 and OCI/AML3 cells to MMS. Cells were incubated with the indicated amounts of MMS for 8h.
Expression of NPM1cþ negatively affects cell viability. Mean±s.d. values are the result of three independent experiments.
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Figure 5. NPM1 mutation alters APE1 localization, reducing cell resistance to genotoxic damage in blasts from AML patients. (a) Representative
images of fluorescence microscopy analysis of APE1 and NPM1 on blasts from AML patients (AML) carrying NPM1cþ mutation and healthy
donors (CTRL). A total of 2 104 cells were centrifuged onto glass slides using a cytospin, and IF analyses were performed as reported in Materials
and Methods section. A secondary a-mouse-Alexa Fluor 488-conjugated antibody was used to visualize APE1 (green), and a secondary a-rabbit-
Rhodamine-conjugated antibody was used to visualize NPM1 (red). Nuclei are stained with 4’,6-diamidino-2-phenylindole. In merged images,
yellow arrows indicate the occurrence of colocalization between APE1 and NPM1. In control cells, NPM1 accumulates within nucleoli while being
mainly excluded from this subcellular compartment in blasts from AML patients, which show a predominant cytoplasmic positivity. Accordingly,
APE1 delocalizes from nucleus to cytoplasm in blasts from AML patients. (b) Representative images of PLA analysis to evaluate the interaction
between APE1 and NPM1 on blasts from AML patients (AML) carrying NPM1cþ mutation and healthy donors (CTRL). A total of 2.5 104 cells
were centrifuged onto glass slides using a cytospin, and PLA was performed as reported in Materials and Methods section. APE1 (green)
accumulates within the nucleus in control cells while being mainly excluded from this subcellular compartment in blasts from AML patients. In
accordance, also PLA signal delocalizes from nucleus to cytoplasm in blasts from AML patients. (c) Cell viability of blasts from healthy donors
(CTRL, n¼ 3), AML patients expressing WT NPM1 (NPM1-WT, n¼ 3) or the NPM1cþmutant form (NPM1cþ , n¼ 4) after 4h of treatment with the
indicated doses of MMS was measured through the MTS assay. AML cells expressing the NPM1-cþ are more sensitive to the alkylating agent than
blasts from healthy donors and AML patients expressing the NPM1-WT form. Mean±s.d. values are the result of three independent experiments.
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occurring on the known bipartite NLS of APE1 have been
described so far, nor alternative splicing forms have been
found that could explain the cytoplasmic accumulation of APE1
in tumors. As the majority of the polymorphisms described in
literature involve residues not responsible for either the DNA
repair or the redox functions of the protein, but rather changes that
often fall within the N domain involved in protein–protein
interactions and protein stability,33,62 a reasonable explanation for
the delocalization of the protein observed in tumors may be
ascribed to alterations of a complex network of interactions
affecting, in turn, APE1 functional status. Here, we showed that in
OCI/AML3 cells expressing the NPM1cþ allele, as well as in blasts
from AML patients, APE1 protein is destabilized (Figures 4b and c). It
can be inferred that, similarly to the case of p19Arf, the physiological
function of NPM1 is to ensure the proper localization of APE1 and
to protect it from degradation, being possible that NPM1 protein
may function as a chaperone for APE1, allowing its correct folding.
Our model (Figure 6a) is in accordance and further extends a
previous one1 trying to explain the relative contribution (direct or
indirect) of NPM1 expression to cellular transformation. Our model
takes into account the evidence that tumors of hematopoietic
origin, such as AML, are associated with WT NPM1 deficiency,
whereas a number of solid tumors (that is, gastric, hepatic and
ovarian) show increased expression of WT NPM1. In the first case,
the contribution of a NPM1 mutation is causally linked to the
transformation process. Indeed, reduced nuclear NPM1 levels, as a
consequence of the mutation of one WT allele, may lead to genomic
instability due to BER impairment, and thus to an increased cellular
burden of DNA damage. Therefore, the impaired DNA-damage
response may block cell proliferation inefficiently, such that some
cells would escape the checkpoint and establish an immortalized
clone prone to further oncogenic transformation. Alternatively
(Figure 6b), elevated WT NPM1 expression levels would contribute
to the generation of permissive condition for oncogenic transforma-
tion. In that case, the presence of high NPM1 levels may limit DNA
damage and promote the DNA-damage response (due to increased
BER), associated with oncogenic stress signals in a normal cell, and
therefore may support cell survival and eventually transformation.
This model could also involve the APE1 protein in two ways: through
an impaired BER response and the resulting genetic instability; and
through the establishment of conditions permissive for transforma-
tion. Our evidence suggests that defects in the APE1–NPM1
interaction can be associated with the genomic instability observed
in tumors, which supports the concept that interfering with this
interaction may sensitize cancer cells to chemotherapy and
radiotherapy.
MATERIALS AND METHODS
Cell lines and materials
HeLa, MEF p53 / /NPM1þ /þ (NPM1þ /þ )36 and MEF p53 / /NPM1 /
(NPM1 / )36 cell lines were grown in Dulbecco’s modified Eagle’s medium
(Euroclone, Milan, Italy) supplemented with 10% fetal bovine serum
(Euroclone), 100U/ml penicillin and 10mg/ml streptomycin sulfate. OCI/
AML2 and 3 cells were grown in alpha-MEM (Euroclone) supplemented with
20% fetal bovine serum, 100U/ml penicillin and 10mg/ml streptomycin
sulfate. Leukemic cells were obtained from the bone marrow of patients with
acute leukemia during diagnostic procedures. Mononuclear cells were
separated on a Ficoll–Hystopaque 1077 (Sigma Aldrich, Milan, Italy) density
gradient, then were washed twice in phosphate-buffered saline, checked for
viability by using the trypan blue exclusion test and suspended in phosphate-
buffered saline. Presence of mutations in the NPM1 gene was detected as
previously described.63 Blast from patients were grown in RPMI (Invitrogen,
Monza, Italy) supplemented with 20% fetal bovine serum. Stable cell lines
reexpressing WT NPM1 in the NPM1 / background were obtained as
previously described.17 All chemical reagents were supplied from Sigma
Aldrich unless otherwise specified.
Cell-viability analyses
Cell viability was measured by using the MTS assay (Promega, Milan, Italy) on
MEF cells (5 103 cells) and blasts from patients (60 103 cells) grown in 96-
well plates. Cells were plated, and after MMS, KBrO3 or acute H2O2 treatment,
20ml of MTS solution was added to each well and plates were incubated for
2h at 37 1C. Absorbance (at 490nm) was measured by using a multiwell plate
reader. The values were standardized to wells containing media alone.
Cytotoxicity induced by BLM was evaluated using a trypan blue exclusion
assay. A total of 4 104 cells per well were plated in six-well plates, treated
for 60min with reported amounts of BLM and then grown for 2 additional
days in fresh media. Cell viability for OCI/AML cell lines (2.5 104 cells) was
measured by CellTiter-Glo Luminescent Cell Viability Assay (Promega)
according to the manufacturer’s protocol. Cells were incubated with the
indicated doses of MMS for 8h at 37 1C in agitation. Luminescent signals
were measured using the Turner BioSystems Luminometer (Promega). Cell
survival upon inhibition of APE1 AP endonuclease activity was measured with
the WST-8 assay. MEF cells were seeded onto 96-well plates (6 103 cells)
and allowed to adhere for 24h. MEFs were then incubated with the
indicated amounts of compound 3 (N-(3-(benzo[d]thiazol-2-yl)-6-isopropyl
-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)acetamide),44 and viability was
measured 24 h later using the CCK-8 Kit (Dojindo, Munich, Germany) as
per the manufacturer’s instructions.
Plasmid preparation
The construct pcDNA3-HA-NPM1cþ was generated by using the
Quickchange II XL Mutagenesis kit (Stratagene, Milan, Italy) and the
pcDNA3-HA-NPM1-WT as template following the manufacturer’s instruc-
tions. Direct sequencing was performed in order to verify the sequence
accuracy. WT NPM1 and NPM1cþ cDNA were also subcloned in
pCMV5.1-FLAG and p3X-FLAG-CMV vectors for reconstitution experiments
on MEF-NPM1 / cells.
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Figure 6. Relative contribution of NPM1/APE1 expression to cellular
transformation: a model for APE1 role in tumorigenesis? (a) Reduced
NPM1 levels due to loss of one WT allele leads to genomic instability
through impairment of BER and increased DNA damage. As a
consequence, the DNA-damage response blocks cellular prolifera-
tion. Few cells may escape the block and establish an immortalized
clone prone to be transformed by oncogene activation. (b)
Oncogene activation in a normal cell leads to unscheduled DNA
replication and DNA damage. Cellular checkpoints are activated
favoring apoptosis or senescence as response to uncontrolled
proliferative signals. The presence of high NPM1/APE1 levels may
limit DNA damage and DNA-damage response, and therefore
support cell survival and eventually transformation. This model also
includes APE1 protein both in the first case as having a causative
role in the transformation process itself and in the second case, in
which NPM1 and APE1 expression levels are simultaneously
elevated, generating a permissive condition for transformation.
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AP-sites measurements
Genomic DNA was isolated from 2 106 cells by using the DNAzol Reagent
(Invitrogen), and then concentration and purity were determined spectro-
photometrically. Samples of 0.1mg/ml of genomic DNA were analyzed to
quantify abasic damage in chromosomal DNA using the DNA Damage
Quantification Kit (Dojindo) according to the manufacturer’s instructions.
IF and PLA analysis
For IF analysis on HeLa and MEFs, cells were grown on glass coverslips,
whereas blasts and OCI/AML 2 and 3 cells were centrifuged onto glass
slides using a cytospin. Then, cells were fixed with 4% (wt/vol)
paraformaldehyde for 20min at room temperature and permeabilized
for 5min with phosphate-buffered saline–0.25% (vol/vol) Triton X-100.
Cells were incubated for 30min with 10% fetal bovine serum in TBS–0.1%
(vol/vol) Tween 20 (blocking solution) to block unspecific binding of the
antibodies. Cells were then incubated with primary antibodies diluted in
blocking solutions: monoclonal-a-APE1 (diluted 1:50, 3 h, 37 1C), polyclonal
a-NPM1 (diluted 1:200, overnight, 4 1C), monoclonal a-FLAG-FITC-
conjugated (diluted 1:100, 3 h, 37 1C) and polyclonal a-HA (diluted 1:500,
overnight, 4 1C). Then cells were washed three times for 5min each with
TBS–0.1% (vol/vol) Tween 20 (Washing Solution) and incubated with
secondary antibody: a-mouse or a-rabbit Rhodamine Red-conjugated or
Alexa Fluor 488-conjugated (diluted 1:200, 2 h, 25 1C) (Jackson Immuno,
West Grove, PA, USA). After washing three times, coverslips were mounted
on microscope slides with a mounting media containing 4’,6-diamidino-2-
phenylindole and an anti-fade reagent. For PLA analysis on blasts from
patient’s primary antibody a-APE1 was previously labeled with the Zenon
a-Mouse IgG Labeling Kit (Invitrogen) using the Alexa Fluor 488 according
to the manufacturer’s instructions.
To study the interaction of APE1 with NPM1 in vivo, we used the in situ
PLA technology (Olink Bioscience, Uppsala, Sweden). After incubation with
monoclonal a-APE1 (1:50) or a-FLAG antibody (1:100) for 3 h at 37 1C, cells
were incubated with polyclonal a-NPM1 (1:200) or polyclonal a-HA
antibody (Sigma-Aldrich) (1:500) overnight at 4 1C. PLA was performed
following the manufacturer’s instructions and as previously reported.36
Technical controls, represented by the omission of a-NPM1/a-HA primary
antibody, resulted in the complete loss of PLA signal. Images were
captured through a confocal microscope, and quantification of PLA signal
was performed using the Blob Finder software (Center for Image Analysis,
Uppsala University).
Cells were visualized through a Leica TCS SP laser-scanning
confocal microscope (Leica Microsystems, Milan, Italy) or a DMB6000B
inverted microscope equipped with a DFC300FX digital camera
(Leica Microsystems).
Preparation of cell extracts and protein quantification
Cell extracts were prepared as already described in Vascotto et al.17 and as
reported in Supplementary Information.
Cell transfection and western blotting analyses
Plasmids were prepared and used for transfection and western blotting
analysis, as already described in Fantini et al.30 and as reported in
Supplementary Information.
Incision assays on abasic double-stranded DNA
APE1 endonuclease activity was evaluated as already described17 and as
reported in Supplementary Information.
Statistical analysis
Statistical analysis on biological data was performed using the Microsoft
Excel data analysis program for Student’s t-test analysis.
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Nucleolar accumulation of APE1 depends on 
charged lysine residues that undergo acetylation 
upon genotoxic stress and modulate its BER 
activity in cells
Lisa Lirussia,*, Giulia Antonialia,*, Carlo Vascottoa, Chiara D’Ambrosiob, Mattia Polettoa, 
Milena Romanelloa, Daniela Marascoc,d, Marilisa Leoned, Franco Quadrifoglioa, Kishor K. Bhakate, 
Andrea Scalonib, and Gianluca Tella
aDepartment of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy; bProteomics and Mass 
Spectrometry Laboratory, Istituto di Ricerche per il Sistema Produzione Animale in Ambiente Mediterraneo, National 
Research Council, 80147 Naples, Italy; cDepartment of Biological Sciences, University of Naples “Federico II,” 80134 
Naples, Italy; dInstitute of Biostructures and Bioimaging, National Research Council, 80134 Naples, Italy; eDepartment 
of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555
ABSTRACT Apurinic/apyrimidinic endonuclease 1 (APE1) is the main abasic endonuclease in 
the base excision repair (BER) pathway of DNA lesions caused by oxidation/alkylation in 
mammalian cells; within nucleoli it interacts with nucleophosmin and rRNA through N-termi-
nal Lys residues, some of which (K27/K31/K32/K35) may undergo acetylation in vivo. Here we 
study the functional role of these modifications during genotoxic damage and their in vivo 
relevance. We demonstrate that cells expressing a specific K-to-A multiple mutant are APE1 
nucleolar deficient and are more resistant to genotoxic treatment than those expressing the 
wild type, although they show impaired proliferation. Of interest, we find that genotoxic 
treatment induces acetylation at these K residues. We also find that the charged status of 
K27/K31/K32/K35 modulates acetylation at K6/K7 residues that are known to be involved in the 
coordination of BER activity through a mechanism regulated by the sirtuin 1 deacetylase. Of 
note, structural studies show that acetylation at K27/K31/K32/K35 may account for local confor-
mational changes on APE1 protein structure. These results highlight the emerging role of 
acetylation of critical Lys residues in regulating APE1 functions. They also suggest the exis-
tence of cross-talk between different Lys residues of APE1 occurring upon genotoxic dam-
age, which may modulate APE1 subnuclear distribution and enzymatic activity in vivo.
INTRODUCTION
Apurinic/apyrimidinic endonuclease 1/redox effector factor-1 (APE1) 
plays a central role in the maintenance of genome stability and re-
dox signaling (Bapat et al., 2009, 2010; Tell et al., 2010a; Wilson and 
Simeonov, 2010). Through its C-terminal domain (residues 61–318), 
it acts as an essential enzyme in the base excision repair (BER) path-
way of DNA damages caused by both endogenous and exogenous 
oxidizing/alkylating agents, including many chemotherapeutic 
drugs. In combination with thioredoxin (Ueno et al., 1999; Seemann 
and Hainaut, 2005) and through its N-terminal domain (residues 
1–127), it also functions as a regulatory redox agent to maintain 
cancer-related transcription factors (Egr-1, NF-?B, p53, HIF-1?, AP-1, 
and Pax proteins) in an active reduced state (Hirota et al., 1997; 
Monitoring Editor
Karsten Weis
University of California, 
Berkeley
Received: Apr 17, 2012
Revised: Jul 25, 2012
Accepted: Aug 16, 2012
This article was published online ahead of print in MBoC in Press (http://www 
.molbiolcell.org/cgi/doi/10.1091/mbc.E12-04-0299) on August 23, 2012.
*These authors contributed equally to this work
The authors declare that they have no conflict of interests.
Address correspondence to: Gianluca Tell (gianluca.tell@uniud.it).
© 2012 Lirussi et al. This article is distributed by The American Society for Cell 
Biology under license from the author(s). Two months after publication it is avail-
able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported 
Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).
“ASCB®,” “The American Society for Cell Biology®,” and “Molecular Biology of 
the Cell®” are registered trademarks of The American Society of Cell Biology.
Abbreviations used: APE1/Ref-1, apurinic/apyrimidinic endonuclease/redox 
effector factor 1; BER, base excision repair; MMS, methyl methanesulfonate; MTS, 
3-(4-5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tet-
razolium salt; NPM1, nucleophosmin 1; SIRT1, sirtuin 1; TBHP, tert-butyl hydroper-
oxide.
???????????? ????????????????????????????????????????????????????????????????
????????????? ?????????????????????????
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
4080 | L. Lirussi et al. Molecular Biology of the Cell
mutants are reintroduced into APE1-silenced cell clones to deter-
mine the role of these crucial amino acids during cell response to 
genotoxic treatment.
RESULTS
Positively charged K27/K31/K32/K35 residues are essential 
for APE1 nucleolar accumulation through stabilization 
of protein interaction with NPM1 and rRNA
We previously demonstrated that charged K residues, located within 
the unstructured APE1 N-terminal domain (i.e., K24/K25/K27/K31/K32), 
are crucial for APE1 interaction with rRNA and NPM1 and for modu-
lating its catalytic activity on abasic DNA through regulation of prod-
uct binding. Of interest, some of these critical amino acids (i.e., K27/
K31/K32 in addition to K35) may undergo in vivo acetylation under 
basal conditions (Fantini et al., 2010). We hypothesized that the de-
gree of positive charges, modified by acetylation at these residues, 
may modulate APE1’s different functions through its redirection to 
different substrates and/or stimulation of its DNA-repair enzymatic 
activity (Fantini et al., 2010). To address this issue, we inspected 
the role of the positively charged residues within the region 27–35 in 
modulating the interaction between APE1 and NPM1. Colocaliza-
tion experiments in HeLa cells transiently transfected with either 
FLAG-tagged, wild-type APE1 (APE1WT), a K-to-A mutant (APE1K4pleA) 
in which the positive charges have been removed as in the case of 
constitutive acetylation, or a nonacetylatable K-to-R APE1 mutant 
(APE1K4pleR) showed that APE1K4pleA mutant has a marked exclusion 
from the nucleoli apparent in all expressing cells (Figure 1A). Silenc-
ing of the endogenous APE1 protein did not alter either the ability 
of the APE1WT and APE1K4pleR proteins to accumulate within the nu-
cleolar compartment or the inability of the APE1K4pleA to accumulate 
within the nucleolus (unpublished data). These data thus demon-
strate that APE1WT and APE1K4pleR nucleolar accumulation is not the 
consequence of their overexpression.
To complement these observations and also to exclude a possi-
ble contribution of the FLAG tag used to generate recombinant ec-
topic proteins, we exploited a live-cell imaging system as suggested 
by Schnell et al. (2012). APE1 cDNA was cloned into a pDendra2 
vector to express APE1 in fusion with the green photoconvertible 
fluorophore Dendra (Chudakov et al., 2007). As reported in Figure 
1B, the fluorophore alone is present in both the cytoplasm and the 
nuclear compartment, but it is completely excluded from the nucle-
oli, as demonstrated by quantitative fluorescence signal analyses. In 
contrast, whereas the expression of Dendra in fusion with APE1WT 
and APE1K4pleR results in an efficient accumulation of the protein 
within the nucleolar compartment, the Dendra-APE1K4pleA mutant 
displays a homogeneous nuclear distribution. This approach con-
firms immunofluorescence-based data on the reduced accumula-
tion of FLAG-tagged APE1K4pleA within the nucleoli and supports the 
evidence that the nucleolar accumulation of APE1 protein does not 
depend on the protein abundance nor does it depend on the spe-
cific tag used to generate the ectopic recombinant proteins (see 
also Supplemental Figure S1).
We supported our immunofluorescence data with biochemical 
interaction experiments. Coimmunoprecipitation analysis showed 
that the APE1K4pleA mutant has a significantly reduced interaction 
with NPM1 (Figure 2A), in accordance with its impaired nucleolar 
accumulation. The altered electrophoretic mobility observed for the 
APE1K4pleA mutant (Figure 2A) was further confirmed by SDS–PAGE 
analysis of recombinant proteins expressed in Escherichia coli and 
purified by chromatography. The effect is likely due to alteration of 
its overall charge, since electrospray ionization mass spectrometry 
analysis confirmed the correctness of protein mass values, and the 
Wei et al., 2000; Ziel et al., 2004; Gray et al., 2005; Pines et al., 2005; 
Tell et al., 2005, 2010a). APE1 can also act as a transcriptional repres-
sor through indirect binding to negative Ca2+-response elements 
(nCaRE), which are regulated by K6/K7 acetylation (Bhakat et al., 
2003). Recently APE1 was demonstrated to bind/cleave abasic RNA 
(Vascotto et al., 2009b; Fantini et al., 2010; Tell et al., 2010b) and to 
control c-Myc expression by cleaving its mRNA (Barnes et al., 2009). 
These discoveries pointed to a new function of APE1 in regulating 
gene expression through posttranscriptional mechanisms and 
brought to light the fact that this protein is a possible target for anti-
cancer therapy.
In this context, we showed that the first 35 amino acids in the 
nonstructured N-terminal domain of APE1 are required for a stable 
interaction with rRNA, nucleophosmin 1 (NPM1), and other proteins 
involved in ribosome biogenesis/RNA processing (Vascotto et al., 
2009b; Tell et al., 2010b). In particular, K residues within the protein 
region spanning amino acids 24–35 are involved in the interaction of 
APE1 with both rRNA and NPM1 and also regulate its in vitro enzy-
matic activity (Fantini et al., 2010). Of interest, some of these critical 
K residues, namely K27/K31/K32/K35, undergo in vivo acetylation. 
These results suggest that protein–protein interactions and/or post-
translational modifications (PTMs) involving the APE1 N-terminal 
domain may play important roles in vivo in coordinating and fine-
tuning the protein’s BER activity and functions on rRNA metabolism. 
Recently it was also demonstrated that APE1 K6/K7 may undergo 
acetylation during cell response to genotoxic treatment (Fantini 
et al., 2008) and that the acetylation status of these K residues, con-
trolled by the sirtuin 1 (SIRT1) deacetylase activity, should be impor-
tant in modulating protein DNA-repair function by regulating the 
kinetics of its interaction with other enzymes involved in BER, for 
example, XRCC1 (Yamamori et al., 2010).
APE1 is mainly a nuclear protein and is critical for controlling cel-
lular proliferative rates (Fung and Demple, 2005; Izumi et al., 2005; 
Vascotto et al., 2009b). We also showed that a considerable amount 
of APE1 is accumulated within the nucleoli of different cell lines 
(Vascotto et al., 2009b; Fantini et al., 2010), but its role within this 
compartment is unknown. Cytoplasmic, mitochondrial, and endo-
plasmic reticulum localizations have also been ascertained (Tell 
et al., 2001; Szczesny and Mitra, 2005; Chattopadhyay et al., 2006; 
Grillo et al., 2006; Mitra et al., 2007). APE1 is an abundant and rela-
tively stable protein in mammalian cells (Tell et al., 2009, 2010a). 
Fine-tuning of the multiple APE1 functions may therefore depend 
on the modulation of its PTMs and, eventually, on its interactome. 
Although a functional role has been determined for some PTMs 
(K6/K7 acetylation and K24/K25/K27 ubiquitination; Bhakat et al., 2003; 
Fantini et al., 2008; Busso et al., 2009), the identity and importance 
of various interacting partners in modulating APE1 biological func-
tions are still under investigation (Parlanti et al., 2007; Busso et al., 
2009; Vascotto et al., 2009b). APE1 may affect cell growth by di-
rectly acting on rRNA quality control mechanisms; in particular, 
APE1 interaction with NPM1 may affect its activity over rRNA mole-
cules. However, many aspects of this new function are undefined 
(Vascotto et al., 2009b; Tell et al., 2010b).
In this study, we address the biological role of APE1 acetylation at 
K27/K31/K32/K35 and, in light of recent evidence showing the emerg-
ing function of the nucleolus as a central sensor of protein trafficking 
during DNA repair after genotoxic treatment (Nalabothula et al., 
2010), the role of the nucleolus itself on the APE1 protective function 
toward genotoxic damage. We used a reconstitution strategy with 
APE1 mutants in which the charged Lys residues were replaced by 
either Ala or Arg to mimic constitutive acetylated (APE1K4pleA) and 
nonacetylatable (APE1K4pleR) protein forms, respectively. These 
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difference in their apparent mobility ob-
served in SDS–PAGE was abolished when 
separating various mutants in urea-contain-
ing denaturing gels (Supplemental Figure 
S2 and unpublished data). It was also ob-
served for other K-to-A mutants of APE1 
(Fantini et al., 2010). We then evaluated 
the contribution of the single K residues to 
the extent of APE1 nucleolar localization 
(Supplemental Figure S3) and the ability to 
interact with NPM1 (Figure 2B). Double mu-
tants APE1K27/35A, APE1K31/32A, APE1K27/35R, 
and APE1K31/32R and a deletion mutant lack-
ing 33 amino acids at the protein N-terminus 
(APE1N?33) were compared with APE1WT. 
Whereas APE1WT, APE1K27/35R, and 
APE1K31/32R displayed a nucleolar and 
nucleoplasmic staining, APE1K27/35A and 
APE1K31/32A showed two alternative stain-
ings, exhibiting nucleolar/nucleoplasmic or 
only nucleoplasmic positivity, respectively 
(Supplemental Figure S3). Coimmunopre-
cipitation experiments (Figure 2B) were in 
accordance with immunofluorescence anal-
yses and showed a substantial reduction of 
the interaction in the case of APE1K4pleA and 
APE1N?33 mutants and a moderate impair-
ment for APE1K27/35A and APE1K31/32A mu-
tants. Glutathione S-transferase (GST) pull-
down assays with recombinant purified 
proteins confirmed that these results were 
due to effects on direct interaction between 
APE1 and NPM1 (Figure 2C). This confirmed 
previous hypotheses (Fantini et al., 2010). 
We also checked the effect of the K-to-A 
mutation on the ability of APE1 to bind nu-
cleolar rRNA (Vascotto et al., 2009b). As ex-
pected, rRNA–chromatin immunoprecipita-
tion (ChIP) analyses showed that K-to-A 
mutations significantly alter APE1 binding to 
FIGURE 1: Positively charged K27/K31/K32/K35 residues are required for APE1 nucleolar 
accumulation. (A) Confocal microscopy of HeLa cells transfected with APE1WT, APE1K4pleA, or 
APE1K4pleR FLAG-tagged proteins and stained with antibodies against NPM1 (red) and ectopic 
FLAG-APE1 (green). Overlap of staining (yellow) demonstrated colocalization of the two 
proteins. Of note, the APE1K4pleA mutant was completely excluded from nucleoli (white 
arrowheads), whereas both APE1WT and the APE1K4pleR were accumulated within. Images are 
representative of 100% of transfected cells. (B) HeLa cells transfected with pDendra2-N empty 
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vector or encoding APE1 (wild-type and 
mutants) in fusion with Dendra fluorophore 
were analyzed with a live confocal 
microscopy workstation. Cells transfected 
with empty vector (Dendra) showed diffuse 
green fluorescence within cytoplasm and 
nucleus, with exclusion of the nucleolar 
compartment. APE1WT and APE1K4pleR mutant 
mainly localized within the nuclear 
compartment and accumulated within 
nucleoli. In contrast, APE1K4pleA did not show 
any nucleolar accumulation. Images were 
captured by using the same settings (488-nm 
laser at 10% of intensity and PMT at 760 V). 
Fluorescence intensity analysis was carried 
out on a 25-μm-long line (white). Graphs 
represent the fluorescence intensity 
measured through a cross section of the 
nucleus and demonstrate an incremental 
fluorescence in corresponding nucleoli only 
in the case of APE1WT and APE1K4pleR-Dendra 
fusion protein–expressing cells.
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FIGURE 2: Positively charged K27/K31/K32/K35 
residues are required for NPM1 interaction. (A) The 
APE1K4pleA mutant shows impaired interaction with 
NPM1. Coimmunoprecipitation (CoIP) analysis on 
HeLa cells transfected with APE1WT, APE1K4pleA, or 
APE1K4pleR FLAG-tagged proteins with endogenous 
NPM1. Western blot analysis was used to quantify 
the interaction among the different APE1 forms 
and NPM1 by using specific antibodies. IB, 
immunoblot. (B) K27/K31/K32/K35 residues are 
responsible for proper interaction of APE1 with 
NPM1. CoIP analysis on HeLa cells transfected with 
FLAG-tagged APE1WT, APE1N?33, or the APE1 
double (APE1K27/35A, APE1K31/32A, APE1K27/35R, and 
APE1K31/32R) or quadruple (APE1K4pleA and 
APE1K4pleR) K-to-A or K-to-R mutants. Western blot 
analysis was performed on total cell extracts (left) 
and on immunoprecipitated material (right) with 
specific antibody for endogenous NPM1. 
Normalized coimmunoprecipitated amounts of 
NPM1 are indicated under each relative bar. 
Anti-FLAG staining was used as loading control. 
(C) Interaction of K-to-A APE1 mutants with NPM1 
and rRNA. A 150-pmol amount of each bait 
GST-APE1 recombinant purified protein (rAPE1) 
was incubated with an equimolar amount of 
recombinant NPM1, as described in Materials and 
Methods. After GST pull-down, samples underwent 
Western blot analysis by using the indicated 
antibodies (right). NPM1 band intensities were 
normalized vs. those of GST-APE1 proteins, and 
the resulting values, expressed as percentage of 
bound with respect to APE1WT, were plotted in the 
histogram (left). Each bar represents the mean of 
two independent experiments whose variation was 
<10%. (D) Interaction of K-to-A APE1 mutants with 
NPM1 and rRNA. After transfection of HeLa cells, 
total cell lysates were prepared as described in 
Materials and Methods, and an RNA-ChIP assay 
was performed to measure the rRNA-binding 
activity of the different APE1 mutants. 
Immunoprecipitated samples underwent either 
Western blot analysis (right) or RNA extraction and 
quantification by reverse transcription and 
quantitative PCR analysis, using 18S and 47S 
rRNA–specific primers. Data are presented as a 
fold percentage of the amount of total 18S or 
47S rRNA with respect to the amount of 
immunoprecipitated FLAG-tagged APE1 protein, 
respectively. The resulting values are plotted in 
the histograms (left), showing the average values 
with SD of three independent experiments. 
(E) Nucleoplasmic interaction between APE1 and 
NPM1 is affected by K-to-A mutation on APE1. 
PLA technology was used to evaluate in vivo the 
effect of positively charged K27/K31/K32/K35 
residues on APE1 interaction with NPM1 in the 
nuclear compartment. Stable HeLa clones 
expressing APE1WT, APE1K4pleA, or APE1K4pleR 
FLAG-tagged proteins were seeded on a glass 
coverslip, and PLA reaction was carried out 
using anti-FLAG and anti-NPM1 antibodies. 
4?,6-Diamidino-2-phenylindole staining is used as a 
reference for the nuclei. The histogram represents 
the average number of PLA blobs scored for at 
least 30 cells per slide. Asterisks represent a 
significant difference between APE1WT and 
mutants.
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rRNA molecules (Figure 2D) and that a partial removal of positive 
charges in the region 27–35 strongly affects the protein binding to 
rRNA molecules.
Interaction between APE1 and NPM1 may also occur in the nu-
cleoplasmic compartment of cells. We measured the effect of the 
K-to-A mutation on the nucleoplasmic interaction of APE1 with 
NPM1 through proximity ligation assay (PLA) analysis, which allows 
in situ detection of two proteins that are at interacting distance of 
<40 nm (Weibrecht et al., 2010). Data displayed in Figure 2E show 
that nucleoplasmic interaction between APE1 and NPM1 was sig-
nificantly affected by the K-to-A mutation. Taken together, these 
data demonstrate that charged lysines within the 27–35 region are 
essential for APE1 maintenance within the nucleoli and for a proper/
stable interaction of this protein with NPM1 or rRNA molecules. 
Moreover, our data suggest that APE1 must lose the positive charge 
at more than two K residues (among K27/K31/K32/K35) to get a signifi-
cant reduction of the APE1/NPM1 interaction in the nucleus and 
loss of APE1 nucleolar accumulation.
Loss of APE1 nucleolar accumulation causes impairment 
of cell proliferation
APE1 protects cells against genotoxic damaging agents (Tell and 
Wilson, 2010). To clarify the biological relevance of the APE1 nucle-
olar accumulation, we estimated the effect of the expression of the 
nucleolar-deficient form of APE1 (i.e., APE1K4pleA) on cell viability 
with respect to APE1WT and APE1K4pleR mutant. To test the effects of 
the mutant proteins and exclude the contribution of the endoge-
nous one, we used inducible APE1-silenced (through small interfer-
ing RNA [siRNA] technology) HeLa cells, which were reconstituted 
with siRNA-resistant APE1 ectopic proteins in place of the endog-
enous one (Figure 3A; Vascotto et al., 2009a). The levels of the ec-
topic proteins expressed by the different cell clones used for the 
following experiments were comparable to that of the wild-type 
endogenous one before silencing, as demonstrated by quantita-
tive Western blot analysis (Supplemental Figure S4); the extent of 
the residual endogenous protein was <10%. Quantification of the 
nuclear amount of ectopic proteins after doxycycline treatment, 
demonstrated by Western blot analysis with a calibration curve, 
gave the following results (expressed as nanograms of APE1 per 
microgram of nuclear extract): 23.22 ? 6.04 for APE1WT, 18.63 ? 
4.84 for APE1K4pleA, and 17.69 ?4.60 for APE1K4pleR (Supplemental 
Figure S4B). Therefore these cell lines represent a reliable system 
for testing our hypothesis. On the basis of previous data showing 
that nucleolar APE1 may act as a cleansing factor in rRNA quality 
control, possibly affecting cellular proliferation through an impair-
ment of the overall protein synthesis machinery (Vascotto et al., 
2009b; Tell et al., 2010b), we investigated the effect of the nucleo-
lar-deficient form APE1K4pleA on cell proliferation rate under basal 
conditions. Of interest, by cell counting assays performed on re-
constituted cell clones, we obtained proof that APE1K4pleA acts as a 
loss-of-function mutation in terms of cell proliferation, whereas 
APE1K4pleR behaves similarly to APE1WT (Figure 3B). These data, 
confirmed by using at least two different clones for each mutant 
cell line, suggest that nucleolar APE1 is required for appropriate 
control of cell proliferation, perhaps through its role in rRNA me-
tabolism (Tell et al., 2010b). Colony formation assays confirmed cell 
proliferation data (Figure 3C). However, although the cell number 
in each colony of APE1K4pleR-expressing cells was always similar to 
that expressing APE1WT, these cells grew in a more widespread 
manner, possibly due to an altered migrating phenotype and/or an 
intercellular adhesion pattern. These data were indicative that abo-
lition of the acetylatable residues of APE1 at K27/K31/K32/K35 may 
significantly affect cell biology, even though it is also possible that 
the lower expression level of the APE1K4pleR (?76%) with respect to 
APE1WT may also have an effect on this phenotype.
Increased APE1 acetylation at K27/K31/K32/K35 residues upon 
genotoxic damage
APE1 acetylation at K6/K7 is known to be enhanced after genotoxic 
insult by methyl methanesulfonate (MMS) and it has been shown to 
play a role in modulating APE1 interaction with XRCC1, possibly 
coordinating different enzymatic steps in the BER pathway 
(Yamamori et al., 2010). We therefore tested whether MMS treat-
ment, which promotes generation of DNA damage specifically re-
paired through BER, may also induce APE1 acetylation at K27/K31/
K32/K35 residues. Immunopurified APE1 samples from control and 
MMS-treated cells were separated by SDS–PAGE and excised 
bands and then analyzed by peptide mapping experiments. Semi-
quantitative nano–electrospray linear ion trap tandem mass spec-
trometry (nanoLC-ESI-LIT-MS/MS) analysis was performed on iden-
tical quantities of immunopurified APE1WT-FLAG protein samples 
obtained from HeLa cells before and after MMS treatment (Supple-
mental Figure S5). In particular, we evaluated the amount of the 
peptides (15–33)Ac3 and (15–35)Ac4 in each APE1 endoprotease 
AspN digest and compared them to that of the nonmodified coun-
terparts. Analysis was performed by extracting and integrating the 
corresponding nanoLC-ESI-LIT-MS peak areas equivalent to the as-
signed m/z values for the acetylated and nonacetylated peptides in 
the same total ion chromatogram. After MMS treatment, the amount 
of the peptide (15–33)Ac3 was significantly increased, and the pep-
tide (15–35)Ac4 was almost doubled as compared with that of the 
nonmodified counterparts (Figure 4A). The MMS-induced acetyla-
tion on the aforementioned residues was further demonstrated by 
Western blotting using a commercial anti–Ac-Lys antibody on im-
munopurified proteins from HeLa cells transiently transfected with 
the FLAG-tagged APE1WT and the nonacetylatable APE1K4pleR 
forms. It is striking that a significant increase of APE1 acetylation 
was observed after MMS treatment but mainly for APE1WT rather 
than for APE1K4pleR (Supplemental Figure S6). These data show that, 
besides increasing the acetylation status of K6/K7 (see later discus-
sion and Yamamori et al., 2010), MMS treatment also promotes 
acetylation at K27/K31/K32/K35 residues. The mild increase of Lys 
acetylation level in the mutant APE1K4pleR may possibly be ascribed 
to K6/K7 acetylation (see later discussion).
We then investigated the cellular distribution pattern of acety-
lated APE1 at K27/K31/K32/K35 residues by using an ad hoc–devel-
oped antibody that specifically recognized the peptide 25–38 fully 
acetylated at K27/K31/K32/K35, hereafter referred to as anti-APE1K27-35Ac 
(Poletto et al., 2012). This antibody was particularly efficient in rec-
ognizing acetylation at K35 with a measured affinity in the nanomolar 
range (196 nM for the tetra-acetylated stretch vs. 26,800 nM for 
the nonacetylated one, as assessed by surface plasmon resonance 
(SPR; Poletto et al., 2012). Preincubation of the antibody with the 
acetylated and nonacetylated peptides confirmed the specificity of 
the antibody (Poletto et al., 2012). The distribution pattern of 
APE1WT, APE1K4pleA, and APE1K4pleR was compared by using anti-
FLAG and anti-APE1K27-35Ac antibodies. Of interest, staining with the 
anti-APE1K27-35Ac antibody gave a pattern quite similar (i.e., nucleo-
lar exclusion) to that of the anti-FLAG antibody but only in the case 
of the APE1K4pleA mutant (Figure 4B). PLA was also carried out to 
demonstrate the in vivo occurrence of acetylation on endogenous 
APE1 by using either the anti-APE1K27-35Ac antibody alone (as a 
control) or together with an anti-APE1 antibody (Figure 4C). This 
assay clearly highlighted the proximity between the target of both 
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FIGURE 3: Expression of the nucleolus-deficient APE1 mutant causes impaired cell proliferation. (A) Generation of 
reconstituted cell lines expressing APE1K4pleA and APE1K4pleR mutants. HeLa cells were stably transfected with the 
inducible siRNA vectors and siRNA resistant APE1WT, APE1K4pleA, and APE1K4pleR–expressing vectors, as previously 
described (Vascotto et al., 2009a; Fantini et al., 2010). Expression of ectopic APE1 forms without silencing and after the 
suppression of endogenous APE1 expression after 10 d of treatment with doxycycline (Doxy) was assayed by Western 
blotting on total cellular extracts with an anti-APE1 antibody. Normalized expression levels for each clone of ectopic 
and endogenous APE1 protein after the silencing are indicated under each relative band. ?-Tubulin was used as loading 
control. (B) Cell proliferation assays for APE1-reconstituted cell lines. APE1-expressing cell clones were seeded in 
60-mm Petri dishes. Growth was followed by measuring cell numbers at various times upon doxycycline treatment, as 
indicated. Cells were harvested at the indicated times, stained with trypan blue, and counted in triplicate. Data, 
expressed as cell number, are the mean ? SD of three independent experiments. (C) Colony formation assays for 
APE1-reconstituted cell lines. After 8 d of doxycycline treatment, 200 cells of APE1WT and the indicated APE1 mutants 
were seeded in 60-mm Petri dishes and grown for 8 d in medium supplemented with doxycycline to promote 
endogenous APE1 silencing. Then cells were stained with crystal violet and images captured by using a Leica S8 
microscope with 80? magnification. Data, expressed as number of cells per colony, are the mean ? SD of 10 colonies for 
each clone.
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antibodies, further suggesting that, in vivo, 
APE1 is acetylated at K27/K31/K32/K35 resi-
dues and that these acetylated forms are 
excluded from the nucleoli. Taken together, 
these data suggest that acetylation at these 
charged amino acids may control the nucle-
olar/nucleoplasmic distribution of APE1 
within cells.
Removal of positively charged K27/K31/
K32/K35 residues increases APE1 
DNA-repair activity in vivo
We tested whether abolition of positive 
charges on acetylatable residues may affect 
the APE1 DNA repair function in cells, as 
previously demonstrated in vitro by using 
recombinant purified proteins bearing two 
different clusters of K-to-A mutation (i.e., on 
residues 24/25/27 and on residues 
24/25/27/31/32; Fantini et al., 2010). For 
this purpose we used nuclear extracts from 
reconstituted cell clones after precise nor-
malization for the APE1 ectopic nuclear con-
tent with a titration curve (as shown in Sup-
plemental Figure S4). This normalization for 
APE1 ectopic protein expression allowed 
comparison of the enzymatic activities of 
the different protein mutants in the nuclear 
fractions from each clone. Figure 5A shows 
that the AP-endonuclease activity of the 
APE1K4pleA mutant, measured through cleav-
age assays performed with nuclear extracts, 
was significantly increased with respect to 
APE1WT-and APE1K4pleR-expressing cells. 
Moreover, Figure 5B shows a lower amount 
of abasic DNA lesions accumulated after 
MMS treatment by the APE1K4pleA- as com-
pared with the APE1WT-expressing cells. 
These results suggest that removal of posi-
tive charges at Lys 27–35, as exerted by 
acetylation, may result in a more enzymati-
cally active protein.
FIGURE 4: Genotoxic treatment promotes APE1 acetylation at K27/K31/K32/K35 residues. 
(A) Relative quantitative changes of APE1 acetylation at K27/K31/K32/K35 after MMS treatment. 
Mass spectrometry analysis of acetylated peptides present in the endoprotease AspN digest of 
FLAG-tagged APE1 WT purified from HeLa cells (see Materials and Methods for details). 
Histograms indicate the relative amounts of the peptides (15–33)Ac3 and (15–35)Ac4 with respect 
to their nonmodified counterparts before and after MMS treatment. Identical ionization 
tendencies were assumed for each peptide pair. Each bar represents the mean of three 
independent experiments. (B) Acetylated APE1 at K27/K31/K32/K35 residues is present within cell 
nucleoplasm but is excluded from nucleoli. Confocal microscopy of HeLa cells transfected with 
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APE1WT, APE1K4pleA, or APE1K4pleR FLAG-
tagged proteins and stained with antibodies 
against endogenous APE1K27–35Ac (anti-
APE1K27–35Ac, red) and ectopic APE1 FLAG-
tagged (green). Overlap of staining (yellow) 
demonstrated the codetection of the two 
protein forms. Images are representative of 
100% of transfected cells. (C) APE1 
acetylation at K27/K31/K32/K35 occurs in vivo. 
PLA signal obtained using the anti-APE1K27–
35Ac antibody together with the anti-APE1 
antibody on fixed HeLa cells. A technical 
control, using the anti-APE1K27–35Ac antibody 
alone, was introduced (top). Nuclei were 
counterstained using an Alexa Fluor 
488–conjugated secondary anti-rabbit 
(recognizing the endogenous APE1K27–35Ac, in 
the control reaction) or anti-mouse antibody 
(recognizing the endogenous APE1 protein in 
the PLA reaction; green).
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FIGURE 5: Abolition of positively charges K27/K31/K32/K35 residues increases APE1 DNA-repair activity. (A) Nuclear 
extracts from APE1K4pleA mutant present an increased AP endonuclease activity on abasic DNA. AP-site incision activity 
of the nuclear extracts from HeLa-reconstituted cell clones was tested using an AP endonuclease activity assay as 
described in Material and Methods. The nuclear APE1 content in each clone was precisely quantified through a titration 
curve obtained using purified recombinant APE1 (Supplemental Figure S4). Nuclear ectopic APE1 protein levels were 
then normalized between the different cell clones in order to compare their relative enzymatic activities. Top left, 
concentration-dependent conversion of an AP site–containing DNA substrate (S) to the incised product (P). A 
representative image of the denaturing polyacrylamide gel of the enzymatic reactions is shown. The amounts 
(femtomoles) of APE1 used in the reaction and the percentage of substrate converted into product, as determined by 
standard phosphorimager analysis, are indicated. NE, no cell extract control. Bottom left, time-dependent kinetics of 
APE1 (2.15 ng) endonuclease activity from nuclear extracts of the different reconstituted cell clones. The image of a 
representative gel analysis is shown (bottom). Right, graph depicting the time-course kinetics of APE1 from incision 
results shown on the left. Average values are plotted ? SD of three independent experiments. Asterisks represent a 
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amino acids during MMS treatment is unknown. We thus checked 
whether the charged status of K27/K31/K32/K35 residues might play 
a role in modulating the acetylation status of K6/K7 through the 
contribution of SIRT1. First, we evaluated the effect of the modifi-
cation at K27/K31/K32/K35 on the ability of SIRT1 to deacetylate K6/
K7 in APE1. We found that recombinant purified APE1 protein is 
nonenzymatically acetylated after incubation with acetyl-CoA, as 
demonstrated for other proteins (Garbutt and Abraham, 1981). 
Thus, to obtain a significant amount of acetylated recombinant 
APE1 protein on K6/K7 residues, we treated purified recombinant 
rAPE1 obtained from E. coli with acetyl-CoA, as described in the 
Supplemental Information. Then we treated in vitro–acetylated 
rAPE1WT, rAPE1K4pleA, rAPE1K27/35A, or rAPE1K31/32A with purified re-
combinant SIRT1 protein and measured the acetylation level on 
K6/K7 through a specific antibody that recognizes only acetylation 
at these residues (Fantini et al., 2008; Sengupta et al., 2011). Of 
interest, although APE1WT was efficiently deacetylated by SIRT1 at 
K6/K7 (Figure 6A), the APE1K4pleA mutant did not show any deacety-
lation in this region; concomitant K-to-A substitutions at positions 
27 and 35 (APE1K27/35A mutant) or at positions 31 and 32 (APE1K31/32A 
mutant) caused an intermediate effect.
We then verified the ability of SIRT1 to directly deacetylate APE1 
at K27/K31/K32/K35 residues through in vitro deacetylation assays car-
ried out on acetylated purified recombinant rAPE1WT or mutant pro-
teins as substrates (Supplemental Figure S7). Protein acetylation 
level was monitored by using the anti-APE1K27-35Ac (Figure 6B). Incu-
bation with recombinant-purified SIRT1 protein revealed a marked 
decrease in acetyl-APE1 signal but only when APE1WT was used. 
These data were corroborated by qualitative peptide mapping ex-
periments on in vitro–acetylated rAPE1WT before and after incuba-
tion with SIRT1. This analysis demonstrated that SIRT1 was indeed 
able to deacetylate in vitro–acetylated rAPE1WT at least at K25/K27/
K32 residues (Supplemental Table S1).
The ability of SIRT1 to deacetylate in vitro APE1 at K27/K31/K32/K35 
was also analyzed on APE1 (25–38) peptides (Figure 6C), which were 
chemically synthesized either in their nonacetylated or tetra-acety-
lated form at these K residues. These peptides were used in a com-
petitive fluorescence-based assay in which a fluorogenic p53 acety-
lated peptide was used as SIRT1 substrate (Marcotte et al., 2004). 
As expected, we observed a dose-dependent decrease in the 
Cell viability experiments, after MMS treatment, were carried out 
to verify the enzymatic data. Thus, the effect of K27/K31/K32/K35 mu-
tation on cell viability after MMS treatment was measured by 
3-(4-5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium salt (MTS) and clonogenic assays using the 
reconstituted cell clones. The MTS data (Figure 5C) showed that the 
APE1K4pleA-mutant–expressing cells were significantly more resistant 
to MMS treatment than those expressing the nonacetylatable 
APE1K4pleR mutant. Of note, clonogenic assay experiments (Figure 
5D) confirmed these results and highlighted the relevant acetylation 
occurring at the K residues, as demonstrated by the higher sensitiv-
ity of APE1K4pleR-expressing cells after MMS treatment. We extended 
our observations on the protective function of the APE1K4pleA mutant 
by using tert-butyl-hydroperoxide (TBHP) as a reactive oxygen spe-
cies (ROS) generator (Lazzé et al., 2003). We recently demonstrated 
that APE1 knockdown sensitizes HeLa cells to TBHP treatment (Li 
et al., 2012). Therefore we now measured the sensitivity of the differ-
ent reconstituted cell clones to TBHP in a dose–response experi-
ment (Figure 5E). As in the case of MMS treatment, expression of the 
APE1K4pleA mutant exerted a protective function with regard to TBHP 
treatment with respect to APE1WT-expressing cells. Similarly to MMS 
treatment, the APE1K4pleR-mutant–expressing clone evidenced even 
more sensitivity than the APE1WT-expressing one. Taken together, 
these data show that acetylation at residues K27/K31/K32/K35 is asso-
ciated with cell response to DNA damage and confers protection to 
genotoxic treatment. The increased activity of the APE1K4pleA mutant 
may explain its proficient protective effect in vivo against genotoxic 
treatment, even though further explanatory mechanisms, such as its 
altered protein association in the cell or its possible higher stability 
(Vascotto et al., 2011), could also be invoked.
K6/K7 deacetylation by SIRT1 is modulated by the charged 
status of K27/K31/K32/K35residues
It was recently demonstrated that APE1 K6/K7 may undergo acety-
lation during cell response to genotoxic treatment (Fantini et al., 
2008; Yamamori et al., 2010) and that modulation of the acetyla-
tion status of these residues through SIRT1 deacetylase activity is 
important for the regulation of APE1 DNA-repair function after 
MMS treatment (Yamamori et al., 2010). However, the molecular 
mechanism regulating the SIRT1-mediated modification at these 
significant difference between APE1WT and APE1K4pleA. (B) Accumulation of genomic abasic (AP) lesions after MMS 
treatment (0.5 mM, 4 h) of reconstituted cell clones with APE1WT and APE1K4pleA mutant as measured by an aldehyde-
reactive probe. APE1WT and APE1K4pleA-expressing HeLa cells were grown in medium supplemented with Doxy (10 d) to 
silence endogenous APE1 expression and were treated with 0.5 mM MMS for 4 h. Counting at the AP sites was 
performed by using the AP-site quantification kit, as described in Materials and Methods. In the histogram, data are 
expressed as number of AP sites per 105 base pairs and represent the mean ? SD of four independent experiments. 
Asterisks represent a significant difference between the two conditions (untreated and MMS-treated cells). (C) Effects of 
APE1 acetylation mutants on cell viability after MMS treatment in reconstituted cells. APE1WT, APE1K4pleA-, and 
APE1K4pleR-expressing cells were grown in medium supplemented with Doxy to silence APE1 endogenous protein and 
treated with increasing concentrations of MMS for 8 h; the cytotoxic effect of this compound was determined by the 
MTS assay (see Materials and Methods for details). Each point, shown as percentage viability with respect to untreated 
clones, represents the mean ? SD of four observations, repeated in at least two independent assays. Asterisks represent 
a significant difference between APE1K4pleA and APE1K4pleR mutants. (D) Cell growth as measured by colony survival 
assay. One thousand cells of APE1WT-, APE1K4pleA-, and APE1K4pleR-expressing clones treated with increasing 
concentrations of MMS for 8 h were seeded in Petri dishes and then treated with Doxy for 10 d to silence endogenous 
APE1. Data, expressed as the percentage of change with respect to untreated clones, are the mean ? SD of three 
independent experiments. (E) Effects of APE1 acetylation mutants on cell viability after TBHP treatment in APE1WT-, 
APE1K4pleA-, and APE1K4pleR-expressing cells grown in medium supplemented with Doxy to silence APE1 endogenous 
protein. Cells were treated with increasing concentrations of TBHP for 6 h, and the cytotoxic effects were determined 
by the MTS assay. Each point, shown as percentage viability with respect to untreated clones, represents the mean ? SD 
of four observations, repeated in at least two independent assays. Asterisks represent a significant difference between 
APE1K4pleA and APE1K4pleR mutants.
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FIGURE 6: SIRT1 deacetylase activity on K6/K7 depends on the charged status of K27/K31/K32/K35 residues. (A) K6/K7 
acetylation, modulated by SIRT1, depends on the charged status of K27/K31/K32/K35 residues. Western blot analysis on 
purified recombinant APE1 proteins in vitro acetylated with acetyl-CoA and then incubated in the presence/absence of 
recombinant GST-SIRT1, as indicated. The analysis was carried out using an antibody specific for acetylated K6/K7 APE1 
(top). The histogram reports data obtained from densitometric quantification of the bands for each APE1 protein after 
normalization on Ponceau S staining (bottom). Data shown are the mean of two independent experimental sets whose 
variation was <10%. (B) SIRT1 deacetylates rAPE1 at K27/K31/K32/K35. Left, Western blot analysis on the in vitro–
acetylated and deacetylated purified recombinant APE1, further subjected to MS analysis (Supplemental Table S1). 
rAPE1WT was incubated with 0.5 mM acetyl-CoA and then with recombinant SIRT1 protein, as shown. Samples were 
separated onto 10% SDS–PAGE, and Western blot analysis was performed by using the anti-APE1K27-35Ac antibody. 
Ponceau S staining was used as loading control. Right, the histogram shows the densitometric quantification of the 
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could be responsible for APE1 subnuclear trafficking. Thus, we 
examined the subnuclear distribution of SIRT1 on c-myc-SIRT1–
transfected cells through immunofluorescence analysis. We found 
that transiently transfected c-myc-SIRT1 mainly localized in the nu-
cleoplasmic compartment and was not found in the nucleoli (Figure 
8A, left); quantification of the endogenous SIRT1 protein in bio-
chemically purified nucleoli confirmed its absence from this subnu-
clear compartment (Figure 8A, right). Evaluation of the acetylation 
status of APE1 present in nucleolar or nucleoplasmic fractions under 
basal conditions showed that APE1 acetylated at K6/K7 is mainly 
present within the nucleoplasm but almost absent in the nucleolus 
(Figure 8B). Of note, these findings may have important implications 
for SIRT1-mediated deacetylation at K6/K7 and demonstrate the 
possibility that APE1 acetylation modulates the protein’s subnuclear 
distribution and enzymatic functions, corroborating our previous 
work (Fantini et al., 2010).
It is known that Lys acetylation may control local conformational 
stability of proteins, thus affecting their activity, subcellular distribu-
tion, and protein–protein interaction network. To examine the effect 
of acetylation on the local structure of the N-terminal APE1 region, 
we analyzed the conformational behavior of the protein portion of 
residues 14–38, which contain K27/K31/K32/K35 residues acetylatable 
in vivo. To this end, we chemically synthesized and purified four 
peptides bearing differential acetylation at positions 27, 31, 32, and 
35 (Supplemental Table S2). To evaluate the effect of acetylation on 
peptide conformation, we undertook structural analysis of these 
peptides in solution by far-ultraviolet (UV) circular dichroism (CD) 
and nuclear magnetic resonance (NMR) spectroscopy. Figure 8C 
shows the overlay of CD spectra of APE1(14–38) and APE1(14–
38)K27/31/32/35Ac in aqueous buffer, indicating a minimum at ?200 nm 
and a shoulder at ?220 nm. These features suggest the presence of 
mixed conformational states in which an unfolded state coexists 
with a certain helical content. The propensity of this domain to 
adopt helical conformation was also confirmed by trifluoroethanol 
(TFE) titration experiments (Supplemental Figure S8A). In particular, 
the CD spectrum of the tetra-acetylated peptide showed a mini-
mum at 220 nm that was deeper than that of the nonacetylated 
counterpart, suggesting a role for the acetyl groups in determining 
structural changes in this protein region. An intermediate behavior 
was observed for the monoacetylated and triacetylated peptides, 
confirming the role of this K modification in modulating the confor-
mation of the N-terminal APE1 region (unpublished data).
To further address this point, we carried out additional NMR ex-
periments. In aqueous buffer, the one-dimensional (1D) spectra pre-
sented poor signal dispersion (Figure 8D, left), confirming a rather 
disordered state for both the tetra-acetylated and nonacetylated 
peptides. This observation was further strengthened by the analysis 
of two-dimensional (2D) [1H, 1H] total correlation spectroscopy 
(TOCSY) spectra (Griesinger et al., 1988; Figure 8D, middle), and 2D 
[1H, 1H] rotating frame nuclear Overhauser effect spectroscopy 
(ROESY) spectra (Bax and Davis, 1985; Figure 8D, right). In the latter 
case, the presence of a restricted set of cross-peaks in the NH-aliphatic 
side-chain proton correlation region made unfeasible the process of 
sequential resonance assignments, as often occurs for small, flexible 
fluorescence signal by using different amounts of the tetra-acety-
lated peptide (25–38); the nonacetylated counterpart was used as 
a negative control substrate. Best data fitting was observed with a 
one-site competition equation, which provided an IC50 value of 
4.6 ? 0.3 μM. These data support the conclusion that the acety-
lated APE1 region spanning amino acids 27–35 is a substrate for 
SIRT1 deacetylase activity. Taken together, these results demon-
strate that SIRT1’s ability to efficiently deacetylate APE1 at K6/K7 
residues relies on the presence of positive charges at K27/K31/K32/
K35. Moreover, SIRT1 is also able to bind and possibly deacetylate 
in vitro–acetylated APE1 K27/K31/K32/K35 residues.
Cross-talk between the charged state of K27/K31/K32/K35 and 
the acetylation status of K6/K7 residues through SIRT1
To understand whether SIRT1 activity on acetylated K6/K7 residues 
might be modulated in vivo by MMS as a function of the charged 
status of K27/K31/K32/K35, we performed coimmunoprecipitation 
experiments on transiently transfected HeLa cells. As shown in 
Figure 7A, an intact N-terminal domain is required for stable APE1 
binding to SIRT1. The APE1/SIRT1 association was induced after 
MMS treatment and was abolished in the case of both APE1N?33 
and APE1K4pleA mutants. Substitution of K27/K31/K32/K35 residues 
with nonacetylatable R residues was ineffective, suggesting that 
SIRT1 binding depends on the presence of positively charged 
amino acids spanning the APE1 region 27–35. Measurements of 
K6/K7 acetylation status with the specific antibody (performed on 
the same samples) clearly showed that, in agreement with the 
binding data, K6/K7 residues resulted in more acetylation both un-
der basal and after MMS treatment but only in the case of the 
APE1K4pleA mutant. In addition, the acetylation status of APE1WT 
and APE1K4pleR, both under basal conditions and after MMS treat-
ment, was comparable (Figure 7B), supporting the existence of 
cross-talk between the charged status of K27/K31/K32/K35 and the 
acetylation level of K6/K7.
We then investigated the cross-talk between K6/K7 and K27/K31/
K32/K35 acetylation status through siRNA experiments. HeLa cell lines 
stably expressing both endogenous APE1 and APE1WT, APE1K4pleA, 
and APE1K4pleR ectopic forms were silenced for SIRT1 expression as 
described in Materials and Methods. The acetylation level of K6/K7 
was then measured through Western blotting. Data shown in Figure 
7C demonstrate that the K6/K7 acetylation level of the ectopic APE1 
forms was increased ?30–40% upon SIRT1 silencing but only in the 
case of APE1WT- and APE1K4pleR-expressing cells, whereas acetylation 
of K6/K7 of APE1K4pleA was <10%. As a control, the acetylation level 
of endogenous APE1 always increased (?60–70%) upon SIRT1 si-
lencing in all the cell lines tested (unpublished data). Taken together, 
these data demonstrate that the acetylation/charged status of K27/
K31/K32/K35 residues controls the stability of the SIRT1/APE1 com-
plex, thus playing a role in the acetylation level of K6/K7.
Possible relevance of acetylation for APE1 subnuclear 
distribution and protein local conformation
The data suggest that a coordinated acetylation/deacetylation dy-
namic modulated by SIRT1 may occur within the cell nucleus and 
band intensities, after normalization to the nonacetylated APE1 form, of the in vitro–acetylated and deacetylated 
purified APE1 mutants. Data are the mean ? SD of three independent replicates. Asterisks represent a significant 
difference. (C) The acetylated APE1 25–38 peptide is a substrate of SIRT1 activity. Purified APE1 peptides (25–38) either 
in fully acetylated form at K27/K31/K32/K35 residues or not acetylated were analyzed as competitors in an in vitro 
deacetylase SIRT1 assay based on a fluorogenic acetylated peptide derived from p53 (region 379–382). Dose–response 
signals allowed an estimated IC50 value of 4.6 ? 0.3 μM of the acetylated APE1 25–38 region with respect to the p53 
peptide.
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FIGURE 7: Cross-talk between the acetylation status of K27/K31/K32/K35 and K6/K7 residues through SIRT1. 
(A) Positive charges at K27/K31/K32/K35 residues strongly influence the stability of SIRT1 binding to APE1. Western 
blot analysis performed on total cell extracts (left) and on immunoprecipitated material (right) from HeLa cells 
cotransfected with c-myc–tagged SIRT1 and APE1WT, APE1N?33, APE1K4pleA, or APE1K4pleR FLAG-tagged proteins and 
treated with 0.5 mM MMS for 8 h. Coimmunoprecipitated amounts of SIRT1 normalized with respect to APE1WT or 
APE1K4pleR, respectively, are indicated under each relative bar. Ponceau S staining was used as loading control. 
(B) Acetylation level of K6/K7 in APE1K4pleA mutant is higher than that of APE1WT both under basal conditions and 
after MMS treatment. Western blot analysis on CoIP material after MMS treatment from HeLa cells transfected with 
APE1WT and FLAG-tagged mutants is shown. The histogram indicates the relative amount of acetylated APE1K6/K7 in 
the different clones obtained from the densitometric quantification of acetylated APE1 bands, normalized with 
respect to the amount of APE1 FLAG-tagged immunopurified protein. Data shown are the mean of two 
independent experimental sets whose variation was <10%. (C) SIRT1 siRNA knockdown increases APE1 K6/K7 
acetylation. HeLa stable clones expressing APE1WT, APE1K4pleA, and APE1K4pleR were transfected with siRNA against 
SIRT1 protein or control siRNA. Western blot analysis was performed to detect differential amount of the 
acetylated K6/K7 APE1 after SIRT1 silencing. Arrows highlight bands of ectopic APE1 protein form; ?-tubulin was 
used as a loading control. The histogram shows densitometric quantification of acetylated K6/K7 APE1 form. Data 
are expressed as percentage of induction of the acetylated K6/K7 APE1 after SIRT1 silencing after normalization 
for the total APE1 protein levels. Data shown are the mean of two independent experimental sets whose variation 
was <10%.
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to our previous data obtained in vitro with recombinant purified pro-
teins (Fantini et al., 2010). In many cases, the presence of the unstruc-
tured N-terminal domain of APE1 seemed essential for interaction of 
APE1 with different substrates (i.e., nucleic acids or proteins). Interac-
tion also increased after histone deacetylase (HDAC) inhibition, 
which promotes APE1 acetylation at K6/K7 residues (Bhakat et al., 
2003; Yamamori et al., 2010). This evidence strongly support the no-
tion that this unstructured domain is responsible for the modulation 
of APE1’s different functions through the recruitment of APE1 in dif-
ferent protein complexes by means of various amino acid side-chain 
modification events. From an evolutionary perspective, it can be hy-
pothesized that mammalian APE1 activity was made adjustable 
(through PTMs and/or interaction with other proteins), or expanded 
toward other substrates, with the acquisition of a protein N-terminus 
containing positively charged residues, without major modifications 
on the enzyme catalytic site, which retained the “canonical” function 
toward abasic DNA. The existence of such an N-terminal extension 
in only mammals may suggest its evolutionary significance in the 
face of increased functional complexity. For the noncomplexed pro-
tein in solution, the intrinsic lack of a secondary structure associated 
with this domain can confer functional advantages to mammalian 
APE1, including the ability to bind to different protein targets (e.g., 
NPM1, XRCC1, CSB, RNA, etc.; Vidal et al., 2001; Wong et al., 2007; 
Vascotto et al., 2009a; Tell et al., 2010a), thus allowing efficient con-
trol over the thermodynamics in the binding process to different sub-
strates. Because the protein’s N-terminus is required for the stabiliza-
tion of APE1 interaction with NPM1 or rRNA and for the control of 
the overall endonuclease activity (possibly decreasing the rate of 
product release once in the positively charged state; Fantini et al., 
2010; Figure 5), this region-specific multitasking function can provide 
a “trigger” for molecular regulation with important biological signifi-
cance. This should be regarded, however, in light of BER coordina-
tion to prevent formation of harmful, unprotected DNA strand 
breaks. Therefore subcellular distribution of APE1 and its enzymatic 
activity seem to be finely tuned to demand and in a time-dependent 
manner through multiple interactions with various protein partners 
and the coordinated occurrence of different PTMs, such as acetyla-
tion and ubiquitination (Busso et al., 2009, 2011). The observation 
that acetylation at K27/K31/K32/K35 residues may favor a transition to-
ward a more organized conformation (Supplemental Figure S8) 
would support the notion that this modification may significantly 
modulate the interaction with several protein partners on a structural 
basis. In addition, acetylation at the mentioned K residues may pro-
foundly affect APE1 protein stability, based on a recent report show-
ing that the same K residues can be also polyubiquitinated by UBR3, 
targeting the protein for degradation by the proteasome (Meisenberg 
et al., 2011). Given that acetylation competes with ubiquitination for 
the same K residues, it may represent the switch for controlling pro-
tein turnover rate. In this context, the acetylation at these residues 
that we observed during cell response to genotoxicants may stabilize 
protein half-life, thus preventing its degradation.
Few studies have reported on the effect of acetylation on the 
structure of small, ordered (Hughes and Waters, 2006; Liu and Duan, 
2008) and disordered (Smet-Nocca et al., 2010) peptides. Molecular 
dynamic simulations carried out on a peptide from the histone H3 
N-terminal tail in the nonacetylated and doubly acetylated forms 
revealed that acetylation, although not appreciably disturbing the 
overall structure of the most-populated states, influenced peptide 
stability (Liu and Duan, 2008). The effect of acetylation at K residues 
on the conformational properties of small random-coil peptides 
from the histone H4 N-terminal tail and from nonhistone thymine 
DNA glycosylase indicated that acetylation had little effect on the 
peptides that tumble very rapidly in solution. On the other hand, a 
detailed comparison of the 1D NMR data for the nonacetylated and 
tetra-acetylated APE1 peptides (Figure 8D, left) indicated that acety-
lation causes a small but clear improvement of spectral dispersion, 
which can be particularly appreciated in the NH region (Figure 8D, 
top left). Moreover, the intensity of ROE cross-peaks is increased in 
the spectra of APE1(14-38)K27/31/32/35Ac peptide as compared with the 
nonmodified counterpart (Figure 8D, right). This evidence, together 
with small chemical shift changes, point toward the presence of more 
organized conformations for the tetra-acetylated peptide in aqueous 
solution, in agreement with CD data. Similar conclusions are drawn 
from the analysis of NMR data for APE1(14–38) and APE1(14–
38)K27/31/32/35Ac peptides in phosphate:TFE solution (Supplemental 
Figure S8B), which suggested again the higher propensity of this 
domain in its acetylated form to adopt a more ordered conformation 
in contrast to the nonmodified counterpart. Also in this case, 
monoacetylated and triacetylated peptides showed an intermediate 
behavior (unpublished data). These data suggest that acetylation 
may account for local conformational changes on APE1 structure that 
may modulate its binding ability to different substrates.
DISCUSSION
APE1 is an unusually abundant DNA-repair protein in mammalian 
cells, with a wide nuclear distribution and an essential role in the 
BER pathway of DNA lesions (Tell and Wilson, 2010). We calculated 
that HeLa cells express ?4 ? 107 molecules per cell (Supplemental 
Figure S4A), whereas other enzymes of the BER pathway, such as Pol 
? or XRCC1, are present at an extent of <1/10 (Demple and DeMott, 
2002; Parsons et al., 2008). Therefore APE1 involvement in pre-
formed DNA-repair complexes may only partially explain the energy 
cost used to maintain such high protein concentration within the 
cells. Recently we found that APE1 may interact with rRNA and with 
proteins involved in RNA metabolism and is associated with nucleo-
lar structures through its interaction with NPM1 (Vascotto et al., 
2009b; Tell et al., 2010b). Interaction with rRNA and NPM1 strictly 
depends on the positive charge of K residues within the APE1 region 
24–35 placed within the unstructured protein N-terminal domain, as 
demonstrated by the inability of the corresponding K-to-A mutants 
(resembling constitutive acetylation at these residues) to stably bind 
both rRNA and NPM1 (Fantini et al., 2010). Of interest, some of 
these amino acids (i.e., K27/K31/K32/K35), which have been acquired 
during evolution, may undergo in vivo acetylation (Fantini et al., 
2010). We conjectured that, under physiological conditions, non-
acetylated APE1 may be stored in the nucleolar compartment 
through its binding to NPM1 and rRNA, but the in vivo relevance of 
APE1 nucleolar accumulation was still unclear. This study was aimed 
at addressing this issue.
We also found that APE1K4pleA binds poorly to NPM1 and rRNA in 
vivo and as a result is unable to accumulate within the nucleoli, 
whereas it is present in the nucleoplasm. Moreover, reconstitution of 
HeLa cells with this mutant gave improved protection from geno-
toxic damage induced by alkylating agents, such as MMS, and oxida-
tive stress-generating compounds, such as TBHP, through increased 
DNA-repair activity. As expected for a regulated pheno menon such 
as the response to a genome insult, an in vivo–augmented acetyla-
tion at K27/K31/K32/K35 residues was observed during cell response to 
genotoxic damage. Furthermore, cross-talk involving the SIRT1 
deacetylase occurred within cells between acetylation at K27/K31/K32/
K35 and at K6/K7 residues. Therefore we hypothesized that genotoxic 
stress may shift the equilibrium between the nonacetylated and 
acetylated APE1 forms toward the latter, which would result in the 
most enzymatically active one on abasic DNA. This also corresponds 
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FIGURE 8: Nucleolar APE1 hypoacetylated on K6/K7 and conformational impact of acetylation at K27/K31/K32/K35 on 
APE1 local structure. (A) SIRT1 resides within the nucleoplasm of HeLa cells. Left, confocal microscopy of HeLa cells 
cotransfected with green fluorescent protein–fused APE1 (APE1GFP) and c-myc-SIRT1 after fixing and staining with 
antibodies against NPM1 (red) and c-myc-SIRT1 (top, green; bottom, red). SIRT1, clearly excluded from nucleoli, 
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This is also underway in our laboratory. Of note, data obtained in 
this work not only show that nucleoli may act as a storage site so that 
an appropriate amount of APE1 is readily available for maintenance 
of genome stability, but also emphasize that nucleolar accumulation 
of APE1 controls cell proliferation, possibly through its rRNA cleans-
ing function. Compatible with this, APE1K4pleA-expressing cells, un-
der basal conditions, showed impairment in proliferation rate with 
respect to APEWT-expressing ones (Figure 3). Therefore it can be 
speculated that nucleolar APE1 is responsible for functional activity 
of the nucleolus in ribosome biogenesis. APE1 release from the nu-
cleoli after genotoxic treatment may constitute a signal to block ac-
tive protein synthesis and allow activation of the proper DNA-repair 
mechanisms. Experiments are in progress along these lines to ad-
dress this in light of the possibility that acetylation may control the 
APE1 trafficking from nucleoli to nucleoplasm.
In conclusion, our data shed light on novel molecular aspects 
highlighting the multifunctional nature of APE1 in regulating differ-
ent biological outcomes and point to acetylation as an important 
mechanism for the fine-tuning of protein functions, subcellular dis-
tribution, and stability. They also emphasize the need for additional 
investigation of the APE1 N-terminal domain in order to understand 
the structural details of the regulatory mechanisms for this multi-
functional protein. In addition, recent evidence on APE1 acetylation 
pattern in triple-negative breast cancer reveals that, concomitantly 
with total APE1 overexpression, a profound deregulation of APE1 
acetylation status occurs under pathological conditions (Poletto 
et al., 2012). This underscores the biological relevance of our find-
ings and the need for future investigation.
MATERIALS AND METHODS
Inducible APE1 knockdown and generation of APE1 
knock-in cell lines
Inducible silencing of endogenous APE1 and reconstitution with 
mutant proteins in HeLa cell clones was performed as described 
(Vascotto et al., 2009a,b) and as reported in the Supplemental 
Information. For inducible shRNA experiments, doxycycline (1 μg/ml; 
Sigma-Aldrich, St. Louis, MO) was added to the cell culture medium, 
and cells were grown for 10 d. All biological data were reproduced 
in at least two different cell clones for each model.
Cell culture and transient transfection with plasmids 
or siRNA knockdown
HeLa cells were grown in DMEM (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (EuroClone, Milan, Italy), 
100 U/ml penicillin, and 100 μg/ml streptomycin sulfate. One day 
overall polypeptide structure, while inducing local conformational 
changes (Smet-Nocca et al., 2010). In agreement with these studies, 
APE1(14–38) and APE1(14–38)K27/31/32/35Ac became disordered, as 
shown by the lack of ROE (Bax and Davis, 1985) cross-peak patterns, 
which are characteristic of ordered secondary structure elements. 
However, small differences in the NMR spectra (Figure 8 and Sup-
plemental Figure S8), concerning both chemical shift values and 
signal intensities, seem to indicate that at least local conformational 
changes may occur following acetylation. We cannot ignore that 
these changes may be important for the interaction of APE1 with 
SIRT1 deacetylase and with NPM1; they highlight the role that the 
charged status of K residues within this region may play at the pro-
tein structural level. Based on our data, it can be speculated that full 
acetylation of K27–35 may reduce SIRT1 binding to APE1, thus delay-
ing its enzymatic activity on K6/K7. This mechanism could represent 
a way to coordinate the kinetics of the overall acetylation status of 
the protein. According to this hypothesis, SIRT1 should first deacety-
late K27–35Ac before deacetylating K6/K7Ac. Our ability to identify 
APE1 peptides with varying amounts of acetylation on K27–35 sup-
ports the existence of a dynamic equilibrium between multiple 
acetylated forms of the protein within cells and thus its functional 
regulatory role. Moreover, the presence of SIRT1, found exclusively 
in the nucleoplasm but not in the nucleoli (similar to the APE1 acety-
lated on K27–35 and the reduced nucleolar presence of APE1 acety-
lated on K6/K7; Figure 8, A and B), suggests that acetylation of APE1 
may force its exit from nucleoli to nucleoplasm, where it can be 
deacetylated by SIRT1. This model is further supported by the sig-
nificantly reduced interaction of AcAPE1K27-35 with NPM1 (Figure 2). 
Further studies to identify the acetyltransferase able to acetylate 
APE1 within the nucleoli are in progress. Furthermore, this work sup-
ports findings by Yu et al. (2010), who demonstrated that these K 
residue conformational adjustments were concomitant with DNA 
binding and catalysis or with interaction with Pol ?.
The nucleolar role of APE1 storage and regulation, as described 
here, may have profound biological consequences during cell re-
sponse to stressor signals, especially in light of recent evidence 
pointing to the nucleolus as a central hub in DNA damage 
(Nalabothula et al., 2010). Accordingly, the nucleolus seems respon-
sible for actively transmitting signals to the molecular complex regu-
lating p53 activity mediated by ARF–NPM1 interaction (Colombo 
et al., 2002; Lee et al., 2005; Nalabothula et al., 2010), and thus it is 
involved in the maintenance of genome stability. A careful elucida-
tion of the NPM1-ARF-p53 signaling networks and their involve-
ment in the DNA-repair pathway coordinated by APE1 is an impor-
tant subject for molecular carcinogenesis and deserves further study. 
colocalizes with APE1 in the nucleoplasm. The inner part of nucleoli, marked in the granular zone by NPM1, is negative 
for SIRT1. Right, biochemical isolation of nucleoli confirms that SIRT1 localizes in the nucleoplasmic fraction and it is 
excluded from nucleoli, where nucleolin, NPM1, and APE1 reside (see Materials and Methods for details). Nucleolin was 
used as a positive control for nuclear and nucleolar compartment. (B) Acetylated K6/K7-containing APE1 is enriched 
within the nucleoplasmic compartment with respect to nucleoli. After normalization for total APE1 protein amount, the 
levels of acetylated APE1 in nucleolar and nucleoplasmic fractions were analyzed through Western blotting. APE1 
acetylated at K6/K7 residues is predominately present within the nucleoplasmic fraction, whereas it is reduced in the 
nucleolar fraction. The histogram indicates the relative percentage amount of acetylated APE1 obtained from the 
densitometric quantification of acetylated APE1 bands normalized with respect to the amount of total APE1 in each 
fraction. Each bar represents the mean of two independent experiments whose variation was <10%. (C) CD spectra of 
the APE1(14–38) and APE1(14–38)K27/31/32/35Ac peptides in 10 mM phosphate buffer, pH 7. (D) Comparison of 1D (left), 
2D [1H, 1H] TOCSY (middle), and 2D [1H, 1H] ROESY (right) spectra of APE1(14–38) and APE1(14–38)K27/31/32/35Ac peptides 
in 10 mM phosphate buffer, pH 7.0. Two different expansions of the proton 1D spectrum are shown; the region 
between 0.8 and 2.4 ppm, in the lower inset, contains signals from side-chain protons. Acetyl methyl groups originate a 
peak around 2 ppm, which can be clearly seen in the spectrum of the acetylated peptide; peaks of backbone and 
side-chain NH atoms appear between 7.0 and 8.8 ppm in the upper inset. For 2D [1H, 1H] TOCSY and 2D [1H, 1H] ROESY 
experiments the HN-aliphatic protons correlation region of the spectra are reported.
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ing the ECL enhanced chemiluminescence procedure (GE Health-
care Piscataway, NJ) or Western Lightning Ultra (PerkinElmer, 
Waltham, MA). Normalization was performed by using a monoclonal 
anti-tubulin antibody (Sigma-Aldrich). Blots were quantified by using 
a Chemidoc XRS video densitometer (Bio-Rad, Hercules, CA).
Plasmids and expression of recombinant proteins
Expression and purification of recombinant proteins from E. coli 
were performed as previously described (Vascotto et al., 2009b; 
Fantini et al., 2010). Where recombinant proteins were used for in 
vitro assays, the acronym rAPE1 is used.
GST pull-down assay
A 150-pmol amount of either GST-tagged rAPE1WT or mutant pro-
teins was added to 15 μl of glutathione–Sepharose 4B beads (GE 
Healthcare), together with equimolar amounts of recombinant 
NPM1. Binding was performed in PBS, supplemented with 1 mM 
dithiothreitol (DTT) and 0.5 mM phenylmethylsulfonyl fluoride 
(PMSF) for 2 h, under rotation, at 4°C. Beads were washed three 
times with PBS, supplemented with 0.1% (vol/vol) Igepal CA-630 
(Sigma-Aldrich), 1 mM DTT, and 0.5 mM PMSF and resuspended in 
Laemmli sample buffer for Western blot analysis.
DNA–RNA ChIP assays
DNA–RNA ChIP assays were carried out by using a modified version 
of a protocol described earlier (Gilbert et al., 2000) and as detailed 
in the Supplemental Information.
Enzymatic fluorescence assays
To examine in vitro deacetylase activity on the acetylated APE1 re-
gion 25–38, we used the SIRT Fluorescent Activity Assay Kit (Biomol, 
Plymouth, PA). Optimizing manufacturer’s instructions, we used 
white plates (OPTI PLATE; PerkinElmer) with 384 wells at reduced 
volume (total reaction volume, 20 μl). Purified peptides were incu-
bated in 25 mM Tris-HCl, pH 8.0, 2.7 mM KCl, 137 mM NaCl, 1 mM 
MgCl2, and 1 mg/ml bovine serum albumin containing the enzyme 
(0.04 U/μl) and 25 μM Fluor de Lys-p53 peptide substrate (Arg-His-Lys-
Lys [Ac], from region 379–382 of human p53) in the presence/
absence of 250 μM NAD+ for 30 min at 37°C. Deacetylase activity 
was measured in arbitrary fluorescence units at 460 nm. Dose–
response experiments were carried out by using a 0–500 μM range 
of peptide concentration. Data fitting was performed using the 
GraphPad Prism 4 software, version 4.02 (GraphPad, La Jolla, CA). 
Data were in triplicate/duplicate from three independent assays.
Immunofluorescence confocal and proximity ligation 
analyses
Immunofluorescence procedures and PLA were carried out as de-
scribed earlier (Vascotto et al., 2009b, 2011). To study the interaction 
between APE1 and NPM1 in vivo, we used the in situ Proximity 
Ligation Assay technology (Olink Bioscience, Uppsala, Sweden). 
After incubation with monoclonal anti-APE1 (1:50) or anti-FLAG anti-
body (1:200) for 3 h at 37°C, cells were incubated with polyclonal 
anti-NPM1 (1:200) overnight at 4°C. PLA was performed following 
manufacturer’s instructions. Technical controls, represented by the 
omission of anti-NPM1 primary antibody, resulted in the complete 
loss of PLA signal. Cells were visualized through a Leica TCS SP laser-
scanning confocal microscope (Leica Microsystems, Wetzlar, 
Germany). Determination of PLA signals was performed using 
BlobFinder software (Center for Image Analysis, Uppsala University, 
Uppsala, Sweden). PLA technology was also used to detect acety-
lated APE1 at K27/K31/K32/K35 residues. Cells were incubated with the 
before transfection, cells were seeded in 10-cm plates at a density 
of 3.0 ? 106 cells/plate. Cells were then transiently transfected 
with the indicated plasmids using the Lipofectamine 2000 reagent 
(Invitrogen), according to the manufacturer’s instructions. Cells were 
harvested either 24 or 48 h after transfection, as indicated.
For SIRT1-knockdown experiments, HeLa clones were trans-
fected with 150 nM siRNA siGENOME SMART pool or negative 
control siRNA 5?-CCAUGAGGUCAUGGUCUGdTdT-3? (Dharmacon, 
Lafayette, CO), using Oligofectamine (Invitrogen). After 72 h the 
cells were harvested.
Preparation of total cell extracts and anti-FLAG 
coimmunoprecipitation
Preparation of total cell lysates and coimmunoprecipitation analyses 
were performed as described (Vascotto et al., 2009a,b).
Determination of AP endonuclease activity 
and abasic site assay
Determination of APE1 AP endonuclease activity was performed 
using an oligonucleotide cleavage assay, as described previously 
(Vascotto et al., 2009b) and detailed in the Supplemental 
Information.
Mass spectrometric analysis of APE1 acetylation
Characterization of APE1 acetylation was performed on the immu-
nopurified protein obtained from APE1-FLAG–expressing HeLa 
cells (Vascotto et al., 2009b). APE1 was resolved by SDS–PAGE; 
corresponding protein bands were excised, S-alkylated, and di-
gested with endoprotease AspN (Fantini et al., 2010). Digest ali-
quots were directly analyzed by nanoLC-ESI-LIT-MS/MS using an 
LTQ XL mass spectrometer (ThermoFisher Scientific, Waltham, MA) 
equipped with a Proxeon nanospray source connected to an Easy-
nanoLC (ThermoFisher Scientific; Arena et al., 2010; Scippa et al., 
2010), and analysis of APE1 acetylation was performed as described 
(D’Ambrosio et al., 2006) and detailed in the Supplemental Infor-
mation. A semiquantitative measurement of the amino acid modifi-
cation was obtained by extracting and integrating nanoLC-ESI-LIT-
MS peak areas corresponding to m/z values of the modified and 
nonmodified peptides in the same total ion chromatogram (Salzano 
et al., 2011). Modification extent was then assayed by evaluating 
the peak area of the modified peptide with respect to that of the 
modified peptide plus that of the nonmodified peptide, assuming 
identical ionization properties for modified and nonmodified spe-
cies. All these analyses were performed in triplicate.
Antibodies for immunofluorescence and immunoblotting
Antibodies used were anti-NPM1 monoclonal, anti-nucleolin mono-
clonal (Zymed, Invitrogen), anti-FLAG peroxidase-conjugated, 
anti-GST peroxidase-conjugated, anti-SIRT1 polyclonal (Abcam, 
Cambridge, MA), anti–c-myc (Santa Cruz Biotechnology, Santa Cruz, 
CA), and anti–?-tubulin monoclonal (Sigma-Aldrich). Anti-APE1 
monoclonal (Vascotto et al., 2009a) and anti-APE1K6K7Ac (Bhakat et al., 
2003) were described previously. Anti-APE1K27-35Ac polyclonal anti-
body was generated by PRIMM (Milan, Italy; Poletto et al., 2012).
Western blot analyses
For Western blot analyses, the indicated amounts of cell extracts 
were resolved in 12% SDS–PAGE and transferred to nitrocellulose 
membranes (Schleicher & Schuell BioScience, Dassel, Germany). 
Membranes were blocked with 5% (wt/vol) nonfat dry milk in phos-
phate-buffered saline (PBS) containing 0.1% (vol/vol) Tween 20 and 
probed with the indicated antibodies; blots were developed by us-
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width, 0.2 nm resolution, 50 mdeg sensitivity, and 4 s response. Pep-
tide concentration was kept at 100 μM, and a 0.1 cm path-length 
quartz cuvette was used. Spectra were acquired in 10 mM phosphate 
buffer, pH 7.0, containing various percentages of TFE.
NMR spectroscopy
NMR samples were prepared by dissolving APE1 peptides (1.5– 
2 mg) either in 600 μl of a 10 mM phosphate buffer, pH 7, contain-
ing 10% (vol/vol) D2O or in a mixture of 10 mM phosphate buf-
fer:2-2-2 trifluorethanol-d3 (98% deuterium; Armar Chemicals, 
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field gradient selective echo techniques (Dalvit, 1998) or continu-
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for spectral processing. The programs MestRe-C2.3a (Universidade 
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ABSTRACT Apurinic/apyrimidinic endonuclease 1 (APE1) is a multifunctional protein contrib-
uting to genome stability via repair of DNA lesions via the base excision repair pathway. It 
also plays a role in gene expression regulation and RNA metabolism. Another, poorly charac-
terized function is its ability to bind to negative calcium responsive elements (nCaRE) of some 
gene promoters. The presence of many functional nCaRE sequences regulating gene tran-
scription can be envisioned, given their conservation within ALU repeats. To look for func-
tional nCaRE sequences within the human genome, we performed bioinformatic analyses and 
identified 57 genes potentially regulated by APE1. We focused on sirtuin-1 (SIRT1) deacety-
lase due to its involvement in cell stress, including senescence, apoptosis, and tumorigenesis, 
and its role in the deacetylation of APE1 after genotoxic stress. The human SIRT1 promoter 
presents two nCaRE elements stably bound by APE1 through its N-terminus. We demon-
strate that APE1 is part of a multiprotein complex including hOGG1, Ku70, and RNA Pol II, 
which is recruited on SIRT1 promoter to regulate SIRT1 gene functions during early response 
to oxidative stress. These findings provide new insights into the role of nCaRE sequences in 
the transcriptional regulation of mammalian genes.
INTRODUCTION
Apurinic/apyrimidinic endonuclease 1 (APE1), also known as redox 
effector factor-1 (Ref-1), is a multifunctional and essential protein in 
mammals. It plays a vital role during cellular response to oxidative 
stress (Fung and Demple, 2005) and contributes to the maintenance 
of genome integrity (Tell et al., 2005, 2009, 2010a). As an AP endo-
nuclease, APE1 is involved in the base excision repair (BER) pathway, 
which deals with DNA damage induced by oxidative and alkylating 
agents, including chemotherapeutic agents (Chen and Stubbe, 
2005). APE1 also has transcriptional regulatory activity, modulating 
gene expression through a redox-based coactivating function on 
several transcription factors involved in cancer promotion and pro-
gression (Huang and Adamson, 1993; Tell et al., 1998; Gaiddon 
et al., 1999). These two major APE1 activities are independent and 
located in distinct protein domains. The N-terminal portion of the 
protein is devoted to the transcriptional coactivating function, and 
the C-terminal domain exerts the endonuclease activity on DNA 
abasic sites (Xanthoudakis et al., 1996; Tell et al., 2005). The latter 
domain is highly conserved, whereas the N-terminal region presents 
wider variability among different organisms, being more conserved 
in mammals, thus suggesting recent acquisition during evolution 
(Georgiadis et al., 2008; Fantini et al., 2010; Poletto et al., 2013). 
Through its N-terminal portion, APE1 also interacts with different 
proteins involved in ribosome biogenesis, pre-mRNA maturation/
splicing, and ribonucleotide catabolism. These observations high-
light an unexpected role of APE1 in RNA metabolism (Vascotto 
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To this purpose, classic DNA pattern-matching studies are inte-
grated with independent information on gene regulation. We use 
three main sources for data filtering: 1) functional annotation data 
collected via the Gene Ontology (GO) project; 2) gene expression 
data derived from the microarray profile of APE1-knockdown HeLa 
cells (Vascotto et al., 2009a); and 3) human–mouse gene sequence 
comparisons. In fact, both expression data and functional annota-
tion database provide a wealth of information about coregulation. 
This is of particular interest, since coregulated genes likely share 
similar transcriptional regulatory mechanisms. Comparison with or-
thologous gene promoters highlights sequences retained during 
evolution, whose conservation suggests their potential functionality. 
As a final result, we obtain a set of genes that pass the mentioned 
filters and are considered bona fide candidates coregulated through 
nCaRE-B sequences (Supplemental Figure S1).
We collected the 6000–base pair upstream regions of all human 
and mouse protein-coding genes, which we then analyzed for the 
presence of nCaRE-B elements using Glsearch for local alignment 
(Pearson, 2000). We found 8724 human genes to contain one or 
more nCaRE-B matches within their promoters; 2173 matches were 
retrieved in the mouse genome. We then cross-checked candidate 
genes with gene expression data obtained from APE1-knockdown 
cells (Vascotto et al., 2009a), verifying coexpression between genes 
carrying nCaRE-B elements. Through this analysis, we identified 384 
common genes in the two data sets (Figure 1A). Then we considered 
the GO annotations of these 384 genes, searching for statistically 
significant common annotations. We observed strong overrepresen-
tation of terms related to RNA processing and metabolism, in ac-
cordance with our previous studies (Vascotto et al., 2009a). All the 
significant associations between genes and GO terms are reported 
in Supplemental Table S1. Finally, we applied the phylogenetic foot-
printing filter, which evaluates whether a significant fraction of the 
selected genes, as obtained through the GO filter, share homolo-
gous genes containing nCaRE-B-related sequences in the upstream 
region with respect to the mouse gene data set. As a final result, we 
extracted 57 genes that may be considered bona fide candidates 
bearing the putative nCaRE-B sequences within their regulatory ele-
ments (Supplemental Table S2). We performed a functional enrich-
ment analysis to determine whether the 57 genes found are involved 
in common biological processes. This showed that candidate genes 
were associated with processes related to gene expression, activa-
tion, or increment of the extent of transcription from an RNA poly-
merase II–driven promoter (Figure 1B and Supplemental Table S3). 
Among these 57 genes, several are involved with DNA repair pro-
cess and cellular response to external stimuli and DNA damage: for 
example, SWI/SNF-related, matrix-associated, actin-dependent reg-
ulator of chromatin, subfamily a member 4 (SMARCA4), sirtuin 1 
(SIRT1), valosin-containing protein (VCP), multiple endocrine neo-
plasia I (MEN1), structural maintenance of chromosomes protein 6 
(SMC6), early growth response 1 (EGR-1), and APE1 itself. We paid 
particular attention to SIRT1, a NAD-dependent histone deacetylase 
belonging to class III of the sirtuin family, based on the recent dem-
onstration of a functional involvement of this enzyme in the deacety-
lation of some K residues in the N-terminal region of APE1 (Yamamori 
et al., 2010; Lirussi et al., 2012). The latter information and the data 
derived from our bioinformatic analysis led us to hypothesize the 
existence of an autoregulatory loop between APE1 and SIRT1.
APE1 binds the nCaRE-B sequences present in the human 
SIRT1 promoter
To prove the functional relevance of the nCaRE-B sequences identi-
fied in the human SIRT1 promoter, we first tested the ability of APE1 
et al., 2009b; Tell et al., 2010b), as also shown by two independent 
studies that demonstrated the ability of APE1 to cleave abasic RNA 
in vitro and in vivo (Berquist et al., 2008; Barnes et al., 2009). Ac-
cordingly, APE1 has been proposed to be a main factor in the abasic 
RNA cleansing process, suggesting that some of the activities of 
APE1 in gene expression may involve posttranscriptional mecha-
nisms (Tell et al., 2010b).
Another interesting, yet poorly characterized aspect of APE1 
transcriptional activity is its role as a component of a trans-acting 
complex that acts as a Ca2+-dependent repressor of the parathyroid 
hormone (PTH) gene by binding the negative calcium responsive 
elements (nCaRE) in its promoter region (Okazaki et al., 1991). In 
particular, an increase in extracellular Ca2+ concentration inhibits 
PTH expression through a mechanism involving APE1 binding to 
two nCaRE elements, nCaRE-A and nCaRE-B (Yamamoto et al., 
1989). This observation was further extended to the promoter re-
gion of renin (Fuchs et al., 2003), Bax (Bhattacharyya et al., 2009), 
and APE1 itself (Izumi et al., 1996). This last case represents the first 
example of such a negative regulatory mechanism for a DNA repair 
enzyme. Other experiments demonstrated that APE1 requires ad-
ditional factors, such as heterogeneous ribonucleoprotein L 
(Kuninger et al., 2002), Ku antigen (Chung et al., 1996), and PARP-1 
(Bhattacharyya et al., 2009), to stably bind to nCaRE elements.
nCaRE-B sequences are located within ALU repeats (McHaffie 
and Ralston, 1995; Shankar et al., 2004). Therefore, given that ALU 
elements are transposable elements that occupy at least 1/10 of the 
expressed human genome, many other functional nCaRE-B se-
quences could exist and play a role in the transcriptional regulation 
of genes. However, information is lacking on 1) an accurate number-
ing, 2) the identity of genes containing these sequences within their 
promoter, and 3) the active biological function of these elements. 
Thus the quest is for functional nCaRE-B sequences in the human 
genome to identify new potential genes whose expression may be 
regulated by APE1 through nCaRE binding.
The present work is devoted to this issue and focuses on the 
characterization of the molecular mechanisms responsible for APE1 
binding to nCaRE-B sequences on sirtuin-1 (SIRT1) promoter. Bioin-
formatic analyses of human gene expression data obtained upon 
APE1 knockdown in cells (Vascotto et al., 2009a) show the presence 
of multiple nCaRE-B sequences in genes deregulated upon APE1 
silencing and conserved in the mouse genome. Among these, we 
focus on the two nCaRE sequences present within the promoter re-
gion of the human deacetylase SIRT1 gene and their role in regulat-
ing the corresponding gene transcription. SIRT1 is a deacetylase 
participating in cell growth, adaptation to caloric restriction, apop-
tosis, and tumorigenesis (Gorospe and de Cabo, 2008; Kim and Um, 
2008), as well as in cell response to genotoxic agents through the 
deacetylation of APE1 (Yamamori et al., 2010). Together the data 
show the importance of APE1 during transcriptional initiation in 
positively promoting transcription of genes under genotoxic 
conditions.
RESULTS
Bioinformatic search for nCaRE sequence–containing genes 
reveals the SIRT1 gene as a novel candidate target of APE1 
regulation
Bioinformatic analysis of the systematic retrieval of functional nCaRE-
B sequences in the human genome was carried out by filtering bio-
logical data obtained from the gene expression profile of HeLa cells 
knocked down for APE1 (Vascotto et al., 2009a). Here we develop a 
method that integrates different approaches to the problem on a 
whole-genome scale while minimizing the number of false positives. 
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importance of the first 33 amino acids at the APE1 N-terminus for 
proper binding of the protein to nCaRE-B sequences. Similar poor 
DNA-binding activity was apparent in the case of zAPE1 (Figure 2B, 
lanes 4 and 8), which bears a nonrelated N-terminal domain (Fantini 
et al., 2010). Together these results suggest that the phylogeneti-
cally evolved N-terminal domain of the protein is essential for stable 
interaction between APE1 and the nCaRE-B sequences. It is con-
ceivable that K residues present within this region and acquired dur-
ing evolution in mammals (Georgiadis et al., 2008; Fantini et al., 
2010; Poletto et al., 2013) play a major role in protein binding to 
these DNA elements.
We then estimated the affinity of APE1 for SIRT1 nCaRE-B se-
quences through surface plasmon resonance (SPR) analysis 
(Figure 2C). Biotinylated versions of the nCaRE-B (SIRT1-B) or polyT 
to specifically bind these elements in vitro. Thus we performed elec-
trophoretic mobility shift assay (EMSA) analyses using different APE1 
recombinant protein forms and two double-stranded (ds) oligonu-
cleotides containing the SIRT1 nCaRE-B elements corresponding to 
the sequences present at ?2701 (SIRT1-A) and ?1754 base pairs 
(SIRT1-B) from the transcription start site (TSS), respectively 
(Figure 2A). Full-length human wild-type (WT) APE1 (APE1WT), the 
N-terminal APE1-deletion mutant (APE1N?33), and the orthologous 
zebrafish APE1 (zAPE1) expressed in Escherichia coli were used for 
this purpose. As clearly demonstrated by EMSA analyses, only the 
APE1WT protein was able to stably bind to both the SIRT1 nCaRE-B 
sequences (Figure 2B, lanes 2 and 6), whereas a complete absence 
of retarded complex was observed in the case of the truncated 
APE1N?33 form (Figure 2B, lanes 3 and 7). These findings show the 
FIGURE 1: Bioinformatic research on nCaRE sequences. (A) Results obtained from the application of the different filters. 
Top, data derived from alignment research on nCaRE sequences on human gene promoters and subsequent cross-
checking with microarray data. Bottom, final results from combined GO and phylogenetic footprinting analyses. 
(B) Functional enrichment analysis of the 57 putative genes regulated by APE1 performed according to their biological 
process annotations. For simplicity, only the most representative functional categories are reported. The number of 
genes for each category is provided on the horizontal axis, together with the list of the first 17 co-occurrence terms. 
Statistical significance for each category is shown within each bar.
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FIGURE 2: APE1 is part of a nuclear protein complex that binds to the SIRT1 nCaRE sequence through its N-terminal 
domain. (A) Schematic representation (top) and multiple sequence alignment (bottom) of two nCaRE-B sequences found 
on the human SIRT1 gene promoter (SIRT1-A and SIRT1-B) with the nCaRE sequence found on the human PTH 
promoter (Okazaki et al., 1991). (B) EMSA analysis of nCaRE SIRT1-A and SIRT1-B sequence challenged with 10 pmol of 
purified APE1WT, APE1N?33, and zAPE1 proteins. Left, Coomassie staining of the purified recombinant proteins. (C) SPR 
analysis of the human APE1 (hAPE1)–nCaRE interaction. Recombinant hAPE1 and biotinylated nCaRE SIRT1-B (Table 1) 
were used as analyte and ligand, respectively. Plot of RUmax from each binding vs. hAPE1 concentrations (0.5–8 μM); 
data were fitted by nonlinear regression analysis. (D) Top, EMSA analysis of nCaRE SIRT1-B incubated with HeLa nuclear 
extract of different clones: control clone, APE1SCR-1 (lane 2), clone silenced for APE1, APE1CL.3 (lane 3), and clones 
reconstituted with APE1WT (lane 4) or APE1N?33 (lane 5). Bottom, Western blot analysis of APE1 protein in HeLa nuclear 
cell extracts. (E) EMSA analysis of nCaRE SIRT1-B with HeLa nuclear extract from APE1SCR-1 clone alone (lane 2) or 
preincubated with monoclonal antibody against APE1 (lane 3) or/and with an antibody against Ku-70 (lanes 4 and 5). 
Lane 6 corresponds to APE1SCR-1 nuclear extract incubated with a nonspecific antibody (?-P2Y6). Free indicates probe 
alone; F shows the position of the free oligonucleotide probe. Specific APE1/nCaRE interaction is indicated by the 
arrow. Asterisk indicates supershift.
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nCaRE-B elements of the SIRT1 promoter. The reduced intensity of 
the retarded complex band upon APE1 silencing or in the reconsti-
tuted cells expressing APE1N?33 protein (Figure 2D), as well as 
the lower apparent electrophoretic mobility of the protein–DNA 
retarded complex when using nuclear extracts in place of the 
recombinant purified protein (Figure 2B), suggests that APE1 may 
be part of a multiprotein complex. Because Ku70 antigen protein 
was already demonstrated to bind nCaRE-A sequences in complex 
with APE1 (Chung et al., 1996), we incubated the HeLa nuclear ex-
tract with an antibody recognizing the Ku70 antigen. We then sub-
jected the reaction to EMSA analysis, showing the formation of a 
supershifted complex (Figure 2E, lane 4). The concurrent presence 
of APE1 and Ku70 in the same retarded complex was confirmed by 
performing simultaneous preincubation with antibodies specific for 
these proteins (Figure 2E, lane 5). The presence of Ku70 in the com-
plex with APE1 was also corroborated by additional EMSA analysis 
performed with the purified recombinant protein attesting that, 
when present alone, Ku70 is not able to stably bind to the SIRT1 
nCaRE-B sequence per se. On the contrary, when concomitantly in-
cubated with APE1, Ku70 significantly enhances APE1 DNA-binding 
activity to SIRT1 nCaRE-B element (Supplemental Figure S3, com-
pare lanes 2–5 and 8–10). Unpublished data demonstrated that this 
stimulatory activity on APE1 binding required interaction through 
the APE1 33N-terminal domain. Overall these data demonstrate 
that APE1 must be part of a multiprotein complex containing Ku70 
to elicit its high-affinity binding potential with regard to the nCaRE-B 
sequences present on the SIRT1 promoter.
Topology of the APE1-nCaRE complex
nCaRE-B element consists of a palindromic sequence that can fold 
into self-complementary hairpins (Figure 3A, left). In silico analyses 
with the mfold program suggested that these elements could fold 
into cruciform-like structures. To evaluate whether SIRT1 nCaRE-B 
sequences can fold into cruciform duplexes and specifically assess 
whether APE1 binding to this element may depend on such second-
ary structures, we performed footprinting analyses by using the T7 
endonuclease I (Figure 3A, right). This protein is a structure-sensitive 
enzyme that specifically recognizes conformationally branched DNA 
and Holliday structures or junctions (Parkinson and Lilley, 1997; Dé-
clais et al., 2003; Fan et al., 2006). Footprinting data support the 
hypothesis of the existence of a secondary structure for the nCaRE-
B sequences (Figure 3A and Supplemental Figure S4). In particular, 
our experiments show the predominant formation of two bands (re-
spectively 10 and 19 nucleotides in length) in the digested samples, 
which correspond to a cutting site close to the predicted loop or 
immediately adjacent to the predicted stem (Figure 3A, arrows). Of 
interest, preincubation of the SIRT1 nCaRE-B oligonucleotide with 
APE1 impairs T7 endonuclease digestion (Figure 3A, lane 4). Con-
sistent with these observations, EMSA analysis demonstrated that 
digestion of the SIRT1 nCaRE-B oligonucleotide with T7 endonu-
clease affects APE1 binding to this element, but, conversely, when 
APE1 was first incubated with the nCaRE-B probe and then digested 
with T7 endonuclease, the binding was not affected. These data 
suggest a protective role of APE1 with regard to T7 endonuclease 
action, strongly supporting the hypothesis that these proteins may 
compete for the same binding site on the nCaRE-B sequences 
(Figure 3B).
The first 33 N-terminal amino acids of APE1 are required for pro-
tein binding to the nCaRE sequences (Figure 2, A and D). To further 
investigate the role of this protein portion on APE1’s ability to bind 
to DNA elements, we performed combined limited proteolysis-mass 
spectrometry experiments on recombinant APE1 protein in either 
sequences were immobilized onto a streptavidin chip for use as li-
gands in SPR experiments. APE1WT and APE1N?33 were then ana-
lyzed for their DNA-binding properties. When testing APE1WT as 
analyte, KD ? 3.90 ? 0.08 μM was measured (Poletto et al., 2013); 
corresponding kinetic parameters are shown in Table 1. Conversely, 
when using APE1N?33, we did not observe any SPR signal variation 
(unpublished data), in accordance with EMSA experiments 
(Figure 2B). This result confirmed that the protein region 1–33 is es-
sential for stable interaction of APE1 with these DNA elements. As a 
DNA-repair enzyme, APE1 has intrinsic ability to bind to DNA in a 
sequence-independent manner. Moreover, independent observa-
tions clearly point to a role of the nucleic acid secondary structure in 
positively modulating this activity (Poletto et al., 2013). Here we 
evaluated the protein capacity to bind to a single-stranded 24-mer 
oligo-dT (here called polyT). A KD ? 308 ? 3 μM was measured in the 
case of APE1WT, whereas no binding was observed for APE1N?33 
(Table 1 and Supplemental Figure S2), in agreement with EMSA 
analysis. These results indicate that APE1 poorly recognizes a non-
structured oligonucleotide formed by a stretch of thymidines, con-
firming that this protein may bind to DNA with different affinities 
and the oligo-dT sequence may be used in EMSA analysis as a non-
specific competitor.
Our EMSA and SPR analyses on APE1 binding activity to the 
SIRT1 nCaRE-B sequences showed low affinity for recombinant 
APE1 alone. Therefore we tested whether additional factors present 
in nuclear extracts of the cells may increase protein-binding affinity 
to its oligonucleotide target. To this aim, further EMSA analyses, 
performed using HeLa cell nuclear fractions, confirmed that nuclear 
activity able to specifically bind nCaRE-B sequences was indeed 
present (Figure 2D). The high-affinity complex measured, even us-
ing much lower amounts of APE1 (0.63 pmol, as estimated from Li-
russi et al., 2012) with respect to that obtained with the recombinant 
purified protein alone (10 pmol; Figure 2B), suggested that addi-
tional factors are required for efficient APE1 binding to SIRT1 
nCaRE-B sequences. To demonstrate the presence of APE1 in the 
retarded complex observed in Figure 2D, we used nuclear extracts 
obtained from a HeLa line (CL.3) for which endogenous APE1 pro-
tein expression was previously knocked down through stable short 
hairpin RNA (shRNA) transfection (Vascotto et al., 2009a). As is ap-
parent from lane 3 in Figure 2D, an overall reduction of the intensity 
(almost 70% with respect to lane 2) of the retarded nCaRE-bound 
complex was observed, similar to what occurred for the clone ex-
pressing APE1N?33 (lane 5; almost 50% with respect to lane 2). Nu-
clear extracts obtained from HeLa cells reconstituted with ectopic 
APE1WT (lane 4) showed the same amount of bound complex as the 
control cell clone expressing a scrambled shRNA vector (indicated 
as SCR-1; recovery of almost 80% with respect to lane 2). 
Preincubation of the nuclear extract from the SCR-1 clone with an 
anti-APE1 antibody resulted in the formation of a supershifted com-
plex (Figure 2E, lane 3). This complex was absent when a nonrelated 
antibody was used (lane 6), clearly demonstrating that APE1, pres-
ent in the nuclear cell extract, is involved in the recognition of the 
Ligand Ka (ms ? 105) Kd (1/s) KD (μM)
SIRT1-B nCaRE 0.270 0.105 3.90 ? 0.08
SIRT1-B mutated 0.0198 0.236 119 ? 8
polyT 0.004 0.112 308 ? 3
TABLE 1: Dissociation constant and kinetic parameter values as 
determined for APE1 by SPR analysis.
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(nCaRE-mut) caused only a slight reduction of the nCaRE-binding 
complex, in agreement with ChIP and SPR data, supporting the no-
tion of sequence-dependent binding specificity (unpublished data). 
These data were also confirmed with the endogenous APE1 pro-
moter via ChIP followed by high-throughput sequencing (ChIP-Seq) 
analyses (unpublished data), further demonstrating the physiologi-
cal relevance of these findings. Together these results confirm our in 
vitro observations (Figure 2) and support the hypothesis that, under 
basal conditions, APE1 is associated with the nCaRE-B sequence 
within the SIRT1 promoter also in vivo, possibly as part of a multipro-
tein complex.
We then evaluated whether APE1 binding to SIRT1 promoter 
plays a role in SIRT1 transcriptional regulation by performing pro-
moter-reporter assays. HeLa cells were cotransfected with a lu-
ciferase reporter vector bearing the SIRT1 promoter and APE1WT 
FLAG-tagged vector (Figure 4C). SIRT1 promoter-reporter assays 
showed that there was a significant increase in the luciferase signal 
detected in the presence of APE1 compared with that of the pro-
moter alone. We evaluated the effect of APE1 silencing on endog-
enous SIRT1 mRNA expression levels through an inducible shRNA 
knockdown strategy (Vascotto et al., 2009a,b). Endogenous APE1 
knockdown (CL.3) caused a significant reduction in the SIRT1 en-
dogenous expression levels (Figure 4D), which was rescued in cells 
reconstituted with a siRNA-resistant APE1 cDNA expression plasmid 
(WT). These data demonstrated a positive effect of APE1 on SIRT1 
transcriptional activation. Although unexpected, since previous data 
reported a transcriptional repressive role for APE1 through nCaRE 
sequence binding (Okazaki et al., 1991; Fuchs et al., 2003), these 
data agree with our previous observations from gene expression 
profiling analysis (Vascotto et al., 2009a), in which reduced expres-
sion of SIRT1 in APE1-knockdown HeLa cells was apparent.
Oxidative stress induces SIRT1 transcription via recruitment 
of BER enzymes
To better understand, at the molecular level, the transcriptional func-
tion exerted by APE1 through binding to nCaRE-B sequences, we 
investigated whether APE1’s positive role in SIRT1 transcription re-
lied on its enzymatic activity on DNA. First, we observed that under 
basal conditions APE1 has no endonuclease activity on the SIRT1 
nCaRE-B sequence, as assessed through an oligonucleotide cleav-
age assay (Figure 5A). APE1 cleavage, occurring at any site on the 
cruciform nCaRE-B sequence, should lead to a site-specific, single-
stranded break that can be detected by the appearance of an extra 
fragment in the cleavage assay. Even using an increasing amount of 
purified recombinant APE1 protein, we did not detect any nuclease 
activity that, on the contrary, was readily visible when using a 
radiolabeled 26-mer ds oligonucleotide containing a tetrahydro-
furan mimicking an AP site (here referred to as THF; Berquist et al., 
2008). Substitution of the guanine residue at position 12, within the 
predicted loop of the nCaRE-B sequence, with a THF residue re-
sulted instead in efficient APE1 cleavage activity on the nCaRE-B 
sequence. This activity depends on APE1 catalytic function, since 
the catalytically inactive APE1E96A mutant (Izumi et al., 1999) was un-
able to efficiently cleave the same substrate (Figure 5B).
Prompted by these findings, we hypothesized that the APE1-
positive function that we observed on the SIRT1 promoter may be 
ascribed to the APE1 catalytic activity on nCaRE-B sequences. This 
can occur after specific stimuli, such as oxidative stress, which can 
lead to abasic site formation on nCaRE-B sequences (Amente et al., 
2010; Francia et al., 2012). It is well known that SIRT1 expression 
and function are regulated by external stressors, including exposure 
to genotoxic agents (Cohen et al., 2004; Kim and Um, 2008; 
the absence or the presence of its target nCaRE oligonucleotide 
(Figure 3C, left). In particular, parallel experiments with a specific 
proteolytic enzyme (used at a defined APE1/protease weight/weight 
ratio) were carried out on a time-course basis on 1) isolated APE1, 2) 
APE1 complexed with SIRT1 nCaRE-B oligonucleotide, and 3) APE1 
complexed with PTH nCaRE-B oligonucleotide (Okazaki et al., 1992; 
Supplemental Figure S5 and Supplemental Table S4). This last was 
used as control. Resulting differential peptide maps provided infor-
mation on amino acid(s) eventually protected from proteolytic attack 
as result of their presence at the protein–DNA complex interface 
(Figure 3C, left). The data were interpreted according to the concept 
of “molecular shielding” of amino acids from proteolytic attack 
(Scaloni et al., 1998, 1999; Renzone et al., 2007) and were rational-
ized on the basis of x-ray crystallographic APE1 structures (Gorman 
et al., 1997; Beernink et al., 2001). To maximize information resulting 
from limited proteolysis experiments, we used different proteolytic 
enzymes in separate assays.
Figure 3C (right) summarizes the results of the limited proteolysis 
experiments, as obtained by using different proteases on recombi-
nant APE1 alone (Figure 3C, top) or after its complex formation with 
the SIRT1 nCaRE substrate (Figure 3C, bottom; see Supplemental 
Figure S5 and Supplemental Table S4 for experimental details). 
General considerations concerning the native protein are as follows. 
Preferential hydrolyzed peptide bonds on isolated APE1 gathered 
into a specific region of the protein, namely the most exposed seg-
ment, the unstructured N-terminal domain, which contained six pro-
teolytic sites (K6, K7, A9, A11, D15, and L17). An additional site was 
within the globular APE1 domain (L111). Of interest, no other cleav-
age sites were detected in other protein regions, although exposed 
on the molecular surface (Gorman et al., 1997; Beernink et al., 2001). 
After complex formation with nCaRE-B oligonucleotides, a marked 
protective effect was observed, as demonstrated by the large de-
crease in the number of proteolytic sites present in the N-terminal 
region (from six to one), thus confirming the involvement of this 
APE1 portion in binding to these DNA elements.
Transcriptional regulation of SIRT1 expression 
by APE1 protein
To determine whether the observations obtained in vitro regarding 
APE1 binding to SIRT1 nCaRE-B sequences have any relevance in 
vivo, we examined the APE1 occupancy of the nCaRE-B sequence 
in the SIRT1 promoter through chromatin immunoprecipitation 
(ChIP) analyses. To this purpose, we used HeLa cells cotransfected 
with a human SIRT1 promoter–containing plasmid (Yamamori et al., 
2010) and FLAG-tagged APE1WT- or APE1N?33-expressing plasmids. 
The amount of immunoprecipitated SIRT1 promoter was signifi-
cantly enriched in APE1WT-transfected cells compared with that ob-
tained from control cells transfected with the empty vector alone 
(Figure 4A). As expected, APE1N?33-transfected cells had a remark-
able reduction, although not completely so, in the amount of im-
munoprecipitated SIRT1 promoter. A similar degree of reduction 
was observed when ChIP analysis was performed by using a SIRT1 
promoter bearing a mutated sequence within the nCaRE-B motif 
(Figure 4B), whose reduced specificity was previously assessed 
through SPR analysis (Table 1 and Supplemental Figure S2). These 
experiments revealed that the mutation introduced in the nCaRE-B 
sequence significantly reduced the APE1 binding to DNA, lowering 
the affinity of the complex by 30-fold (KD ? 119 ? 3 μM). Competi-
tive EMSA analyses were in agreement with these findings. In fact, 
addition of the unlabeled nCaRE ds oligonucleotide resulted in al-
most complete elimination of bound complex formation. On the 
other hand, competition with the unlabeled mutant nCaRE oligo 
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FIGURE 3: APE1 recognizes structured nCaRE sequences through its N-terminal domain. (A) Left, predicted cruciform 
structure of nCaRE SIRT1-B ds oligonucleotide. Arrows indicate the cleavage site of T7 endonuclease I and the length of 
the products. Right, 5?-32P-end-labeled nCaRE was preincubated (lane 4) or not (lane 3) with APE1 recombinant protein 
and then subject to T7 endonuclease digestion. (B) EMSA analysis of APE1 binding to nCaRE sequence after digestion 
with T7 endonuclease (lanes 7 and 8) or upon preincubation with APE1 and subsequent digestion with T7 endonuclease 
(lanes 9 and 10). Lane 1 is the probe alone; APE1 incubation with the probe was performed temporally before (1st) or 
after (2nd) T7 digestion; F shows the position of the free oligonucleotide probe. F** indicates the T7 endonuclease–
digested probe. Specific APE1/nCaRE interaction is indicated by the arrow. (C) Schematic representation of the amino 
acids within the N-terminal domain of APE1 and involved in nCaRE oligonucleotide binding. Left, proteolytic maps 
obtained after incubation of recombinant APE1 alone (top) or recombinant APE1 complexed with SIRT1 nCaRE-B 
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FIGURE 4: APE1 positively regulates SIRT1 expression at the promoter level. (A). Top, schematic representation of the 
human SIRT1 promoter used for HeLa transfection. For and Rev arrows indicated the reverse transcription-PCR primer 
designed for the quantification of the human SIRT1 nCaRE sequence bound to APE1. Bottom, ChIP assay for APE1-
nCaRE sequence association. Percentage of immunoprecipitated nCaRE DNA relative to that present in total input 
chromatin. Data were further normalized to the amount of immunoprecipitated protein. Western blot analysis was 
performed on total cell extracts (input) and immunoprecipitated material (IP) with specific antibody for FLAG and APE1. 
IB, immunoblot. (B) ChIP analysis on mutated human SIRT1 promoter. Top, base composition of the nCaRE SIRT1-B 
mutated sequence used for site-directed mutagenesis of SIRT1 promoter. Divergent sequences in the mutant nCaRE are 
bold. Bottom, HeLa cells were cotransfected with vector expressing APE1WT and, alternatively, wild-type or mutated 
hSIRT1 promoter. The histogram represents the amount of hSIRT1 promoter sequence that was immunoprecipitated. 
Data are percentage of input and are normalized to the amount of APE1 immunoprecipitated, as evaluated by Western 
blot analysis. (C) hSIRT1 promoter is activated in presence of APE1, as shown in the reporter assay. Western blot 
analysis showing the normalization of protein levels. (D) Analysis of SIRT1 mRNA level with qPCR in clones expressing 
APE1WT or APE1 silenced (CL.3) cells. Western blot analysis on protein extract of clones showing the suppression of 
endogenous APE1 expression upon 10 d of treatment with doxycycline.
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oligonucleotide (bottom) with endoprotease AspN. Experiments were performed on a recombinant APE1 form bearing 
three additional amino acids at the protein N-terminus with respect to the native counterpart. Peptides identified by 
mass spectrometry analysis are indicated at the top of the corresponding chromatographic peaks. Right, proteolytic 
sites identified in native APE1 alone (top) and in APE1 complexed with SIRT1 nCaRE-B oligonucleotide (bottom); 
summary of results from independent experiments performed by using different proteases. See the Supplemental 
Information for experimental details and Supplemental Figure S4 and Supplemental Table S4 for complete data.
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FIGURE 5: Recruitment of BER enzymes on the SIRT1 promoter. (A) APE1 endonuclease activity on ds, nCaRE SIRT1-B 
radiolabeled oligonucleotide. A radiolabeled ds, THF-containing deoxyoligonucleotide (THF) was used as control. 
Reactions were performed with increasing amounts (picomoles) of recombinant APE1WT protein. (B) APE1 AP 
endonuclease activity on nCaRE SIRT1-B THF-containing probe incubated with increasing amounts of recombinant 
APE1WT protein or a catalytic inactive APE1 mutant (APE1E96A). (C) Reporter assay with HeLa cells transfected with 
hSIRT1 firefly reporter vector and challenged with increasing doses of H2O2 for 1 h as indicated. (D) qPCR analysis of 
SIRT1 mRNA levels in clones expressing APE1WT or APE1-silenced cells APE1CL.3 after 1 mM H2O2 treatment for 1 h. 
Western blot analysis on the protein extracts. (E) qPCR analysis of SIRT1, EGR-1, and EIF4EBP mRNA levels in APE1CL.3 
or APE1WT clones after 1 mM H2O2 treatment for 1 h. Data shown are reported as fold of activation after H2O2 
treatment. (F) Results of four independent ChIP analyses relative to accumulation of 8-oxodeoxyguanine, OGG1, APE1, 
and RNA polymerase II protein on the SIRT1 promoter after 1 mM H2O2 treatment for different times (as reported). 
Data are percentage of input and normalized to quantity of DNA immunoprecipitated by ?-tubulin (?-tub). See 
Supplemental Figure S4 for detailed information.
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relatively low abundance on the SIRT1 nCaRE-B sequence; con-
versely, the polymerase was progressively recruited as soon as the 
oxidative stress began (15 min after H2O2 treatment). Afterward 
(40 min after H2O2 addition), RNAPII was again recruited on the 
SIRT1 promoter, showing a wave-like behavior. In concert with this 
observation, we also noticed augmented interaction between 
APE1 and RNPII in accordance with the kinetics observed during 
ChIP analysis (Supplemental Figure S8). This oxidatively induced 
recruitment of RNPII to the SIRT1 promoter may suggest that oxi-
dative stress can trigger SIRT1 transcriptional activation. One 
could envision a mechanism in which H2O2, causing oxidation of 
the guanine at the SIRT1 nCaRE-B sequence, promotes recruit-
ment of components of the base excision repair system—OGG1 
and APE1, together with proteins involved in nCaRE-B binding 
such as Ku70. When recruited to the SIRT1 promoter, APE1 
(through its endonuclease activity) produces nicks on the SIRT1 
nCaRE-B sequence, possibly favoring the DNA relaxation neces-
sary for the formation of chromatin loops that bring RNAPII at the 
transcription start site (Figure 6); this last enzyme in turn can initi-
ate transcription.
DISCUSSION
After its cloning by independent groups, first as a DNA-repair en-
zyme (Demple et al., 1991; Robson and Hickson, 1991) and then 
as a redox coactivator protein (Xanthoudakis and Curran, 1992), a 
number of articles described different APE1 functions, elucidating 
its involvement in several biological contexts. As the main apurinic/
apyrimidinic endonuclease in mammalian cells, APE1 is classically 
known for its essential function as a DNA-repair enzyme in the 
BER pathway. Besides this crucial role in the maintenance of ge-
nome stability, APE1 was demonstrated to be involved in redox 
signaling and the regulation of gene expression (Tell et al., 2010a; 
Wilson and Simeonov, 2010), supporting the notion that it is a 
multifunctional protein, with features that go beyond the classic 
activities of a DNA-repair enzyme. Of note, its multifunctional na-
ture suggests APE1 as an ideal candidate protein linking DNA-
damage sensing/repair and transcriptional regulation of genes 
during cell response to genotoxic damage. Among these non-
canonical activities, another interesting APE1 function is its ability 
to bind the nCaRE sequence of some gene promoters, thus acting 
as a transcriptional regulator. Okazaki’s group was the first to iden-
tify two nCaRE sequences within the PTH gene promoter (nCaRE-
A and nCaRE-B; Okazaki et al., 1991). The presence of these ele-
ments was also described in the regulatory region of a few other 
genes, such as human APE1 (Izumi et al., 1996), rat atrial natriuretic 
polypeptide (Okazaki et al., 1992), human renin (Fuchs et al., 
2003), and Bax (Bhattacharyya et al., 2009). Besides these few 
genes, no further evidence has been provided. However, since 
nCaRE-B elements are present within ALU repeats, which are 
widely distributed throughout the expressed genome, it is ex-
pected that APE1 could regulate the expression of a large number 
of genes. Here we performed an unbiased investigation of the 
whole human genome, searching for putative genes whose tran-
scription may be mediated through APE1’s ability to bind nCaRE-
B elements. In particular, although nCaRE elements seem to be 
active also at downstream regions (Izumi et al., 1996), here we 
specifically focused on nCaRE-B elements present only on the up-
stream sequence of human genes. In the near future, we plan to 
extend this approach to downstream and intron regions. Bioinfor-
matic analyses revealed a number of genes potentially regulated 
by APE1, which are involved in several pathways related to gene 
expression (Figure 1). Among the 57 candidate genes retrieved 
Yamamori et al., 2010). We therefore measured SIRT1 transcription 
after oxidative stress, such as that generated by H2O2 exposure. 
First, we demonstrated that SIRT1 promoter activation was in-
creased by H2O2 treatment in a concentration-dependent manner 
(Figure 5C). Next we examined the effect of APE1 silencing or re-
expression on SIRT1 transcriptional activation in HeLa cell clones 
upon H2O2 treatment (Figure 5D and Supplemental Figure S6). We 
treated control (SCR-1), APE1-silenced (CL.3), and APE1WT cell 
clones with 1 mM H2O2 for 1 h. SIRT1 mRNA levels were then evalu-
ated by quantitative PCR (qPCR) and compared with those for un-
treated clones. On oxidative treatment, SIRT1 mRNA significantly 
increased, and, of note, this response was higher in the presence of 
APE1WT protein, whereas it was lower in the case of APE1-knock-
down–expressing cells. The residual activation of SIRT1 mRNA ex-
pression, which was apparent also in APE1-knockdown cells, might 
be ascribable to the presence of residual endogenous APE1 protein 
and/or of further limiting factors, as already speculated (Chung 
et al., 1996; Kuninger et al., 2002; Bhattacharyya et al., 2009). The 
observed induction of SIRT1 mRNA transcription in HeLa cells upon 
oxidative stress correlates with a parallel increase in its protein lev-
els. Confirmation of the biological relevance of our findings comes 
from the observation of concomitant increased deacetylation activ-
ity of SIRT1 protein toward its substrate, that is, K382 of p53 (Vaziri 
et al., 2001; Supplemental Figure S6).
We also confirmed the general relevance of our model by testing 
other hypothetical APE1 target genes containing an nCaRE-B ele-
ment in their promoters and resulting dysregulation in the APE1-kd 
cell model (Figure 1 and Supplemental Table S2; Vascotto et al., 
2009a). To this aim, we evaluated by qPCR the expression levels, 
upon H2O2 treatment, of EGR-1 and eukaryotic translation initiation 
factor 4E–binding protein 1 (EIF4EBP1) in the HeLa cell inducible-kd 
(CL.3) clone and the reconstituted cell clone (WT) used here 
(Figure 5E). Similar results were obtained using another genotoxic 
agent, methyl methanesulfonate (Supplemental Figure S9). These 
data, showing inducible expression of these genes dependent on 
APE1 expression to a similar extent of that observed in the case of 
SIRT1, were suggestive of a general mechanism of gene activation 
upon DNA damage that involves APE1 binding to nCaRE-B 
elements.
To find a relationship between SIRT1 transcription induced by 
oxidative stress and the APE1 regulatory activity on the nCaRE-B 
sequences located within the promoter, we studied the dynamics 
of oxidative repair enzyme recruitment on the SIRT1 nCaRE-B se-
quence at early time upon H2O2 treatment. DNA base oxidation 
determines the formation of 8-oxodeoxyguanine (8-oxodG), which 
is recognized by the DNA glycosylase OGG1. This enzyme initi-
ates the BER pathway by removing the 8-oxodG lesion, which is 
further processed by APE1, which cleaves the apurinic site. To as-
sess the dynamics of occupation of the nCaRE-B sequence on the 
SIRT1 promoter by these enzymes upon oxidative stress, we per-
formed a time-course ChIP analysis on the SIRT1 nCaRE-B se-
quence after 1 mM H2O2 treatment (Figure 5F and Supplemental 
Figure S7). We immunoprecipitated SIRT1 nCaRE-B sequence 
with antibodies against 8-oxodG, OGG1, and APE1. We observed 
that the signal of 8-oxodG promptly reached its plateau 10 min 
after H2O2 treatment and subsequently decreased, concomitant 
with accumulation of OGG1, which is recruited immediately after 
(15 min), in accordance with the BER processes. Occupancy by 
APE1 follows OGG1 recruitment. To demonstrate a direct link be-
tween DNA repair and SIRT1 transcriptional initiation, we exam-
ined the assembly of RNA polymerase II (RNPII) on the SIRT1 
nCaRE-B sequence. Under basal condition, RNPII was found with 
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ing that this deacetylase controls the 
acetylation status of APE1 lysine residues 
K6-7 (Yamamori et al., 2010) and K27-35, 
thus modulating the subnuclear distribu-
tion of this protein and coordinating its 
enzymatic functions in the BER pathway 
(Lirussi et al., 2012). Therefore we hypoth-
esized the existence of a possible auto-
regulatory loop between the two proteins: 
APE1 modulates SIRT1 expression, which, 
in turn, regulates APE1 function through 
deacetylation.
To investigate APE1’s transcriptional reg-
ulatory function on SIRT1 expression, we 
first examined APE1’s ability to bind the 
nCaRE-B sequences found in the SIRT1 pro-
moter. Through different in vitro approaches, 
we showed that APE1 is able to bind SIRT1 
nCaRE-B sequences (Figures 2 and 3). In 
particular, by a combination of EMSA and 
SPR analyses with limited proteolysis experi-
ments, we demonstrated that the APE1 N-
terminal domain is essential for the proper 
binding of these elements. The essential 
role of this protein domain in DNA binding 
is remarkable, particularly if one considers 
the phylogenesis of the nCaRE-B elements 
and that of the APE1 N-terminal region. 
nCaRE-B sequences are present within ALU 
repeats, which belong to the short inter-
spersed nucleotide element family of repeti-
tive sequences that originally derived from 
the reverse transposition of 7SL RNA. This 
event took place in the genome of an ances-
tor of Supraprimates (Kriegs et al., 2007): 
these repetitive elements have been found 
exclusively in primates (Deininger et al., 
1981), scandentians (Nishihara et al., 2002), 
and rodents (Krayev et al., 1980), all mem-
bers of the placental mammalian clade 
Supraprimates (Euarchontoglires; Murphy 
et al., 2001). Similarly, information on the se-
quence homology of the APE1 N-terminal 
domain across species points to the recent 
phylogenetic acquisition of this region. 
Sequence conservation of this domain is 
very high in mammals but almost absent in 
other organisms, with the exception of 
Danio rerio, Dictyostelium, and Drosophila. 
Accordingly, it could be envisioned that 
once ALU elements appeared in primates 
and were stabilized in their genomes, 
progressively losing their transcriptional po-
tential, these organisms needed to evolve 
novel mechanisms to cope with the acquired 
RNA Pol II regulatory sites present within the 
ALU region. The concomitant acquisition of 
the APE1 N-terminal domain in mammals 
could explain new modulatory functions to-
ward these DNA elements. The observation that specific K residues 
(K24-27) within this reduced APE1 portion seem to be required for 
the correct binding of nCaRE-B (unpublished data) nicely fits with 
from our bioinformatic analysis, we chose to study the human 
deacetylase SIRT1, which bears two nCaRE-B elements in its pro-
moter. Increased interest in SIRT1 was due to recent articles show-
FIGURE 6: Mechanistic model for the role of APE1 in oxidatively mediated SIRT1 transcription. 
Under normal conditions, APE1, together with other protein factors, is bound to the nCaRE 
element present within the SIRT1 promoter involved in the basal activation of SIRT1 
transcription. Conversely, upon oxidative stress conditions, DNA oxidation determines the 
formation of 8-oxodeoxyguanine (8-oxoG) lesions at the nCaRE sequence present in the SIRT1 
promoter, which are recognized and processed by BER enzymes, including APE1. The nicks 
introduced at the chromatin level by APE1 during 8-oxoG removal might promote the formation 
of chromatin loops moving the active form of RNA polymerase II closer to the TSS of the gene, 
turning on the transcription.
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sequence of SIRT1 promoter in vivo and confirmed this through 
ChIP-Seq analysis (unpublished data). In particular we observed 
that APE1 positively affects SIRT1 gene transcription. Although 
APE1 was implicated in the repression of PTH gene transcription in 
a Ca2+-dependent manner, APE1 overexpression activated the 
SIRT1 promoter (Figure 4C) apparently through a Ca2+-indepen-
dent mechanism. This unexpected positive function on the tran-
scription of an nCaRE-containing promoter was also reported in 
other work, in which the authors suggested that the role of the 
nCaRE sequences in the context of different promoters and cells 
conditions could affect nCaRE activity (Bhakat et al., 2003; Fuchs 
et al., 2003). Of interest, we noticed that the positive effect of APE1 
was particularly pronounced during oxidative stress, through its 
binding to SIRT1 nCaRE-B sequences (Figure 5D). Treatment with 
H2O2 leads to activation of the SIRT1 promoter, which determines 
an increase of the corresponding transcriptional expression in an 
APE1-dependent manner. This positive transcriptional effect was 
also observed when we looked at the expression of other genes 
that have nCaRE-B elements in their promoters (Figure 5E), thus 
corroborating the hypothesis of a general mechanism of SIRT1 
gene activation upon DNA damage that involves functional activa-
tion of APE1. These findings are in line with data from Yamamori 
et al. (2010) showing that genotoxic insult stimulates SIRT1 expres-
sion and therefore its deacetylase activity on APE1 K6/7, favoring 
APE1 binding to XRCC1. Of interest, these authors sowed that a 
decrease of APE1 acetylation at later times after oxidative treat-
ment is usually accompanied by SIRT1 up-regulation. Together 
these findings are in accordance with a model of a positive auto-
regulatory loop between the two proteins. Thus SIRT1 seems to be 
involved in a feedback mechanism that shuts off the cellular re-
sponse mediated by APE1 acetylation (Yamamori et al., 2010). Fur-
ther proof of APE1 and SIRT1 collaboration comes from the recent 
demonstration that APE1 stimulates SIRT1 activity in endothelial 
cells by reducing thiol moieties of cysteine residues in SIRT1, thus 
protecting endothelium from oxidative stress (Jung et al., 2013).
It has been suggested that DNA oxidation could trigger posi-
tive transcription in the context of Myc-mediated transcription 
through the involvement of BER enzymes, including APE1 (Perillo 
et al., 2008; Gillespie et al., 2010). Similarly, we speculated that 
APE1’s positive effect on SIRT1 transcription might depend on 
APE1 endonuclease activity over the nCaRE-B elements present 
within the SIRT1 promoter. We propose a model in which oxida-
tive-mediated DNA repair and gene transcription are linked 
(Figure 6). During oxidative stress, DNA oxidation determines the 
formation of 8-oxodG lesions, which are recognized and pro-
cessed by enzymes of the BER pathway, including APE1. In our 
model, the oxidative burst is an early event, essential for formation 
of a productive transcription initiation complex, which relies on 
initial recruitment of BER enzymes. The nicks introduced at the 
chromatin level by APE1 during 8-oxodG removal might promote 
the local relaxation required for formation of chromatin loops 
moving the active form of RNA polymerase II closer to the TSS of 
the gene, as previously recruited by APE1 on the nCaRE-B se-
quence, turning on the transcription. Our data therefore can be 
generalized to a regulatory model for all genes that contain 
nCaRE-B elements. Accordingly, a new hypothesis can be pro-
posed for the molecular activation of specific genes during early 
response to DNA damage. This model links DNA-repair enzymes 
and transcriptional regulation effectors and may constitute a gen-
eral model for explaining the adaptive cell response to oxidative 
stress involving gene regulation and DNA damage in which APE1 
plays a central role.
this hypothesis. The zebrafish homologue of APE1, which shares 
<40% of the N-terminal amino acid sequence with the human pro-
tein and lacks two of five K residues in this region, is indeed no 
longer able to stably bind these nCaRE-B sequences (Figure 2B; 
Poletto et al., 2013). Similar results were obtained using a human 
recombinant APE1 mutant protein bearing specific K-to-A multiple 
substitution at K27/31/32/35, in which the positive charges at the 
amino acid side chain were removed to mimic a condition similar to 
that exerted by K acetylation (unpublished data).
The APE1 N-terminal domain seems required for stable binding 
to the SIRT1 nCaRE-B elements, even though it is not sufficient 
(Poletto et al., 2013). EMSA analysis, performed with nuclear extracts 
of HeLa cells expressing the deletion form of APE1, demonstrated 
that APE1 is part of a multiprotein complex, not the limiting factor in 
the binding reaction. As speculated by Okazaki and also in later 
work, the binding affinity observed for the multiprotein complex is 
higher than that detected when using purified APE1 protein alone 
(Figure 2). This suggested that other factors are necessary and coop-
erate with APE1 to fully exert this function, confirming previous ob-
servations (Chung et al., 1996; Kuninger et al., 2002). The two sub-
units of Ku antigen (Ku70 and Ku80) were among the protein factors 
already described by Chung et al. (1996) to be involved in the spe-
cific binding of nCaRE-A sequences. Here we demonstrated that 
Ku70 binding is not exclusively limited to the nCaRE-A elements, 
since we identified this protein in the complex that binds to the 
nCaRE-B sequence of SIRT1. The Ku heterodimer is a main compo-
nent of the nonhomologous end-joining pathway that repairs DNA 
double-strand breaks (DSBs), which are generally produced upon 
extensive oxidative and infrared damage to DNA (Lieber, 2010). The 
peculiar structure of Ku allows recognition and tight binding to DSBs, 
together with the recruitment of DNA-PKcs and other factors to form 
the active protein kinase complex DNA-PK that facilitates processing 
and ligation of broken ends (Walker et al., 2001; Postow, 2011). Its 
involvement in nCaRE binding is not clear, but emerging evidence 
suggests a biological role in its noncanonical functions (Adelmant 
et al., 2012). We envisage that Ku70 association with nCaRE ele-
ments could further facilitate APE1 binding, especially after DNA 
damage, since we observed increased interaction between the two 
proteins upon oxidative stress (Supplemental Figure S8).
We also better characterized the topology of the APE1-nCaRE 
complex. The palindromic nature of nCaRE-B sequences was 
described by Okazaki et al. (1991), who suggested the possible in-
volvement of a dimeric nuclear protein in this process. Here we sug-
gest that the SIRT1 nCaRE-B, due to its palindromic sequence, can 
potentially fold into a cruciform-like structure, and APE1 binding 
activity toward these elements strongly relies on the secondary con-
formation adopted by the oligonucleotide, as established for other 
DNA and RNA substrates (Figure 3B and Supplemental Figure S4; 
Poletto et al., 2013). Formation of similar cruciform-like structures by 
palindromic sequences has been described in eukaryotic cells, and 
their biological consequences have been related to different pro-
cesses, including regulation of transcriptional events when present 
in close proximity to gene promoters (Pearson et al., 1994; 
Shlyakhtenko et al., 2000; Alvarez et al., 2002; Cunningham et al., 
2003; Kurahashi et al., 2004). We therefore hypothesize a similar 
mechanism for SIRT1 transcriptional regulation. However, the re-
quirement of a specific recognition motif cannot be excluded since 
mutations in the SIRT1 nCaRE-B sequence, determining only a par-
tial disruption of the oligonucleotide secondary structure, did not 
completely affect APE1-binding activity in vivo (Figure 4B).
We further studied APE1’s transcriptional function on the SIRT1 
promoter. We found that APE1 is able to bind the nCaRE-B 
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et al., 2007; Nogales-Cadenas et al., 2009; Tabas-Madrid et al., 
2012), selecting Homo sapiens as the source for annotations and 
Biological Process as the GO category to perform the gene annota-
tion cooccurrence analysis.
Cell culture and transient transfection experiments
HeLa cells were grown in DMEM (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (Euroclone, Milan, Italy), 100 U/
ml penicillin, and 10 μg/ml streptomycin sulfate. One day before 
transfection, cells were seeded in 10-cm plates at a density of 3 ? 106 
cells/plate. Cells were then transiently transfected with plasmids of 
interest by using Lipofectamine 2000 reagent (Invitrogen), according 
to the manufacturer’s instructions. Cells were harvested 48 h after 
transfection.
Inducible APE1 knockdown and generation of APE1 
knock-in cell lines
Inducible silencing of endogenous APE1 and reconstitution with 
mutant proteins in HeLa cell clones was performed as described 
(Vascotto et al., 2009a,b). For inducible shRNA experiments, doxy-
cycline (1 μg/ml) (Sigma-Aldrich, St. Louis, MO) was added to the 
cell culture medium, and cells were grown for 10 d.
Plasmids and expression of recombinant proteins
Plasmid containing the human SIRT1 promoter was kindly provided by 
K. Irani, University of Pittsburgh (Pittsburgh, PA). This plasmid consists 
of a fragment of the human SIRT1 promoter (–1266 to +137 relative to 
transcription start site) cloned into the pGL4.1 firefly luciferase reporter 
vector (Promega, Madison, WI; Yamamori et al., 2010). The human 
SIRT1 promoter carrying the mutation at nCaRE-B sequences was 
generated with a Site-Directed Mutagenesis Kit (Stratagene, Santa 
Clara, CA), using the primers SIRT1-B mut, forward, 5?-TCATCTAGG-
TTTTATTTATATATTTTTTTGCTAAGG AGCGTCGCTCTTGCTGC C-
CAGGCTGGTGTG-3?, and SIRT1-B mut, reverse, 5?-CACACCAGCC-
TGGGC AGCAAGAGCGACGCTCCTTAGCAAAAAAATATATAAATA
AAACCTAGATGA-3?.
Expression and purification of recombinant proteins from E. coli 
were performed as previously described (Vascotto et al., 2009b; 
Fantini et al., 2010).
Antibodies and Western blot analysis
For Western blot analyses, the indicated amounts of cell extracts 
were resolved in 10% SDS–PAGE and transferred to nitrocellulose 
membranes (Schleicher & Schuell, BioScience, Dassel, Germany). 
Membranes were blocked with 5% (wt/vol) nonfat dry milk in phos-
phate-buffered saline containing 0.1% (vol/vol) Tween 20 and 
probed with monoclonal anti-FLAG antibody (Sigma), monoclonal 
anti-APE1 antibody (Vascotto et al., 2009a), monoclonal anti-Ku70 
(sc-12729; Santa Cruz Biotechnology, Santa Cruz, CA), monoclonal 
anti–RNA polymerase II (Abcam, Cambridge, MA), monoclonal anti-
SIRT1 (Abcam), monoclonal anti-p32 (Santa Cruz Biotechnology), 
and polyclonal anti-p53(acetyl K382) (Abcam). Blots were devel-
oped by using the enhanced chemiluminescence procedure 
(GE Healthcare, Piscataway, NJ) or Western Lightning Ultra (Perkin 
Elmer, Waltham, MA). Data normalization was performed by using a 
monoclonal anti-tubulin antibody (Sigma). Blots were quantified by 
using a Chemidoc XRS video densitometer (Bio-Rad, Hercules, 
CA).
Alignments and secondary structure predictions
Multiple alignments were performed using CLUSTALW2 (www.ebi 
.ac.uk/Tools/msa/clustalw2/).
MATERIALS AND METHODS
Bioinformatic analysis
All human and mouse DNA sequences were retrieved from the En-
sembl database, release 56 (www.ensembl.org/), by using a dedi-
cated program written in Perl that collects entries from this archive. 
A sequence window was selected that contains 5? genomic DNA of 
every gene coding for a protein. This region extends from 6000 
base pairs upstream and 1000 base pairs downstream of each tran-
scriptional start site. Gene Ontology (GO) annotations were ob-
tained from the Ensembl database by using the data-mining tool 
BioMart (www.ensembl.org/; Spudich et al., 2007). Human and 
mouse promoter regions were scanned for significant similarities to 
nCaRE-B by using Glsearch as program for local alignment (avail-
able in the Fasta3 program package; Pearson, 2000). Glsearch was 
chosen because it calculates an alignment that is global in the query 
and local in the library. The following nCaRE-B sequences were used 
as query (Izumi et al., 1996):
Alignments were computed with Altschul and Gish’s statistical 
estimates, which are more suitable for searching short query se-
quences (–z 3 option; Altschul, 1991). We selected only those pro-
moter genes that showed one or more matches for nCaRE-B 
sequences, allowing up to two mismatches in the case of the hu-
man genome and up to three mismatches in the case of the mouse 
genome; in fact, in the latter case, most alignments were found 
with three mismatches. From mouse promoter genes that con-
tained nCaRE-B elements, we retrieved only orthologous human/
mouse genes, as obtained from the BioMart Ensembl database. 
For the microarray filter, we cross-checked human genes selected 
from alignment search with microarray data obtained from the 
gene expression profile of HeLa cells silenced for APE1 by RNA 
interference (Vascotto et al., 2009a). The GO filter identified co-
regulated human genes, as determined by microarray analysis, 
studying the prevalence of their GO annotation terms. This analy-
sis was obtained by using a Perl program kindly provided by Corà 
et al. (2004), which performs an exact Fisher’s test based on hyper-
geometric distribution to determine whether the term appears 
in the set significantly more often than what is expected by 
chance. This program uses four different entries: 1) a file contain-
ing the whole GO database structure (OBO version 1.2; www 
.geneontology.org/); 2) the list of genes from the whole human 
genome, 4) a list of all genes with all the GO terms associated with 
them (as obtained from Ensembl), and 4) the set of genes to be 
tested. In general, a GO annotation term was considered to be 
significantly overexpressed when the corresponding p value (not 
corrected for multiple testing) was <1E-4. Phylogenetic footprint-
ing analysis consisted of the last selection from significant data 
obtained from the GO filter of that gene also present in the mouse 
orthologous data set.
Gene annotation co-occurrence analysis
Gene identifiers corresponding to the list of 57 putative genes regu-
lated by APE1 were submitted to GeneCodis (http://genecodis.cnb 
.csic.es/), a Web-based tool for ontological analysis (Carmona-Saez 
Name Sequence (5? to 3?)
nCaRE-B (PTH) TTTTTGAGACAGGGTCTCACTCTG
nCaRE-B1 (APE1) TTTTGAGACAGTCTCAGCTCTG
nCaRE-B2 (APE1) TTTTGAGACAGAGTTTCACTCTTG
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14, which is cleaved to a 14-mer in the presence of AP endonu-
clease activity. Alternatively, a 5?-32P-end-labeled ds SIRT1-B 
nCaRE-B oligonucleotide or a 5?-32P-end-labeled ds nCaRE SIRT1-
B oligonucleotide, bearing a single THF residue at position 12 
(bold) 5?-TTTTTGAGACGGAGTTTCGCTCTTG-3? (Integrated DNA 
Technologies, Munich, Germany), was used. The conversion of the 
radiolabeled THF-containing oligonucleotide substrate (S) to the 
shorter product (P) was evaluated on a denaturing 20% polyacryl-
amide gel.
Reporter assays
For reporter assay experiments, we used a human SIRT1 promoter 
plasmid allowing for promoter activity measurements upon lu-
ciferase assay, as already described (Yamamori et al., 2010). To this 
purpose, 2.5 ? 104 HeLa cells were seeded in a 96-well plate and 
cotransfected with 15 ng of human SIRT1 promoter, 0.3 ng of a 
constitutive Renilla reporter plasmid, and 75 ng of a vector express-
ing FLAG-tagged APE1 protein. When performing luciferase assays 
upon H2O2, cells were challenged with increasing amounts of H2O2 
in serum-free medium for 1 h at 37°C, and then firefly and Renilla 
luciferase activities were measured 24 h after the treatment by using 
the Dual-Glo Luciferase assay system (Promega), according to man-
ufacturer’s recommendations. Firefly activity was normalized to Re-
nilla activity to correct for differences in transfection efficiency. Re-
sults are from triplicate experiments.
Quantitative PCR
Total RNA from cell lines was extracted with the SV Total RNA isola-
tion System kit (Promega). One microgram of total RNA was reverse 
transcribed using the iScript cDNA synthesis kit (Bio-Rad), accord-
ing to the manufacturer’s instructions. Quantitative reverse-tran-
scription PCR was performed with a CFX96 Real-Time System 
(Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad). Primer se-
quences for human SIRT1 were those reported in Yamamori et al. 
(2010). Human glyceraldehyde-3-phosphate dehydrogenase was 
used as internal control; sense, 5?-CCCTTCATTGACCTCAACTA-
CATG-3?; antisense, 5?-TGG GATTTCCATTGATGACAAGC-3?.
Surface plasmon resonance analysis
Real-time binding assays were performed on a Biacore 3000 SPR 
instrument (GE Healthcare). Biotinylated ds oligonucleotides were 
immobilized on an SA-chip at the desired level, as a result of their 
injection at a concentration of 500 nM in HBS (20 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 150 mM NaCl, 
3.4 mM EDTA, and 0.005% [vol/vol] P20 surfactant, 0.1 mM Tris(2-
carboxyethyl)phosphine) at 10 μl/min as flow rate. Flow cell 2 con-
tained 100 RU of poly(dT); flow cells 3 and 4 contained 77 and 
60 RU of SIRT1-B nCaRE-B and SIRT1-B nCaRE-B mutated, re-
spectively; and flow cell 1 (with streptavidin) was left blank to be 
used as a reference surface. APE1 and its deletion mutant APE1N?33 
were serially diluted in running buffer to the indicated concentra-
tions and injected at a flow rate of 20 μl/min for 4.5 min at 20°C. 
Disruption of any complex that remained bound after a 3-min dis-
sociation was achieved by using an injection of 1 M NaCl at 20 μl/
min for 1 min. The BIAevaluation analysis package, version 4.1 
(GE Healthcare), was used to subtract blank signal and evaluate 
kinetic and dissociation constants. Kinetic parameters were esti-
mated assuming a 1:1 binding model and using Evaluation, ver-
sion 7 4.1 (GE Healthcare). An affinity steady-state model was ap-
plied to fit the RUmax data versus protein concentrations, and 
fitting was performed with Prism, version 4.00 (GraphPad, San 
Diego, CA; Fantini et al., 2010).
Potential secondary structures for SIRT1-B nCaRE-B oligonucle-
otide were determined by using the mfold Web Server program 
(http://mfold.rna.albany.edu/?q?mfold). Structure predictions were 
run by setting the program parameters as close as possible to the 
conditions used in binding assays (37°C and 50 mM monovalent 
cation).
Chromatin immunoprecipitation analysis
ChIP assay was performed by using a protocol described previously 
(Lirussi et al., 2012) on HeLa cells cotransfected with hSIRT1 pro-
moter and APE1-FLAG–tagged expressing vectors.
Preparation of nuclear cell extracts
Nuclear protein extracts were prepared as described earlier (Ziel 
et al., 2005).
Electrophoretic mobility shift assay analysis
APE1 binding to nucleic acids was assessed as already described 
(Fantini et al., 2010), with some modifications. Briefly, the indi-
cated amount of recombinant proteins or 5 μg of the reported 
nuclear extract was incubated at 37°C for 15 min with 250 pmol of 
unlabeled poly(dT) or 250 ng of sonicated salmon sperm DNA 
(Sigma). A 2.5-pmol amount of 32P-labeled, ds oligonucleotides 
was then added, incubated for additional 15 min, and further sep-
arated onto a native 6% wt/vol polyacrylamide gel at 150 V for 4 h. 
When performing supershift assays, 5 μl of monoclonal anti-APE1 
(Vascotto et al., 2009a), anti-Ku-70 (sc-12729; Santa Cruz Biotech-
nology) or anti-P2Y6 (Alomone Labs, Jerusalem, Israel) was prein-
cubated with HeLa nuclear extract from APE1SCR-1 clone at 4°C 
for 3 h.
Oligonucleotides used for EMSA were the following:
T7 endonuclease I footprinting
Footprinting analysis on the SIRT1 nCaRE-B sequence was con-
ducted using T7 endonuclease I. Briefly, 5?-32P-end-labeled nCaRE-
B SIRT1-B was digested with 5 U of T7 endonuclease I at 37°C for 
1 h and then incubated with 35 pmol of APE1 recombinant protein 
for 15 min at 37°C. The reaction mixtures were then loaded and 
separated for 2 h onto a denaturing 8 M urea sequencing gel. After 
separation, the gel was incubated for 30 min in a 10% methanol and 
10% acetic acid solution and then wrapped in Saran wrap and ex-
posed to film for autoradiography.
Determination of AP endonuclease activity
Determination of APE1 AP endonuclease activity was performed 
using an oligonucleotide cleavage assay, as described previously 
(Vascotto et al., 2009b). The indicated amount of recombinant 
APE1 protein was incubated with a 5?-32P-end-labeled 26-mer ds 
oligonucleotide containing a single THF artificial AP site at position 
Name Sequence (5? to 3?)
nCaRE-B 
SIRT1-A
Forward TTTTTGAGACAGAGTTTCACTCTTG
Reverse CAAGAGTGAAACTCTGTCTCAAAAA
nCaRE-B 
SIRT1-B
Forward TTTTTGAGACGGAGTTTCGCTCTTG
Reverse CAAGAGCGAAACTCCGTCTCAAAAA
Poly(dT) Forward TTTTTTTTTTTTTTTTTTTTTTTT
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Limited proteolysis
Suitable experimental conditions were chosen by testing proteolysis 
with different enzyme/substrate values; no preventive removal of 
DNA was performed. Thus limited proteolysis experiments on 
recombinant APE1 were conducted in 50 mM NH4HCO3, pH 7.5 
(reaction buffer), at 37°C by using an enzyme-to-substrate ratio 
ranging from 1:500 to 1:5000 (wt/wt). Three identical aliquots of 
APE1 (500 pmol) were combined with reaction buffer or DNA 
nCaRE-B ds oligonucleotides (PTH or nCaRE SIRT1-B; 5:1 mol DNA/
protein) dissolved in reaction buffer to generate samples (100-μl 
final volume each), which were incubated for 15 min at 37°C before 
protease addition. After digestion started, the extent of proteolysis 
was monitored on a time-course basis by sampling 10 μl of the mix-
ture at time intervals ranging from 5 to 120 min. Reaction samples 
were immediately quenched with 5% formic acid and then frozen in 
dry ice before liquid chromatography–electrospray ionization–mass 
spectrometry (LC-ESI-MS) analysis.
LC-ESI-MS analysis
APE1 digests were analyzed with a Q-TOF Premier mass spectrom-
eter (Waters, Milford, MA) equipped with a nanospray source. Pep-
tide mixtures were separated on an Atlantis C18 column (100 μm ? 
100 mm, 3 μm), using a linear gradient ranging from 30 to 60% ac-
etonitrile in 1% formic acid, over a period of 50 min at a flow rate of 
800 nl/min. Spectra were acquired in the m/z ? 650–2500 range. 
Data were processed by using MassLynx software (Waters). Mass 
calibration was performed using multiply charged ions from horse 
heart myoglobin (Sigma). Depending on polypeptide size, mass val-
ues are reported as monoisotopic or average values. Observed 
mass values are assigned to specific polypeptides by using Paws 
software (Proteometrics, New York, NY), based on APE1 sequence 
and selectivity of the protease used for protein digestion.
Statistical analysis
Statistical analyses were performed by using the Excel (Microsoft, 
Redmond, WA) data analysis program for Student’s t test analysis. 
p < 0.05 was considered as statistically significant.
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Emerging Roles of the Nucleolus in Regulating
the DNA Damage Response:
The Noncanonical DNA Repair Enzyme APE1/Ref-1
as a Paradigmatical Example
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Abstract
Significance: An emerging concept in DNA repair mechanisms is the evidence that some key enzymes, besides
their role in the maintenance of genome stability, display also unexpected noncanonical functions associated
with RNA metabolism in specific subcellular districts (e.g., nucleoli). During the evolution of these key enzymes,
the acquisition of unfolded domains significantly amplified the possibility to interact with different partners and
substrates, possibly explaining their phylogenetic gain of functions. Recent Advances: After nucleolar stress or
DNA damage, many DNA repair proteins can freely relocalize from nucleoli to the nucleoplasm. This process
may represent a surveillance mechanism to monitor the synthesis and correct assembly of ribosomal units
affecting cell cycle progression or inducing p53-mediated apoptosis or senescence. Critical Issues: A paradigm
for this kind of regulation is represented by some enzymes of the DNA base excision repair (BER) pathway, such
as apurinic/apyrimidinic endonuclease 1 (APE1). In this review, the role of the nucleolus and the noncanonical
functions of the APE1 protein are discussed in light of their possible implications in human pathologies. Future
Directions: A productive cross-talk between DNA repair enzymes and proteins involved in RNA metabolism
seems reasonable as the nucleolus is emerging as a dynamic functional hub that coordinates cell growth arrest
and DNA repair mechanisms. These findings will drive further analyses on other BER proteins and might imply
that nucleic acid processing enzymes are more versatile than originally thought having evolved DNA-targeted
functions after a previous life in the early RNA world. Antioxid. Redox Signal. 20, 621–639.
Overview on RNA Oxidative Damages, a Glimpse
on Human Pathologies
An emerging body of evidence links DNA repair pro-teins to specific aspects of RNA metabolism associated
with quality control processes toward damaged RNA mole-
cules (e.g., oxidized or abasic RNA) (Fig. 1). Due to its intrinsic
nature (i.e., mostly single-stranded and with bases not pro-
tected by hydrogen bonding or binding to specific proteins)
and to its relatively higher amount, RNA may be more sus-
ceptible to oxidative insults than DNA (107). Not only 8-
hydroxyguanosine (8-OHG) but also 5-hydroxycytidine,
5-hydroxyuridine, and 8-hydroxyadenosine have been iden-
tified in oxidized RNA (160).While oxidative damage toDNA
is essentially repaired through the base excision repair (BER)
pathway, no evidences of similar repair processes have been
described for RNA molecules, even though some BER pro-
teins recently entered the arena of the RNome world (138). If
not repaired, damage to RNA molecules may lead to ribo-
somal dysfunctions and erroneous translation; thus, signifi-
cantly affecting the overall protein synthesis mechanism (38,
135). Moreover, RNA damage has been shown to cause cell
cycle arrest and cell death with or without the contribution of
p53 and inhibition of protein synthesis (11). Oxidative RNA
modifications can occur not only in protein-coding RNAs, but
also in noncoding RNAs that recently have been revealed to
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contribute to the complexity of the mammalian brain (109). It
has been hypothesized that RNA oxidation, causing aberrant
expression of microRNAs and proteins, may initiate inap-
propriate cell fate pathways. Such sublethal damage to cells,
while less toxic than genomic mutations and not inheritable,
might be associated with underlying mechanisms of degen-
eration, such as age-associated neurodegeneration.
Currently, little is known about how cells may cope with
damaged RNA, either modified or oxidized, but it is clear that
such RNA can impair protein synthesis; thus, affecting cell
function and viability. Therefore, specific surveillance mech-
anisms are needed to remove damaged molecules from the
RNA pool to guarantee the biological integrity of cells. The
idea that quality control mechanisms might exist to repair
RNA was put forward after the identification of the bio-
chemical activities of the mammalian AlkB homologs. In
particular, it was discovered that AlkB (from Escherichia coli)
and the human homolog hABH3, besides being able to di-
rectly reverse alkylation damage on DNA bases, were able to
demethylate damaged bases on RNA; thus, playing a key role
in the repair of specific RNA lesions (1, 111). While repair
mechanisms have been demonstrated for alkylated RNA, the
existence of such cleansing activities has not yet been identi-
fied for oxidatively damaged RNA. However, their existence
appears unlikely, in the absence of direct reversal strategies,
due to the lack of a template for accurate repair, as happens in
the case of double-stranded DNA. The observation that under
oxidative stress RNA modifications can occur up to a 10–20-
fold higher extent than DNA (88), raises the question of how
oxidized RNA may be specifically removed or repaired. The
recent findings by Berquist et al. (12), Barnes et al. (7), and
Vascotto et al. (149) highlight a novel ‘‘moonlighting’’ role for
the repair apurinic/apyrimidinic (AP) endonuclease 1 (APE1)
in RNA metabolism, both as a possible ‘‘cleansing’’ factor for
damaged abasic RNA and as a regulator of c-myc gene ex-
pression through mRNA decay. In agreement with this hy-
pothesis, a significant reduction in the protein synthesis rate
occurs upon silencing of APE1 expression (149). Enzymatic
(e.g., by specific N-ribohydrolases, including the toxin ricin)
(126), besides spontaneous (91), generation of abasic sites
occurs upon ribosomal RNA (rRNA) oxidation. A role for the
Y box binding protein 1 (YB-1) in recognizing 8-OHG sites has
also been hypothesized (56), but no specific enzymatic
mechanisms that can remove the oxidized base have been
described yet. The accumulation of the 8-OHG substrates,
which occurs upon silencing of APE1 expression (149), may
thus, be explained under the assumption that enzymatic re-
moval of oxidized RNA bases represents the limiting step in
the process. According to this model, as already hypothesized
for DNA substrates, APE1 could act through stimulation of a
yet unknown glycosylase activity, by allowing a faster turn-
over (152). The APE1 interaction with RNA and with proteins
FIG. 1. Potential consequences of unrepaired RNA damage. RNA intrinsic nature renders it more susceptible to damage,
such as oxidation. The molecular and surveillance mechanisms that cope with RNA damage are still poorly understood. If
unrepaired, aberrant RNA may give rise to translation of defective and toxic protein aggregates that eventually leads to cell
cycle arrest and consequently to cell death. These molecular processes have been associated with cancer onset, aging, and
neurodegeneration.
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involved in ribosome assembly (i.e., RSSA, RLA0) and RNA
maturation (i.e., PRP19) within the cytoplasm (149), could also
represent a molecular proof of concept for the ‘‘extranuclear’’
functions of this noncanonical DNA repair enzyme. The RNA-
mediated association with some of the APE1 protein partners
would reinforce the view of APE1 as an essential factor in the
RNA quality control process and may also explain the cyto-
plasmic accumulation of APE1 observed in a number of tu-
moral cell types (136, 137). An age-associated increase in
oxidative nucleic acids damage, predominantly to RNA, has
been recently highlighted in neurons from human and rodent
brains; this phenomenon may play a fundamental role in the
development of age-associated neurodegeneration (109). Oxi-
dative damage to RNA molecules, both coding for proteins
(mRNA) or performing translation (rRNA and tRNA), has
been recently associated with the occurrence of neurodegen-
erative diseases, such as Alzheimer’s disease (AD), Parkinson
disease (PD), dementia with Lewy bodies, and amyotrophic
lateral sclerosis (107) and its impact in cancer development
cannot be excluded, at present (11). Remarkably, studies per-
formed on either human samples or experimental models,
show that RNA oxidation is a characteristic of aging neurons.
Its prominent occurrence in vulnerable neurons at early stage
of age-associated neurodegenerative disorders indicates that
RNA oxidation actively contributes to the development of the
degeneration. Therefore, all the hypotheses concerning the in-
volvement of APE1 in the development of such pathologies
should be re-interpreted in light of these findings. The role
played by APE1 in RNA-related processes needs further in-
vestigations, since its ability to recognize and cleave the RNA
abasic sites (12, 42, 89, 138, 149) is compatible with a leading
role in the early stages of the RNA quality control process.
Additional studies aiming at the understanding the mecha-
nisms related to oxidative RNA damage processing and their
consequences may provide significant insights into the patho-
genesis of neurodegenerative disorders, leading to improve-
ments in the current therapeutic strategies.
The vast majority of cellular RNA is transcribed, assem-
bled, and processed within nucleoli. These subcellular com-
partments appear to be perfect sensors for cellular stress, as
they integrate RNA damage and growth control with signals
to the DNA repair machineries. The following paragraphs
will describe the emerging dynamics roles of this organelle in
regulating the trafficking of DNA repair proteins during
genotoxic damage.
Structure, Composition, and Classical Functions
of the Nucleolus
The nucleolus is considered the ribosome factory of eu-
karyotic cells (18, 62) in which synthesis, maturation, and
processing of rRNA, as well as assembly of rRNA with ribo-
somal proteins (RPs) take place (62) (Fig. 2). This membrane-
less organelle is considered a dynamic structure (4, 84), where
protein complexes are continuously exchanged with the nu-
cleoplasm. Its classical tripartite organization has been dis-
sected using electron microscopy and reflects the different
steps of ribosomal biogenesis (130): (i) the fibrillar center,where
the RNA polymerase I (Pol I) transcription starts; (ii) the dense
fibrillar component, where the initial stages of pre-rRNA pro-
cessing occur and (iii) the granular component involved in the
late processing steps (62). Transcription of the ribosomal DNA
(rDNA) repeats generates a 47S pre-rRNA precursor that is
further cleaved and processed into 28S, 18S, and 5.8S rRNAs
and concomitantly assembled into large and small ribosomal
subunits together with the 5S rRNA molecules (18, 32a). These
complex series of events is controlled, in yeast, by roughly 150
small nucleolar RNAs (snoRNAs) and two large ribonucleo-
protein complexes, named small subunit processosome (for the
40S ribosomal subunit) and large subunit processosome (for
the 60S ribosomal subunit) (130). Two types of nucleotide
modifications (2¢-O-methylation and pseudouridylation) are
introduced during the maturation process by snoRNAs be-
longing to the box C/D or box H/ACA families and mediate
endonucleolytic cleavages of pre-RNAs (130, 32a). In addition,
ribosomal gene transcription is regulated through the modu-
lation of the transcriptional apparatus and epigenetic silencing
(131). Large and small mature ribosome particles are inde-
pendently exported to the cytoplasm through an exportin 1
(CRM1) and Ran-GTP-dependent mechanism: export of 60S
subunit requires the exchange of complexes Noc1-Noc2 by
Noc3-Noc2 (102) and the associationwith the adaptor shuttling
protein NMD3 (142), whereas the 40S needs the heterodimer
Noc4p/Nop14p (103). The work by Hinsby et al. exploited a
machine learning-based predictor of nuclear export signals to
analyze the late stage pre-40S complex, suggesting a role also
for the human homolog of yeast DIM2p in the targeting and
translocation of the late 40S to the cytoplasm (63).
The organization, the number, and the size of nucleoli in
each cell is directly linked to the nucleolar activity (i.e., Pol I
transcription rate), which, in turn, depends on cell growth and
metabolism (20). Generally, highly proliferating cells present
many small nucleoli (62, 130). Ribosomal biosynthesis is a
highly energy- and resources-consuming process (134); this
explains why this process is tightly regulated by changes in cell
proliferation, growth rates, and metabolic activities. Nucleoli
constantly integrate different signaling events, maintaining the
ribosomal subunit pool required to properly support protein
synthesis during cell growth and division (18).
Biosynthesis of ribosomes is a very efficient process, since it
has been estimated that 14,000 new ribosomal subunits can be
synthesized every minute in an exponentially growing cell
(125). The process has to be fine-tuned and several evidences
indicate that ubiquitin and ubiquitin-like proteins-based
regulatory circuits may control different stages of ribosome
formation (129). Lam et al. (83) demonstrated that the levels of
unassembled RPs within nucleoli exceed the required
RP:rRNA ratio and identified an ubiquitin-proteasome-
mediated mechanism, that monitors and degrades this excess
(115). Ribosomal structural proteins are imported from the
cytoplasm in supra-stoichiometric complexes and exported in
the form of assembled ribosomal subunits; this ensures that
RPs are never rate-limiting for the ribosomal assembly (83).
The excess of protein undergoes ubiquitylation and degra-
dation in the nucleoplasm through the proteasome system
(114, 129), indicating that mammalian cells produce large
amount of these proteins and degrade those that are not as-
sembled with rRNA.
‘‘Dynamic Trafficking:’’
Keywords of the Nucleolar Physiology
The nucleolus appears as a very dynamic organelle and
different types of rearrangements involve this subnuclear
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district. First, the ribosome assembly is a vectorial process, in
which the ribosomal particles move away from their biogen-
esis sites. The second dynamic aspect is represented by the
constant flux of proteins from the nucleoli to the nucleoplasm.
Lastly, nucleolar components present scheduled reorganiza-
tion every cell cycle, with assembly and disassembly steps
required for the redistribution of nucleolar components be-
tween the two daughter cells (110).
The cyclic reorganization observed during cell cycle in-
volves the nucleolus as a whole, as this organelle assembles at
the end of each mitosis to remain functionally active until the
beginning of the next one (4, 62). The nucleolar disassembly
observed during mitosis is linked to rDNA transcriptional
repression induced by CDK1-cyclin B-directed phosphoryla-
tion of components of the rDNA transcription machinery
(130). Conversely, the formation of functional nucleoli at the
exit of mitosis is not uniquely controlled by the resumption of
rDNA transcription, but by a two-steps process regulated by
cyclin-dependent kinases that connects the resumption of
rDNA transcription and the restoration of rRNA processing
(130). During late telophase, nucleoli form around the nucle-
olar organization regions, which are chromosomal domains
where rDNAs, clustered in head-to-tail arrays (62, 84), are
transcribed. This sub-nuclear compartmentalization allows
the cells to locally concentrate all the factors required for the
ribosomal biogenesis (18, 20).
The Way to Move: Visitors Versus Resident
Nucleolar Proteins
Differently from nuclear localization signals (NLSs), nu-
cleolar localization sequences (NoLSs) are not well charac-
terized and no clear consensus sequences have been described
yet (115, 130). NoLSs identified so far are rich in basic residues
(e.g., Arg and Lys) (40), but also Trp residues were described
to play a functional role for the nucleolar localization of nu-
cleophosmin 1 (NPM1) (108a). Since the mass per unit nu-
cleolar volume is only twofold higher compared with the
nucleoplasm, all diffusing macromolecules should theoreti-
cally be able to enter nucleoli: it is now clear that the residence
time of nucleolar proteins depends on their relative affinity for
preanchored complexes present within the nucleolus itself
FIG. 2. The nucleolus, a multifunctional domain. The unveiling of the ‘‘nucleolome’’ allowed the understanding of the
complexity of the nucleolus, firstly described only as a ribosome factory. The multifunctionality of the nucleolus includes
different noncanonical functions as the control of cell proliferation and cell growth, regulation of protein stability, stress and
DDR, telomere metabolism, maturation of small RNAs, and control of viral life-cycle. An illustrative mechanism for each
function is summarized. MDM2, mouse double minute 2 homolog; ARF, p14 alternative reading frame; ADAR2, double-
stranded RNA-specific adenosine deaminase 2; NS, nucleostemin; VHL, von Hippel-Lindau protein; HIF, hypoxia-inducible
factor; ING1, inhibitor of growth family protein, member 1; PML, promyelocytic leukemia protein; DNA Topo I, DNA
topoisomerase I; TERC, telomerase RNA component; TERT, telomerase reverse transcriptase; GNL3L, guanine nucleotide
binding protein-like 3 (nucleolar)-like; TRF, telomeric repeat-binding factor 2; REV, regulator of expression of virion protein;
Tat, trans-activator of transcription; Ub, ubiquitin; DDR, DNA damage response. To see this illustration in color, the reader is
referred to the web version of this article at www.liebertpub.com/ars
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(114, 115). The ability of different proteins to localize within
the nucleolus has been linked to the stable interaction with
anchored resident proteins, such asNPM1 or nucleolin (NCL),
that may act as carriers, or as a retention scaffolds, supporting
the idea that the residence time of proteins within the nucle-
olar compartment is strongly related to their specific interac-
tions in a process known as ‘‘nucleolar sequestration’’ (40, 115,
130). Though all the molecules resident in the nucleoplasm
may, in principle, enter into nucleoli, only those with an af-
finity for nucleolar resident proteins, are retained for longer
times (110). For this reason some authors suggested the con-
cept of ‘‘retention signal’’ in place of ‘‘targeting signal’’ for the
nucleoli (121). Since the residence time is quite short andmost
of the nucleolar proteins shuttle from nucleoli to nucleoplasm
and vice versa, the interaction of visitor proteins with an-
chored nucleolar residents has to be reversible (110, 115).
Current models show that proteins and RNAs continuously
flow and freely diffuse through the nuclear space (131): the
average residence time for most nucleolar proteins within
nucleoli is estimated to be only a few tens of seconds. Thus,
nucleolus appears as a steady state structure with its com-
ponent in a dynamic equilibrium with the surrounding nu-
cleoplasm (121). However, in spite of this continual exchange
of molecules between these two compartments, nucleolar
domains are maintained because the number of retained
proteins is higher than the amount of molecules that are re-
leased from the same domain (32a). Resident factors, able to
connect and bind multiple protein partners, are considered as
‘‘hub proteins’’ and might be responsible for the nucleolar
localization of the vast majority of visitor proteins in the ab-
sence of RNA–protein interactions. Each hub protein may
have different recognition requirements; thus, possibly ex-
plaining the occurrence of different NoLSs. Two typical ex-
amples of hub proteins are NCL and NPM1, which contain
disordered regions involved in protein–RNA interactions
(40).
Recently, an additional protein retention mechanism based
on GTP-driven cycles has been identified for nucleostemin
(121). The GTP-GDP exchange mechanism is not the only
intracellular signal able to move nucleolar proteins: stimuli as
the hydrogen ion were already described by Mekhail et al.
(98), who demonstrated how the nucleolar sequestration of
the von Hippel-Lindau protein after a pH change promotes
the stabilization of the hypoxia-inducible factor, triggering a
general cell response to hypoxic conditions (115).
New Concepts in the Nucleolus Physiology:
Beyond the Ribosome Factory
In the 60s, after the identification of the localization of ri-
bosomal genes, the main function of the nucleolus was nicely
summarized as ‘‘an organelle formed by the act of building a
ribosome’’ (63). In the last decades, thanks to the development
of technologies, such as protocols for the isolation of large
amounts of nucleoli and the improvement of high-throughput
mass-spectrometry-based proteomic approaches, several
proteomic analyses were undertaken, unveiling the ‘‘nucleo-
lome’’ (4, 5, 18, 32a, 125). Over 4500 proteins were described to
localize within nucleoli and both bibliographic and bioinfor-
matics analyses allowed to classify eight major functional
groups (RPs, ribosome biogenesis, chromatin structure,
mRNAmetabolism, translation, chaperones, fibrous proteins,
and others [see Fig. 3 for further details]) (3, 18, 32a, 108).
Characterization of the nucleolar proteome under different
stress conditions (e.g., actinomycin D) further underlined the
complexity of the nucleolome dynamics (5).
FIG. 3. Classification of functional groups
and subgroups for the ‘‘nucleolome.’’
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The nucleolome includes proteins related to cell cycle reg-
ulation, DNA damage and pre-mRNA processing (84), sug-
gesting that this organelle may act as a multitasking district,
beingmore than a simple ribosome factory (18, 62, 63, 84, 125).
These particular multifunctional features are possibly related
to the presence of many different nucleolar proteins endowed
with multiple roles (e.g., NCL and Nopp140) (90a). Nucleolar
proteins unrelated to ribosome assembly mostly contain an
RNA-bindingmotif or have a chaperone function and are able
to shuttle between the nucleolus and the nucleoplasm (90a). It
is currently known that nucleoli carry outmany nonribosomal
activities, such as: control of cell cycle and proliferation (62,
63, 130), stress sensing (18, 21, 64, 96, 108, 124, 139), tumor
surveillance, DNA damage repair (18, 41, 84), regulation of
protein stability and apoptosis, telomere metabolism (18),
maturation of small RNAs, including tRNAs and small nu-
clear RNAs, maturation of the spliceosome and of the signal
recognition particle (63, 115, 121), and also control of viral life-
cycle (62, 71), acting in several ways as a sequestration core
facility (Fig. 2) (21, 40, 63).
The assumption that a protein acts and executes its func-
tions where it is more abundant is invalid for some nucleolar
components: a high protein concentration in a given cellular
compartment might not correspond to a quantitative signal
for its activity (114). A clear example is represented by the
many DNA repair proteins that reside within nucleoli (see
Table 1 for more details), which in this instance, appear to act
as storage sites (see below). After nucleolar stress or DNA
damage, these proteins can relocalize to the nucleoplasm. The
nucleolar stress responsemay therefore, act as amechanism of
surveillance monitoring the synthesis and the correct assem-
bly of ribosomal units: it may halt the cell cycle progression
until enough functional ribosomes are built or it may induce
p53-mediated apoptosis or senescence (134). This represents
an elegant and efficient way to coordinate arrest of cell growth
and induction of DNA repair by controlling only the subcel-
lular distribution of proteins.
Linking Nucleolar Physiology to Human Diseases
Several reports highlighted the presence of a layer of het-
erochromatin, called perinucleolar compartment (PNC), at
the nucleolar periphery. The PNC is associated with specific
DNA loci and it is enriched in RNA-binding proteins and
RNA polymerase III transcripts (62, 114). These discoid-
shaped caps are usually found in mammalian transformed
cells, tumor-derived cell lines, and tumor biopsies, accounting
for a possible connection between PNC and tumor initiation
and progression (114). Despite the apparent link between
cancer and PNC, the exact role of these nucleolar subdomains
has not been identified yet.
Nucleoli are closely linked to cellular homeostasis and
human health (62): rapidly proliferating cells, such as cancer
cells, usually present a strong upregulation of genes involved
in the ribosomal biogenesis. This phenomenon accounts for
the presence of several prominent nucleoli that are a typical
cytological feature of neoplastic cells (129). Morphological
and functional changes associated with cancer usually corre-
late with quantitative and qualitative differences in the ribo-
some biosynthesis rate (62) and are a consequence of the
increasedmetabolic needs of the cell (105). This could indicate
that the nucleolus undergoes an adaptive response upon
cellular transformation; on the other hand, the increased rate
of ribosome biogenesis might be actively involved in, and
contribute to, tumorigenesis (105). More recently, the accu-
mulation of chemically modified ribosomes upon oxidative
stress (e.g., bearing 8-OHG modifications, or cross-linked
rRNA-RPs complexes) is emerging as a contributing factor in
the progression of neurodegenerative diseases, such as AD
and PD (62). In addition, a novel link between nucleolar
damage and neurodegeneration has recently been established
through the association of PD with nucleolar integrity. These
interesting findings also establish the existence of a direct
signaling axis connecting the ribosomal synthesis rate and
oxidative stress (122). Under this perspective, the deep un-
derstanding of changes related to tumor progression and the
composition and dynamics of the nucleolome might be im-
portant to clarify the mechanisms of tumorigenesis and for
designing new therapeutic strategies.
Dynamics of DNA Repair Proteins During Genotoxic
Damage: Nucleolus and RNA Binding
Cellular life is continuously threatened by stressful condi-
tions, such as viral infections, oncogenic activations, temper-
ature shocks, and genotoxic damage, which must be
immediately dealt with by the cell tomaintain its homeostasis.
DNA damage typically involves the storage sites of the
genetic material, such as nucleus and mitochondria. De-
pending on the origin of the genotoxin (exogenous vs.
endogenous), its nature (physical vs. chemical) or its uptake
mechanisms, differential burden of damage can be accu-
mulated both in nuclear and in mitochondrial DNA. Upon
genotoxic insults a dynamic redistribution of DNA repair
proteins to the site of damage is frequently observed; this
phenomenon leads to the accumulation of DNA repair fac-
tors, often into spatially restricted foci. Relocalization events
usually occur through cytoplasmic-mitochondrial, cyto-
plasmic-nucleoplasmic, and nucleolar-nucleoplasmic shut-
tling regulated by post-translational modifications (PTMs)
and triggered by the damage itself (51).
Why nature selected such a time-consuming process in-
volving reorganization of cell proteome upon DNA damage,
instead of constitutively accumulating eachDNA repair factor
within the proper target compartment? Is there any functional
relationship between RNAmetabolism and the DNA damage
response (DDR), which may involve an active site of RNA
production, such as the nucleolus? These legitimate questions
are still a matter of debate; however, based on existing data at
least four possible explanations, not mutually exclusive, ap-
pear reliable: (i) the concentration, under physiological levels
of DNA damage, of high amounts of DNA repair proteins in
specific subcellular regions might be deleterious for nucleic
acids integrity. Many repair proteins, in fact, are endowed
with DNA trimming or modifying activities. Examples in-
clude APE1 or the DNA polymerase b (Polb); overexpression
of these proteins has already been shown to promote genomic
instability, possibly due to the lack of coordination of their
enzymatic activities (26); (ii) repair factors may exert more
than one specific function that cannot be directly linked to
their DNA repair activity. This situation is nicely exemplified
by the APE1 protein, which nucleolar localization is necessary
for cellular proliferation (see below), or by proteins, such
as the Werner syndrome helicase (WRN), or the flap
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endonuclease 1 (FEN1) (54), that are required for the active
transcription of ribosomal genes in the nucleolus. All these
factors promptly relocalize to the nucleoplasm to exert their
DNA repair function upon UV irradiation; (iii) while a lower
steady-state amount of DNA repair enzymes is sufficient to
grant a basal level of genome stability maintenance, it is likely
that genotoxin-induced protein accumulation mechanisms
have evolved, to cope with sustained DNA damage. Thus,
increasing the local concentration of DNA repair factors may
be a simple and fast way to amplify the local DNA repair
capacity; (iv) disruption of the nucleolar structure, often ob-
served occurring upon DNA damage, may halt rRNA pro-
duction; thus, leading to a block of the protein synthesis
machinery and allowing proper DNA repair. This may rep-
resent an efficient coupling mechanism involving nucleolus
dynamics, RNA-binding, and DNA repair, which allows
synchronization of DDR and arrest of cellular growth.
While many examples of proteome dynamics have been
reported to occur during DDR, this review will focus on the
relocalization of nucleolar proteins; for detailed information
concerning general subcellular reorganization, please refer to
Tembe and Henderson (139) and references therein.
The Nucleolus as DNA Damage Sensor and Storage
Facility for DNA Repair Proteins
As already mentioned, recent proteomic analyses have
pointed at the nucleolus as a mediator of the cell cycle regu-
lation, tumor suppressing or protumorigenic activities, and
DDR (5, 17, 63, 108). The presence of rRNA and hub proteins,
such as NCL and NPM1 is likely the critical factor for the
nucleolar accumulation ofmany proteins not uniquely related
to ribosome biogenesis (27, 40). Among these, many DNA
repair factors have been shown to localize within the nucle-
olus (Table 1), which acts as a stress response organelle and
responds, in a unique damage-specific manner, to different
cellular stresses (5, 17, 30, 106). During a stress response a
broad reorganization of the nucleolar proteome occurs; in-
terestingly, the vast majority of nucleolar proteins migrate
toward the nucleoplasm and not vice versa, indicating that
the nucleolus may act as a reservoir able to release critical
factors upon DNA damage (108, 139). Very few proteins have
been reported to migrate to the nucleolus during the stress
response. Among these ING1 and PML, which are thought to
participate in triggering of apoptosis and in cell cycle arrest,
respectively (139). Intriguingly, chaperones, such asHsc70 are
targeted to the nucleolus after the stress response, possibly to
restore the nucleolar function during the cellular recovery
from stress. Typically, during the response to DNAdamage or
transcriptional inhibition, one of the first events is represented
by the interruption of the ribosomal synthesis (108). This
mechanism likely represents a cellular strategy to maintain
homeostasis, indeed, as already pointed out, the ribosomal
biogenesis is a rather expensive energy-consuming process
(20). The impairment of rRNA transcription and processing is
often, but not always, associatedwith nucleolar disintegration
and condensation phenomena that lead to the formation of
caps and necklace-like structures (20, 106). An extensive
analysis of the effects of chemotherapeutic drugs on ribosome
biogenesis and nucleolar integrity has recently been carried
out by Burger et al. (23). For a broader list of responses to
different stress stimuli, please refer to Boulon et al. (20). Along
with the inhibition of ribosomal biogenesis, massive reorga-
nization occurs, with a rapid outflow of ‘‘nucleolar effectors’’,
such as p14Arf, NCL, and NPM1, which slow down or arrest
the cell-cycle in both p53-dependent and independent man-
ners (20, 31, 34, 49, 86). Concurrently, also DNA repair factors
stored within nucleoli and frequently bound to NCL and
NPM1 are released into the nucleoplasm; the transient arrest
of the cell-cycle progression possibly facilitates the DNA re-
pair process. Only after resolution of DNA damage, rRNA
synthesis is restored, as suggested by the inverse correlation
existing between the rDNA transcription rate and c-H2AX
foci number (80). Notably, many nucleolar effectors also play
a role within the nucleoplasm: beside the contribution to the
modulation of the cell-cycle, several reports have pointed out
that NCL or NPM1 may directly participate in the DDR. For
instance, NCL has been shown to tune proliferating cell nu-
clear antigen (PCNA) activity in the nucleotide excision repair
(NER) pathway (161), while NPM1 has been involved in the
BER modulation (see below). Interestingly, both these pro-
teins display strand annealing activity in vitro (19, 55) and
have been identified as stress-responsive RNA-binding pro-
teins, suggesting that upon genotoxic damage these factors
maymodulate DNA, as well as RNA repair or cleansing (162).
More importantly, emerging evidences further highlight the
importance of nucleolar hub proteins in human pathology.
The link between NPM1 and oncogenesis, for example, is a
well-established paradigm (31, 52, 151) and we recently
demonstrated that in acute myeloid leukemia bearing NPM1
mutations, the cytoplasmic de-localization of the mutant
NPM1c + leads to extensive BER impairment due to APE1
nuclear deprivation (150). This evidence denotes how the
deregulation of an important nucleolar factormight impact on
the overall cellular dynamics and not only on the ribosome
biogenesis, supporting the view of the nucleolus as a multi-
functional and versatile organelle. Recent evidences from
Lewinska et al. showed that, in yeast, the nucleolus acts as
stress sensor also for oxidative stress. Their work linked the
nucleolar exit of the Pol I-specific transcription factor Rrn3p,
to the response to oxidation, suggesting that oxidative dam-
age is indeed a cellular stress that is sensed from the nucleolus
leading to arrest of the ribosome transcription (87). Interest-
ingly, diethyl maleate-induced oxidative stress has been
demonstrated to modulate also the whole nuclear export
system through impairment of the CRM1-mediated nuclear
export, coupled to relocalization of the nuclear pore compo-
nent Nup98 to the nucleolus (33). Altogether, these observa-
tions underline the role of the nucleolus as stress sensor,
further confirming the validity of the aforementioned model
involving arrest of ribosome biogenesis, followed by nucleo-
plasmic and nucleolar proteome rewiring.
The damage-specificity of the nucleolar response is clearly
depicted by the differential response to diverse DNA dam-
aging stimuli: DNA repair factors undergo selective mobili-
zation upon specific genotoxic conditions (Table 1). UV and
ionizing radiation (IR), for instance, elicit markedly differen-
tial responses in terms of nucleolar proteome reorganization.
Whereas UV stress is characterized by fast and persistent
(hours), fluctuations of nucleolar nonhomologous end joining
(NHEJ) proteins, IR lead to quicker (minutes), but less per-
sistent responses, which are more limited, in terms of mag-
nitude (106). The dynamic reorganization of nucleolar
proteins upon DNA damage has been nicely described by
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Adelmant et al., who showed that microinjection of sheared
DNA, to mimic the presence of strand breaks, leads to
the rearrangement of Ku complexes. Intriguingly, in the ab-
sence of DNA damage, Ku associates with rRNA- and RP-
containing complexes; a DDR onset elicits the exit of Ku from
nucleoli and the modification of its interactome (2). This
process likely represents a general response mechanism,
where the nucleolus acts as a sensitive ‘‘antenna’’ for stress
and DNA damage and as central hub for the coordination of
the cellular response to stress conditions. The ability to un-
dergo highly dynamic and selective reorganization allow for
prompt release of DNA repair factors that are stored within
this organelle. An essential question still remains to be an-
swered: which is the triggering event that begins the signaling
cascade linking DNAdamage to the early nucleolar response?
PTMs are usually a quick way to rewire the cellular proteome.
APE1 and WRN translocation from the nucleolus is for in-
stance triggered by acetylation (16, 89); on the contrary, FEN1
has been shown to migrate to the nucleoplasm upon UV ir-
radiation in a phosphorylation-dependent manner. Re-
markably, mutations that mimic or impair the UV-induced
FEN1 phosphorylation, cause UV sensitivity (54), suggesting
thatDNAdamage-inducedprotein translocation is essential for
a correct DDR. Griffiths et al. pointed to SUMOylation as the
major PTM targeting DNA glycosylases in yeast (51); this PTM
has also been implicated in the modulation of rDNA repair
through export of the rDNAdouble-strandbreaks (DSBs) to the
nucleoplasm by the homologous recombination (HR) machin-
ery (39). In addition, the nucleolus has been reported to contain
several DNA damage sensors (e.g., the ataxia telangiectasia
mutated [ATM], the ataxia telangiectasia and Rad3-related
[ATR], and p53) (5, 123) and it has been demonstrated that,
upon DNA damage induction, Pol I-mediated transcription is
blocked in an ATM-dependent manner, and not by the DNA
damage itself. Interestingly, through microirradiation studies,
Kruhlak et al. showed that transcription of rDNA is transiently
arrested only in damaged nucleoli, whereas the neighboring
ones maintain normal transcriptional activity (80). Moreover,
Rubbi and Milner, have elegantly shown that nucleolar dis-
ruption, rather than DNA damage, may lead to p53 stabiliza-
tion, suggesting that the nucleolus may constitutively promote
p53 degradation, unlessDNAdamage occurs (124). Itwould be
interesting to understand if and how the extra-nucleolar DNA
damage is ultimately signaled to the nucleolus andwhich is the
event that triggers the nucleolar segregation.
The Paradigmatic Example of the APE1/NPM1
Interaction
APE1 is a typical example of DNA repair protein activated
during the nucleolar stress response. APE1 is a multifunctional
and essential factor in mammals that was identified about 20
years ago as the major AP-endonuclease in the BER pathway,
as well as a redox coactivator of transcription factors (37, 157).
The recent observation that APE1 is able to bind and cleave
RNA highlighted previously unsuspected roles for the protein
(77, 138). We found indeed that this protein associates with
NPM1 in the nucleolus, where it may have a functional role as
RNA cleansing factor. This hypothesis is corroborated by
studies performedwith inducible HeLa APE1 knock down cell
lines, which showed how APE1 depletion leads to a wide-
spread accumulation of unrepaired oxidized RNA species (i.e.,
8-OHG) upon oxidative stress. Notably, under unstressed
conditions, APE1 knock down cells display impaired transla-
tion ability, lower protein content and overall cell growth im-
pairment (149). These evidences point to a major contribution
for APE1 as cellular scavenger of damaged RNA species. The
nucleolar storage of APE1 is mediated by the interaction of the
flexible and evolutionarily acquired N-terminal extension of
the protein with both rRNA andNPM1 (42, 89, 116). However,
the protein does not constitutively accumulate in the nucleoli;
in fact, upon Pol I inhibitionwith actinomycinD,APE1 shuttles
to the nucleoplasm (149). The evidence that treatment with the
E3330 redox inhibitor (45) causes APE1 nucleolar exit and its
accumulation to the nucleoplasm (147) suggests that the redox
status of APE1 may play a significant role in controlling its
subcellular trafficking. Interestingly, the APE1/NPM1 associ-
ation is also impaired during oxidative stress (149), suggesting
that the protein may be released from the nucleolus during
stress conditions, possibly to operate within the BER pathway.
In accordance with this observation, we delineated a complex
regulatory pattern of NPM1 on APE1 endonuclease activities:
NPM1 acts as an inhibitor of the APE1 ribonuclease function,
but as an activator of the AP-endonuclease function on DNA
(149, 150). This model suggests that when APE1 resides within
the nucleolus, its activity is mainly focused on the rRNA
quality control machinery, possibly modulated by NPM1.
Whereas, during the DDR, the simultaneous outflow of APE1
and NPM1 to the nucleoplasm, leads to the activation of the
APE1 AP-endonuclease function (Fig. 4). In agreement with
this view, many reports point to the involvement of NPM1 in
different aspects of the DDR, yet, the exact contribution(s) of
this protein to the stress response is currently elusive (31, 79,
127). It is worth pointing out that the lack of NPM1 has been
proved to sensitize cells to genotoxins that elicit a BER response
and that APE1 catalytic activity is impaired inNPM1knock out
cells (150). These elements suggest that NPM1 plays a direct
role in the BER modulation, which is still poorly understood.
As discussed in the previous section of this review, the key
event that triggers the APE1 release from nucleoli upon geno-
toxic stress is still amatter of debate. It is known that theAPE1/
NPM1 interaction is modulated by acetylation on the N-
terminal domain of APE1 (42, 89). Acetylation of this protein
region is induced upon genotoxic stress (89, 128); it is therefore,
likely that, once again, stress-induced PTMs drive APE1 shut-
tling to the nucleoplasm in response to DNA damage. In an
effort to characterize the response of APE1 to genotoxic stress,
we generated a quadruple lysine to alanine substitution that
mimics constitutive APE1 acetylation. As anticipated, the in-
ability of this mutant to interact with NPM1 leads to nucleolar
exclusion of the APE1 mutant. Interestingly, the lack of APE1
nucleolar accumulation causes a severe impairment of cellular
proliferation, indicating that the presence of APE1 within nu-
cleoli is required to ensure a proper cellular growth rate (89).
These aspects of the APE1 biology still deserve thorough in-
vestigation and fascinatingly open novel perspectives for an-
titumor therapy, as targeting theAPE1/NPM1 interactionmay
prove effective in counteracting cellular proliferation.
The APE1 protein is commonly renowned as DNA repair
protein and only recently it has been identified as an enzyme
active on abasic RNA molecules, unveiling its noncanonical
function. Perhaps earlier examples of this versatility of func-
tion in dealing with genotoxic damage were described for the
RP S3, both in Drosophila and humans. Specifically, S3 has
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been found to protect cells from genotoxic stress through: (i)
its DNase activity on abasic sites in Drosophila (155); (ii) its
ability to stimulate, the activity of the uracil-DNA glycosylase
hUNG in human cells (78); (iii) its ability to bind with high
affinity the oxidative lesion 8-OHG in humans (60) and (iv) its
functional interaction, always in human cells, with other
well-known DNA repair proteins, such as the 8-OHG DNA
glycosylase (OGG1) and APE1 (61). Recent findings are in-
creasingly pointing to the involvement of noncanonical pro-
teins (57) and even of noncoding RNA molecules (46) in the
DDR, addingmore layers of complexity to this mechanism. An
intriguing emerging evidence is that the association of DNA
repair proteins to noncanonical binding partners (i.e.,RNA and
RNA-binding proteins) is mainly driven by the presence of
unfolded protein domains acquired during phylogenesis,
which may be responsible for novel gain of function activities.
Relevance of the Unfolded Domains in BER Proteins:
The Missing Link for a Phylogenetic Gain of Function?
Until recently, BER was considered the simplest among the
DNA repair pathways since an in vitro reconstituted nuclear
BER required only four or five core enzymes. However, recent
studies have revealed that BER is much more complex, in-
volving a network of distinct and integrated cell cycle- and
genome-specific sub-pathways in which numerous non-
canonical proteins take part (58, 59). Notably, many of these
proteins are involved in RNA-metabolism processes. Actu-
ally, several noncanonical factors have been demonstrated to
participate BER, even though their in vivo functions are yet to
be fully unraveled. The list of non-BER proteins includes for
instance: YB-1 [which has been shown to interact with the
endonuclease VIII-like 2 (NEIL2) glycosylase (35), the endo-
nuclease III-like glycosylase (NTH1) and APE1 (29)], NEIL2
[which was also found to interact with the RNA-binding
protein hnRNP-U (6)], HMGB1 [which has been implicated in
single-strand break (SSB) repair involving Polb (90)] and the
tumor suppressor p53, which was also shown to play a role in
DNAdamage repair through direct binding to APE1 and Polb
(168). The list of these non-BER proteins is still growing,
supporting the notion that BER in vivo is far more complex
than the simple model that we can reconstitute in vitro. In
particular, the characterization of the BER interactome iden-
tified multiprotein complexes; thus, suggesting that complete
FIG. 4. Dynamic turnover of the APE1/NPM1 complex in response to cellular stress. Under basal conditions (left) the
cellular APE1 pool is dynamically distributed throughout the cell, with prevalent accumulation in the nucleus and nucleoli.
This accounts for the maintenance of a basal DNA repair capacity (both nuclear and mitochondrial), redox-mediated tran-
scriptional modulation, cell proliferation, and RNA cleansing activity. Upon genotoxic stress and/or arrest of Pol I tran-
scription (right) the dynamic equilibrium of APE1 localization is tipped towards a nucleoplasmic accumulation of the protein
(149). The APE1 relocalization is likely mediated by simultaneous migration of NPM1 outside the nucleolus and hyper-
acetylation of the N-terminal region of APE1 itself (90). This situation ensures a potentiated DNA repair response, as both the
nucleoplasmic APE1/NPM1 association and its acetylation have been linked to increased catalytic activity of the protein. The
absence of APE1 from nucleoli, moreover, might favor a temporary arrest of cellular proliferation, useful to allow for more
efficient DNA repair. If the DNA damage is sustained, it is likely a redistribution of a pool of APE1 to the cytoplasm. This
phenomenon should boost the mitochondrial BER and possibly contribute to the cellular RNA cleansing capacity. APE1,
apurinic/apyrimidinic endonuclease 1; BER, base excision repair; NPM1, nucleophosmin 1; Pol I, RNA polymerase I. To see
this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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repair occurs through the action of BER complexes formed by
core proteins and noncanonical factors (BERosomes) (59). The
previous and simplistic view of the BERmechanism, based on
the analysis of cocrystal structures of substrate-bound pro-
teins, proposed a pathway consisting of sequential steps in
which individual repair enzymes carry out reactions inde-
pendently. In contrast with this original concept, recent dis-
coveries showed that early BER enzymes stably interact with
most of the downstream repair components. The initial view
of BER as a ‘‘hand-off’’ or ‘‘passing the baton’’ process has
been revisited by Hegde et al. who introduced, rather, a new
paradigm in which the dynamic interplay of highly coordi-
nated interactions between different BER proteins would in-
crease the efficiency and the versatility of the process.
It has been observed that frequently those machines whose
operations must be tuned rapidly in response to specific and
diverse cellular needs, present components that are not fully
structured. Such ‘‘malleable machines’’ (47), conversely to rigid
entities, might presumably better respond to different condi-
tions, for instance by promoting conformational rearrange-
ments and facilitating multiple targets recognition. Structural
analyses exploiting both experimental and modeling ap-
proaches have indeed evidenced the presence of disordered
segments preferentially localized at the N- or C-terminus of
different mammalian DNA repair proteins, a peculiar feature
which is absent in their bacterial prototypes. These observa-
tions thus, suggest that, during evolution, higher organisms
have acquired these binding domains to regulate multiprotein
interactions and to improve pathways (e.g., BER) efficiency, in
an increasingly oxidizing environment. Long disordered seg-
ments are a common feature observed in a large percentage of
proteins; being prevalent especially among proteins involved
in vital processes, such as transcription, translation, signal
transduction, and protein phosphorylation (47, 145). Such un-
structured regions may provide versatility in recognizing
multiple targets, promoting communication with many pro-
teins in response to environmental changes; thus, expanding
the capacities of ordered complexes and representing a pow-
erful strategy selected by nature to quickly explore a vast in-
teraction space with unique thermodynamic advantages (132).
Disordered regions were shown to be prevalent in DNA
binding proteins, particularly in those involved in targeted
sequence binding (e.g., repair proteins and transcription fac-
tors) (143, 153). Disordered prediction tools (PONDR and
PrDOS) have been used to compare the secondary structure of
human and bacterial early BER proteins (59). These analyses
showed that mammalian DNA glycosylases are endowedwith
unique nonconserved extensions at their N- or C-termini,
which are absent in their homologs in lower organisms (58).
The human NEIL1 glycosylase, for instance, contains an ex-
tended disordered region spanning about 100 residues at the
C-terminus, absent in the E. coli Nei-like protein. Similar com-
parisons between the human DNA glycosylases hNTH1, the
MutY homolog (hMYH), and their E. coli prototypes (i.e., en-
donuclease III and MutY, respectively), indicate that both
hNTH1 and hMYH have extended disordered tails at the N-
terminus that are absent in the E. coli enzymes (66, 140). Like-
wise, the N-terminal disordered region present in the human
APE1 is absent in exonuclease III (Xth), its E. coli ortholog. The
size range of the unstructured extensions is about 50–100 res-
idues. In the case of human APE1 it consists of*65 residues,
being mostly disordered (59).
These disordered regions, due to their structural flexibility
and plasticity have been shown to provide BER proteins with
functional advantages and appear to be essential for their
biological functions, including damage sensing (153), protein–
protein interactions, repair regulation via PTMs and contain-
ing NLSs (118). Furthermore, the presence of disordered
segments only in eukaryotic proteins, with the highest degree
of disorder in mammals, suggests their evolutionary acqui-
sition and well correlates with the increase in regulatory
complexity observed in higher organisms.
FIG. 5. Schematic representation
of multiple regulatory functions of
the APE1 disordered N-terminal
region. APE1 crystal structure
(yellow) bound to abasic DNA
(grey) is from the pdb (1DEW) and
displayed using the PDBV soft-
ware. The deposited APE1 crystal
structure was obtained using a
truncated APE1 form (residues 40–
318); missing residues have been
manually added. The unstructured
N-terminal portion of APE1 (resi-
dues 1–42) is essential for APE1 bi-
ological functions being site of
PTMs, target of many interactions
and, including the NLS. NLS, nu-
clear localization signal; PTMs,
post-translational modifications. To
see this illustration in color, the
reader is referred to the web ver-
sion of this article at www
.liebertpub.com/ars
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Among the BER enzymes, APE1 offers a paradigmatic ex-
ample of how a disordered tail can endow a protein with
unique activities. The first crystallographic structure of the
human APE1 in complex with DNA was obtained using a
truncated protein lacking the first 35 amino acids and reveled
that this protein consists of two symmetric alpha/beta fold
with a significant structural similarity to both bovine DNase I
and its E. coli homologue Xth (50). A crystal structure of the
full-length protein has also been reported, but again, the N-
terminal region was unresolved (10). Three functionally in-
dependent domains can be distinguished within the APE1
protein (Fig. 5): (i) the first 33–35 amino acid region consists of
a structurally disordered segment (133) essential for the in-
teraction with other proteins (148, 149) and harboring sites for
PTMs (14, 24, 70, 89, 159, 165, 166) and RNA interaction (89);
(ii) the redox domain is located in a region between amino
acids 35 and 127; and (iii) the DNA repair domain, which
spans the C-terminal domain of the protein from about resi-
due 61 onwards (42, 68). Whereas the APE1 C-terminal do-
main involved in AP endonuclease activity is conserved from
bacteria to humans, the N-terminal region is unique to
mammals suggesting a recent acquisition during evolution.
Remarkably, this peculiar region also accounts for non-
canonical activities that have been ascribed to APE1, includ-
ing its role in RNA metabolism (42, 89, 116, 138, 148, 149).
Over the past two decades, knowledge of the biological
functions, mechanisms of action, interactions, and regulation
of the APE1 protein has increased exponentially. In particular,
it has become apparent that APE1 participates in multiple
cellular processes not only confined to the maintenance of
genome stability, in accordance with the current general view
that many DNA repair enzymes may exert miscellaneous
activities, being implicated, for example, in different steps of
gene regulation (74, 113). As already mentioned, RNA decay
and processing events require a wide spectrum of proteins,
including RNA helicases, polymerases and, above all, exori-
bonucleases and endoribonucleases. For many years, it has
been assumed that eukaryotes RNA cleavage relies mostly on
the action of exoribonucleases, in contrast with prokaryotes,
where RNA decay is mainlymediated by endoribonucleolytic
processes (82, 101). In recent years, the unexpected implica-
tion of numerous endoribonucleases in the RNA turnover in
eukaryotes significantly contributed to a change of perspec-
tive on the eukaryotic RNAmetabolism (141). APE1 is among
the several examples of recently identified enzymes whose
endoribonucleolytic activity has been found to associate with
the regulation of RNA stability. Evidence of its RNase H-like
activity was first suggested by Barzilay et al. who demon-
strated that APE1 is able to bind with relatively low affinity
undamaged single- and double-stranded RNA molecules,
albeit not exhibiting unspecific nuclease activity (9). Later on,
it has been discovered that APE1 possesses the ability to
cleave AP sites within single-stranded RNA molecules and
that the nucleic acid secondary structure significantly influ-
ences the APE1 incision activity (12). Despite these first in vitro
suggestions of APE1 biological relevance in the removal of
AP-site-containing RNA, the unequivocal demonstration of
APE1 involvement in RNA processing was brought only few
years later. Very recently, in fact, Barnes et al. identified APE1
as the major endonuclease associated with polysomes and
capable of cleaving the coding region determinant of the c-myc
mRNA; thus, influencing c-myc half-life in cells (7). Surpris-
ingly, recent biochemical studies performed using recombi-
nant APE1 demonstrated that the APE1 endoribonuclease
function is not limited to c-mycmRNA, but it may potentially
influence the biogenesis and hence, the stability of other
transcripts, including also miRNAs (77). These works dem-
onstrated that APE1-mediated RNA cleavage occurred,
in vitro, at single-stranded or weakly paired regions, prefer-
entially 3¢ of pyrimidines at UA, UG, and CA sites. This latter
finding, in particular, led to hypothesize the possible in-
volvement of APE1 in mRNA splicing events, since CA re-
peats are renowned as potent splicing modulators (15).
Furthermore, the in vivo involvement of APE1 in RNA meta-
bolic pathways was further corroborated by the observation
of the APE1 association, through its N-terminal domain, with
rRNA and the ribosome processing protein NPM1 within
nucleoli (149). Furthermore, APE1 has been shown to interact
with factors involved in the splicing process, such as the
heterogeneous nuclear ribonucleoprotein L (81) [which is a
key regulator of splicing that binds CA repeats with high
affinity (65)], YB-1 (29, 119), as well as with proteins involved
in the ribosome assembly and RNA maturation within cyto-
plasm (149).
So far, many studies have characterized the involvement of
the APE1 C-terminal domain in RNA metabolism, demon-
strating that the APE1 endoribonuclease activity and its nu-
clease function on DNA share the same active site (76).
However, few groups have investigated the role of the un-
structured N-terminal extension, possibly as a consequence of
its disordered nature. A recent work published form our
group systematically characterized the binding properties of
the APE1 N-terminal disordered region towards nucleic acids
and NPM1. We demonstrated that the N-terminus, in partic-
ular acquired Lys residues therein located, appear to be es-
sential for the stabilization of both protein–protein and
nucleic acids–protein interactions, as well as influencing the
thermal stability of the protein. These evidences clearly sup-
port the notion that this unstructured domainmight represent
an evolutionary gain function necessary for mammals to cope
with a progressively complex cellular environment (116).
In light of these recent findings and taking into account also
previous reports on the pivotal role of APE1 disordered N-
terminal region, we speculate that the targeting of this un-
folded protein domain could be a valuable tool to interfere
with the different APE1 functions in vivo.
Relevance of the Unstructured Domain of BER
Proteins for Designing Novel Anticancer Strategies
BER proteins have been broadly explored as targets for
cancer therapy (67); in particular, current approaches to can-
cer treatment report more effective results when specific DNA
repair inhibitors are used in combination with DNA damag-
ing drugs. The foremost rationale of the combined therapy is
that impairment of BER enzymes is likely to sensitize cancer
cells to chemotherapeutic agents. Druggable BER targets for
cancer treatment include: FEN1, Polb, APE1, and the poly
[ADP-ribose] polymerase 1 (PARP1); while targeting of DNA
glycosylases results inefficacious because of the functional
redundancy of this class of enzymes (58).
In the last decade, remarkable attention has been posed on
the development of PARP1 and APE1 inhibitors. The APE1
relevance for cell survival is demonstrated by the fact that
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knocking out the APE1 gene induces either apoptosis in dif-
ferentiated cells (69) or developmental failure during em-
bryogenesis (158). Accumulating evidences have indicated
that deregulation of APE1 in both expression and subcellular
localization is indeed associated with different tumorigenic
processes: APE1 upregulation or dysregulated expression has
been described in a variety of cancers, including prostate,
pancreatic, ovarian, cervical, germ cell, rhabdomyosarcoma,
and colon (43, 92). Furthermore, it has been reported that el-
evated APE1 levels and anomalous intracellular localization
are also typically correlated with aggressive proliferation and
increased resistance to chemotherapeutic drugs and IR, im-
plying that APE1 enhances repair and survival of tumor cells
(92). Therefore, considering that APE1 expression appears to
be linked to chemoresistance and taking into account that
several studies have shown that decreasing APE1 levels may
lead to cell growth arrest and to an increased cellular sensi-
tivity to DNA damaging agents (44, 45, 85, 154), APE1 rep-
resents a promising target for pharmacological treatment. A
description of all the APE1-targeting molecules currently
under investigation is beyond the focus of this review, for an
exhaustive review on APE1 inhibitors, the reader is redirected
to (146). All the APE1 small-molecule inhibitors developed so
far were designed to target specific APE1 functions, namely
the DNA repair or the redox activity of the protein. It is
however, still a matter of debate whether the enhanced sen-
sitivity to cytotoxic agents observed upon APE1 inhibition is
solely related to the loss of DNA repair activity, or is also
linked to the loss of its transcriptional regulatory function, or
both. Despite the efforts aimed at determining the relative
importance of the attenuation of the APE1’s repair or tran-
scriptional functions, all currently available APE1 inhibitors
display limited specificity for cancer cells. Therefore, explo-
ration of novel opportunities for APE1 targeting is obviously a
path that deserves further consideration. Based on several
observations attesting the critical role of disordered segments
in many BER enzyme functions, we propose that the N-
terminal unstructured portion of the APE1 protein could be
considered as a new potential target for cancer therapy.
Classical pharmacological strategies usually target structured
regions of proteins; however, considering the biological rele-
vance of intrinsically disordered proteins, the ability to in-
terfere with their interactions opens enormous potentials for
drug discovery. Actually, there is a continuous progress in
the development of small molecules directed against disor-
dered protein regions; several low molecular weight com-
pounds are effective in the specific inhibition of molecular
interactions based on intrinsically disordered domains. For
example, small molecules binding the disordered regions of c-
myc, Ab, EWS-Fli1 have recently been discovered (100, 144).
Although the binding of a small molecule to a disordered
region/protein may appear counterintuitive due to the in-
trinsic poor selectivity, this may also be considered a major
advantage because it would facilitate the screening of initial
compounds, which affinity and specificity could be succes-
sively improved through standard molecular optimization
procedures.
In conclusion, we suggest that it would be interesting to
investigate novel pharmacological approaches aimed at in-
terfering with the APE1 N-terminal region in light of its im-
portant role in the coordination of many different functions of
the protein, both in DNA repair and RNA metabolism.
Conclusions and Speculations
Different independent studies provided in vitro and in vivo
evidence that many DNA repair proteins, particularly in the
BER pathway (e.g., APE1), are involved in RNA metabolism.
Interestingly, many of these proteins are also part of the nu-
cleolar proteome where they bind specific carrier proteins
(e.g., NPM1, NCL) and rRNA. Upon genotoxic stress, many
DNA repair proteins exit from nucleoli and switch their in-
teractome network from proteins involved in RNA metabo-
lism to DNA repair complexes. Although still in the early
phases, these findings have raised many questions and spec-
ulations concerning the role of these proteins, including APE1
as a paradigmatic example, in RNAmetabolism. For instance:
1. Why should a protein involved in DNA repair play a
role in RNA metabolism? One possible explanation is
that this duality would preserve genetic stability not
only through the DNA repair activity, but also through
the ability to cleanse damaged RNA that may otherwise
be inaccurately translated, or degrade unwanted for-
eign RNA (e.g., viral RNA).
2. Do the redox function of APE1 and its role in RNA
metabolism represent two sides of the same coin devoted
to modulate gene expression through transcriptional and
post-transcriptional mechanisms? Modulation of APE1
subcellular distribution through its redox status may
represent an elegant, specific, and energetically economic
mechanism to tune gene expression upon genotoxic
stress conditions.
3. IsAPE1 an ancient proteinwith a newly identified andyet
unappreciated role? The current information regarding
the primary amino acid sequence of APE1 across species
seems to suggest a phylogenetic ‘‘gain-of-function’’ and
hence, support this hypothesis. However, further experi-
mental and bioinformatics studies ofAPE1 orthologsmay
reveal additional insights into this question.
4. Suppressing the amount of APE1 has proven effective
in sensitizing cancer cells to chemotherapeutic agents.
This finding has led to the proposal that selective in-
hibition of the APE1 DNA repair activity is an attractive
avenue for the development of novel anticancer thera-
pies. Similarly, one can envision targeting the non-DNA
repair functions of APE1, namely its RNA-repair and/
or RNA-cleavage activities, as novel approaches for the
treatment of cancer or neurological disorders. None-
theless, such therapeutic aims still need further studies
to increase our understanding of the role of APE1 in its
noncanonical functions.
In closing, a productive cross-talk between DNA repair
enzymes and proteins involved in RNA metabolism seems
reasonable and nucleolus is emerging as a dynamic functional
hub that coordinates cell growth arrest and DNA repair
mechanisms. These findings will drive further analysis of
other BER proteins, such as FEN1, and might imply that nu-
cleic acid processing enzymes are more versatile than origi-
nally thought andmay have evolved DNA-targeted functions
after a prior life in the early RNA world. The observation of
cytoplasmic localization for canonical DNA repair proteins,
such as APE1, simply beyond their mitochondrial targeting,
may therefore, suggest much more than just an ‘‘abnormal’’
distribution pattern.
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Abbreviations Used
8-OHG¼ 8-hydroxyguanosine
AD¼Alzheimer’s disease
AP¼ apurinic/apyrimidinic
APE1¼ apurinic/apyrimidinic endonuclease 1
ATM¼ ataxia telangiectasia mutated
ATR¼ ataxia telangiectasia and Rad3-related
BER¼ base excision repair
CRM1¼ exportin 1
DDR¼DNA damage response
DSB¼double-strand break
FEN1¼flap endonuclease 1
hMYH¼human MutY glycosylase homolog
HR¼homologous recombination
IR¼ ionizing radiation
NCL¼nucleolin
NEIL2¼ endonuclease VIII-like 2
NER¼nucleotide excision repair
NHEJ¼nonhomologous end joining
NLS¼nuclear localization signal
NPM1¼nucleophosmin 1
NoLS¼nucleolar localization sequence
NTH1¼ endonuclease III-like glycosylase
OGG1¼ 8-OHG DNA glycosylase
PARP1¼poly [ADP-ribose] polymerase 1
PCNA¼proliferating cell nuclear antigen
PD¼Parkinson disease
PNC¼perinucleolar compartment
Polb¼DNA polymerase b
Pol I¼RNA polymerase I
PTMs¼post-translational modifications
rDNA¼ ribosomal DNA
rRNA¼ ribosomal RNA
RP¼ ribosomal protein
RPA¼ replication protein A
snoRNA¼ small nucleolar RNA
SSB¼ single-strand break
WRN¼Werner syndrome helicase
XRCC1¼X-ray repair cross-complementing pro-
tein 1
Xth¼ exonuclease III
YB-1¼Y box binding protein 1
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Role of the unstructured N-terminal domain of the hAPE1 (human
apurinic/apyrimidinic endonuclease 1) in the modulation of its interaction
with nucleic acids and NPM1 (nucleophosmin)
Mattia POLETTO*, Carlo VASCOTTO*, Pasqualina L. SCOGNAMIGLIO†‡, Lisa LIRUSSI*, Daniela MARASCO†‡
and Gianluca TELL*1
*Department of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy, †Department of Pharmacy, CIRPEB (Centro Interuniversitario di Ricerca sui Peptidi Bioattivi),
University of Naples ‘Federico II’, 80134 Naples, Italy, and ‡Institute of Biostructures and Bioimaging CNR, 80134 Naples, Italy
The hAPE1 (human apurinic/apyrimidinic endonuclease 1) is an
essential enzyme, being the main abasic endonuclease in higher
eukaryotes. However, there is strong evidence to show that hAPE1
can directly bind specifi gene promoters, thus modulating their
transcriptional activity, even in the absence of specifi DNA
damage. Recent f ndings, moreover, suggest a role for hAPE1 in
RNA processing, which is modulated by the interaction with
NPM1 (nucleophosmin). Independent domains account for many
activities of hAPE1; however, whereas the endonuclease and the
redox-active portions of the protein are well characterized, a better
understanding of the role of the unstructured N-terminal region is
needed. In the present study, we characterized the requirements
for the interaction of hAPE1 with NPM1 and undamaged nucleic
acids. We show that DNA/RNA secondary structure has an impact
on hAPE1 binding in the absence of damage. Biochemical studies,
using the isolated N-terminal region of the protein, reveal that the
hAPE1 N-terminal domain represents an evolutionary gain of
function, since its composition affects the protein’s stability and
ability to interact with both nucleic acids and NPM1. Although
required, however, this region is not suff cient itself to stably
interact with DNA or NPM1.
Key words: apurinic/apyrimidinic endonuclease 1 (APE1), nuc-
leophosmin (NPM1), protein–DNA interaction, protein–protein
interaction, phylogenesis.
INTRODUCTION
The hAPE1 [human APE1 (apurinic/apyrimidinic endonuclease
1)] is an essential and multifaceted protein involved in the DNA
BER (base excision repair) pathway and in the regulation of
gene expression, acting both as a redox co-activator for several
transcription factors and as a transcriptional repressor on nCaRE
(negative calcium response elements)-containing promoters
[1–3]. These biological activities are located in two distinct, but
partially overlapping, regions. The conserved C-terminal portion
(residues 61–318) is responsible for the enzymatic activity
on abasic DNA, whereas the N-terminal domain (residues
1–127) is mainly devoted to the redox co-activating function
towards different transcription factors such as Egr1 (early growth
response 1), NF-κB (nuclear factor κB) and p53 [4,5]. The
mechanisms of hAPE1 binding and recognition of its canonical
substrate, the abasic site containing DNA, have been thoroughly
investigated by several laboratories [6–8]. However, the notion
that hAPE1 is constitutively bound to undamaged nucleic acids is
getting stronger. Examples include the interaction of the protein
with genomic regions, such as the nCaRE sequences [2] or
the MDR1 (multidrug resistance protein 1) gene promoter [9],
and the reported association of hAPE1 with undamaged RNA
[10]. Acquisition of particular secondary structures (i.e. bulges,
hairpins, cruciforms, quadruplex etc.) by nucleic acids and their
regulatory roles in vivo are a well-known paradigm in molecular
biology. A previous study has carefully explored the interaction
between hAPE1 and undamaged nucleic acids [11]; nonetheless,
potential impacts of the secondary structure of the nucleic acid
on the binding affinit of hAPE1 have never been investigated.
In the last few years, an unexpected involvement of hAPE1 in
RNA metabolism has been unveiled: the protein is accumulated
within nucleoli through interaction with NPM1 (nucleophosmin;
also known as nucleolar phosphoprotein B23) and rRNA and
affects cell growth by directly acting on the RNA quality
control mechanisms [10,12,13]. Notably, the N-terminal domain
of hAPE1 (the f rst 43 residues) plays a pivotal role in this non-
canonical function of the protein, serving as an adaptable device
for protein–protein interactions and modulating its enzymatic
activity on abasic DNA, as well as its binding to RNA
molecules. Although many studies have thoroughly characterized
the structure of the hAPE1 C-terminal globular domain, only a
few have addressed the role of its N-terminal extension, perhaps as
a consequence of its intrinsic disordered folding [14–16]. A basic
cluster of lysine residues located within this region (Lys25–Lys35)
controls the binding affinit of hAPE1 for both NPM1 and nucleic
acids. Furthermore, several strands of evidence suggest that the
different functions of hAPE1 might be rapidly modulated in vivo
by post-translational modification on its N-terminal domain,
such as ubiquitination, acetylation and proteolysis [2,17–21].
Interestingly, whereas the C-terminal portion of the protein shares
extensive similarity with most of its orthologue counterparts,
from Escherichia coli to mammals, its N-terminal extension is
considerably less conserved. The importance of this protein region
in modulating the many activities of hAPE1 suggests that the N-
terminal domain may be a recent acquisition during evolution
Abbreviations used: APE1, apurinic/apyrimidinic endonuclease 1; BER, base excision repair; DSP, dithiobis(succinimidyl propionate); DTT, dithiothreitol;
FBS, fetal bovine serum; GST, glutathione transferase; hAPE1, human APE1; MAT, metal-affinity tag; nCaRE: negative calcium response elements; NPM1,
nucleophosmin; PLA, proximity ligation assay; RU, response unit; SPR, surface plasmon resonance; zAPE1, zebrafish APE1.
1 To whom correspondence should be addressed (email gianluca.tell@uniud.it).
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[17], as already suggested for other BER proteins [22]. Aberrant
hAPE1 expression and localization patterns have been linked
to neurodegeneration and cancer; therefore, many groups are
currently directing their efforts to develop specifi small-molecule
modulators of the different activities of the protein [23].
In the present study, we systematically characterized the
functional properties of the hAPE1 N-terminal domain, exploring
its nucleic acid-binding properties and its role in hAPE1–NPM1
interaction. In an effort to better characterize the features guiding
the binding of hAPE1 to undamaged nucleic acids, we used a
combined approach based on SPR (surface plasmon resonance),
EMSA analyses and GST (glutathione transferase) pull-down
experiments. The results of the present study show that the aff nity
of hAPE1 for nucleic acids is enhanced by certain structural
elements and that the nucleic acid-binding activity of hAPE1 is
promoted by the N-terminal extension of the protein. This region,
although necessary for both the stabilization of the hAPE1–
nucleic acids and hAPE1–NPM1 interactions, shows only a weak
affinit for DNA or NPM1 when isolated from the hAPE1 globular
domain. Finally, exploiting a ‘domain swapping’ approach, we
demonstrate that lysine residues located within the N-terminal
domain of hAPE1 represent a phylogenetic gain of function
for the protein, since the composition of this domain influence
the stability of the protein and its ability to interact with both
nucleic acids and NPM1. Altogether, these data highlight the
role for the hAPE1 N-terminal region in modulating the many
functions of this pleiotropic protein. Further structural analyses
on this overlooked extension of the protein would be therefore
worthwhile in order to fully understand the substrate specificit of
hAPE1 and to design new anti-cancer drugs targeting this protein.
EXPERIMENTAL
Cell culture and transient transfection experiments
HeLa cells were grown in DMEM (Dulbecco’s modifie Eagle’s
medium) supplemented with 10% FBS (fetal bovine serum),
100 units/ml penicillin and 10 mg/ml streptomycin sulfate. At
1 day before transfection, cells were seeded in 10-cm plates
at a density of 3×106 cells/plate. Cells were then transiently
transfected with 6 μg of either pcDNA5.1 (empty vector) or
pcDNA5.1-hAPE1 (full-length or amino acids 1–49) plasmids
per dish using the LipofectamineTM 2000 Reagent (Invitrogen)
according to the manufacturer’s instructions. Cells were harvested
at 24 h after transfection.
Multiple sequence alignments
For the multiple sequence alignments full-length hAPE1
orthologous metazoan sequences (human, Pan troglodytes,
Macaca mulatta, Equus caballus, Mus musculus, Rattus
norvegicus, Canis lupus familiaris, Sus scrofa, Bos taurus,
Ornithorhyncus anatinus, Salmo salar, Gasterosteus aculeatus,
Danio rerio, Xenopus tropicalis and Xenopus laevis) were
retrieved from the RefSeq protein database using the
BLAST algorithm (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and
aligned using the ClustalW2 program with default parameters
(http://www.ebi.ac.uk/Tools/msa/clustalw2/ ).
Western blotting analyses
The protein samples were electrophoresed by SDS/PAGE (10–
18% gels) or discontinuous Tris/Tricine SDS/PAGE [24].
Proteins were then transferred on to nitrocellulose membranes
(PerkinElmer), developed as described previously [12] using an
ECL (enhanced chemiluminescence) procedure (GE Healthcare)
and then quantifie by using a ChemiDoc XRS video-
densitometer (Bio-Rad Laboratories).
Plasmids and expression of recombinant proteins
The constructs pGEX-3X-hAPE1 and pGEX-3X-zAPE1, enco-
ding for the GST-fused hAPE1 and zAPE1 (zebrafis APE1)
full-length proteins respectively, were provided by Dr Mark
R. Kelley (Indiana University, Indianapolis, IN, U.S.A.). The
plasmid encoding for full-length GST–NPM1 was provided by
Dr P.G. Pelicci (European Institute of Oncology, Milan, Italy).
The pTAC-MAT/hAPE1 and the pETM-20/zAPE1 constructs,
encoding for C-terminal-tagged MAT (metal-aff nity tag)–hAPE1
and His6–zAPE1 respectively, were generated by subcloning. All
proteins were expressed in E. coli BL21(DE3) cells, induced
with 1 mM IPTG (isopropyl β-D-thiogalactopyranoside) and then
purifie on an A¨KTA Purifie FPLC system (GE Healthcare)
by using a GSTrap HP column (GE Healthcare) for the GST-
tagged proteins, or a HisTrap HP column (GE Healthcare) for the
His6- and MAT-tagged proteins. The quality of purificatio was
checked by SDS/PAGE analysis. Extensive dialysis against PBS
was performed to remove any trace of imidazole from the HisTrap-
purifie proteins. Accurate quantificatio of all recombinant
proteins was performed by colorimetric Bradford assays (Bio-Rad
Laboratories) and confirme by SDS/PAGE and Western blotting
analysis. To remove the GST tag, GST–hAPE1 was further
hydrolysed with Factor Xa as described previously [17]. The
zAPE1 K27 ‘swapping mutant’ and the hAPE1 N43 and zAPE1
N36 deletion mutants, as well as the hAPE1 1–48 and 1–49
constructs, were generated using the QuikChange Mutagenesis kit
(Stratagene) and the respective full-length constructs as templates,
following the manufacturer’s instructions and using standard
subcloning procedures.
GST pull-down assays with RNA or NPM1 and
co-immunoprecipitation
The indicated amount of GST-tagged protein was mixed, together
with the prey protein or 10 μg of total RNA, with 10 μl of
glutathione–Sepharose 4B beads (GE Healthcare). RNA was
extracted using the TRIzol® Reagent (Invitrogen). Binding was
performed in PBS supplemented with 5 mM DTT (dithiothreitol)
and 0.5 mM PMSF for 2 h under rotation at 4 ◦C. The beads
were washed three times with washing buffer [PBS supplemented
with 0.1% Igepal CA-630 (Sigma), 5 mM DTT and 0.5 mM
PMSF]. Beads were then resuspended in Laemmli sample buffer
for Western blotting analyses or in TRIzol® Reagent for RNA
extraction and rRNA quantification The levels of 28S and 18S
rRNA transcripts were determined as described previously [17]
by using the iScript cDNA synthesis kit (Bio-Rad Laboratories)
according to the manufacturer’s instructions. Quantitative PCR
was then performed in an iQ5 multicolour real-time PCR detection
system (Bio-Rad Laboratories) according to the manufacturer’s
protocol. GST-tagged proteins were detected with an HRP
(horseradish peroxidase)-conjugated anti-GST antibody (Sigma),
whereas the prey proteins were detected using the indicated
antibodies. Co-immunoprecipitation analyses were performed as
described previously [12].
DSP [dithiobis(succinimidyl propionate)] cross-linking
The indicated amounts of recombinant NPM1 and hAPE1 (either
full-length or the amino acids 1–48 peptide), were allowed to
c© The Authors Journal compilation c© 2013 Biochemical Society
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interact at 37 ◦C for 15 min in a total volume of 10 μl; DSP (2 μg
in DMSO) was added and cross-linking was carried out for 30 min
at room temperature (22 ◦C). The reactions were quenched by
adding 0.5 volumes of ice-cold 0.4 M ammonium acetate and
incubating on ice for 10 min. Non-reducing Laemmli sample
buffer was immediately added and the samples were separated
by SDS/PAGE (8% gel).
Immunofluorescence confocal analyses and PLA (proximity
ligation assay)
Immunofluorescenc was carried out as described previously [12].
FLAG-tagged 1–49 hAPE1 was labelled using an anti-FLAG
antibody and stained with a secondary anti-mouse Alexa FluorTM
488-conjugated antibody (Jackson ImmunoResearch). Nuclei
were counterstained with DAPI (4′,6-diamidino-2-phenylindole).
For the PLA analyses we used the Duolink II® reagent kit (Olink
Bioscience); cells were fi ed in 4% (w/v) paraformaldehyde,
permeabilized with 0.25% PBS-Triton (PBS with Triton X-100)
and saturated with 10% (v/v) FBS. Slides were incubated with
primary antibodies (mouse anti-FLAG, 1:100 dilution and rabbit
anti-NPM1, 1:200 dilution) and then reactions were carried out
following the manufacturer’s instructions. Microscope slides were
mounted and visualized through a Leica TCS SP laser-scanning
confocal microscope.
hAPE1–nucleic acid binding through EMSA
hAPE1 binding to nucleic acids was assessed as described
previously [1] with some modifications Briefl , in order to reduce
unspecifi binding and to obtain more define bound complexes,
recombinant proteins or peptides were incubated at 37 ◦C with
250 pmol of unlabelled poly(dT) for 15 min and then 2.5 pmol of
32P-labelled probe was added. The reactions were then incubated
for further 15 min and separated by native PAGE (6–10% gel) at
150 V for 4 h.
Southwestern assays
Bait proteins were separated using a pre-cast SDS/PAGE (Bio-
Rad Laboratories), electrotransferred on to a nitrocellulose
membrane and subsequently denatured and renatured by washing
six times in 1:1 serial dilutions of 6 M guanidinium/HCl in EMSA
buffer [40 mM Hepes (pH 8.0), 50 mM KCl, 2 mM EDTA, 10%
(v/v) glycerol and 1 mM DTT]. The membrane was then saturated
in 5% (w/v) BSA in EMSA buffer and incubated with 50 pmol of
the indicated 32P-labelled DNA probe at 37 ◦C, washed in EMSA
buffer to remove unspecifi bound probe and f nally subjected to
autoradiography.
SPR
Real-time binding assays were performed on a Biacore T-100
SPR instrument (GE Healthcare). Streptavidin was immobilized
on to a research-grade CM5 sensor chip using amine-coupling
chemistry. The immobilization steps were carried out at a f ow
rate of 10 μl/min in Hepes buffer {20 mM Hepes, 150 mM NaCl,
3.4 mM EDTA, 0.005% P20 surfactant and 0.1 mM TCEP [tris-
(2-carboxyethyl)phosphine]}. All surfaces were simultaneously
activated for 30 s with a mixture of NHS (N-hydroxysuccinimide;
0.05 M) and EDC [N-ethyl-N ′-(3-dimethylaminopropyl)carbodi-
imide; 0.2 M]. Streptavidin was injected at a concentration of
20 μg/ml in 10 mM sodium acetate (pH 4.5) for 1 min. Ethan-
olamine (1 M, pH 8.5) was injected for 7 min to saturate the re-
maining activated groups. An average of 5000 RU (response units)
of streptavidin was immobilized on each fl w cell. Biotinylated
oligonucleotides were injected at a concentration of 500 nM until
the desired level of immobilization was achieved (average value of
300 RU). Proteins were serially diluted in running buffer (80 nM–
2.0 μM) and injected at 20 ◦C at a f ow rate of 60 μl/min for 1 min.
Disruption of any complex that remained bound after a 5-min
dissociation was achieved using a 30 s injection of 1 M NaCl at
100 μl/min. When the experimental data met the quality criteria,
the kinetic parameters were estimated assuming a 1:1 binding
model and using version 4.1 Evaluation Software (GE Health-
care). Conversely, an affinit steady-state model was applied to
fi the RUmax data compared with the protein concentrations and
fittin was performed with GraphPad Prism v4.00 [17].
CD
Far-UV CD spectra were recorded on a Jasco J-810
spectropolarimeter (JASCO) in a 195–260 nm interval.
Experiments were performed employing a protein concentration
of 5 μM in 10 mM phosphate buffer (pH 7.0), supplemented with
1 mM DTT and using a 0.1 cm path-length cuvette. Thermal
denaturation profile were obtained by measuring the temperature
dependence of the signal at 225 nm in the 20–100 ◦C range with a
resolution of 0.5 ◦C and 1.0-nm bandwidth. A Peltier temperature
controller was used to set up the temperature of the sample with
the heating rate set to 1 ◦C/min. Data were collected at a 0.2-nm
resolution, 20 nm/min scan speed and a 4 s response and were
reported as the unfolded fraction against the temperature.
Statistical analyses
Statistical analyses were performed by using the Microsoft Excel
data analysis software for Student’s t test analysis. P < 0.05 was
considered statistically significant
RESULTS AND DISCUSSION
The binding affinity of hAPE1 for undamaged nucleic acids is
dependent on their secondary structure
Several studies have thoroughly characterized hAPE1 structure
and its enzymatic activities on abasic DNA, examining its
substrate specificit and recognition mechanisms [7,11,25–28].
However, when considering undamaged structured nucleic acids,
the knowledge of hAPE1 substrate selectivity is still scarce.
In the present study we sought to determine whether some partic-
ular structural features were favoured by hAPE1 when binding to
nucleic acids. Hence, we used a biophysical approach exploiting
the SPR technique to quantitatively measure the binding affinit
of hAPE1 for intact oligonucleotides [29,30]. We compared
the binding affinit of recombinant purifie full-length hAPE1
toward different single-stranded DNA probes, either intrinsically
lacking secondary structure (i.e. 34dT), or having a stem and
loop-like folding (e.g. Stem10 and Stem20) as predicted by
bioinformatics analyses (Figure 1A and Table 1). The results of
the SPR experiments (representative sensorgrams in Figure 1B
and Supplementary Figure S1C at http://www.biochemj.org/
bj/452/bj4520545add.htm) are summarized in Table 2. As already
observed by Beloglazova et al. [11], an increased length in
the stem region of the oligonucleotides augmented the affinit
of hAPE1 for undamaged DNA (compare the Stem10 and the
Stem20 sequences). This observation was confirme by direct
EMSA experiments (Figure 1C) and by competition EMSA
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Figure 1 The secondary structure of the substrate determines the binding selectivity of hAPE1
(A) The predicted structures for the oligonucleotides used in the present study. Calculations were performed using either the Mfold web server (http://mfold.rna.albany.edu/?q=mfold) or the DINAMelt
web server (http://mfold.rna.albany.edu/?q=DINAMelt). The calculated minimum free energy for folding (G) at 37◦C and 50 mM Na+ is also reported. The arrow indicates the absence of loop in
the Stem20 no loop probe. (B) Representative overlay sensorgrams relative to a typical SPR experiment for the binding of hAPE1 to immobilized Biot-Stem20. The kinetic parameters were measured
injecting purified recombinant hAPE1 solutions at increasing concentrations (i.e. 87.5, 175, 350, 700, 1050, 1400 and 1750 nM). The K d values were estimated for each concentration using the
BIAevaluation v.4.1 software. (C) Positive effect of the stem length on ability of hAPE1 to bind undamaged DNA as evaluated through EMSA using the Stem10 and Stem20 oligonucleotides (Table 1).
For each reaction the indicated amount of purified recombinant hAPE1 was used. The results confirm a different binding capacity of hAPE1 towards double-stranded oligonucleotides of different
lengths. The arrow indicates the hAPE1–DNA complexes, whereas F denotes the position of the free oligonucleotide probe. wt, wild-type.
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Table 1 Oligonucleotide sequences used in the present study
The underlined nucleotides denote the position of the predicted loops.
Name Sequence
34dT 5′-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-3′
Stem10 5′-CGATCGACGGATCCCCGTCGATCG-3′
Stem10 3′ A 5′-CGATCGACGGATCCCCGTCGATCGAAAAAA-3′
Stem10 5′ A 5′-AAAAAACGATCGACGGATCCCCGTCGATCG-3′
Stem20 5′-ATCGATCGATCGATCGACGGATCCCCGTCGATCGATCGATCGAT-3′
Stem20 no loop Forward, 5′-ATCGATCGATCGATCGACGGAT-3′ and reverse,
5′-CCCCGTCGATCGATCGATCGAT-3′
Stem20_2 5′-CGATCGATCGATCGATCGACGGATCCCCGTCGATCGATCGATCGATGC-3′
Stem20 Loop8 5′-CGATCGATCGATCGATCGACGGATCCTAGTCGATCGATCGATCGATCG-3′
Bulge Forward, 5′-CATTACTCATATCCCCGTCCATTG-3′ and reverse,
5′-CAATGGACGGTACAATGAGTAATG-3′
nCaRE_B2 Forward, 5′-TTTTTGAGACGGAGTTTCGCTCTTG-3′ and reverse,
5′-CAAGAGCGAAACTCCGTCTCAAAAA-3′
Table 2 Dissociation constants and kinetic parameters for the interaction
of full-length hAPE1 with different undamaged oligonucleotides
Data reported were obtained through SPR analyses using hAPE1 as analyte on the indicated
biotinylated oligonucleotide ligands. The kinetic parameters highlight the importance of
secondary structure for the recognition of undamaged nucleic acids by hAPE1.
Ligand k on (M− 1 · s− 1×105) k off (s− 1) Kd (μM)
34dT 0.004 0.112 308 +− 3.00
Stem10 0.270 0.020 1.03 +− 0.02
Stem20 0.292 0.007 0.25 +− 0.01
Stem20 no loop 0.068 0.024 4.06 +− 0.01
Stem10 3′A 0.060 0.240 6.20 +− 0.01
Stem10 5′A 0.059 0.059 2.11 +− 0.03
Stem20_2 0.284 0.007 0.25 +− 0.01
Stem20 Loop8 0.061 0.004 0.74 +− 0.02
Bulge 0.834 0.019 0.23 +− 0.02
nCaRE_B2 0.270 0.105 3.90 +− 0.80
experiments demonstrating the poor competitive ability of the
Stem10 toward the Stem20 oligonucleotide (results not shown).
The effect of the presence of an intact loop structure on the stability
of the protein–DNA complex then was investigated by comparing
the aff nities of the Stem20 and the Stem20 no loop sequences.
Notably, hAPE1 showed a reduced affinit toward the ligand
without a loop (approximately 16-fold, Table 2). Accordingly,
EMSA experiments confirme these f ndings, showing a more
stable hAPE1–DNA complex in the presence of an intact loop
(Supplementary Figures S1A and S1B). Furthermore, competitive
EMSA assays demonstrated that the Stem20 probe was a more
efficien competitor if compared with the Stem20 no loop (results
not shown). Binding affinitie were also negatively affected by the
presence of an unstructured nucleotide stretch either 3′ or 5′ to the
double-stranded stem region (compare Stem10 3′A and Stem10
5′A with the Stem10 sequence). Experimental data allowed us to
speculate that the steric hindrance of a free poly(A) tail on the
double-stranded region bound by hAPE1 might accelerate
the dissociation rate, if protruding from the 3′-side. When
using the same stem length the size of the loop region affected
the binding: the expansion from 4 to 8 nucleotides reduced the
affinit of hAPE1 approximately 3-fold (compare the Stem20_2
and the Stem20 Loop8 sequence). The difference in Kd value can
be accounted for by a reduction in the association rate, suggesting
that hAPE1 preferentially approaches the DNA molecules from
the loop side as the stem side remains invariant between the
two oligonucleotides. A lower stability of the stem region in the
Stem20 Loop8 sequence could also reflec the decreased binding
affinity bioinformatic predictions, however, do not suggest any
major difference in the unfolding free energy of the two molecules
(Figure 1A). We finall investigated whether the position of
the unstructured region might affect the binding capacity of
hAPE1 (compare Bulge, Stem20 and Stem20_2). Despite the
differences in both the dissociation and the association rates,
the overall affinit of hAPE1 for the oligonucleotides remained
unchanged, suggesting that a local denaturation of the double
helix, rather than its location within the double-stranded region,
is a feature that enhances binding of hAPE1 to undamaged DNA.
To compare our measurements on synthetic oligonucleotides
with a physiologically relevant undamaged DNA substrate, we
investigated the binding properties of hAPE1 towards an nCaRE
duplex sequence, namely nCaRE_B2 (G. Antoniali, L. Lirussi, C.
D’Ambrosio, F. Dal Piaz, C. Vascotto, D. Marasco, A. Scaloni,
F. Fogolari and G. Tell, unpublished work). This sequence
displayed a Kd value akin to that of the unstructured Stem20
no loop sequence (Table 2). It is worth pointing out that our
in vitro assays, performed with the isolated purifie recombinant
protein, might underestimate the real affinit of hAPE1 for this
sequence, since interactions with other protein partners [e.g.
Ku70/80 and hnRNPL (heterogeneous nuclear ribonucleoprotein
L)] significantl increase the protein–DNA complex stability, as
already demonstrated previously (G. Antoniali, L. Lirussi, C.
D’Ambrosio, F. Dal Piaz, C. Vascotto, D. Marasco, A. Scaloni, F.
Fogolari and G. Tell, unpublished work) [31].
EMSA analyses were also performed on RNA substrates to
test whether the nature of the sugar backbone might affect the
binding activity of hAPE1 toward structured nucleic acids. The
results obtained confirme that the structural requirements for
hAPE1 binding to undamaged substrates are not influence by
the composition of the sugar backbone (results not shown). These
observations suggest that hAPE1 shows no apparent preference
for DNA or RNA substrates, as long as the nucleic acid is
undamaged and is endowed with a secondary structure. The results
of the present study are in agreement with experimental data
from other laboratories that have estimated Kd values for the
interaction of hAPE1 with structured RNA that is similar to our
values for DNA (∼0.9 μM) [32]. It must be noted, however, that
these experiments do not allow the exclusion of the existence of a
differential aff nity of hAPE1 for abasic site-containing DNA or
RNA molecules, as has been suggested by others [12,26].
In summary, hAPE1 binding to undamaged nucleic acids
appears to be strongly affected by the presence of secondary
structural elements. In particular, the presence of a double-
stranded region is a primary element required for hAPE1 binding.
The occurrence of a single-stranded local distortion, moreover,
greatly enhances the interaction with nucleic acids. These factors
are corroborated by studies reporting a significan reduction in
the APE activity of the protein on single-stranded unstructured
(or poorly structured) substrates (e.g. [7]). The requirement of a
double-stranded DNA region is conceivable, on the basis of the
observation that hAPE1 contacts both of the DNA strands [27,28].
The presence of a loop or a bulge within a double-stranded stem
could mimic a local denaturation region that resembles a baseless
spot, hence explaining the increased affinit for loop-containing
structures displayed in vitro by hAPE1.
The N-terminal domain contributes to nucleic acid-binding
by hAPE1
We have shown previously that the N-terminal 33 amino acids of
hAPE1 is able itself to bind RNA oligonucleotides in solution [17].
Sequence alignment analyses, performed on different metazoan
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Figure 2 The isolated N-terminal region of hAPE1 interacts weakly with nucleic acids
(A) Multiple sequence alignment between full-length APE1 protein sequences from 15 different metazoan species. Only the N-terminal region of the alignment is reported. The arrow indicates the
beginning of the high-similarity region within the C-terminal globular domain; whereas the N-terminal part of the sequences is significantly less conserved. (B) The isolated recombinant 1–48 hAPE1
N-terminal peptide is able to compete (comp.) with the full-length protein for RNA binding. The binding ability of the peptide was evaluated through competition RNA pull down using GST-tagged
full-length hAPE1 as the bait and whole HeLa RNA as the prey in the presence of the indicated competitor. To quantify the amount of residual hAPE1-bound rRNA the pulled-down RNA was then
retrotranscribed and 28S or 18S rRNAs were amplified by real-time PCR. The affinity for the 18S rRNA was similar to that shown for the 28S (results not shown). The competition activity of the
1–48 hAPE1 peptide was also confirmed using an untagged synthetic 1–33 hAPE1 peptide. The histogram shows the relative affinity to rRNA with respect to the GST–hAPE1 sample. The error bars
represent the S.D. (n = 3). *P < 0.05. (C) EMSA dose–response analysis showing that the 1–48 peptide binds undamaged DNA with a low affinity when compared with the full-length hAPE1 protein.
For each reaction the indicated amount of purified recombinant protein was used. F denotes the position of the free oligonucleotide probe. (D) Southwestern blot assay showing a dose–response
binding of the nCaRE_B2 duplex to the 1–48 peptide. The indicated amounts of protein or peptide were separated by SDS/PAGE, electrotransferred on to nitrocellulose membranes (left-hand panel)
and probed with 32P-labelled nCaRE_B2 (right-hand panel). Note the difference in binding affinity between the full-length hAPE1 protein and the isolated peptide. MT, Mat; wt, wild-type.
species, highlight that the phylogenetic conservation of the amino
acid sequence among APE1 proteins from different organisms
starts at position 48 in the human protein, and is significantl lower
in the region spanning amino acids 1–48 (Figure 2A). In order
to better clarify the relevance of the non-conserved N-terminal
domain in modulating the binding ability of hAPE1 to nucleic
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acids, we cloned and expressed in E. coli cells the 1–48 amino
acid region of hAPE1 in fusion with a C-terminal MAT (Sup-
plementary Figures S2A and S2B at http://www.biochemj.org/
bj/452/bj4520545add.htm) and evaluated the binding properties
of the recombinant purifie peptide toward different substrates,
including DNA and RNA. We indirectly estimated the rRNA-
binding activity of the peptide exploiting a GST pull-down
competition strategy. In these experiments, the full-length GST–
hAPE1 was used as the bait and total HeLa RNA as the prey,
while either the recombinant purifie 1–48 peptide or its synthetic
untagged 1–33 counterpart were used as soluble competitors. The
data obtained revealed that both soluble peptides were able to
compete with full-length hAPE1 for rRNA binding, independently
of the presence of a tag (Figure 2B).
In order to compare the nucleic acid-binding activity of
the 1–48 peptide and that of the full-length hAPE1 protein,
we used EMSA analyses. Under our experimental conditions we
observed a low-aff nity binding activity for the hAPE1 N-terminal
peptide towards the nCaREB_2 duplex sequence (Figure 2C
and Supplementary Figure S2C). Although at a reduced affinit ,
however, the interaction with DNA was specific as demonstrated
by both Southwestern assays (Figure 2D and Supplementary
Figure S2D) and Western blotting performed after the EMSA
analysis (Supplementary Figure S2E). These results, along with
the notion that the N-terminal 1–33 amino acid portion of hAPE1
is absolutely required for the stable interaction of the protein
with nucleic acids [12,17], suggest that this lysine-rich region
might act by stabilizing the association of hAPE1 with nucleic
acids through electrostatic interactions, whereas the remaining C-
terminal domain accounts for the specifi binding to DNA/RNA.
Our data support a two-step model to describe the mechanism
through which hAPE1 contacts nucleic acids. The unstructured
N-terminal domain would be required for the preliminary low-
affinit binding process in search of the proper lesion to be
repaired, as suggested for other DNA-binding proteins [33].
Recognition of a local distortion (or an abasic site) involves
and is stabilized by a higher-affinit binding event. The whole
hAPE1 molecule would, at this point, become necessary for the
recognition of the structured nucleic acid region. Intriguingly, this
model nicely f ts previous hypothesis proposed by Masuda et al.
[34] more than a decade ago.
The N-terminal domain of hAPE1 is necessary, but not sufficient,
for a stable binding to NPM1
In our previous work, we demonstrated that the N-terminal 1–
33 amino acid domain of hAPE1, besides being essential for
stabilizing its binding to nucleic acids, is also required for a stable
interaction with NPM1 [12] and that lysine residues spanning
the region 27–35 of hAPE1 are directly involved in stabilizing
this interaction [17]. However, we did not check whether the N-
terminal domain of hAPE1 was able to directly bind to NPM1
itself. In an effort to better characterize the protein–protein
interaction features of the hAPE1 N-terminal domain and its
relative contribution to the overall binding, we analysed the ability
of the 1–48 peptide to directly interact with NPM1. We expressed
both the full-length hAPE1 and the 1–48 peptide in fusion with a
MAT. The recombinant proteins were aff nity purifie and tested
for their binding ability toward GST-tagged NPM1 through GST
pull-down assays (Figure 3A). Although the full-length hAPE1
protein was able to directly interact with NPM1 (Figure 3A,
left-hand panel), we failed to detect any stable peptide–NPM1
association in vitro (Figure 3A, right-hand panel), even under less
stringent binding conditions (results not shown). This negative
result prompted us to hypothesize that, if present, any peptide–
NPM1 association could be too weak to be detected through a
direct pull-down assay. We confirme this hypothesis through a
competition GST pull-down assay, in which the 1–48 peptide
was used to squelch the binding occurring between the full-
length hAPE1 and GST–NPM1 (Figure 3B). The peptide, as
well as an untagged full-length hAPE1, was able to displace the
association between the MAT-tagged hAPE1 and GST–NPM1.
However, whereas the competitor untagged hAPE1 was also
efficientl recovered in the pulled-down fraction, the competitor
1–48 peptide was not. This indicates that the peptide was able
to mask the hAPE1-binding site on NPM1, thus competing with
the hAPE1–NPM1 association, although its interaction with the
protein was too weak to be maintained during the washing steps.
The observed competition effect could also be interpreted by
assuming a masking effect of the peptide on the full-length hAPE1
N-terminal region, however, to the best of our knowledge, no
oligomerization ability has ever been described for hAPE1.
To definitel prove the ability of the N-terminal peptide
to directly associate with NPM1, we performed an in vitro
stabilization of the complex exploiting the bifunctional cross-
linker DSP (Figure 3C). As expected, treatment of NPM1 alone
with DSP resulted in the stabilization of slow migrating oligomers,
as documented previously [35]. Moreover, the full-length hAPE1
protein and its N-terminal peptide were detected as slow migrating
signals only in the presence of both NPM1 and DSP, indicating a
direct association for both with NPM1. The lower aff nity of the
1–48 peptide toward NPM1, in comparison with that of the full-
length protein, indicates that the C-terminal domain of hAPE1
contributes to the stabilization of the protein–protein interaction.
To evaluate whether the interaction between the hAPE1 N-
terminal extension and NPM1 also occurs in vivo, we created a
HeLa cell line expressing a FLAG-tagged 1–49 hAPE1 peptide
upon treatment with doxycycline, as already described previously
[36]. As assessed using Western blotting, the peptide expression
increased after the addition of doxycycline to the culture medium
(Figure 4A, upper panel). Interestingly, the ectopically expressed
peptide showed a peculiar localization pattern, being cytoplasmic
and nuclear, but excluded from nucleoli (Figure 4A, lower panel),
in contrast with the nuclear/nucleolar accumulation observed
for the wild-type protein both under basal conditions [12,21]
and when ectopically expressed (Figure 4A, lower panel). This
result confirm that the C-terminal domain of hAPE1 contributes
to the nucleolar accumulation of the protein within cells,
despite the fact that the N-terminal domain retains the nuclear
localization signal of the protein [37]. This phenomenon may
be explained by the relevance that the C-terminal domain has
in stabilizing both rRNA and NPM1 binding. By exploiting this
cell model, we performed co-immunoprecipitation experiments
and demonstrated the occurrence of a molecular interaction
between NPM1 and the isolated hAPE1 N-terminal peptide.
However, the FLAG-tagged 1–49 peptide was only able to co-
precipitate NPM1 poorly when compared with the full-length
protein (Figure 4B). This result parallels our in vitro results with
recombinant purifie proteins and confirm that the unstructured
N-terminal region of hAPE1 does indeed interact with NPM1,
albeit with a lower affinit in the absence of the remaining
C-terminal domain. We further confirme the presence of an
interaction occurring between the FLAG-tagged 1–49 hAPE1
peptide and endogenous NPM1 using a PLA [21], which allows
the quantificatio of physical proximity between molecules
at a distance lower than 40 nm (Supplementary Figure S3A
at http://www.biochemj.org/bj/452/bj4520545add.htm) [38]. The
PLA signal was present in the nucleoplasmic compartment only in
the presence of both the anti-FLAG and the anti-NPM1 antibodies,
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Figure 3 The unstructured N-terminal domain of hAPE1 is required, but not sufficient, for stable binding to NPM1 in vitro
(A) A representative GST pull-down experiment showing the absence of a stable interaction, in vitro, between recombinant GST-tagged NPM1 (bait) and the MAT-tagged 1–48 hAPE1 N-terminal
peptide (prey) (right-hand panel). The same assay using full-length MAT-tagged hAPE1 is reported as a positive control (left-hand panel). The assay was performed as described in the Experimental
section using the indicated amounts of recombinant proteins. (B) The recombinant 1–48 hAPE1 peptide is able to compete, in vitro, with the full-length hAPE1 protein for the binding to NPM1.
Competition GST pull down using GST–NPM1 as the bait and MAT-tagged full-length hAPE1 as the prey. The hAPE1–NPM1 interaction was evaluated in the presence of a 10-fold excess competitor
(comp.; i.e. untagged full-length hAPE1 as a positive control or MAT-tagged 1–48 peptide). The extent of interaction was assessed using an anti-MAT antibody to recognize the pulled down hAPE1
prey. The competing untagged hAPE1 was visualized using an anti-APE1 antibody. The histogram shows the average of three independent experiments with the error bars representing the S.D.
*P < 0.05. ¥, Residual GST contaminant in the untagged hAPE1 preparation. (C) The low-affinity binding between the N-terminal recombinant hAPE1 peptide and NPM1 is stabilized by in vitro
cross-linking. Recombinant purified NPM1 was incubated alone or together with either the 1–48 peptide or full-length hAPE1 as indicated. The bifunctional cross-linker DSP was also added where
indicated. The presence of high-molecular-mass complexes was assessed by Western blotting using an anti-NPM1, an anti-APE1 or an anti-MAT antibody. The formation of high-molecular-mass
complexes in the presence of DSP denotes the ability of the 1–48 peptide to interact weakly with NPM1. MT, Mat; WB, Western blot; wt, wild-type.
being absent when using either the anti-FLAG or the anti-NPM1
alone. This demonstrates the existence of an interaction between
the isolated hAPE1 N-terminal domain and endogenous NPM1
only in the nucleoplasmic compartment. We also measured, using
PLA, the extent of endogenous hAPE1–NPM1 interaction in the
presence or absence of expression of the 1–49 peptide. In this
case, the expression of the N-terminal region resulted in a poor,
but statistically significant competing effect (about 10% loss in
interaction, Figure 4C). Altogether, these results confir that the
unstructured hAPE1 N-terminal domain alone is required, but not
suff cient, for a stable binding of hAPE1 to NPM1 both in vitro and
in vivo. Notably, several studies have demonstrated that hAPE1,
targeted by granzymes A and K, undergoes proteolysis in living
cells and its truncation products (hAPE1 N31 or 35) have
been proposed to take part in the apoptotic process [18,39,40].
In light of the results of the present paper, it may be tempting
to speculate that the N-terminal proteolytic products (the 1–31
or 1–35 peptides) might also exert an active regulatory function
within cell, for example by competing with the full-length protein
for binding to nucleic acids or protein partners, such as NPM1,
XRCC1 (X-ray repair complementing defective repair in Chinese
hamster cells) [41], DNA polymerase β [42] or CSB (Cockayne
syndrome B) [43] and thus possibly acting as decoy peptide.
The evolutionarily acquired N-terminal domain of hAPE1 influences
the stability and the binding properties of the protein
Given the importance of the unstructured N-terminal region
of hAPE1 in tuning many of the protein’s functions, the poor
evolutionary conservation of this domain appears remarkable.
hAPE1 belongs to the exonuclease III family of endonucleases,
being 27% identical with the archetype E. coli ExoIII (xth)
[14]. Although the C-terminal domain of the human protein is
conserved from prokaryotes to mammals, the N-terminal portion
of hAPE1, comprising the redox domain, is not [17,44]. Metazoan
hAPE1 orthologues, in fact, share a unique basic N-terminal
extension that heavily affects the isoelectric point of the whole
protein. Interestingly, the overall positive charges number within
this basic region increased during evolution (from nine in f shes
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Figure 4 The hAPE1 N-terminal peptide interacts weakly with endogenous NPM1 in HeLa cells
(A) Upper panels, Western blotting analysis of the expression kinetics of the FLAG-tagged 1–49 hAPE1 peptide following the doxycycline treatment of HeLa. The peptide expression is induced after
2 days of treatment. Lower panel, immunofluorescence confocal analysis on HeLa cells after 5 days of doxycycline treatment shows the lack of nucleolar accumulation of the 1–49 peptide (white
arrowheads), in contrast with the nucleolar positivity shown by the full-length hAPE1. (B) The recombinant 1–49 peptide binds poorly to endogenous NPM1 in vivo. NPM1 co-immunoprecipitation
carried out using HeLa cells transfected either with an empty vector (mock) or a FLAG–full-length hAPE1- or a FLAG–1–49-expressing vector as shown. The amount of immunoprecipitated NPM1
was evaluated using Western blotting with an anti-NPM1 antibody. (C) The competition effect of the 1–49 hAPE1 peptide on endogenous hAPE1–NPM1 interaction. The extent of endogenous
hAPE1–NPM1 interaction was measured by PLA of HeLa cells either expressing the 1–49 hAPE1 peptide or mock transfected. The hAPE1–NPM1 association was estimated by scoring the interaction
signals in transfected cells. Peptide expression resulted in a significant competing effect, leading to a 10 % reduction in hAPE1–NPM1 interaction. The boxplot shows the relative amount of
hAPE1–NPM1 interaction in 1–49-expressing cells with respect to the mock-transfected cells +− S.D. (n = 70). *P < 0.05. IP, immuoprecipitation; WB, Western blot; wt, wild-type.
to 11 in mammals; Figure 2A; [17]), this event has possibly
been paralleled by an improved ability of APE1 to cope with
a progressively complex cellular environment.
Our recent work showed that the DNA-binding activity of
hAPE1 is substantially higher than that of the orthologous
protein from a phylogenetically distant organism, such as
zebrafis (zAPE1) [17]. In the present study, we hypothesized
that evolutionarily acquired amino acids within the N-terminal
domain of the protein could account for the increased binding
properties of hAPE1 towards both nucleic acids and NPM1.
As a proof of concept, we performed interaction experiments
with recombinant purifie hAPE1 and zAPE1 enzymes. Initially,
through GST pull-down experiments, we confirme that zAPE1
has a lower binding activity towards both NPM1 (Figure 5A)
and rRNA (Figure 5B). We then used insertional mutagenesis to
generate a mutant recombinant zAPE1 protein (namely, zAPE1
K27) bearing, after Glu26, a lysine residue followed by a TAA
(threonine–alanine–alanine) spacer spanning amino acids 28–30,
in order to mimic the local charge density and distribution present
within the wild-type hAPE1 N-terminal 24–35 region (Figure 5C).
Interestingly, the theoretical isoelectric point, calculated for the
whole unstructured N-terminal domain, is identical in both
the wild-type human protein and the zAPE1 K27 mutant (Table 3).
The NPM1-binding activity of the purifie recombinant
proteins was then analysed using GST pull down with equimolar
amounts of each protein (Figure 5D and Supplementary Figure
S4A at http://www.biochemj.org/bj/452/bj4520545add.htm). The
data obtained indicate that, whereas the wild-type zAPE1 is less
able to interact with NPM1 than hAPE1, the full NPM1-binding
activity of the ‘swapping mutant’ is clearly restored. Notably, both
the hAPE1 N43 and the zAPE1 N36 deletion mutants, lacking
the entire N-terminal extension, showed neglectable interaction
ability. Although recognizing the limitations of this approach
when evaluating the binding of zAPE1 to a human NPM1 protein
(even though both human and zebrafis NPM1 share extensive
similarity and have a nearly identical pI value), our ‘domain
swapping’ approach supports the notion that the reduction
in binding affinit might be a consequence of a decreased
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Figure 5 The amino acidic composition of the N-terminal region enhances the affinity of the human APE1 protein for nucleic acids and NPM1
(A) zAPE1 has a lower affinity than hAPE1 for NPM1. GST pull-down assay using equimolar amounts of recombinant GST-tagged hAPE1 or zAPE1 as baits and His-tagged NPM1 as the prey. The
amount of pulled-down NPM1 was quantified through densitometric analysis (right-hand panel). The histogram show the results from three independent experiments with the error bars representing
the S.D. (n = 3), *P < 0.05. ¥, Residual GST contaminant in the GST–hAPE1 preparation. (B) zAPE1 has lower affinity than hAPE1 for rRNA. The APE1–RNA-binding capacity was evaluated through
RNA pull down using GST-tagged full-length hAPE1 or zAPE1 as the bait and whole HeLa RNA as the prey. To quantify the amount of residual hAPE1-bound rRNA the pulled-down RNA was then
retrotranscribed and 28S or 18S rRNAs were amplified by real-time PCR. The affinity for the 18S rRNA was similar to what shown for the 28S (results not shown). The histogram reports the relative
affinity to rRNA with respect to the GST–hAPE1 sample. Error bars represent the S.D. (n = 3). *P < 0.001. (C) Multiple sequence alignment of the N-terminal region of wild-type hAPE1, zAPE1 and
the mutant zAPE1 K27. The four-amino-acid insertion mutation in zAPE1 K27 is boxed. (D) The NPM1-binding affinity of the ‘domain swapping’ mutant measured using GST pull down. GST-tagged
NPM1 was used as the bait, whereas wild-type or mutant APE1 proteins were used as preys. The amount of pulled-down preys was assessed by Western blotting using an anti-APE1 antibody and
is shown as the percentage of input prey. Whereas wild-type zAPE1 and the deletion mutants N43 hAPE1 and N36 zAPE1 show a loss of function phenotype, the NPM1-binding capacity of
the zAPE1 K27 mutant is restored. (E) Binding affinity of the ‘domain swapping’ mutant for the nCaRE_B2 (left-hand panel) or the Stem20 (right-hand panel) oligonucleotides as measured using
EMSA. The nucleic acid-binding activity of the proteins reflects what was observed using SPR (Table 4): the wild-type zAPE1 protein and the deletion mutants N43 hAPE1 and N36 zAPE1 show
a reduced binding ability, whereas the zAPE1 K27 mutant displays a gain of function. F, the position of the free oligonucleotide probe. Arrows indicate the bound complex. (F) Overlay of thermal
melting profiles for recombinant hAPE1, zAPE1 and zAPE1 K27 in the 25–65◦C range shown as the unfolded fraction against temperature, measured by CD at 222 nm. The difference in thermal
stability observed between the wild-type hAPE1 and zAPE1 is clearly restored by the N-terminal insertions in the zAPE1 K27 mutant. WB, Western blot; wt, wild-type.
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Table 3 Predicted biophysical characteristics of the recombinant proteins
used in the present study
The table reports the theoretical molecular masses and isoelectric points calculated using the
Expasy pI/Mw tool (http://web.expasy.org/compute_pi/). The pI value of the N-terminal region
was calculated restricting the analysis to the human Ala43 or the homologue Ile36 in fish. Note the
identical pI values between the wild-type (wt) hAPE1 and the zAPE1 K27 N-terminal extensions.
N/A, not available.
Molecular Isoelectric point Isoelectric point
Protein mass (whole protein) (N-terminal)
hAPE1 wt 35564 8.33 9.10
zAPE1 wt 34881 5.77 8.04
hAPE1 N43 31217 7.59 N/A
zAPE1 N36 31207 5.54 N/A
zAPE1 K27 35252 5.96 9.10
number of positive charges within the N-terminal region of
zAPE1.
A similar functional rescue for the zAPE1 K27 mutant was
also observed when analysing the DNA-binding activity of the
proteins (Figure 5E). EMSA experiments carried out with either
a nCaRE_B2 duplex (Figure 5E, left-hand panel) or the Stem20
sequence (Figure 5E, right-hand panel) revealed a reduced binding
activity for wild-type zAPE1 and both the hAPE1 N43 and
the zAPE1 N36 deletion mutants, with a restored functionality
in the case of the zAPE1 K27 protein. EMSA analyses showed
clear differences in the electrophoretic mobility of the hAPE1 and
zAPE1 in complex with the nucleic acid substrates, suggesting
the existence of possible conformational differences between
the two recombinant proteins when bound to the cognate DNA.
The formation of a DNA–protein complex between the hAPE1
N43 mutant and the Stem20 substrate (Figure 5E, right-hand
panel), but not with the nCaRE_B2 DNA, is probably owing
to the presence of a highly stable stem-loop structure within
the Stem20 sequence, absent in the case of the nCaRE_B2
duplex (also see the SPR data below). This observation again
supports the concept that the C-terminal domain of hAPE1
may account for the high-affinit binding to structured nucleic
acid substrates. Moreover, the complete lack of nucleic acid-
binding activity observed for the hAPE1 N33 mutant [12,17]
suggests that the acidic residues in the 33–42 region might have a
negative effect on the overall nucleic acid-binding capacity of the
protein.
In order to corroborate these findings we carried out SPR
experiments on zAPE1 and its mutants (Table 4) using both
the Stem20 and nCaRE_B2 sequences, which showed different
affinitie for hAPE1 (Table 2). Interestingly, both the association
and dissociation rate constants could be determined when the
Stem20 was used as ligand; whereas, they were too high to
be determined with the nCaRE_B2 (in this case aff nities were
determined through Langmuir isotherm f tting; Supplementary
Figure S4B). These results further point to the relevance of
the presence of a stable stem-loop secondary structure within
the oligonucleotide for a robust APE1–nucleic acid interaction.
This result is corroborated by the presence of a detectable
binding activity of the N-terminal truncated proteins (hAPE1
N43 and zAPE1 N36) only for the stem-loop substrate
(i.e. Stem20). Similarly to what was observed in the EMSA
experiments (Figure 5E) with both DNA substrates, the measured
Kd values were higher for zAPE1 than for hAPE1 (for the
kinetic parameters with the human protein see Table 2). The
zAPE1 K27 mutant, in turn, displayed an intermediate behaviour,
Table 4 Dissociation constants and kinetic parameters for the interaction of
the mutated APE1 proteins with the Stem20 and nCaRE_B2 oligonucleotides
Results were obtained using SPR analyses using different APE1 mutants as analytes on the
indicated biotinylated oligonucleotide ligands. The affinity values for the nCaRE_B2 sequence
were determined through Langmuir isotherm fitting (see the text for details). wt, wild-type.
Stem20 nCaRE_B2
Protein k on (M− 1 · s− 1×105) k off (s− 1) K d (μM) K d (μM)
zAPE1 wt 0.174 0.053 3.28 +− 0.07 5.7 +− 0.2
zAPE1 N36 0.232 0.530 23.0 +− 0.5 No binding
hAPE1 N43 0.841 0.733 10.3 +− 0.3 No binding
zAPE1 K27 0.419 0.067 1.60 +− 0.02 2.4 +− 0.9
confirmin the restored binding activity of the ‘swapping mutant’
(Table 4).
In order to correlate the solution stability with binding ability,
we performed CD analyses on wild-type, mutant and truncated
APE1 proteins. The crystal structures of two vertebrate redox-
inactive enzymes C65A hAPE1 and zAPE1, in their N-terminally
truncated variants (C65A 40–318 hAPE1 and 33–310 zAPE1),
revealed no substantial differences in the structural organization
of the globular region of APE1 [44]. This was confirme by
our analyses as the CD spectra of all our proteins exhibited
minima at 225 and 208 nm, typical of α-helices and β-strands
(results not shown). This indicates that, as expected, the C-
terminal globular region of the protein predominantly accounts
for the folded portion of the APE1 proteins. Thermal denaturation
experiments were carried out to investigate protein stability:
the sigmoidal profil of folded fraction against temperature
(Figure 5F) shows that the unfolding process was fully co-
operative for all of the proteins tested. By comparing the Tm
values, however, an influenc of the N-terminal extension on
protein stability could be highlighted. Indeed, whereas hAPE1
has a Tm value of 41.5 ◦C, the Tm value measured for zAPE1 was
46.5 ◦C. Interestingly, the mutations and insertions in the zAPE1
K27 mutant effectively reduced the stability of the protein, since
the measured Tm value (39.5 ◦C) was closer to that of hAPE1
(Figure 5F). These results suggest a direct correlation between
the ability to recognize different oligonucleotides or protein
substrates and the fl xibility of the N-terminal region of APE1.
Moreover, these data also support the hypothesis that the altered
mobility observed in the EMSA experiments between hAPE1
and zAPE1 bound to the cognate DNA sequences (Figure 5E)
might be ascribed to substantial conformational differences in
the two protein–DNA complexes. Similar CD analyses carried
out on both the hAPE1 N43 and the zAPE1 N36 deletion
mutants indicated that the differences in thermal stability between
human and zebrafis proteins are already present in their globular
portions (the Tm values were 44 ◦C and 50.5 ◦C respectively),
despite the similar structural organization (Supplementary
Figure S4C).
Taken together, these results indicate that the amino acid
composition and the local charge distribution within the N-
terminal domain of hAPE1 are responsible for its evolutionarily
acquired binding properties towards both nucleic acids and NPM1
and have an impact on the f exibility of the N-terminal region
of APE1. Therefore the results of the present study point to
the insertion of human Lys27, as well as the proper charge
distribution, as central steps in the phylogenesis of this protein.
From a phylogenic perspective, the acquisition of additional lysine
residues could have provided the human protein with novel ways
to fine-tun its different activities by the means of new ‘hot spots’
c© The Authors Journal compilation c© 2013 Biochemical Society
Tesi di dottorato di Lisa Lirussi, discussa presso l'Università degli Studi di Udine
556 M. Poletto and others
that can undergo acetylation or ubiquitination [17,19–21] and
regulate substrate accessibility, on the basis of protein plasticity
in solution. In conclusion, in light of the results of the present study
and others [17,21,42,45], we suggest that the hAPE1 unstructured
N-terminal domain might represent a fl xible device that has been
selected during evolution to specificall modulate the nucleic
acid- and NPM1-binding functions of the protein. It would be
interesting to explore novel pharmacological strategies aiming at
the functional modulation of the protein using small molecules
and/or peptides that target its N-terminal region.
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RESULTS
Purification of the recombinant hAPE1 1–48 peptide
The recombinant MAT-tagged hAPE1 1–48 peptide (Figure S2A)
was purifie to homogeneity by metal-affinit followed by cation-
exchange chromatography. The purity of the peptide was verifie
by SDS/PAGE separation and silver staining (Figure S2B). The
predicted molecular mass for the tagged peptide is 6.3 kDa;
however, its migration pattern on SDS/PAGE is quite peculiar
as its apparent molecular mass is between 11 and 17 kDa. We
hypothesize that this phenomenon could be ascribed to the high
content of positive charges of the molecule (predicted isoelectric
point = 8.04) that are not efficientl neutralized by SDS treatment.
The exact molecular mass of the peptide was confirme through
LC/MS (liquid chromatography MS) analysis (results not shown).
Affinity of the recombinant hAPE1 1–48 peptide for nucleic acids
We investigated the nucleic acid-binding activity of the reco-
mbinant MAT-tagged 1–48 peptide in order to confir the
presence of the hAPE1 N-terminal domain in the low aff nity
complexes seen in our EMSA experiments. To this aim, in addition
to the Southwestern assays (Figure 2D of the main text and Figure
S2D), we performed an EMSA experiment coupled to a Western
blotting using an antibody directed against the hAPE1 N-terminal
domain (amino acids 1–14; Novus; Figure S2E, right-hand
panel). A signal showing the same migration pattern observed
in the silver-stained EMSA (Figure S2E, right-hand panel)
confirme the presence of the 1–48 hAPE1 peptide in the shifted
complex.
1 To whom correspondence should be addressed (email gianluca.tell@uniud.it).
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Figure S1 The presence of a single-stranded loop enhances hAPE1-binding capacity
(A) The positive effect of the presence of a loop on the ability of hAPE1 to bind undamaged DNA as evaluated by EMSA using the Stem20 and Stem20 no loop oligonucleotides (Table 1 of the main
text). For each reaction the indicated amount of purified recombinant hAPE1 was used. The results highlight the lower binding capacity of hAPE1 in the absence of a stem and loop structure. The
arrow indicates the hAPE1–DNA complexes, whereas F shows the position of the free oligonucleotide probe. wt, wild-type. (B) Annealing control for the Stem20 no loop duplex used in the EMSA in
(A). Equimolar amounts of the indicated individually 32P-labelled probes were separated by native PAGE (15 % gel). As expected, the Stem20 no loop duplex migrates similarly to the Stem20 probe,
but differently from its own forward strand (Stem20 no loop_for, which is the labelled in the duplex probe). (C) A representative plot of residuals of the SPR data fitting (related to the experiment
reported in Figure 1B of the main text). The adopted 1:1 Langmuir binding model provides low residuals levels both in the association and dissociation phases.
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Figure S2 Characterization of the 1–48 hAPE1 recombinant peptide
(A) Amino acid sequence of the MAT-tagged hAPE1 1–48 peptide. The two extra residues from the cloning procedures are underlined, whereas the C-terminal MAT is shown in italic font. (B)
Silver-stained Tris/Tricine SDS/PAGE showing the purified MAT-tagged hAPE1 1–48 peptide. M, molecular mass markers. The molecular mass of the markers is shown on the left-hand side in kDa.
(C) EMSA dose–response analysis showing that the 1–48 peptide binds undamaged DNA with a low affinity when compared with the full-length hAPE1 protein. For each reaction the indicated
amount of purified recombinant protein was used. F, the position of the free oligonucleotide probe. (D) Southwestern assay showing a dose–response binding of the Stem20 oligonucleotide to the
1–48 peptide. The indicated amounts of protein or peptide were separated by SDS/PAGE, electrotransferred on to nitrocellulose membranes (left-hand panel) and probed with 32P-labelled Stem20
(right-hand panel). Note the difference in binding affinity between the full-length hAPE1 protein and the isolated peptide. Molecular mass is shown on the left-hand side in kDa. (E) EMSA coupled to
Western blotting to confirm the presence of the N-terminal hAPE1 peptide in the bound complex. The indicated amounts of hAPE1 protein or peptide were incubated with different unlabelled DNA
probes and separated on two parallel native gels. The first one was silver-stained, to reveal the presence of shifted DNA–protein complexes (left-hand), whereas the second one was subjected to
Western blotting followed by immunorecognition with an anti-hAPE1 N-terminal antibody (right-hand panel). MT, MAT; wt, wild-type.
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Figure S3 In vivo interaction of the 1–49 hAPE1 peptide with endogenous
NPM1
(A) PLA analysis of 1–49 hAPE1-expressing HeLa cells using an anti-FLAG and an anti-NPM1
antibody reveals the interaction occurring in vivo between the hAPE1 N-terminal peptide and
endogenous NPM1 (red dots in the upper middle panel). The lower panels represent the technical
control where the immunoreaction was carried out while omitting the anti-NPM1 antibody.
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Figure S4 Evolutionary characterization of the hAPE1 N-terminal region
(A) A Coomassie Blue-stained gel showing the recombinant purified APE1 proteins used in the present study. M, molecular mass marker. The molecular mass of the markers is shown on the left-hand
side in kDa. (B) Representative SPR analysis on the wild-type zAPE1–nCaRE_B2 interaction. Recombinant zAPE1 was used as the analyte and biotinylated nCaRE_B2 was used as the ligand. Plot of
RUmax from each binding against concentration of wild-type zAPE1 is shown. The data were fitted by non-linear regression analysis. (C) Overlay of thermal melting profiles of recombinant hAPE1
N43 and zAPE1 N36 in the 25–65◦C range, reported as unfolded fraction against temperature measured using a CD signal at 222 nm. wt, wild-type.
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